Antigenic Polypeptides And Methods Of Use Thereof Patent Application (2024)

U.S. patent application number 17/582445 was filed with the patent office on 2022-09-01 for antigenic polypeptides and methods of use thereof.The applicant listed for this patent is AGENUS INC.. Invention is credited to Mark Arthur FINDEIS, Bishnu JOSHI, Benjamin Maxime MORIN.

ANTIGENIC POLYPEPTIDES AND METHODS OF USE THEREOF

Abstract

Provided are novel antigenic polypeptides comprisingtumor-associated peptides, and compositions comprising the same.Such antigenic polypeptides and compositions are particularlyuseful as immunotherapeutics (e.g., cancer vaccines). Also providedare methods of inducing a cellular immune response using suchpolypeptides and compositions, methods of treating a disease usingsuch polypeptides and compositions, kits comprising suchpolypeptides and compositions, and methods of making suchcompositions.

Related U.S. Patent Documents

Claims

1. An antigenic polypeptide comprising: an WIC-binding peptidecomprising an amino acid sequence selected from the groupconsisting of SEQ ID NOs: 98-3000 and 8808; and an HSP-bindingpeptide comprising the amino acid sequence ofX.sub.1X.sub.2X.sub.3X.sub.4X.sub.5X.sub.6X.sub.7 (SEQ ID NO: 1),wherein X.sub.1 is omitted, N, F, or Q; X.sub.2 is W, L, or F;X.sub.3 is L or I; X.sub.4 is R, L, or K; X.sub.5 is L, W, or I;X.sub.6 is T, L, F, K, R, or W; and X.sub.7 is W, G, K, or F.

2. (canceled)

3. The antigenic polypeptide of claim 1, wherein the HSP-bindingpeptide comprises the amino acid sequence of: (a)X.sub.1LX.sub.2LTX.sub.3 (SEQ ID NO: 2), wherein X.sub.1 is W or F;X.sub.2 is R or K; and X.sub.3 is W, F, or G; (b)NX.sub.1LX.sub.2LTX.sub.3 (SEQ ID NO: 3), wherein X.sub.1 is W orF; X.sub.2 is R or K; and X.sub.3 is W, F, or G; (c)WLX.sub.1LTX.sub.2 (SEQ ID NO: 4), wherein X.sub.1 is R or K; andX.sub.2 is W or G; (d) NWLX.sub.1LTX.sub.2 (SEQ ID NO: 5), whereinX.sub.1 is R or K; and X.sub.2 is W or G; or (e)NWX.sub.1X.sub.2X.sub.3X.sub.4X.sub.5 (SEQ ID NO: 6), whereinX.sub.1 is L or I; X.sub.2 is L, R, or K; X.sub.3 is L or I;X.sub.4 is T, L, F, K, R, or W; and X.sub.5 is W or K; optionallywherein the amino acid sequence of the HSP-binding peptidecomprises an amino acid sequence selected from the group consistingof SEQ ID NOs: 7-42.

4.-40. (canceled)

41. The antigenic polypeptide of claim 1, wherein the MHC-bindingpeptide is 8 to 50 amino acids in length, optionally 8, 9, 10, 11,12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28,29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45,46, 47, 48, 49, or 50 amino acids in length; the C-terminus of theMHC-binding peptide is linked to the N-terminus of the HSP-bindingpeptide, or the N-terminus of the MHC-binding peptide is linked tothe C-terminus of the HSP-binding peptide; and/or the HSP-bindingpeptide is linked to the MHC-binding peptide via a chemical orpeptide linker, optionally wherein the peptide linker comprises theamino acid sequence FR or the amino acid sequence of SEQ ID NO:43.

42.-47. (canceled)

48. The antigenic polypeptide of claim 41, wherein the N-terminusof the MHC-binding peptide is linked to the C-terminus of: (a) theamino acid sequence ofX.sub.1X.sub.2X.sub.3X.sub.4X.sub.5X.sub.6X.sub.7FFRK (SEQ ID NO:68), wherein X.sub.1 is omitted, N, F, or Q; X.sub.2 is W, L, or F;X.sub.3 is L or I; X.sub.4 is R, L, or K; X.sub.5 is L, W, or I;X.sub.6 is T, L, F, K, R, or W; and X.sub.7 is W, G, K, or F; (b)the amino acid sequence of X.sub.1LX.sub.2LTX.sub.3FFRK (SEQ ID NO:69), wherein X.sub.1 is W or F; X.sub.2 is R or K; and X.sub.3 isW, F, or G; (c) the amino acid sequence ofNX.sub.1LX.sub.2LTX.sub.3FFRK (SEQ ID NO: 70), wherein X.sub.1 is Wor F; X.sub.2 is R or K; and X.sub.3 is W, F, or G; (d) the aminoacid sequence of WLX.sub.1LTX.sub.2FFRK (SEQ ID NO: 71), whereinX.sub.1 is R or K; and X.sub.2 is W or G; (e) the amino acidsequence of NWLX.sub.1LTX.sub.2FFRK (SEQ ID NO: 72), whereinX.sub.1 is R or K; and X.sub.2 is W or G; (f) the amino acidsequence of NWX.sub.1X.sub.2X.sub.3X.sub.4X.sub.5FFRK (SEQ ID NO:73), wherein X.sub.1 is L or I; X.sub.2 is L, R, or K; X.sub.3 is Lor I; X.sub.4 is T, L, F, K, R, or W; and X.sub.5 is W or K; or (g)an amino acid sequence selected from the group consisting of SEQ IDNOs: 74-97.

49.-72. (canceled)

73. The isolated polypeptide of claim 41, wherein the C-terminus ofthe MHC-binding peptide is linked to the N-terminus of: (a) theamino acid sequence ofFFRKX.sub.1X.sub.2X.sub.3X.sub.4X.sub.5X.sub.6X.sub.7 (SEQ ID NO:44), wherein X.sub.1 is omitted, N, F, or Q; X.sub.2 is W, L, or F;X.sub.3 is L or I; X.sub.4 is R, L, or K; X.sub.5 is L, W, or I;X.sub.6 is T, L, F, K, R, or W; and X.sub.7 is W, G, K, or F; (b)the amino acid sequence of FFRKX.sub.1LX.sub.2LTX.sub.3 (SEQ ID NO:45), wherein X.sub.1 is W or F; X.sub.2 is R or K; and X.sub.3 isW, F, or G; (c) the amino acid sequence ofFFRKNX.sub.1LX.sub.2LTX.sub.3 (SEQ ID NO: 46), wherein X.sub.1 is Wor F; X.sub.2 is R or K; and X.sub.3 is W, F, or G; (d) the aminoacid sequence of FFRKWLX.sub.1LTX.sub.2 (SEQ ID NO: 47), whereinX.sub.1 is R or K; and X.sub.2 is W or G; (e) the amino acidsequence of FFRKNWLX.sub.1LTX.sub.2 (SEQ ID NO: 48), whereinX.sub.1 is R or K; and X.sub.2 is W or G; (f) the amino acidsequence of FFRKNWX.sub.1X.sub.2X.sub.3X.sub.4X.sub.5 (SEQ ID NO:49), wherein X.sub.1 is L or I; X.sub.2 is L, R, or K; X.sub.3 is Lor I; X.sub.4 is T, L, F, K, R, or W; and X.sub.5 is W or K; or (g)an amino acid sequence selected from the group consisting of SEQ IDNOs: 50-67.

74.-91. (canceled)

92. The antigenic polypeptide of claim 1, comprising an amino acidsequence selected from the group consisting of SEQ NOs: 3001-8806,8809, and 8810.

93. The antigenic polypeptide of claim 1, wherein the antigenicpolypeptide is 15 to 100 amino acids in length, optionally 15, 16,17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33,34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50,51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67,68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84,85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100amino acids in length.

94. (canceled)

95. The antigenic polypeptide of claim 1, wherein the antigenicpolypeptide is: chemically synthesized; and/or comprises aphosphopeptide selected from the group consisting of SEQ ID NOs:98-3000 and 8808, wherein a phosphorylated amino acid residue ofthe phosphopeptide is replaced by a non-hydrolyzable mimetic of thephosphorylated amino acid residue.

96. (canceled)

97. A composition comprising at least one of the antigenicpolypeptides of claim 1, optionally wherein the compositioncomprises 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34,35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50different antigenic polypeptides, and/or the composition comprisesan adjuvant, optionally wherein the adjuvant comprises a saponin oran immunostimulatory nucleic acid, optionally wherein the adjuvantcomprises QS-21, a TLR agonist, a TLR4 agonist, a TLR5 agonist, aTLR7 agonist, a TLR8 agonist, and/or a TLR9 agonist.

98. A composition comprising a complex of the antigenic polypeptideof claim 1 and a purified stress protein, optionally wherein: thestress protein is selected from the group consisting of Hsc70,Hsp70, Hsp90, Hsp110, Grp170, Gp96, Calreticulin, and a mutant orfusion protein thereof, optionally wherein the Hsc70 comprises ahuman Hsc70, optionally wherein the Hsc70 comprises the amino acidsequence of SEQ ID NO: 8807; the stress protein is a recombinantprotein; and/or each of the different polypeptides comprise thesame HSP-binding peptide and a different WIC-binding peptide.

99.-115. (canceled)

116. A method of inducing a cellular immune response to anantigenic polypeptide in a subject, the method comprisingadministering to the subject an effective amount of an antigenicpolypeptide of claim 1.

117. (canceled)

118. A method of treating a disease in a subject, the methodcomprising administering to the subject an effective amount of anantigenic polypeptide of claim 1.

119.-128. (canceled)

129. A kit comprising a first container containing an antigenicpolypeptide of claim 1 and a second container containing a purifiedstress protein capable of binding to the antigenic polypeptide,optionally wherein the kit comprises a third container containingan adjuvant.

130.-142. (canceled)

143. A method of making a vaccine, the method comprising mixing oneor more antigenic polypeptides of claim 1 with a purified stressprotein under suitable conditions such that the purified stressprotein binds to at least one of the polypeptides.

144.-150. (canceled)

Description

1. RELATED APPLICATIONS

[0001] This application is a Continuation Application ofInternational Patent Application No. PCT/US2020/043431, filed Jul.24, 2020, which claims priority to U.S. Provisional PatentApplication Ser. No. 62/878,157, entitled "Antigenic PolypeptidesAnd Methods Of Use Thereof", filed Jul. 24, 2019. The contents ofthe aforementioned application is hereby incorporated by referenceherein in its entirety.

2. SEQUENCE LISTING

[0002] The sequence listing attached herewith, named404293_AGBW_129US_188615_Sequence_Listing.txt and created on Jul.24, 2020, is herein incorporated by reference in its entirety.

3. FIELD

[0003] The instant disclosure relates to novel antigenicpolypeptides and compositions, and uses of such antigenicpolypeptides and compositions as immunotherapeutics (e.g., cancervaccines).

4. BACKGROUND

[0004] Immunotherapies are becoming important tools in thetreatment of cancer. One immunotherapy approach involves the use oftherapeutic cancer vaccines comprising cancer-specific antigenicpeptides that actively educate a patient's immune system to targetand destroy cancer cells. However, the generation of suchtherapeutic cancer vaccines is limited by the immunogenicity ofcancer-specific antigenic peptides.

[0005] Accordingly, there is a need in the art for improvedimmunogenic cancer-specific peptides and for creating effectiveanti-cancer vaccines comprising these peptides.

5. SUMMARY OF INVENTION

[0006] The instant disclosure provides novel antigenic polypeptidescomprising tumor-associated peptides, and compositions comprisingthe same. Such antigenic polypeptides and compositions areparticularly useful as immunotherapeutics (e.g., cancer vaccines).Also provided are methods of inducing a cellular immune responseusing such polypeptides and compositions, methods of treating adisease using such polypeptides and compositions, kits comprisingsuch polypeptides and compositions, and methods of making suchcompositions.

[0007] Accordingly, the instant disclosure provides the following,non-limiting, embodiments:

Embodiment 1. An antigenic polypeptide comprising: an WIC-bindingpeptide comprising an amino acid sequence selected from the groupconsisting of SEQ ID NOs: 98-3000 and 8808; and an HSP-bindingpeptide comprising the amino acid sequence ofX.sub.1X.sub.2X.sub.3X.sub.4X.sub.5X.sub.6X.sub.7 (SEQ ID NO: 1),wherein X.sub.1 is omitted, N, F, or Q; X.sub.2 is W, L, or F;X.sub.3 is L or I; X.sub.4 is R, L, or K; X.sub.5 is L, W, or I;X.sub.6 is T, L, F, K, R, or W; and X.sub.7 is W, G, K, or F.Embodiment 2. The antigenic polypeptide of embodiment 1, whereinthe amino acid sequence of the WIC-binding peptide consists of anamino acid sequence selected from the group consisting of SEQ IDNOs: 98-3000 and 8808. Embodiment 3. The antigenic polypeptide ofembodiment 1 or 2, wherein the HSP-binding peptide comprises theamino acid sequence of: (a) X.sub.1LX.sub.2LTX.sub.3 (SEQ ID NO:2), wherein X.sub.1 is W or F; X.sub.2 is R or K; and X.sub.3 is W,F, or G; (b) NX.sub.1LX.sub.2LTX.sub.3 (SEQ ID NO: 3), whereinX.sub.1 is W or F; X.sub.2 is R or K; and X.sub.3 is W, F, or G;(c) WLX.sub.1LTX.sub.2 (SEQ ID NO: 4), wherein X.sub.1 is R or K;and X.sub.2 is W or G; (d) NWLX.sub.1LTX.sub.2 (SEQ ID NO: 5),wherein X.sub.1 is R or K; and X.sub.2 is W or G; or (e)NWX.sub.1X.sub.2X.sub.3X.sub.4X.sub.5 (SEQ ID NO: 6), whereinX.sub.1 is L or I; X.sub.2 is L, R, or K; X.sub.3 is L or I;X.sub.4 is T, L, F, K, R, or W; and X.sub.5 is W or K. Embodiment4. The antigenic polypeptide of embodiment 1 or 2, wherein theHSP-binding peptide comprises an amino acid sequence selected fromthe group consisting of SEQ ID NOs: 7-42, optionally wherein theamino acid sequence of the HSP-binding peptide consists of an aminoacid sequence selected from the group consisting of SEQ ID NOs:7-42. Embodiment 5. The antigenic polypeptide of embodiment 1 or 2,wherein the HSP-binding peptide comprises the amino acid sequenceof SEQ ID NO: 7, optionally wherein the amino acid sequence of theHSP-binding peptide consists of the amino acid sequence of SEQ IDNO: 7. Embodiment 6. The antigenic polypeptide of embodiment 1 or2, wherein the HSP-binding peptide comprises the amino acidsequence of SEQ ID NO: 8, optionally wherein the amino acidsequence of the HSP-binding peptide consists of the amino acidsequence of SEQ ID NO: 8. Embodiment 7. The antigenic polypeptideof embodiment 1 or 2, wherein the HSP-binding peptide comprises theamino acid sequence of SEQ ID NO: 9, optionally wherein the aminoacid sequence of the HSP-binding peptide consists of the amino acidsequence of SEQ ID NO: 9. Embodiment 8. The antigenic polypeptideof embodiment 1 or 2, wherein the HSP-binding peptide comprises theamino acid sequence of SEQ ID NO: 10, optionally wherein the aminoacid sequence of the HSP-binding peptide consists of the amino acidsequence of SEQ ID NO: 10. Embodiment 9. The antigenic polypeptideof embodiment 1 or 2, wherein the HSP-binding peptide comprises theamino acid sequence of SEQ ID NO: 11, optionally wherein the aminoacid sequence of the HSP-binding peptide consists of the amino acidsequence of SEQ ID NO: 11. Embodiment 10. The antigenic polypeptideof embodiment 1 or 2, wherein the HSP-binding peptide comprises theamino acid sequence of SEQ ID NO: 12, optionally wherein the aminoacid sequence of the HSP-binding peptide consists of the amino acidsequence of SEQ ID NO: 12. Embodiment 11. The antigenic polypeptideof embodiment 1 or 2, wherein the HSP-binding peptide comprises theamino acid sequence of SEQ ID NO: 13, optionally wherein the aminoacid sequence of the HSP-binding peptide consists of the amino acidsequence of SEQ ID NO: 13. Embodiment 12. The antigenic polypeptideof embodiment 1 or 2, wherein the HSP-binding peptide comprises theamino acid sequence of SEQ ID NO: 14, optionally wherein the aminoacid sequence of the HSP-binding peptide consists of the amino acidsequence of SEQ ID NO: 14. Embodiment 13. The antigenic polypeptideof embodiment 1 or 2, wherein the HSP-binding peptide comprises theamino acid sequence of SEQ ID NO: 15, optionally wherein the aminoacid sequence of the HSP-binding peptide consists of the amino acidsequence of SEQ ID NO: 15. Embodiment 14. The antigenic polypeptideof embodiment 1 or 2, wherein the HSP-binding peptide comprises theamino acid sequence of SEQ ID NO: 16, optionally wherein the aminoacid sequence of the HSP-binding peptide consists of the amino acidsequence of SEQ ID NO: 16. Embodiment 15. The antigenic polypeptideof embodiment 1 or 2, wherein the HSP-binding peptide comprises theamino acid sequence of SEQ ID NO: 17, optionally wherein the aminoacid sequence of the HSP-binding peptide consists of the amino acidsequence of SEQ ID NO: 17. Embodiment 16. The antigenic polypeptideof embodiment 1 or 2, wherein the HSP-binding peptide comprises theamino acid sequence of SEQ ID NO: 18, optionally wherein the aminoacid sequence of the HSP-binding peptide consists of the amino acidsequence of SEQ ID NO: 18. Embodiment 17. The antigenic polypeptideof embodiment 1 or 2, wherein the HSP-binding peptide comprises theamino acid sequence of SEQ ID NO: 19, optionally wherein the aminoacid sequence of the HSP-binding peptide consists of the amino acidsequence of SEQ ID NO: 19. Embodiment 18. The antigenic polypeptideof embodiment 1 or 2, wherein the HSP-binding peptide comprises theamino acid sequence of SEQ ID NO: 20, optionally wherein the aminoacid sequence of the HSP-binding peptide consists of the amino acidsequence of SEQ ID NO: 20. Embodiment 19. The antigenic polypeptideof embodiment 1 or 2, wherein the HSP-binding peptide comprises theamino acid sequence of SEQ ID NO: 21, optionally wherein the aminoacid sequence of the HSP-binding peptide consists of the amino acidsequence of SEQ ID NO: 21. Embodiment 20. The antigenic polypeptideof embodiment 1 or 2, wherein the HSP-binding peptide comprises theamino acid sequence of SEQ ID NO: 22, optionally wherein the aminoacid sequence of the HSP-binding peptide consists of the amino acidsequence of SEQ ID NO: 22. Embodiment 21. The antigenic polypeptideof embodiment 1 or 2, wherein the HSP-binding peptide comprises theamino acid sequence of SEQ ID NO: 23, optionally wherein the aminoacid sequence of the HSP-binding peptide consists of the amino acidsequence of SEQ ID NO: 23. Embodiment 22. The antigenic polypeptideof embodiment 1 or 2, wherein the HSP-binding peptide comprises theamino acid sequence of SEQ ID NO: 24, optionally wherein the aminoacid sequence of the HSP-binding peptide consists of the amino acidsequence of SEQ ID NO: 24. Embodiment 23. The antigenic polypeptideof embodiment 1 or 2, wherein the HSP-binding peptide comprises theamino acid sequence of SEQ ID NO: 25, optionally wherein the aminoacid sequence of the HSP-binding peptide consists of the amino acidsequence of SEQ ID NO: 25. Embodiment 24. The antigenic polypeptideof embodiment 1 or 2, wherein the HSP-binding peptide comprises theamino acid sequence of SEQ ID NO: 26, optionally wherein the aminoacid sequence of the HSP-binding peptide consists of the amino acidsequence of SEQ ID NO: 26. Embodiment 25. The antigenic polypeptideof embodiment 1 or 2, wherein the HSP-binding peptide comprises theamino acid sequence of SEQ ID NO: 27, optionally wherein the aminoacid sequence of the HSP-binding peptide consists of the amino acidsequence of SEQ ID NO: 27. Embodiment 26. The antigenic polypeptideof embodiment 1 or 2, wherein the HSP-binding peptide comprises theamino acid sequence of SEQ ID NO: 28, optionally wherein the aminoacid sequence of the HSP-binding peptide consists of the amino acidsequence of SEQ ID NO: 28. Embodiment 27. The antigenic polypeptideof embodiment 1 or 2, wherein the HSP-binding peptide comprises theamino acid sequence of SEQ ID NO: 29, optionally wherein the aminoacid sequence of the HSP-binding peptide consists of the amino acidsequence of SEQ ID NO: 29. Embodiment 28. The antigenic polypeptideof embodiment 1 or 2, wherein the HSP-binding peptide comprises theamino acid sequence of SEQ ID NO: 30, optionally wherein the aminoacid sequence of the HSP-binding peptide consists of the amino acidsequence of SEQ ID NO: 30. Embodiment 29. The antigenic polypeptideof embodiment 1 or 2, wherein the HSP-binding peptide comprises theamino acid sequence of SEQ ID NO: 31, optionally wherein the aminoacid sequence of the HSP-binding peptide consists of the amino acidsequence of SEQ ID NO: 31. Embodiment 30. The antigenic polypeptideof embodiment 1 or 2, wherein the HSP-binding peptide comprises theamino acid sequence of SEQ ID NO: 32, optionally wherein the aminoacid sequence of the HSP-binding peptide consists of the amino acidsequence of SEQ ID NO: 32. Embodiment 31. The antigenic polypeptideof embodiment 1 or 2, wherein the HSP-binding peptide comprises theamino acid sequence of SEQ ID NO: 33, optionally wherein the aminoacid sequence of the HSP-binding peptide consists of the amino acidsequence of SEQ ID NO: 33. Embodiment 32. The antigenic polypeptideof embodiment 1 or 2, wherein the HSP-binding peptide comprises theamino acid sequence of SEQ ID NO: 34, optionally wherein the aminoacid sequence of the HSP-binding peptide consists of the amino acidsequence of SEQ ID NO: 34. Embodiment 33. The antigenic polypeptideof embodiment 1 or 2, wherein the HSP-binding peptide comprises theamino acid sequence of SEQ ID NO: 35, optionally wherein the aminoacid sequence of the HSP-binding peptide consists of the amino acidsequence of SEQ ID NO: 35. Embodiment 34. The antigenic polypeptideof embodiment 1 or 2, wherein the HSP-binding peptide comprises theamino acid sequence of SEQ ID NO: 36, optionally wherein the aminoacid sequence of the HSP-binding peptide consists of the amino acidsequence of SEQ ID NO: 36. Embodiment 35. The antigenic polypeptideof embodiment 1 or 2, wherein the HSP-binding peptide comprises theamino acid sequence of SEQ ID NO: 37, optionally wherein the aminoacid sequence of the HSP-binding peptide consists of the amino acidsequence of SEQ ID NO: 37. Embodiment 36. The antigenic polypeptideof embodiment 1 or 2, wherein the HSP-binding peptide comprises theamino acid sequence of SEQ ID NO: 38, optionally wherein the aminoacid sequence of the HSP-binding peptide consists of the amino acidsequence of SEQ ID NO: 38. Embodiment 37. The antigenic polypeptideof embodiment 1 or 2, wherein the HSP-binding peptide comprises theamino acid sequence of SEQ ID NO: 39, optionally wherein the aminoacid sequence of the HSP-binding peptide consists of the amino acidsequence of SEQ ID NO: 39. Embodiment 38. The antigenic polypeptideof embodiment 1 or 2, wherein the HSP-binding peptide comprises theamino acid sequence of SEQ ID NO: 40, optionally wherein the aminoacid sequence of the HSP-binding peptide consists of the amino acidsequence of SEQ ID NO: 40. Embodiment 39. The antigenic polypeptideof embodiment 1 or 2, wherein the HSP-binding peptide comprises theamino acid sequence of SEQ ID NO: 41, optionally wherein the aminoacid sequence of the HSP-binding peptide consists of the amino acidsequence of SEQ ID NO: 41. Embodiment 40. The antigenic polypeptideof embodiment 1 or 2, wherein the HSP-binding peptide comprises theamino acid sequence of SEQ ID NO: 42, optionally wherein the aminoacid sequence of the HSP-binding peptide consists of the amino acidsequence of SEQ ID NO: 42. Embodiment 41. The antigenic polypeptideof any one of the preceding embodiments, wherein the MHC-bindingpeptide is 8 to 50 amino acids in length, optionally 8, 9, 10, 11,12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28,29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45,46, 47, 48, 49, or 50 amino acids in length. Embodiment 42. Theantigenic polypeptide of any one of the preceding embodiments,wherein the C-terminus of the WIC-binding peptide is linked to theN-terminus of the HSP-binding peptide. Embodiment 43. The antigenicpolypeptide of any one of embodiments 1-41, wherein the N-terminusof the MHC-binding peptide is linked to the C-terminus of theHSP-binding peptide. Embodiment 44. The antigenic polypeptide ofany one of embodiments 1-43, wherein the HSP-binding peptide islinked to the WIC-binding peptide via a chemical linker. Embodiment45. The antigenic polypeptide of any one of embodiments 1-43,wherein the HSP-binding peptide is linked to the WIC-bindingpeptide via a peptide linker. Embodiment 46. The antigenicpolypeptide of embodiment 45, wherein the peptide linker comprisesthe amino acid sequence of SEQ ID NO: 43, optionally wherein theamino acid sequence of the peptide linker consists of the aminoacid sequence of SEQ ID NO: 43. Embodiment 47. The antigenicpolypeptide of embodiment 45, wherein the peptide linker comprisesthe amino acid sequence of FR, optionally wherein the amino acidsequence of the peptide linker consists of the amino acid sequenceof FR. Embodiment 48. The antigenic polypeptide of embodiment 46 or47, wherein the N-terminus of the MHC-binding peptide is linked tothe C-terminus of: (a) the amino acid sequence ofX.sub.1X.sub.2X.sub.3X.sub.4X.sub.5X.sub.6X.sub.7FFRK (SEQ ID NO:68), wherein X.sub.1 is omitted, N, F, or Q; X.sub.2 is W, L, or F;X.sub.3 is L or I; X.sub.4 is R, L, or K; X.sub.5 is L, W, or I;X.sub.6 is T, L, F, K, R, or W; and X.sub.7 is W, G, K, or F; (b)the amino acid sequence of X.sub.1LX.sub.2LTX.sub.3FFRK (SEQ ID NO:69), wherein X.sub.1 is W or F; X.sub.2 is R or K; and X.sub.3 isW, F, or G; (c) the amino acid sequence ofNX.sub.1LX.sub.2LTX.sub.3FFRK (SEQ ID NO: 70), wherein X.sub.1 is Wor F; X.sub.2 is R or K; and X.sub.3 is W, F, or G; (d) the aminoacid sequence of WLX.sub.1LTX.sub.2FFRK (SEQ ID NO: 71), whereinX.sub.1 is R or K; and X.sub.2 is W or G; (e) the amino acidsequence of NWLX.sub.1LTX.sub.2FFRK (SEQ ID NO: 72), whereinX.sub.1 is R or K; and X.sub.2 is W or G; (f) the amino acidsequence of NWX.sub.1X.sub.2X.sub.3X.sub.4X.sub.5FFRK (SEQ ID NO:73), wherein X.sub.1 is L or I; X.sub.2 is L, R, or K; X.sub.3 is Lor I; X.sub.4 is T, L, F, K, R, or W; and X.sub.5 is W or K; or (g)an amino acid sequence selected from the group consisting of SEQ IDNOs: 74-97. Embodiment 49. The antigenic polypeptide of embodiment46 or 47, wherein the N-terminus of the MHC-binding peptide islinked to the C-terminus of the amino acid sequence set forth inSEQ ID NO: 74. Embodiment 50. The antigenic polypeptide ofembodiment 46 or 47, wherein the N-terminus of the MHC-bindingpeptide is linked to the C-terminus of the amino acid sequence setforth in SEQ ID NO: 75. Embodiment 51. The antigenic polypeptide ofembodiment 46 or 47, wherein the N-terminus of the MHC-bindingpeptide is linked to the C-terminus of the amino acid sequence setforth in SEQ ID NO: 76. Embodiment 52. The antigenic polypeptide ofembodiment 46 or 47, wherein the N-terminus of the MHC-bindingpeptide is linked to the C-terminus of the amino acid sequence setforth in SEQ ID NO: 77.

Embodiment 53. The antigenic polypeptide of embodiment 46 or 47,wherein the N-terminus of the MHC-binding peptide is linked to theC-terminus of the amino acid sequence set forth in SEQ ID NO: 78.Embodiment 54. The antigenic polypeptide of embodiment 46 or 47,wherein the N-terminus of the WIC-binding peptide is linked to theC-terminus of the amino acid sequence set forth in SEQ ID NO: 79.Embodiment 55. The antigenic polypeptide of embodiment 46 or 47,wherein the N-terminus of the WIC-binding peptide is linked to theC-terminus of the amino acid sequence set forth in SEQ ID NO: 80.Embodiment 56. The antigenic polypeptide of embodiment 46 or 47,wherein the N-terminus of the WIC-binding peptide is linked to theC-terminus of the amino acid sequence set forth in SEQ ID NO: 81.Embodiment 57. The antigenic polypeptide of embodiment 46 or 47,wherein the N-terminus of the WIC-binding peptide is linked to theC-terminus of the amino acid sequence set forth in SEQ ID NO: 82.Embodiment 58. The antigenic polypeptide of embodiment 46 or 47,wherein the N-terminus of the WIC-binding peptide is linked to theC-terminus of the amino acid sequence set forth in SEQ ID NO: 83.Embodiment 59. The antigenic polypeptide of embodiment 46 or 47,wherein the N-terminus of the WIC-binding peptide is linked to theC-terminus of the amino acid sequence set forth in SEQ ID NO: 84.Embodiment 60. The antigenic polypeptide of embodiment 46 or 47,wherein the N-terminus of the WIC-binding peptide is linked to theC-terminus of the amino acid sequence set forth in SEQ ID NO: 85.Embodiment 61. The antigenic polypeptide of embodiment 46 or 47,wherein the N-terminus of the WIC-binding peptide is linked to theC-terminus of the amino acid sequence set forth in SEQ ID NO: 86.Embodiment 62. The antigenic polypeptide of embodiment 46 or 47,wherein the N-terminus of the WIC-binding peptide is linked to theC-terminus of the amino acid sequence set forth in SEQ ID NO: 87.Embodiment 63. The antigenic polypeptide of embodiment 46 or 47,wherein the N-terminus of the WIC-binding peptide is linked to theC-terminus of the amino acid sequence set forth in SEQ ID NO: 88.Embodiment 64. The antigenic polypeptide of embodiment 46 or 47,wherein the N-terminus of the WIC-binding peptide is linked to theC-terminus of the amino acid sequence set forth in SEQ ID NO: 89.Embodiment 65. The antigenic polypeptide of embodiment 46 or 47,wherein the N-terminus of the WIC-binding peptide is linked to theC-terminus of the amino acid sequence set forth in SEQ ID NO: 90.Embodiment 66. The antigenic polypeptide of embodiment 46 or 47,wherein the N-terminus of the WIC-binding peptide is linked to theC-terminus of the amino acid sequence set forth in SEQ ID NO: 91.Embodiment 67. The antigenic polypeptide of embodiment 46 or 47,wherein the N-terminus of the WIC-binding peptide is linked to theC-terminus of the amino acid sequence set forth in SEQ ID NO: 92.Embodiment 68. The antigenic polypeptide of embodiment 46 or 47,wherein the N-terminus of the WIC-binding peptide is linked to theC-terminus of the amino acid sequence set forth in SEQ ID NO: 93.Embodiment 69. The antigenic polypeptide of embodiment 46 or 47,wherein the N-terminus of the WIC-binding peptide is linked to theC-terminus of the amino acid sequence set forth in SEQ ID NO: 94.Embodiment 70. The antigenic polypeptide of embodiment 46 or 47,wherein the N-terminus of the WIC-binding peptide is linked to theC-terminus of the amino acid sequence set forth in SEQ ID NO: 95.Embodiment 71. The antigenic polypeptide of embodiment 46 or 47,wherein the N-terminus of the WIC-binding peptide is linked to theC-terminus of the amino acid sequence set forth in SEQ ID NO: 96.Embodiment 72. The antigenic polypeptide of embodiment 46 or 47,wherein the N-terminus of the WIC-binding peptide is linked to theC-terminus of the amino acid sequence set forth in SEQ ID NO: 97.Embodiment 73. The isolated polypeptide of embodiment 46 or 47,wherein the C-terminus of the WIC-binding peptide is linked to theN-terminus of: (a) the amino acid sequence ofFFRKX.sub.1X.sub.2X.sub.3X.sub.4X.sub.5X.sub.6X.sub.7 (SEQ ID NO:44), wherein X.sub.1 is omitted, N, F, or Q; X.sub.2 is W, L, or F;X.sub.3 is L or I; X.sub.4 is R, L, or K; X.sub.5 is L, W, or I;X.sub.6 is T, L, F, K, R, or W; and X.sub.7 is W, G, K, or F; (b)the amino acid sequence of FFRKX.sub.1LX.sub.2LTX.sub.3 (SEQ ID NO:45), wherein X.sub.1 is W or F; X.sub.2 is R or K; and X.sub.3 isW, F, or G; (c) the amino acid sequence ofFFRKNX.sub.1LX.sub.2LTX.sub.3 (SEQ ID NO: 46), wherein X.sub.1 is Wor F; X.sub.2 is R or K; and X.sub.3 is W, F, or G; (d) the aminoacid sequence of FFRKWLX.sub.1LTX.sub.2 (SEQ ID NO: 47), whereinX.sub.1 is R or K; and X.sub.2 is W or G; (e) the amino acidsequence of FFRKNWLX.sub.1LTX.sub.2 (SEQ ID NO: 48), whereinX.sub.1 is R or K; and X.sub.2 is W or G; (f) the amino acidsequence of FFRKNWX.sub.1X.sub.2X.sub.3X.sub.4X.sub.5 (SEQ ID NO:49), wherein X.sub.1 is L or I; X.sub.2 is L, R, or K; X.sub.3 is Lor I; X.sub.4 is T, L, F, K, R, or W; and X.sub.5 is W or K; or (g)an amino acid sequence selected from the group consisting of SEQ IDNOs: 50-67. Embodiment 74. The antigenic polypeptide of embodiment46 or 47, wherein the C-terminus of the WIC-binding peptide islinked to the N-terminus of the amino acid sequence set forth inSEQ ID NO: 50. Embodiment 75. The antigenic polypeptide ofembodiment 46 or 47, wherein the C-terminus of the WIC-bindingpeptide is linked to the N-terminus of the amino acid sequence setforth in SEQ ID NO: 51. Embodiment 76. The antigenic polypeptide ofembodiment 46 or 47, wherein the C-terminus of the WIC-bindingpeptide is linked to the N-terminus of the amino acid sequence setforth in SEQ ID NO: 52. Embodiment 77. The antigenic polypeptide ofembodiment 46 or 47, wherein the C-terminus of the WIC-bindingpeptide is linked to the N-terminus of the amino acid sequence setforth in SEQ ID NO: 53. Embodiment 78. The antigenic polypeptide ofembodiment 46 or 47, wherein the C-terminus of the WIC-bindingpeptide is linked to the N-terminus of the amino acid sequence setforth in SEQ ID NO: 54. Embodiment 79. The antigenic polypeptide ofembodiment 46 or 47, wherein the C-terminus of the WIC-bindingpeptide is linked to the N-terminus of the amino acid sequence setforth in SEQ ID NO: 55. Embodiment 80. The antigenic polypeptide ofembodiment 46 or 47, wherein the C-terminus of the WIC-bindingpeptide is linked to the N-terminus of the amino acid sequence setforth in SEQ ID NO: 56. Embodiment 81. The antigenic polypeptide ofembodiment 46 or 47, wherein the C-terminus of the WIC-bindingpeptide is linked to the N-terminus of the amino acid sequence setforth in SEQ ID NO: 57. Embodiment 82. The antigenic polypeptide ofembodiment 46 or 47, wherein the C-terminus of the WIC-bindingpeptide is linked to the N-terminus of the amino acid sequence setforth in SEQ ID NO: 58. Embodiment 83. The antigenic polypeptide ofembodiment 46 or 47, wherein the C-terminus of the WIC-bindingpeptide is linked to the N-terminus of the amino acid sequence setforth in SEQ ID NO: 59. Embodiment 84. The antigenic polypeptide ofembodiment 46 or 47, wherein the C-terminus of the WIC-bindingpeptide is linked to the N-terminus of the amino acid sequence setforth in SEQ ID NO: 60. Embodiment 85. The antigenic polypeptide ofembodiment 46 or 47, wherein the C-terminus of the WIC-bindingpeptide is linked to the N-terminus of the amino acid sequence setforth in SEQ ID NO: 61. Embodiment 86. The antigenic polypeptide ofembodiment 46 or 47, wherein the C-terminus of the WIC-bindingpeptide is linked to the N-terminus of the amino acid sequence setforth in SEQ ID NO: 62. Embodiment 87. The antigenic polypeptide ofembodiment 46 or 47, wherein the C-terminus of the WIC-bindingpeptide is linked to the N-terminus of the amino acid sequence setforth in SEQ ID NO: 63. Embodiment 88. The antigenic polypeptide ofembodiment 46 or 47, wherein the C-terminus of the WIC-bindingpeptide is linked to the N-terminus of the amino acid sequence setforth in SEQ ID NO: 64. Embodiment 89. The antigenic polypeptide ofembodiment 46 or 47, wherein the C-terminus of the WIC-bindingpeptide is linked to the N-terminus of the amino acid sequence setforth in SEQ ID NO: 65. Embodiment 90. The antigenic polypeptide ofembodiment 46 or 47, wherein the C-terminus of the WIC-bindingpeptide is linked to the N-terminus of the amino acid sequence setforth in SEQ ID NO: 66. Embodiment 91. The antigenic polypeptide ofembodiment 46 or 47, wherein the C-terminus of the WIC-bindingpeptide is linked to the N-terminus of the amino acid sequence setforth in SEQ ID NO: 67. Embodiment 92. The antigenic polypeptide ofembodiment 1, comprising an amino acid sequence selected from thegroup consisting of SEQ ID NOs: 3001-8806, 8809, and 8810.Embodiment 93. The antigenic polypeptide of any one of thepreceding embodiments, wherein the antigenic polypeptide is 15 to100 amino acids in length, optionally 15, 16, 17, 18, 19, 20, 21,22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38,39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55,56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72,73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89,90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100 amino acids inlength. Embodiment 94. The antigenic polypeptide of embodiment 1,wherein the amino acid sequence of the antigenic polypeptideconsists of an amino acid sequence selected from the groupconsisting of SEQ ID NOs: 3001-8806, 8809, and 8810. Embodiment 95.The antigenic polypeptide of any one of the preceding embodiments,wherein the antigenic polypeptide is chemically synthesized.Embodiment 96. The antigenic polypeptide of any one of thepreceding embodiments, comprising a phosphopeptide selected fromthe group consisting of SEQ ID NOs: 98-3000 and 8808, wherein aphosphorylated amino acid residue of the phosphopeptide is replacedby a non-hydrolyzable mimetic of the phosphorylated amino acidresidue. Embodiment 97. A composition comprising: (i) at least oneof the antigenic polypeptides of any one of embodiments 1-96; (ii)at least one polypeptide comprising an amino acid sequence selectedfrom the group consisting of SEQ ID NOs: 98-3000 and 8808,optionally, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34,35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50different polypeptides comprising an amino acid sequence selectedfrom the group consisting of SEQ ID NOs: 98-3000 and 8808; (iii) atleast one polypeptide, wherein the amino acid sequence of thepolypeptide consists of an amino acid sequence selected from thegroup consisting of SEQ ID NOs: 98-3000 and 8808, optionally 2, 3,4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21,22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38,39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 differentpolypeptides, wherein the amino acid sequence of each polypeptideconsists of an amino acid sequence selected from the groupconsisting of SEQ ID NOs: 98-3000 and 8808; or (iv) at least onepolypeptide, wherein the polypeptide consists of an amino acidsequence selected from the group consisting of SEQ ID NOs: 98-3000and 8808, optionally 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48,49, or 50 different polypeptides, wherein each polypeptide consistsof an amino acid sequence selected from the group consisting of SEQID NOs: 98-3000 and 8808. Embodiment 98. A composition comprising acomplex of the antigenic polypeptide of any one of embodiments 1-96and a purified stress protein. Embodiment 99. The composition ofembodiment 98, wherein the stress protein is selected from thegroup consisting of Hsc70, Hsp70, Hsp90, Hsp110, Grp170, Gp96,Calreticulin, and a mutant or fusion protein thereof. Embodiment100. The composition of embodiment 99, wherein the stress proteinis an Hsc70, optionally a human Hsc70. Embodiment 101. Thecomposition of embodiment 100, wherein the Hsc70 comprises theamino acid sequence of SEQ ID NO: 8807. Embodiment 102. Thecomposition of embodiment 100, wherein the amino acid sequence ofthe Hsc70 consists of the amino acid sequence of SEQ ID NO: 8807.Embodiment 103. The composition of any one of embodiments 98-102,wherein the stress protein is a recombinant protein. Embodiment104. The composition any one of embodiments 97-103, comprising 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20,21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37,38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 differentantigenic polypeptides. Embodiment 105. The composition ofembodiment 104, wherein each of the different polypeptides comprisethe same HSP-binding peptide and a different MHC-binding peptide.Embodiment 106. The composition of any one of embodiments 97-105,wherein the total amount of the antigenic polypeptide(s) in thecomposition is about 0.1 to 20 nmol, optionally about 3, 4, 5, or 6nmol. Embodiment 107. The composition of any one of embodiments98-106, wherein the amount of the stress protein in the compositionis about 10 .mu.g to 600 .mu.g, optionally about 120 .mu.g, 240.mu.g, or 480 .mu.g. Embodiment 108. The composition of any one ofembodiments 98-107, wherein the molar ratio of the antigenicpolypeptide(s) to the stress protein is about 0.5:1 to about 5:1,optionally about 1:1, 1.25:1, 1.5:1, 2:1, 2.5:1, 3:1, 3.5:1, 4:1,4.5:1, or 5:1. Embodiment 109. The composition of any one ofembodiments 97-108, wherein the composition further comprises anadjuvant. Embodiment 110. The composition of embodiment 109,wherein the adjuvant comprises a saponin or an immunostimulatorynucleic acid. Embodiment 111. The composition of embodiment 110,wherein the adjuvant comprises QS-21. Embodiment 112. Thecomposition of embodiment 111, wherein the amount of the QS-21 inthe composition is about 10 .mu.g to about 200 optionally about 25.mu.g, 50 .mu.g, 75 .mu.g, 100 .mu.g, 125 .mu.g, 150 .mu.g, 175.mu.g, or 200 .mu.g. Embodiment 113. The composition of any one ofembodiments 109-112, wherein the adjuvant comprises a TLR agonist,optionally a TLR4 agonist, TLR5 agonist, TLR7 agonist, TLR8agonist, and/or TLR9 agonist. Embodiment 114. The composition ofany one of embodiments 97-113, further comprising apharmaceutically acceptable carrier or excipient. Embodiment 115.The composition of embodiment 114, wherein the composition is in aunit dosage form. Embodiment 116. A method of inducing a cellularimmune response to a polypeptide (e.g., an antigenic polypeptide)in a subject, the method comprising administering to the subject aneffective amount of the antigenic polypeptide of any one ofembodiments 1-96 or the composition of any one of embodiments97-115. Embodiment 117. The method of embodiment 116, wherein thesubject has cancer, optionally Acute Myeloid Leukemia (AML) orcolorectal cancer. Embodiment 118. A method of treating a diseasein a subject, the method comprising administering to the subject aneffective amount of the antigenic polypeptide of any one ofembodiments 1-96 or the composition of any one of embodiments97-115. Embodiment 119. The method of embodiment 118, wherein thedisease is an infection of a pathogenic microbe. Embodiment 120.The method of any one of embodiments 116-119, wherein thecomposition is administered to the subject weekly for four weeks.Embodiment 121. The method of embodiment 120, wherein at least twofurther doses of the composition are administered biweekly to thesubject after the four weekly doses. Embodiment 122. The method ofembodiment 120 or 121, wherein at least one booster dose of thecomposition is administered three months after the final weekly orbiweekly dose. Embodiment 123. The method of embodiment 122,wherein the composition is further administered every three monthsfor at least 1 year. Embodiment 124. The method of any one ofembodiments 116-123, further comprising administering to thesubject lenalidomide, dexamethasone, interleukin-2, recombinantinterferon alfa-2b, or PEG-interferon alfa-2b. Embodiment 125. Themethod of any one of embodiments 116-124, further comprisingadministering to the subject an indoleamine dioxygenase-1 (IDO-1)inhibitor. Embodiment 126. The method of embodiment 125, whereinthe IDO-1 inhibitor is4-amino-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboxi-midamide. Embodiment 127. The method of any one of embodiments116-126, further comprising administering to the subject an immunecheckpoint antibody. Embodiment 128. The method of embodiment 127,wherein the immune checkpoint antibody is selected from the groupconsisting of an agonistic anti-GITR antibody, an agonisticanti-OX40 antibody, an

antagonistic anti-PD-1 antibody, an antagonistic anti-CTLA-4antibody, an antagonistic anti-TIM-3 antibody, an antagonisticanti-LAG-3 antibody, an antagonistic anti-TIGIT antibody, anagonistic anti-CD96 antibody, an antagonistic anti-VISTA antibody,an antagonistic anti-CD73 antibody, an agonistic anti-CD137antibody, an antagonist anti-CEACAM1 antibody, an agonist anti-ICOSantibody, and/or an antigen-binding fragment thereof. Embodiment129. A kit comprising a first container containing the antigenicpolypeptide of any one of embodiments 1-96, or the composition ofany one of embodiments 97-115 and a second container containing apurified stress protein capable of binding to the antigenicpolypeptide. Embodiment 130. The kit of embodiment 129, wherein thetotal amount of the polypeptide(s) in the first container is about0.1 to 20 nmol, optionally about 3, 4, 5, or 6 nmol. Embodiment131. The kit of embodiment 129 or 130, wherein the stress proteinis selected from the group consisting of Hsc70, Hsp70, Hsp90,Hsp110, Grp170, Gp96, Calreticulin, and a mutant or fusion proteinthereof. Embodiment 132. The kit of embodiment 131, wherein thestress protein is an Hsc70, optionally a human Hsc70. Embodiment133. The kit of embodiment 132, wherein the Hsc70 comprises theamino acid sequence of SEQ ID NO: 8807. Embodiment 134. The kit ofembodiment 132, wherein the amino acid sequence of the Hsc70consists of the amino acid sequence of SEQ ID NO: 8807. Embodiment135. The kit of any one of embodiments 129-134, wherein the stressprotein is a recombinant protein. Embodiment 136. The kit of anyone of embodiments 129-135, wherein the amount of the stressprotein in the second container is about 10 .mu.g to 600 .mu.g,optionally about 120 .mu.g, 240 .mu.g, or 480 .mu.g. Embodiment137. The kit of any one of embodiments 129-136, wherein the molarratio of the polypeptide to the stress protein is about 0.5:1 to5:1, optionally about 1:1, 1.25:1, 1.5:1, 2:1, 2.5:1, 3:1, 3.5:1,4:1, 4.5:1, or 5:1. Embodiment 138. The kit of any one ofembodiments 129-137, further comprising a third containercontaining an adjuvant. Embodiment 139. The kit of embodiment 138,wherein the adjuvant comprises a saponin or an immunostimulatorynucleic acid. Embodiment 140. The kit of embodiment 139, whereinthe adjuvant comprises QS-21. Embodiment 141. The kit of embodiment140, wherein the amount of the QS-21 in the third container isabout 10 .mu.g to about 200 .mu.g, optionally about 25 .mu.g, 50.mu.g, 75 .mu.g, 100 .mu.g, 125 .mu.g, 150 .mu.g, 175 .mu.g, or 200.mu.g. Embodiment 142. The kit of any one of embodiments 138-141,wherein the adjuvant comprises a TLR agonist, optionally a TLR4agonist, TLR5 agonist, TLR7 agonist, TLR8 agonist, and/or TLR9agonist. Embodiment 143. A method of making a vaccine, the methodcomprising mixing one or more of the polypeptides of any one ofembodiments 1-96, or the composition of any one of embodiments97-115, with a purified stress protein under suitable conditionssuch that the purified stress protein binds to at least one of thepolypeptides. Embodiment 144. The method of embodiment 143, whereinthe stress protein is selected from the group consisting of Hsc70,Hsp70, Hsp90, Hsp110, Grp170, Gp96, Calreticulin, and a mutant orfusion protein thereof. Embodiment 145. The method of embodiment144, wherein the stress protein is an Hsc70, optionally human aHsc70. Embodiment 146. The method of embodiment 145, wherein theHsc70 comprises the amino acid sequence of SEQ ID NO: 8807.Embodiment 147. The method of embodiment 145, wherein the aminoacid sequence of the Hsc70 consists of the amino acid sequence ofSEQ ID NO: 8807. Embodiment 148. The method of any one ofembodiments 143-147, wherein the stress protein is a recombinantprotein. Embodiment 149. The method of any one of embodiments143-148, wherein the molar ratio of the polypeptide to the stressprotein is about 0.5:1 to 5:1, optionally about 1:1, 1.25:1, 1.5:1,2:1, 2.5:1, 3:1, 3.5:1, 4:1, 4.5:1, or 5:1. Embodiment 150. Themethod of any one of embodiments 143-149, wherein the suitableconditions comprise a temperature of about 37.degree. C.

6. DETAILED DESCRIPTION

[0008] The instant disclosure provides novel antigenic polypeptidescomprising tumor-associated peptides, and compositions comprisingthe same. Such antigenic polypeptides and compositions areparticularly useful as immunotherapeutics (e.g., cancer vaccines).Also provided are methods of inducing a cellular immune responseusing such polypeptides and compositions, methods of treating adisease using such polypeptides and compositions, kits comprisingsuch polypeptides and compositions, and methods of making suchcompositions.

6.1 Definitions

[0009] Unless otherwise defined herein, scientific and technicalterms used herein have the meanings that are commonly understood bythose of ordinary skill in the art. In the event of any latentambiguity, definitions provided herein take precedent over anydictionary or extrinsic definition. Unless otherwise required bycontext, singular terms shall include pluralities and plural termsshall include the singular. The use of "or" means "and/or" unlessstated otherwise. The use of the term "including", as well as otherforms, such as "includes" and "included", is not limiting.

[0010] As used herein, the terms "about" and "approximately," whenused to modify a numeric value or numeric range, indicate thatdeviations of 5% to 10% above (e.g., up to 5% to 10% above) and 5%to 10% below (e.g., up to 5% to 10% below) the recited value orrange remain within the intended meaning of the recited value orrange.

[0011] As used herein, the term "antigenic polypeptide" refers to anon-naturally occurring polymer comprising one or more peptides(e.g., an MHC-binding peptide and/or an HSP-binding peptide). Anantigenic polypeptide can comprise one or morenon-amino-acid-residue structures. In certain embodiments, anantigenic polypeptide comprises a chemical linker, e.g., a chemicallinker linking two peptide portions of the polypeptide.

[0012] As used herein, the terms "major histocompatibility complex"and "MHC" are used interchangeably and refer to an MHC class Imolecule and/or an MHC class II molecule.

[0013] As used herein, the terms "human leukocyte antigen" and"HLA" are used interchangeably and refer to majorhistocompatibility complex (MHC) in humans. An HLA molecule may bea class I MHC molecule (e.g., HLA-A, HLA-B, HLA-C) or a class IIMHC molecule (e.g., HLA-DP, HLA-DQ, HLA-DR).

[0014] As used herein, the terms "major histocompatibilitycomplex-binding peptide" and "MHC-binding peptide" are usedinterchangeably and refer to a peptide that binds to or ispredicted to bind to an MHC molecule, e.g., such that the peptideis capable of being presented by the MHC molecule to a T-cell.

[0015] As used herein, the terms "heat shock protein-bindingpeptide" and "HSP-binding peptide" are used interchangeably andrefer to a peptide that non-covalently binds to a heat shockprotein (HSP).

[0016] As used herein, the term "peptide linker" refers to apeptide bond or a peptide sequence that links a C-terminal aminoacid residue of a first peptide to an N-terminal amino acid residueof a second peptide.

[0017] As used herein, the term "chemical linker" refers to anychemical bond or moiety that is capable of linking two molecules(e.g., two peptides), wherein the bond or moiety is not a peptidelinker.

[0018] As used herein, the term "O-GlcNAcylated" means O-GlcNAcmodified, wherein the O-GlcNAc is fused either directly orindirectly to the modified amino acid, as described in Malaker, S.A. et al. "Identification of Glycopeptides as Post-TranslationallyModified Neoantigens in Leukemia" Cancer Immunol Res. 5(5):376-384(2017), which is incorporated by reference in its entirety herein.One of skill in the art would understand the term"hexose-GlcNAcylated" to have the meaning described in Malaker, S.A. et al. "Identification and Characterization of ComplexGlycosylated Peptides Presented by the MHC Class II ProcessingPathway in Melanoma" J. Proteome Res. 16(1):228-237 (2017), whichis incorporated by reference in its entirety herein.

[0019] As used herein, the terms "treat," "treating," and"treatment" refer to methods that generally involve administrationof an agent (e.g., a polypeptide disclosed herein) to a subjecthaving a disease or disorder, or predisposed to having such adisease or disorder, in order to cure, delay, reduce the severityof, or ameliorate one or more symptoms of the disease or disorder,or in order to prolong the survival of the subject beyond thatexpected in the absence of such treatment.

[0020] As used herein, the term "effective amount" in the contextof the administration of a therapy to a subject refers to theamount of a therapy that achieves a desired prophylactic ortherapeutic effect.

[0021] As used herein, the term "subject" includes any human ornon-human animal.

6.2 Antigenic Polypeptides

[0022] In one aspect, the instant disclosure provides an antigenicpolypeptide comprising a tumor-associated MHC-binding peptide andan HSP-binding peptide.

[0023] Exemplary HSP-binding peptides are set forth in Table 1herein. Exemplary MHC-binding peptides are set forth in Tables 2and 3 herein. Exemplary antigenic polypeptides are set forth inTables 4-7 herein.

TABLE-US-00001 TABLE 1 Amino acid sequences of exemplaryHSP-binding peptides, linkers, and HSPs SEQ ID Description AminoAcid Sequence NO ConsensusX.sub.1X.sub.2X.sub.3X.sub.4X.sub.5X.sub.6X.sub.7, wherein: 1sequence 1 X.sub.1 is omitted, N, F, or Q; X.sub.2 is W, L, or F;X.sub.3 is L or I; X.sub.4 is R, L, or K; X.sub.5 is L, W, or I;X.sub.6 is T, L, F, K, R, or W; and X.sub.7 is W, G, K, or FConsensus X.sub.1LX.sub.2LTX.sub.3, wherein: 2 sequence 2 X.sub.1is W or F; X.sub.2 is R or K; and X.sub.3 is W, F, or G ConsensusNX.sub.1LX.sub.2LTX.sub.3, wherein: 3 sequence 3 X.sub.1 is W or F;X.sub.2 is R or K; and X.sub.3 is W, F, or G ConsensusWLX.sub.1LTX.sub.2, wherein: 4 sequence 4 X.sub.1 is R or K; andX.sub.2 is W or G Consensus NWLX.sub.1LTX.sub.2, wherein: 5sequence 5 X.sub.1 is R or K; and X.sub.2 is W or G ConsensusNWX.sub.1X.sub.2X.sub.3X.sub.4X.sub.5, wherein: 6 sequence 6X.sub.1 is L or I; X.sub.2 is L, R, or K; X.sub.3 is L or I;X.sub.4 is T, L, F, K, R, or W; and X.sub.5 is W or K HSP1 NLLRLTG7 HSP016 WLRLTW 8 HSP017 NWLRLTW 9 HSP018 WLKLTW 10 HSP019 NWLKLTW11 HSP020 WLRLTG 12 HSP021 NWLRLTG 13 HSP022 FLRLTF 14 HSP023NFLRLTF 15 HSP024 WLRLTF 16 HSP025 NWLRLTF 17 HSP040 WLKLTF 18HSP041 NWLKLTF 19 HSP042 WLKLTG 20 HSP043 NWLKLTG 21 HSP044 FLRLTW22 HSP045 NFLRLTW 23 HSP046 FLRLTG 24 HSP047 NFLRLTG 25 HSP048FLKLTW 26 HSP049 NFLKLTW 27 HSP050 FLKLTF 28 HSP051 NFLKLTF 29HSP103 FLKLTG 30 HSP104 NFLKLTG 31 HSP185 NWLLLTW 32 HSP186 NLLRWTG33 HSP188 FWLRLTW 34 HSP189 NWLRLLW 35 HSP190 NWLRLFW 36 HSP191NWLRLKW 37 HSP192 NWIRITW 38 HSP193 QWLRLTW 39 HSP194 NWLKLKW 40HSP195 NWLKLRW 41 HSP196 NWLKLWK 42 Linker1 FFRK 43 Linker2 FR N/AConsensus FFRKX.sub.1X.sub.2X.sub.3X.sub.4X.sub.5X.sub.6X.sub.7,wherein: 44 sequence 1 X.sub.1 is omitted, N, F, or Q; with N-X.sub.2 is W, L, or F; terminal X.sub.3 is L or I; linker X.sub.4is R, L, or K; X.sub.5 is L, W, or I; X.sub.6 is T, L, F, K, R, orW; and X.sub.7 is W, G, K, or F ConsensusFFRKX.sub.1LX.sub.2LTX.sub.3, wherein: 45 sequence 2 X.sub.1 is Wor F; with N- X.sub.2 is R or K; and terminal X.sub.3 is W, F, or Glinker Consensus FFRKNX.sub.1LX.sub.2LTX.sub.3, wherein: 46sequence 3 X.sub.1 is W or F; with N- X.sub.2 is R or K; andterminal X.sub.3 is W, F, or G linker ConsensusFFRKWLX.sub.1LTX.sub.2, wherein: 47 sequence 4 X.sub.1 is R or K;and with N- X.sub.2 is W or G terminal linker ConsensusFFRKNWLX.sub.1LTX.sub.2, wherein: 48 sequence 5 X.sub.1 is R or K;and with N- X.sub.2 is W or G terminal linker ConsensusFFRKNWX.sub.1X.sub.2X.sub.3X.sub.4X.sub.5, wherein: 49 sequence 6X.sub.1 is L or I; with N- X.sub.2 is L, R, or K; terminal X.sub.3is L or I; linker X.sub.4 is T, L, F, K, R, or W; and X.sub.5 is Wor K Linker1- FFRKNLLRLTG 50 HSP1 Linker2- FRNLLRLTG 51 HSP1 HSP001FFRKNLLRLTG 52 HSP003 FFRKNWLLLTW 53 HSP004 FFRKNLLRWTG 54 HSP006FFRKNWLRLTW 55 HSP012 FFRKNWLKLTW 56 HSP013 FFRKNWIRITW 57 HSP014FFRKQWLRLTW 58 HSP026 FFRKNWLRLTG 59 HSP027 FFRKNFLRLTF 60 HSP028FRNWLRLTW 61 HSP029 FRNWLKLTW 62 HSP030 FRNWLRLTG 63 HSP031FRNFLRLTF 64 HSP055 FFRKNWLKLKW 65 HSP057 FFRKNWLKLRW 66 HSP058FFRKNWLKLWK 67 ConsensusX.sub.1X.sub.2X.sub.3X.sub.4X.sub.5X.sub.6X.sub.7FFRK, wherein: 68sequence 1 X.sub.1 is omitted, N, F, or Q; with C- X.sub.2 is W, L,or F; terminal X.sub.3 is L or I; linker X.sub.4 is R, L, or K;X.sub.5 is L, W, or I; X.sub.6 is T, L, F, K, R, or W; and X.sub.7is W, G, K, or F Consensus X.sub.1LX.sub.2LTX.sub.3FFRK, wherein:69 sequence 2 X.sub.1 is W or F; with C- X.sub.2 is R or K; andterminal X.sub.3 is W, F, or G linker ConsensusNX.sub.1LX.sub.2LTX.sub.3FFRK, wherein: 70 sequence 3 X.sub.1 is Wor F; with C- X.sub.2 is R or K; and terminal X.sub.3 is W, F, or Glinker Consensus WLX.sub.1LTX.sub.2FFRK, wherein: 71 sequence 4X.sub.1 is R or K; and with C- X.sub.2 iS W or G terminal linkerConsensus NWLX.sub.1LTX.sub.2FFRK, wherein: 72 sequence 5 X.sub.1is R or K; and with C- X.sub.2 iS W or G terminal linker ConsensusNWX.sub.1X.sub.2X.sub.3X.sub.4X.sub.5FFRK, wherein: 73 sequence 6X.sub.1 is L or I; with C- X.sub.2 is L, R, or K; terminal X.sub.3is L or I; linker X.sub.4 is T, L, F, K, R, or W; and X.sub.5 is Wor K HSP1- NLLRLTGFFRK 74 Linker1 HSP1- NLLRLTGFR 75 Linker2 HSP032NWLRLTWFFRK 76 HSP033 NWLKLTWFFRK 77 HSP034 NWLRLTGFFRK 78 HSP035NFLRLTFFFRK 79

HSP036 NWLRLTWFR 80 HSP037 NWLKLTWFR 81 HSP038 NWLRLTGFR 82 HSP039NFLRLTFFR 83 HSP197 NLLRLTWFFRK 84 HSP198 NRLLLTGFFRK 85 HSP199NWLLLTWFFRK 86 HSP200 NLLRWTGFFRK 87 HSP201 NRLWLTGFFRK 88 HSP202FWLRLTWFFRK 89 HSP203 NWLRLLWFFRK 90 HSP204 NWLRLFWFFRK 91 HSP205NWLRLKWFFRK 92 HSP206 NWIRITWFFRK 93 HSP207 QWLRLTWFFRK 94 HSP208NWLKLKWFFRK 95 HSP209 NWLKLRWFFRK 96 HSP210 NWLKLWKFFRK 97 rh-Hsc70SKGPAVGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVA 8807FTDTERLIGDAAKNQVAMNPTNTVFDAKRLIGRRFDDAVVQSDMKHWPFMVVNDAGRPKVQVEYKGETKSFYPEEVSSMVLTKMKEIAEAYLGKTVTNAVVTVPAYFNDSQRQATKDAGTIAGLNVLRIINEPTAAAIAYGLDKKVGAERNVLIFDLGGGTFDVSILTIEDGIFEVKSTAGDTHLGGEDFDNRMVNHFIAEFKRKHKKDISENKRAVRRLRTACERAKRTLSSSTQASIEIDSLYEGIDFYTSITRARFEELNADLFRGTLDPVEKALRDAKLDKSQIHDIVLVGGSTRIPKIQKLLQDFFNGKELNKSINPDEAVAYGAAVQAAILSGDKSENVQDLLLLDVTPLSLGIETAGGVMTVLIKRNTTIPTKQTQTFTTYSDNQPGVLIQVYEGERAMTKDNNLLGKFELTGIPPAPRGVPQIEVTFDIDANGILNVSAVDKSTGKENKITITNDKGRLSKEDIERMVQEAEKYKAEDEKQRDKVSSKNSLESYAFNMKATVEDEKLQGKINDEDKQKILDKCNEIINWLDKNQTAEKEEFEHQQKELEKVCNPIITKLYQSAGGMPGGMPGGFPGGGAP PSGGASSGPTIEEVD

TABLE-US-00002 TABLE 2 Amino acid sequences of exemplaryMHC-binding peptides SEQ ID NO Amino Acid Sequence 98(AcS)AARESHPHGVKRSAsPDDDLG 99 AAEsPSFL 100 AASNFKsPVKTIR 101ADLsPEREV 102 AEDEIGtPRKF 103 AEDEIGtPRKY 104 AEEEIGtPRKF 105AEEEIGtPRKW 106 AEEEIGtPRKY 107 AENARSAsF 108 AENsPTRQQF 109AENsPTRQQW 110 AENsPTRQQY 111 AENsSSREL 112 AEQGsPRVSY 113AESsPTAGKKF 114 AESsPTAGKKL 115 AESsPTAGKKW 116 AESsPTAGKKY 117AGDsPGSQF 118 AILsPAFKV 119 AIMRsPQMV 120 AIsDLQQL 121 AKLsETIS 122ALAAsPHAV 123 ALDsGASLLHL 124 ALDsGASLLHV 125 ALGNtPPFL 126ALGsRESLATI 127 ALGsRESLATV 128 ALIHQsLGL 129 ALIHQsLGV 130ALLGSKsPDPYRL 131 ALLGSKsPDPYRV 132 ALLsLLKRV 133 ALMGsPQLV 134ALMGsPQLVAA 135 ALRSsPIMRK 136 ALRSsPIMRY 137 ALVsPPALHNA 138ALVsPPALHNV 139 ALYsGVHKK 140 ALYsGVHKY 141 ALYsPAQPSL 142ALYsPAQPSV 143 ALYtPQAPK 144 ALYtPQAPY 145 AMAAsPHAV 146AMDsGASLLHL 147 AMDsGASLLHV 148 AMGsRESLATI 149 AMGsRESLATV 150AMLGSKsPDPYRL 151 AMLGSKsPDPYRV 152 AMPGsPVEV 153 AMRSsPIMRK 154AMVsPPALHNA 155 AMVsPPALHNV 156 AMYsGVHKK 157 APDsPRAFL 158APLARASsL 159 APPAYEKLs 160 APPAYEKLsAEQ 161 APPAYEKLsAEQSPP 162APPAYEKLsAEQSPPP 163 APPAYEKLsAEQSPPPY 164APPPLVPAPRPSsPPRGPGPARADR 165 APRAPsASPLAL 166 APRDRRAVsF 167APRKGsFSAL 168 APRKGsFSALF 169 APRKGsFSALL 170 APRKGsFSALM 171APRKGsFSALV 172 APRNGsGVAL 173 APRRYsSSF 174 APRRYsSSL 175APRRYsSSM 176 APRRYsSSV 177 APRsPPPSRF 178 APRsPPPSRL 179APRsPPPSRM 180 APRsPPPSRP 181 APRsPPPSRV 182 APSLFHLNtL 183APSSARAsPLL 184 APSTYAHLsPAK 185 APSTYAHLsPAKTPPPP 186 APSVRsLSL187 APSVRSLsL 188 ARFsPDDKYSF 189 ARFsPDDKYSK 190 ARFsPDDKYSL 191ARFsPDDKYSM 192 ARFsPDDKYSR 193 ARFsPDDKYSY 194 ASDEIGtPRKF 195ASDEIGtPRKY 196 ASEEIGtPRKF 197 ASEEIGtPRKY 198 AsISRLsGEQVDGKG 199AsISRLSGEQVDGKG 200 ASISRLsGEQVDGKG 201 AsIsRLSGEQVDGKGQ 202AsISRLSGEQVDKGKG 203 ASKAsPTLDFTER 204 ASKMTQPQSKSAFPLSRKNKGsGsLDG205 AsLGFVF 206 AsPTIEAQGTSPAHDN 207 AsPTIEAQGTSPAHDNI 208AsPTIEAQGTSPAHDNIA 209 AtAGPRLGF 210 AtAGPRLGW 211 AtAGPRLGY 212ATDEIGtPRKF 213 ATDEIGtPRKY 214 ATEEIGtPRKF 215 ATEEIGtPRKY 216ATWsGSEFEV 217 ATYtPQAPK 218 ATYtPQAPKY 219 AVIHQsLGL

220 AVIHQsLGV 221 AVRPTRLsL 222 AVVsPPALHNA 223 AVVsPPALHNV 224AYEKLsAEQSPP 225 DAKKsPLAL 226 DDDWTHLsSKEVDP 227 DDDWTHLsSKEVDPS228 DDDWTHLsSKEVDPST 229 DDDWTHLsSKEVDPSTG 230 DDWTHLsSKEVDPS 231DEFERIKtF 232 DEFERIKtW 233 DEFERIKtY 234 DEISHRAsF 235 DEISHRAsW236 DEISHRAsY 237 DERLRINsF 238 DERLRINsL 239 DERLRINsW 240DERLRINsY 241 DKLsVIAEDSESGKQ 242 DKLsVIAEDSESGKQN 243DKLsVIAEDSESGKQNP 244 DKLsVIAEDSESGKQNPG 245 DKLsVIAEDSESGKQNPGDS246 DLKRRsmSI 247 DLKRRsMSI 248 DLKSSKAsL 249 DLRtVEKEL 250DLsEEKFL 251 DLsEEKFV 252 DLVPLsPLKK 253 DLWKItKVMD 254 DMVPLsPLKK255 DPTRRFFKVtPPPGSGPQ 256 DQFERIKtL 257 DQISHRAsL 258 DSDPLsPLKY259 DSEPLsPLKY 260 DSsEEKFL 261 DSsEEKFV 262 DSVPLsPLKY 263DTDPLsPLKY 264 DTEPLsPLKY 265 DTVPLSPLKY 266 DWTHLsSKEVDPS 267DWTHLsSKEVDPSTG 268 EEGsPTMVEKGLEPGVFTL 269 EELsPTAKF 270 EELsPTKAF271 EEMPENALPsDEDDKDPNDPYRAL 272 EERRsPPAP 273 EEsSDDGKKF 274EESsDDGKKF 275 EEsSDDGKKW 276 EESsDDGKKW 277 EEsSDDGKKY 278EESsDDGKKY 279 EGEEPTVYsDEEEPKDESARKND 280 EGsPTMVEKGLEPGVFTL 281ELFSsPPAV 282 ELKKsPTSLK 283 ELKKsPTSLY 284 ELLMPHRIsSHF 285ELLMPHRIsSHFL 286 ELRISGsVQL 287 EMKKsPTSLK 288EPAsPAAsISRLsGEQVDGKG 289 EPAsPAAsISRLSGEQVDGKG 290 EPKRRsARF 291EPKRRsARL 292 EPKRRsARM 293 EPKRRsARV 294 EPRsPSHSF 295 EPRsPSHSL296 EPRsPSHSM 297 EPRsPSHSV 298 ERsPLLSQETAGQKP 299ERsPLLSQETAGQKPL 300 ESDsLPRY 301 ESESLPRY 302 ESsVRSQEDQLSR 303ESsVRSQEDQLSRR 304 ETDsLPRY 305 ETEsLPRY 306 FDKHTLGDsDNES 307FEDDDsNEKL 308 FIEsPSKL 309 FIEsPSKY 310 FIGsPTTPAGL 311FKMPQEKsPGYS 312 FKsPVKTIR 313 FKtQPVTF 314 FLDNsFEKV 315FLDRPPtPLFI 316 FLDsLRDLI 317 FLDtPIAKV 318 FLFDKPVsPLLL 319FLGVRPKsA 320 FLIIRtVLQL 321 FLITGGGKGsGFSL 322 FLLsQNFDDE 323FLYsGKETK 324 FLYsGKETY 325 FPHsLLSVF 326 FPHsLLSVI 327 FPHsLLSVL328 FPHsLLSVM 329 FPHsLLSVV 330 FPIsPVRF 331 FPIsPVRL 332 FPIsPVRM333 FPIsPVRV 334 FPLDsPKTLVL 335 FPRRHsVTL 336 FPRsPTKSSF 337FPRsPTKSSL 338 FPRsPTKSSLDF 339 FPRsPTKSSLDL 340 FPRsPTKSSLDM 341FPRsPTKSSLDV 342 FPRsPTKSSM 343 FPRsPTKSSV 344 FRFsGRTEY 345FRGRYRsPY

346 FRKsMVEHY 347 FRRsPIKSSLDY 348 FRRsPTKSSF 349 FRRsPTKSSL 350FRRsPTKSSLD 351 FRRsPTKSSLDF 352 FRRsPTKSSLDL 353 FRRsPTKSSLDM 354FRRsPTKSSLDV 355 FRRsPTKSSLDY 356 FRRsPTKSSM 357 FRRsPTKSSV 358FRsPTKSSLDF 359 FRsPTKSSLDL 360 FRsPTKSSLDM 361 FRsPTKSSLDV 362FRYsGKTEF 363 FRYsGKTEK 364 FRYsGKTEL 365 FRYsGKTEM 366 FRYsGKTER367 FRYsGKTEY 368 FSDsHEGFSY 369 FSEsHEGFSY 370 FSEsPSKL 371FSEsPSKY 372 FSIsPVRF 373 FSIsPVRL 374 FSIsPVRM 375 FSIsPVRV 376FSsSHEGFSY 377 FSSsHEGFSY 378 FTDsHEGFSY 379 FTEsHEGFSY 380FTEsPSKL 381 FTEsPSKY 382 FTKsPYQEF 383 FTsSHEGFSY 384FVSKVMIGsPKKV 385 GALsPSLLHSL 386 GAQPGRHsF 387 GAQPGRHsL 388GAQPGRHsV 389 GDDDWTHLsSKEVD 390 GDDDWTIILsSKEVDP 391GDDDWTHLsSKEVDPS 392 GDDDWTHLsSKEVDPST 393 GDDDWTHLsSKEVDPSTG 394GEAsPSHII 395 GEEsSDDGKKF 396 GEEsSDDGKKW 397 GEEsSDDGKKY 398GEEsSDIDGKKF 399 GEIsPQREV 400 GERSPLLSQETAGQKP 401GERsPLLSQETAGQKPL 402 GETsPRTKI 403 GGDDDWTHLsSKEVDPS 404GGDDDWTHLsSKEVDPSTG 405 GGSFGGRSSGsP 406 GGSFGGRSSGsV 407 GIDsPSSSV408 GIMsPLAKK 409 GLAPtPPSM 410 GLDsGFHSV 411 GLDsLDQVEI 412GLGELLRsL 413 GLIRSRsFIFK 414 GLIRSRsFIFY 415 GLIsPELRHL 416CLIsPNVQL 417 GLIsPVWGA 418 GLItPGGFSSV 419 GLLDsPTSI 420 GLLGsPARL421 GLLGsPVRA 422 GLLGsPVRV 423 GLLsPARLYAI 424 GLLsPARLYAV 425GLLsPRFVDV 426 GLLsPRHSL 427 GLSFGGRSSGsP 428 GLSFGGRSSGsV 429GMLGsPVRV 430 GMLsPARLYAI 431 GMLsPARLYAV 432 GMLsPGKSIEV 433GPKPLFRRMsS 434 GPKPLFRRMsSL 435 GPKPLFRRMsSLV 436 GPKPLFRRMsSLVG437 GPKPLFRRMsSLVGP 438 GPKPLFRRMsSLVGPT 439 GPKPLFRRMsSLVGPTQ 440GPKPLFRRMsSLVGPTQS 441 GPPYQRRGsL 442 GPQPGRHsF 443 GPQPGRHsL 444GPQPGRHsV 445 GPRPGsPSAF 446 GPRPGsPSAL 447 GPRPGsPSAM 448GPRPGsPSAV 449 GPRSAsLL 450 GPRsASLLSF 451 GPRSAsLLsF 452GPRSASLLsF 453 GPRsAsLLSL 454 GPRsASLLSL 455 GPRSAsLLsL 456GPRSAsLLSL 457 GPRSASLLsL 458 GPRsASLLSM 459 GPRSAsLLsM 460GPRSASLLsM 461 GPRsASLLSV 462 GPKSAsLLSV 463 GPRSASLLsV 464GPRsPKAPP 465 GPRsPPVTL 466 GQLsPGVQF 467 GRKsPPPSF 468 GRKsPPPSK469 GRKsPPPSL 470 GRKsPPPSM

471 GRKsPPPSR 472 GRKsPPPSY 473 GRLGsPHRF 474 GRLGsPHRK 475GRLGsPHRL 476 GRLGsPHRM 477 GRLGsPHRR 478 GRLGsPHRY 479 GRLsPAYSL480 GRLsPKASQVF 481 GRLsPKASQVK 482 GRLsPKASQVL 483 GRLsPKASQVM 484GRLsPKASQVR 485 GRLsPKASQVY 486 GRLsPVPVPF 487 GRLsPVPVPK 488GRLsPVPVPL 489 GRLsPVPVPM 490 GRLsPVPVPR 491 GRLsPVPVPY 492GRQsPSFKL 493 GRsSPPPGY 494 GRSsTASLVKF 495 GRSsTASLVKK 496GRSsTASLVKKK 497 GRSsTASLVKL 498 GRSsTASLVKM 499 GRSsTASLVKR 500GRSsTASLVKY 501 GRtGLPDL 502 GSALGGGGAGLSGRASGGAQsPLRYLHV 503GSDsSDDGKKY 504 GSEsSDDGKKY 505 GsPHYFSPF 506 GsPHYFSPFRPY 507GsPTMVEKGLEPGVFTL 508 GsQLAVMMYL 509 GTDsSDDGKKY 510 GTEsSDDGKKY511 GTIRSRsFIFK 512 GTIRSRsFIFY 513 GtLPKY 514 GtLRRSDSQQAVK 515GtLRRSDSQQAVKS 516 GtLRRSDSQQAVKSPP 517 GVAsPTITV 518 GVVsPTFEL 519HEKKAYsF 520 HKGEIRGASTPFQFRAssP 521 HLHsPQHKL 522 HPKRSVsL 523HPRsPNVL 524 HPRsPNVLSF 525 HPRsPNVLSL 526 HPRsPNVLSM 527HPRsPNVLSV 528 HPRsPTPTF 529 HPRSPtPTF 530 HPRsPTPTL 531 HPRSPtPTL532 HPRsPTPTM 533 HPRSPtPTM 534 HPRSPtPTV 535 HPsSPTPTV 536HRLsPVKGEF 537 HRLsPVKGEK 538 HRLsPVKGER 539 HRLsPVKGEY 540HRNsMKVFL 541 HRNsNPVIAEF 542 HRNsNPVIAEK 543 HRNsNPVIAEL 544HRNsNPVIAER 545 HRNsNPVIAEY 546 HRYsTPHAF 547 HTAsPTGMMK 548HVYtPSTTK 549 IEKIyIMKADTVIVG 550 IIEtPHKEI 551 IIEtPHKEY 552IISsPLKGY 553 IISsPLTGK 554 ILDRtPEKL 555 ILDRtPEKV 556 ILDsGIYRI557 ILDsGIYRV 558 ILKPRRsL 559 ILKsPEIQRA 560 ILKsPEIQRV 561ILQtPQFQM 562 ILQVsIPSL 563 IMDRtPEKL 564 IMDRtPEKV 565 IMDsGIYRI566 IMDsGIYRV 567 IMKsPEIQRA 568 IMKsPEIQRV 569 INKERRSsL 570IPVgSSHNSL 571 IQFsPPFPGA 572 ISDGtLKY 573 ISDGtPLKY 574 ISDSAHtDY575 ISDsMHSLY 576 ISDtPHKEI 577 ISDtPHKEY 578 ISEGtLKY 579ISEGtPLKY 580 ISESAHtDY 581 ISEsMHSLY 582 ISELPHKEI 583 ISEtPHKEY584 ISFSAHtDY 585 ISSsMIISLY 586 IStDRDPL 587 IStDRDPY 588 ITDGtLKY589 ITDGtPLKY 590 ITDSAHtDY 591 ITDsMHSLY 592 ITDtPHKEI 593ITDtPHKEY 594 ITEGtLKY 595 ITEGtPLKY 596 ITESAHtDY

597 ITEsMHSLY 598 ITEtPHKEI 599 ITEtPHKEY 600 ITQGtLKY 601ITQGtPLKK 602 ITQGtPLKY 603 ITtDRDPL 604 ITtDRDPY 605 IVLsDSEVIQL606 IVRyHQL 607 IVtDRDPL 608 IVtDRDPY 609 IYQyIQSRF 610 KAFsPVR 611KAFsPVRSV 612 KAKsPAPGL 613 KAKsPAPGV 614 KARsPGRAF 615 KARsPGRAL616 KARsPGRAM 617 KARsPGRAV 618 KASPKRLsL 619 KAVsLFLcY 620KAVsLFLCY 621 KEGEEPTVYsDEEEPKDESARKND 622 KEKsPFRET 623 KELARQIsF624 KEMsPTRQF 625 KEmsPTRQL 626 KEMsPTRQL 627 KEMsPTRQW 628KEMsPTRQY 629 KESsPLSSRKI 630 KFRPPPLsL 631 KGIsSSSLKEK 632KIAsEIAQL 633 KIDIVsSQKV 634 KIDsPTKVKK 635 KIEKIyIMKADTVIVG 636KIEsLENLYL 637 KIFsGVFVK 638 KIFsGVFVKV 639 KIFsKQQGK 640 KIFsKQQGY641 KIGsIIFQV 642 KIKsFEVvF 643 KIRSsPREAK 644 KIRSsPREAY 645KIRTsPTFR 646 KIRTsPTFY 647 KLAsLEREASV 648 KLAsLLHQV 649KLAsPEKLAGL 650 KLAsPELERL 651 KLAsPELERV 652 KLDIVsSQKV 653KLDsFLDMQV 654 KLDsPRVTV 655 KLDsPTKVKK 656 KLDsPTKVKY 657KLFPDtPLAL 658 KLFPDtPLAV 659 KLFsGTVRK 660 KLFsGVFVKV 661KLFsKQQGK 662 KLFsKQQGY 663 KLFsPAHKK 664 KLFsPAIIKY 665KLFsPSKEAEL 666 KLFsPSKEAEV 667 KLHGsLARAGK 668 KLHGsLARAGY 669KLIDIVsSQKV 670 KLIDRTEsL 671 KLIDVsSQKV 672 KLIsSSSLKEK 673KLIsSSSLKEY 674 KLKDRLPsI 675 KLKsNPDFLK 676 KLKsNPDFLKK 677KLKsNPDFLKY 678 KLKsPAPGL 679 KLKsPAPGV 680 KLKsQEIFL 681KLKSsPLIEKK 682 KLKSsPLIEKY 683 KLKtPLVAK 684 KLKtPLVAR 685KLLDFGSLsNLQV 686 KLLQFYPsL 687 KLLQFYPsV 688 KLLsPSDEKL 689KLLsPSNEKL 690 KLLsPSNEKV 691 KLLSSAQRtL 692 KLLSSAQRtV 693KLLsTEEMEL 694 KLLsTEEMEV 695 KLLsVERIK 696 KLLtPIKEK 697 KLLtPIKEK698 KLMAPDIsL 699 KLMAPDIsV 700 KLMIDRTEsV 701 KLMsDVEDV 702KLMsPKADV 703 KLMsPKADVKL 704 KLMsPKADVKV 705 KLPDsPALA 706KLPDsPALAK 707 KLPDsPALAKK 708 KLPDsPALAKY 709 KLPDsPALAY 710KLPsPAPARK 711 KLPTsPLKMK 712 KLPTsPLKMY 713 KLPTtPVKAK 714KLPTtPVKAY 715 KLQEFLQtL 716 KLQVtSLSV 717 KLRsPFLQK 718 KLRsPFLQY719 KLRSsPREAK 720 KLRTsPTFK 721 KLsGDQPAAR

722 KLSGLsF 723 KLSsLGNLK 724 KLSsLGNLKK 725 KLSsLGNLKY 726KLSsPRGGMK 727 KLSsPRGGMKK 728 KLSsPRGGMKY 729 KLsVIAEDSESGKQN 730KLsVIAEDSESGKQNP 731 KLsVIAEDSESGKQNPG 732 KLVSFHDDsDEDL 733KLYsEIDIKV 734 KLYsGNMEK 735 KMAsLLHQV 736 KMAsPELERL 737KMAsPELERV 738 KMDIVsSQKV 739 KMDsFLDMQL 740 KMDsFLDMQV 741KMDsPRVTV 742 KMDsPTKVKK 743 KMFPDtPLAL 744 KMFPDtPLAV 745KMFsGTVRK 746 KMFsGVFVKV 747 KMFsKQQGK 748 KMFsPAHKK 749KMFsPSKEAEL 750 KMFsPSKEAEV 751 KMHGsLARAGK 752 KMIDIVsSQKV 753KMIDRTEsL 754 KMIsSSSLKEK 755 KMKsNPDFLK 756 KMKsNPDFLKK 757KMKsNPDFLKY 758 KMKSsPLIEKK 759 KMKtPLVAK 760 KMKtPLVAR 761KMLDFGSLsNLOV 762 KMLDFGSLsNLQV 763 KMLQFYPsL 764 KMLsPSNEKL 765KMLsPSNEKV 766 KMLSSAQRtL 767 KMLSSAQRtV 768 KMLsVERIK 769KMLtPIKEK 770 KMMAPDIsV 771 KMMsPKADVKL 772 KMMsPKADVKV 773KMPTsPLKMK 774 KMPTtPVKAK 775 KMPTtPVKAY 776 KMRsPFLQK 777KMRSsPREAK 778 KMRTsPTFK 779 KMSsLGNLK 780 KMSsLGNLKK 781KMSsLGNLKY 782 KMSsPRGGMK 783 KMSsPRGGMKK 784 KMYsEIDIKV 785KMYsGNMEK 786 KNRsWKYN 787 KNRsWKYNQ 788 KNRsWKYNQSISLR 789KNRsWKYNQSISLRRP 790 KPAsPARRF 791 KPAsPARRL 792 KPAsPARRM 793KPAsPARRV 794 KPAsPKFIVTF 795 KPAsPKFIVTL 796 KPAsPKFIVTM 797KPAsPKFIVTV 798 KPEsRRSSL 799 KPEsRRsSLL 800 KPEsRRSsLL 801KPEsRRSSLL 802 KPLIRsQSL 803 KPLIRSQsL 804 KPPHsPLVF 805 KPPHsPLVL806 KPPHsPLVM 807 KPPHsPLVV 808 KPPsPEHQSF 809 KPPsPEHQSL 810KPPsPEHQSM 811 KPPsPEHQSV 812 KPPsPSPIEF 813 KPPsPSPIEL 814KPPsPSPIEM 815 KPPsPSPIEV 816 KPPtPGASF 817 KPPtPGASL 818 KPPtPGASM819 KPPtPGASV 820 KPPYRSHsF 821 KPPYRSHsL 822 KPPYRSHsM 823KPPYRSHsV 824 KPQTRGKtF 825 KPQTRGKtL 826 KPQTRGXtM 827 KPQTRGKtV828 KPRPLsMDL 829 KPRPPPLsF 830 KPRPPPLsL 831 KPRPPPLsM 832KPRPPPLsP 833 KPRPPPLsV 834 KPRRFsRsL 835 KPRRFsRSL 836 KPRsPDHVF837 KPRsPDHVL 838 KPRsPDHVM 839 KPRsPDHVV 840 KPRsPFSKI 841KPRsPPRAF 842 KPRsPPRAL 843 KPRsPPRALF 844 KPRsPPRALL 845KPRsPPRALM 846 KPRsPPRALV 847 KPRsPPRALVF

848 KPRsPPRALVL 849 KPRsPPRALVLF 850 KPRsPPRALVLL 851 KPRsPPRALVLM852 KPRsPPRALVLP 853 KPRsPPRALVLV 854 KPRsPPRALVM 855 KPRsPPRALVV856 KPRsPPRAM 857 KPRsPPRAV 858 KPRsPVVEF 859 KPRsPVVEL 860KPRsPVVEM 861 KPRsPVVEV 862 KPSsPRGSL 863 KPSsPRGSLL 864 KPVsPKSGTL865 KPYsPLASF 866 KPYsPLASL 867 KPYsPLASM 868 KPYsPLASV 869KQDsLVINL 870 KRAsFAKSF 871 KRAsFAKSK 872 KRAsFAKSL 873 KRAsFAKSM874 KRAsFAKSR 875 KRAsFAKSV 876 KRAsFAKSY 877 KRAsGQAFEF 878KRAsGQAFEK 879 KRAsGQAFEL 880 KRAsGQAFER 881 KRAsGQAFEY 882KRASSPFRF 883 KRASsPFRK 884 KRASsPFRL 885 KRASsPFRM 886 KRASsPFRR887 KRASsPFRY 888 KRAsVFVKF 889 KRAsVFVKK 890 KRAsVFVKL 891KRAsVFVKM 892 KRAsVFVKR 893 KRAsVFVKY 894 KRAsYILRL 895 KRFsFKF 896KRFsFKK 897 KRFsFKKsF 898 KRFsFKKSF 899 KRFsFKKSK 900 KRFsFKKSL 901KRFsFKKSM 902 KRFsFKKSR 903 KRFsFKKSY 904 KRFsFKL 905 KRFsFKM 906KRFsFKR 907 KRFsFKsSF 908 KRFsFKY 909 KRFsGTVRF 910 KRFsGTVRK 911KRFsGTVRL 912 KRFsGTVRM 913 KRFsGTVRR 914 KRFsGTVRY 915 KRIVIsPKPF916 KRKsFTSLY 917 KRLEKsPSF 918 KRLEKSPsF 919 KRLsPAPQF 920KRLsPAPQK 921 KRLsPAPQL 922 KRLsPAPQM 923 KRLsPAPQR 924 KRLsPAPQY925 KRLsTSPVRL 926 KRLsVERIF 927 KRLsVERIK 928 KRLsVERIL 929KRLsVERIM 930 KRLsVERIR 931 KRLsVERIY 932 KRMsPKEF 933 KRMsPKEK 934KRMsPKEL 935 KRMsPKER 936 KRMsPKEY 937 KRmsPKPEL 938 KRMsPKPEL 939KRMsPKPF 940 KRMsPKPK 941 KRMsPKPL 942 KRMsPKPM 943 KRMsPKPR 944KRMsPKPY 945 KRPEsPPSI 946 KRWQsPVTK 947 KRYsEPVSL 948 KRYsGNMEF949 KRYsGNMEK 950 KRYsGNMEL 951 KRYsGNMEM 952 KRYsGNMER 953KRYsGNmEY 954 KRYsGNMEY 955 KRYsRALYL 956 KSDsRQERY 957 KSEsRQERY958 KSGELLAtW 959 KSKsNPDFLKK 960 KSKsNPFLKK 961 KSKtPLVAK 962KSKtPLVAR 963 KSKtPLVAY 964 KsLVRLLLL 965 KSSsLGNLKK 966KsVKALSSLHGDDQ 967 KsVKALSSLHGDDQD 968 KsVKALSSLHGDDQDsEDE 969KSVKALSSLHGDDQDsEDE 970 KTDsRQERY 971 KTEsRQERY 972KtLSPGKNGVVK

973 KtLSPGKNGVVY 974 KTMsGTFLL 975 KTMsPSQMIM 976 KTPTsPLKMK 977KTPTsPLKMY 978 KTWKGsIGL 979 KVAsLLHQV 980 KVDsPVIF 981 KVHGsLARAGK982 KVHGsLARAGY 983 KVKSsPLIEKK 984 KVKsSPLIEKL 985 KVKSsPLIEKL 986KVKSsPLIEKY 987 KVLsKEFHL 988 KVLSPtAAK 989 KVLsSLVTL 990KVLsTEEMEL 991 KVLStEEMEL 992 KVLtPIKeK 993 KVLtPIKEK 994 KVLtPIKEY995 KVPDsPALAK 996 KVPDsPALAKK 997 KVPDsPALAKY 998 KVPDsPALAY 999KVPTsPLKMY 1000 KVQsLRRAL 1001 KVQVtSLSV 1002 KVYsSSEFL 1003KYIsGPHEL 1004 KYsPGKLRGN 1005 LGGGGAGLSGRASGGAQsPLRYLHV 1006LKLsYLTWV 1007 LLAsPGHISV 1008 LLDPSRSYsY 1009 LLDtPVKTQY 1010LLFsPVTSL 1011 LLFsPVTSV 1012 LLLsEEVEL 1013 LLNKSsPVK 1014LLNKSsPVKK 1015 LLNKSsPVKY 1016 LMFsPVTSL 1017 LMFsPVTSV 1018LMFsVTSI 1019 LMFsVTSL 1020 LMNKSsPVK 1021 TiMNKSsPVKK 1022LMNKSsPVKY 1023 LPAsPHQF 1024 LPAsPHQL 1025 LPAsPHQM 1026 LPAsPHQV1027 LPAsPRARF 1028 LPAsPRARL 1029 LPAsPRARM 1030 LPAsPRARV 1031LPIFSRLsF 1032 LPIFSRLsI 1033 LPIFSRLsL 1034 LPIFSRLsM 1035LPIFSRLsV 1036 LPKGLsASL 1037 LPKGLSAsL 1038 LPKsPPYTAF 1039LPKsPPYTAL 1040 LPKsPPYTAM 1041 LPKsPPYTAV 1042 LPRGSsPSVF 1043LPRGsSPSVL 1044 LPRGSsPSVL 1045 LPRGSsPSVM 1046 LPRGSsPSVV 1047LPRmIsHSEL 1048 LPRMIsHSEL 1049 LPRPAsPAL 1050 LPRSSsMAA 1051LPRSSsMAAGL 1052 LPRtPRPEL 1053 LPVsPRLQL 1054 LQLsPLKGLSL 1055LQNItENQL 1056 LSDPSRSYsY 1057 LSDsDTEAKL 1058 LSDsDTEAKY 1059LSDtPVKTQY 1060 LSEPSRSYsY 1061 LSEsDTEAKL 1062 LSEsDTEAKY 1063LSEtPVKTQY 1064 LSKFRMPQPSSGREsPRH 1065 LSSsVIREL 1066 LTDPSRSYsY1067 LTDPSsPTISSY 1068 LTDsDTEAKL 1069 LTDSDTEAKY 1070 LTDtPVKTQY1071 LTEPSRSYsY 1072 LTEsDTEAKL 1073 LTEsDTEAKY 1074 LTEtPVKTOY1075 LTEtPVKTQY 1076 MLAEsPSVPRL 1077 MLAEsPSVPRV 1078 MLRsPPRVSK1079 MMRsPPRVSK 1080 MPRPsIKKAQNSQAARQ 1081 MPRQPsAIRM 1082MPRQPsATRF 1083 MPRQPsATRL 1084 MPRQPsATRM 1085 MPRQPsATRV 1086MRLsEWLQL 1087 MRLsRELQF 1088 MRLsRELQK 1089 MRLsRELQL 1090MRLsRELQM 1091 MRLsRELQR 1092 MRLsRELQY 1093 MSDtYRLKY 1094MSEtYRLKY 1095 MTDtYRLKY 1096 MTEtYRLKY 1097 MTRsPPRVSK 1098MTRsPPRVSY

1099 NAPPAYEKLsAE 1100 NFKsPVKTIR 1101 NLELSKFRMPQPSSGREsPRH 1102NLGsRNHVHQL 1103 NLLsPDGKMISV 1104 NLVERKNsK 1105 NLVERKNsL 1106NMDsPGPML 1107 NMVERKNsK 1108 NMVERKNsL 1109 NRAMRRVsSVPSR 1110NRAMRRVsSVPSRAQ 1111 NRsWKYNQSISLR 1112 NRsWKYNQSISLRRP 1113NRYtNRVVTF 1114 NRYtNRVVTK 1115 NRYtNRVVTL 1116 NRYtNRVVTM 1117NRYtNRVVTR 1118 NRYtNRVVTY 1119 NSDsPLRY 1120 NSEsPLRY 1121NTDsPLRY 1122 NTEsPLRY 1123 NYVERKNsK 1124 NYVERKNsL 1125 NYVERKNsY1126 PARsPVTEI 1127 PAYEKLsAE 1128 PAYEKLsAEQSP 1129 PmVTLsLNL 1130PMVTLsLNL 1131 PNAPPAYEKLsA 1132 PPAYEKLsA 1133 PPAYEKLsAEQS 1134PPLPEDSIKVIRNMRAAsPPA 1135 PYDPALGsPSR 1136 QAASNFKsPVKTIR 1137QLDsPQRALY 1138 QLEsPQRALY 1139 QLFsPKKGQK 1140 QMFsPKKGQK 1141QPQRRsLRL 1142 QPRsPGPDYSF 1143 QPRsPGPDYSL 1144 QPRsPGPDYSM 1145QPRsPGPDYSV 1146 QPRtPsPLVF 1147 QPRtPSPLVF 1148 QPRtPsPLVL 1149QPRtPSPLVL 1150 QPRtPsPLVM 1151 QPRtPSPLVM 1152 QPRtPsPLVV 1153QPRtPSPLVV 1154 QPSFPsVLPA 1155 QRLsPLSAAY 1156 QSDsPQRALY 1157QSEsPQRALY 1158 QTEsPQRALY 1159 QTEsPQRALY 1160QVAMPVKKSPRRSsSDEQGLSYSSLKNV 1161 QVFsPKXGQK 1162 QVFsPKKGQY 1163RADsPVHM 1164 RAFsFSKTPK 1165 RAFsFSKTPY 1166 RAFsVKFEV 1167RAHsEPLAL 1168 RAHsSPASL 1169 RAHSsPASL 1170 RAKsPISLK 1171RAKsPISLY 1172 RAPsPSSRF 1173 RAPsPSSRL 1174 RAPsPSSRM 1175RAPsPSSRV 1176 RARGIsPIVF 1177 RASsDIVsL 1178 RASsDIVSL 1179RASsLSITV 1180 REAPsPLmI 1181 REAPsPLMI 1182 REAsPAPLA 1183REAsPRLRV 1184 REAsPSRLSV 1185 REDsTPGKVFL 1186 REIMGtPEYL 1187REKsPGRmL 1188 REKsPGRML 1189 REKsPLFQF 1190 REKsPLFQW 1191REKsPLFQY 1192 RELARKGsL 1193 RELsPLISL 1194 REPsPLPEL 1195RERsPSPSF 1196 RESsPTRRL 1197 REVsPAPAV 1198 REYGsTSSI 1199RFKtQPVTF 1200 RGDGYGtF 1201 RGDsPKIDL 1202 RIDsKDSASEL 1203RIGsPLSPK 1204 RILsGVVTK 1205 RILsGVVTY 1206 RILsPSMASK 1207RILsPSMASY 1208 RINsFEEHV 1209 RIQsKLYRA 1210 RIQyIQSRF 1211RIQyIQSRFY 1212 RIsHELDS 1213 RITsLIVHV 1214 RIVQyIQSR 1215 RIYQyIQ1216 RIYQyIQSK 1217 RIYQyIQSR 1218 RIYQyIQSRF 1219 RIYQyIQSRFK 1220RIYQyIQSRFY 1221 RIYQyIQSRK 1222 RIYQyIQSRY 1223 RIYQyIQSY

1224 RIYQyLQSRF 1225 RIYQyLQSRFY 1226 RKLRsLEQL 1227 RKLsVILIK 1228RKLsVILIL 1229 RKLsVILIY 1230 RKPsIVTKY 1231 RKSsIIIRM 1232RLAsASRAL 1233 RLAsFAVRK 1234 RLAsFAVRY 1235 RLAsIELPSM 1236RLAsIELPSMAV 1237 RLAsIELPSV 1238 RLAsLNAEAL 1239 RLAsLNAEAV 1240RLAsLQSEV 1241 RLAsLSISV 1242 RLAsPLVHK 1243 RLAsPLVHY 1244RLAsPPPPPK 1245 RLAsPPPPPY 1246 RLAsPTSGV 1247 RLAsPTSGVK 1248RLAsPTSGVKK 1249 RLAsPTSGVKR 1250 RLAsPTSGVKY 1251 RLAsRPLLL 1252RLAsSATQVHK 1253 RLAsYLDKV 1254 RLAsYLDRV 1255 RLDsTPGKVFL 1256RLDsTPGKVFV 1257 RLDsYLRAP 1258 RLDsYVR 1259 RLDsYVRS 1260RLDsYVRSL 1261 RLDsYVRSV 1262 RLDtGPQSL 1263 RLEsANRRL 1264RLFsFSKTPK 1265 RLFsKEL 1266 RLFsKELR 1267 RLFsKELRC 1268 RLFsKELRV1269 RLFSLsNPSL 1270 RLFsPTYGL 1271 RLFsPTYGV 1272 RLFsQGQDV 1273RLFVGsIPK 1274 RLGsFHELLL 1275 RLIsFKAEV 1276 RLIsPYKKK 1277RLIsQDVKL 1278 RLIsQDVKV 1279 RLKLPsGSK 1280 RLKLPsGSKK 1281RLKLPsGSKY 1282 RLKsDERPVHI 1283 RLKsPFRKK 1284 RLKsPGsGHVK 1285RLKsPISLK 1286 RLKsPISLY 1287 RLKsPSPKSEK 1288 RLKsPSPKSER 1289RLKtPTSQSYK 1290 RLKtPTSQSYR 1291 RLKTtPLRK 1292 RLKTtPLRR 1293RLLDPsSPLAL 1294 RLLDPSsPLAL 1295 RLLDRSPsRSAK 1296 RLLDRSPsRSAY1297 RLLsDGQQIIL 1298 RLLsDLEEL 1299 RLLsDQTRL 1300 RLLsFQRYL 1301RLLsGVVTK 1302 RLLsGVVTY 1303 RLLsHISEA 1304 RLLsHISEV 1305RLLsPLSSA 1306 RLLsPLSSARL 1307 RLLsPLSSV 1308 RLLsPQQPAL 1309RLLsPRPSL 1310 RLLsPRPSLL 1311 RLLsPSMASK 1312 RLLsSGVSEI 1313RLLsSGVSEV 1314 RLLsTDAEAV 1315 RLLsVEIVK 1316 RLLsVEIVY 1317RLLsVHDFDF 1318 RLLsVILIK 1319 RLMsMPVAK 1320 RLMsMPVAY 1321RLNtSDFQKL 1322 RLPNRIPsL 1323 RLPsFLKKNK 1324 RLPsLVHGY 1325RLPsSTLKK 1326 RLPsSTLKR 1327 RLPsSTLKY 1328 RLQsLIKNI 1329RLQsTSERL 1330 RLQsTSERV 1331 RLR(sLss)PTVTL 1332 RLR(sLss)PTVTV1333 RLRQsPLATK 1334 RLRQsPLATR 1335 RLRQsPLATY 1336 RLRRsPLLK 1337RLRsAGAAQK 1338 RLRsLSSLREK 1339 RLRsPPPVSK 1340 RLRsYEDMI 1341RLRTsPITRK 1342 RLRTsPITRR 1343 RLSDtPPLL 1344 RLSsLIRHK 1345RLSsLRASTSK 1346 RLSsPISKK 1347 RLSsPISKR 1348 RLSsPISKY 1349RLsSPLHFV

1350 RLSsPLHFV 1351 RLSsPVLHK 1352 RLSsPVLHR 1353 RLSsPVLHY 1354RLSsRFSSK 1355 RLSsRFSSR 1356 RLSsRFSSY 1357 RLSsRYSQK 1358RLSsRYSQY 1359 RLSsVKLISK 1360 RLSsVKLISY 1361 RLTFsPTYGV 1362RLVsLSMRK 1363 RLVsLSMRY 1364 RLYKsPLRH 1365 RLYKsPLRK 1366RLYQyIQSK 1367 RLYQyIQSR 1368 RLYQyIQSRFK 1369 RLYQyIQSRFY 1370RLYQyIQSY 1371 RLYQylOSK 1372 RLYQyLQSRF 1373 RLYQyLQSRFK 1374RLYQyLQSRFY 1375 RLYQyLQSRK 1376 RLYsGPMNKV 1377 RLYsGSRsK 1378RLYsGSRsR 1379 RLYsGSRsY 1380 RLYsKSRDK 1381 RLYsPDHRQK 1382RLYsPERSK 1383 RLYsPRNSK 1384 RLYsPYNHK 1385 RLYsPYNHR 1386RLYsPYNHY 1387 RLYSRsFSK 1388 RLYSRsFSY 1389 RLYsYPRQK 1390RLYVTTSTRTYsLG 1391 RLYVTTSTRTYsLK 1392 RLYVTTSTRTYsLY 1393RMAsPPPPPK 1394 RMAsPTSGV 1395 RMAsPTSGVK 1396 RMAsPTSGVKK 1397RMAsPTSGVKR 1398 RMAsPTSGVKY 1399 RMAsSATQVHK 1400 RMDsTPGKVFL 1401RMDsTPGKVFV 1402 RMDsYVRSL 1403 RMDsYVRSV 1404 RMFPtPPSL 1405RMFsFSKTPK 1406 RMFsKELRC 1407 RMFsKELRV 1408 RMFsPMEEK 1409RMFsPMEEKELL 1410 RMFsPTYGL 1411 RMFsPTYGV 1412 RMIsPYKKK 1413RMIsQDVKL 1414 RMIsQDVKV 1415 RMIsTGSEL 1416 RMKLPsGSK 1417RMKLPsGSKK 1418 RMKLPsGSKY 1419 RMKsPFRKK 1420 RMKsPGsGHVK 1421RMKsPSPKSEK 1422 RMKtPTSQSYK 1423 RMKtPTSQSYR 1424 RMKTtPLRK 1425RMKTtPLRR 1426 RMLDRSPsRSAK 1427 RMLDRSPsRSAY 1428 RMLsHISEA 1429RMLsHISEV 1430 RMLsLRDQRL 1431 RMLsPLSSA 1432 RMLsPLSSV 1433RMLsPSMASK 1434 RMLsSGVSEI 1435 RMLsSGVSEV 1436 RMLsVILIK 1437RMPsFLKKNK 1438 RMPsSTLKK 1439 RMPsSTLKR 1440 RMQsTSERL 1441RMQsTSERV 1442 RMRQsPLATK 1443 RMRQsPLATR 1444 RMRRsPLLK 1445RMRsAGAAQK 1446 RMRsLSSLREK 1447 RMRsPPPVSK 1448 RMRTsPITRK 1449RMRTsPITRR 1450 RMSsLIRHK 1451 RMSsPISKK 1452 RMSsPISKR 1453RMSsPLHFV 1454 RMSsPVLHK 1455 RMSsRYSQK 1456 RMSsVKLISK 1457RMGsVKLISY 1458 RMVsLSMRK 1459 RMVsLSMRY 1460 RMYKsPLRH 1461RMYKsPLRK 1462 RMYQyIQSK 1463 RMYQyIQSR 1464 RMYQyLQSRF 1465RMYQyLQSRFK 1466 RMYQyLQSRFY 1467 RMYQyLQSRK 1468 RMYsFDDVL 1469RMYsGSRsK 1470 RMYsGSRsR 1471 RMYsKSRDH 1472 RMYsKSRDK 1473RMYsKSRDY 1474 RMYsPDHRQK

1475 RMYsPERSK 1476 RMYsPIIYQA 1477 RMYsPIPPSL 1478 RMYsPRNSK 1479RMYsPYNHK 1480 RMYsPYNHR 1481 RMYsYPRQK 1482 RMYVTTSTRTYsLG 1483RMYVTTSTRTYsLK 1484 RMYVTTSTRTYsLY 1485 RNLsSPFIF 1486 RPAFFsPSL1487 RPAKsMDSF 1488 RPAKsMDSL 1489 RPAKsMDSM 1490 RPAKsMDV 1491RPAsAGAMF 1492 RPAsAGAmL 1493 RPAsAGAML 1494 RPAsAGAMM 1495RPAsAGAMV 1496 RPAsARAQPGF 1497 RPAsARAQPGL 1498 RPAsARAQPGM 1499RPAsARAQPGV 1500 RPAsEARAPGL 1501 RPAsPAAKF 1502 RPAsPAAKL 1503RPAsPAAKM 1504 RPAsPAAKV 1505 RPAsPEPEL 1506 RPAsPGPSL 1507RPAsPKRAKI 1508 RPAsPKRAKL 1509 RPAsPKRAKX 1510 RPAsPKRAQI 1511RPAsPKRAQL 1512 RPAsPKRAQX 1513 RPAsPQRAKI 1514 RPAsPQRAKL 1515RPAsPQRAKX 1516 RPAsPQRAQI 1517 RPAsPQRAQL 1518 RPAsPQRAQX 1519RPAsPSLQL 1520 RPAsPSLQLL 1521 RPAsPtAIRRTGSVTSRQT 1522 RPAsRFEVL1523 RPAsYKKKSML 1524 RPAtGGPGVA 1525 RPAtGGPGVF 1526 RPAtGGPGVL1527 RPAtGGPGVM 1528 RPAtGGPGVV 1529 RPAtPTSQF 1530 RPAtPTSQL 1531KPAtPTSQM 1532 RPAtPTSQV 1533 RPDsAHKML 1534 RPDsPTRPTL 1535RPDsRLGKTEF 1536 RPDsRLGKTEL 1537 RPDsRLGKTEM 1538 RPDsRLGKTEV 1539RPDVAKRLsL 1540 RPEsDSGLKF 1541 RPEsDSGLKL 1542 RPEsDSGLKM 1543RPEsDSGLKV 1544 RPEsKDRKF 1545 RPEsKDRKL 1546 RPEsKDRKM 1547RPEsKDRKV 1548 RPFARsHSF 1549 RPFARSHsF 1550 RPFHGISTVsL 1551RPFsPREAF 1552 RPFsPREAL 1553 RPFsPREAM 1554 RPFsPREAV 1555RPGsLERKF 1556 RPGsLERKL 1557 RPGsLERKM 1558 RPGsLERKV 1559RPGsRQAGL 1560 RPGsRqAGL 1561 RPHsPEKAF 1562 RPHsPEKAL 1563RPHsPEKAM 1564 RPHsPEKAV 1565 RPHtPTGIYM 1566 RPHtPTPGIYM 1567RPIsPGLSF 1568 RPIsPGLSL 1569 RPIsPGLSM 1570 RPIsPGLSV 1571RPIsPGLSY 1572 RPIsPPHTY 1573 RPIsPRIGAL 1574 RPItPPRNSA 1575RPItPPRNSF 1576 RPItPPRNSL 1577 RPItPPRNSM 1578 RPItPPRNSV 1579RPKLSsPAF 1580 RPKLSsPAL 1581 RPKLSsPAM 1582 RPKLSsPAV 1583RPKPSSsPF 1584 RPKPSSsPL 1585 RPKPSSsPM 1586 RPKPSSsPV 1587RPKsNIVLF 1588 RPKsNIVLL 1589 RPKsNIVLM 1590 RPKsNIVLV 1591RPKsPLSKm 1592 RPKsPLSKM 1593 RPKsQVAEF 1594 RPKsQVAEL 1595RPKsQVAEM 1596 RPKsQVAEV 1597 RPKsVDFDSL 1598 RPKtPPVVI 1599RPLsLLLAL 1600 RPLsPGGAF

1601 RPLsPGGAL 1602 RPLsPGGAM 1603 RPLsPGGAV 1604 RPLsPLLF 1605RPLsPLLL 1606 RPLsPLLM 1607 RPLsPLLV 1608 RPLsYVL 1609 RPMsESPHM1610 RPNsPSPTAF 1611 RPNsPSPTAL 1612 RPNsPSPTAM 1613 RPNsPSPTAV1614 RPPIgTQSSL 1615 RPPPPPDtPF 1616 RPPPPPDtPL 1617 RPPPPPDtPM1618 RPPPPPDtPP 1619 RPPPPPDtPV 1620 RPPsPGPVF 1621 RPPsPGPVL 1622RPPsPGPVM 1623 RPPsPGPVV 1624 RPPsPSSRF 1625 RPPsPSSRL 1626RPPsPSSRM 1627 RPPsPSSRV 1628 RPPsSEFLDF 1629 RPPsSEFLDL 1630RPPsSEFLDM 1631 RPPsSEFLDV 1632 RPQKTQsII 1633 RPQRAtSNVF 1634RPQRATsNVF 1635 RPQRAtSNVL 1636 RPQRATsNVL 1637 RPQRAtSNVM 1638RPQRATsNVM 1639 RPQRAtSNVV 1640 RPQRATsNVV 1641 RPR(sLss)PTVTL 1642RPR(sLss)PTVTV 1643 RPRAAtVV 1644 RPRAAtVVA 1645 RPRAAtW 1646RPRAAtWA 1647 RPRANsGGVDF 1648 RPRANsGGVDL 1649 RPRANsGGVDM 1650RPRANsGGVDV 1651 RPRARsVDAL 1652 RPRDtRRISL 1653 RPRGsESLL 1654RPRGsQSLF 1655 RPRGsQSLL 1656 RPRGsQSLM 1657 RPRGsQSLV 1658RPRIPsPIGF 1659 RPRLSsTNSSRF 1660 RPRPAsSPAL 1661 RPRPHsAPSF 1662RPRPHsAPSL 1663 RPRPHsAPSM 1664 RPRPHsAPSV 1665 RPRPSsAHVGL 1666RPRPsSVL 1667 RPRPsSVLRTL 1668 RPRPVsPSSF 1669 RPRPVsPSSL 1670RPRPVsPSSLL 1671 RPRPVsPSSM 1672 RPRPVsPSSV 1673 RPRRsSTQF 1674RPRRsSTQL 1675 RPRRsSTQM 1676 RPRRsSTQV 1677 RPRsAVEQL 1678RPRsAVLF 1679 RPRsAVLL 1680 RPRsAVLM 1681 RPRsAVLV 1682 RPRSGsTGSSL1683 RPRsISVEEF 1684 RPRsISVEEL 1685 RPRsISVEEM 1686 RPRsISVEEV1687 RPRsLEVTF 1688 RPRsLEVTI 1689 RPRsLEVTL 1690 RPRsLEVTM 1691RPRsLEVTV 1692 RPRSLsSPTV 1693 RPRSLsSPTVTF 1694 RPRSLsSPTVTL 1695RPRSLsSPTVTM 1696 RPRSLsSPTVTV 1697 RPRsMTVSA 1698 RPRsMVRSF 1699RPRsPAARF 1700 RPRsPAARL 1701 RPRsPAARM 1702 RPRsPAARV 1703RPRsPGSNSKV 1704 RPRsPNMQDL 1705 RPRsPPGGP 1706 RPRsPPPRAF 1707RPRsPPPRAL 1708 RPRsPPPRAM 1709 RPRsPPPRAP 1710 RPRsPPPRAV 1711RPRsPPSSP 1712 RPRsPRENSF 1713 RPRsPRENSI 1714 RPRsPRENSL 1715RPRsPRENSM 1716 RPRsPRENSV 1717 RPRsPRPPP 1718 RPRsPRQNLI 1719RPRsPRQNSF 1720 RPRsPRQNSI 1721 RPRsPRQNSM 1722 RPRsPRQNSV 1723RPRsPSPIF 1724 RPRsPSPIL 1725 RPRsPSPIM

1726 RPRsPSPIS 1727 RPRSPsPIS 1728 RPRsPSPIV 1729 RPRsPTGF 1730RPRsPTGL 1731 RPRsPTGM 1732 RPRsPTGP 1733 RPRsPTGPsNSF 1734RPRsPTGPSNSF 1735 RPRsPTGPSNSFL 1736 RPRsPTGPsNSL 1737 RPRsPTGPsNSM1738 RPRsPTGPsNSV 1739 RPRsPTGV 1740 RPRsPTRSF 1741 RPRsPTRSL 1742RPRsPTRSM 1743 RPRsPTRSV 1744 RPRsPWGKL 1745 RPRsQYNTKL 1746RPRSTsQSIVSL 1747 RPRtPLRSL 1748 RPSGRREsF 1749 RPSGRREsL 1750RPSGRREsM 1751 RPSGRREsV 1752 RPsNPQL 1753 RPSRSsPGF 1754 RPSRSsPGL1755 RPSRSsPGM 1756 RPSRSsPGV 1757 RPSsGFYEL 1758 RPSsLDAEIDSF 1759RPSsLDAEIDSL 1760 RPSsLDAEIDSM 1761 RPSsLDAEIDSV 1762 RPSsLPDF 1763RPSsLPDL 1764 RPSsLPDM 1765 RPSsLPDV 1766 RPsSPALYF 1767 RPSsPALYF1768 RPsSPALYL 1769 RPsSPALYM 1770 RPsSPALYV 1771 RPStPKSDSEF 1772RPStPKSDSEL 1773 RPSLPKSDSEM 1774 RPStPKSDSEV 1775 RPTKIGRRsL 1776RPTsFADEL 1777 RPTsPIQIM 1778 RPTsRLNRF 1779 RPTsRLNRL 1780RPTsRLNRM 1781 RPTsRLNRV 1782 RPVsPFQEF 1783 RPVsPFQEL 1784RPVsPFQEM 1785 RPVsPFQEV 1786 RPVsPGKDF 1787 RPVsPGKDI 1788RPVsPGKDL 1789 RPVsPGKDM 1790 RPVsPGKDV 1791 RPVSPsSLL 1792RPVsTDFAQY 1793 RPVtPVSDF 1794 RPVtPVSDL 1795 RPVtPVSDM 1796RPVtPVSDV 1797 RPWsNSRGL 1798 RPWsPAVSA 1799 RPWsPAVSF 1800RPWsPAVSL 1801 RPWsPAVSM 1802 RPWsPAVSV 1803 RPYsPPFFSF 1804RPYsPPFFSL 1805 RPYsPPFFSM 1806 RPYsPPFFSV 1807 RPYSPsQAL 1808RPYsPSQYAL 1809 RPYSPsQYAL 1810 RPYsQVNVL 1811 RQAsIELPSM 1812RQAsIELPSMAV 1813 RQAsIELPSV 1814 RQAsLSISV 1815 RQAsPLVHK 1816RQAsPLVIIR 1817 RQAsPLVHY 1818 RQDsTPGKVFL 1819 RQDStPGKVFL 1820RQDsTPGKVFV 1821 RQIsFKAEV 1822 RQIsQDVKL 1823 RQIsQDVKV 1824RQKsPLFQF 1825 RQLsALHRA 1826 RQLsLEGSGLGV 1827 RQLsSGVSEI 1828RQLsSGVSEV 1829 RQSsSRFNL 1830 RRAsFAKSF 1831 RRAsFAKSK 1832RRAsFAKSL 1833 RRAsFAKSM 1834 RRAsFAKSR 1835 RRAsIITKY 1836RRAsLSEIGF 1837 RRAsLSEIGK 1838 RRAsLSEIGY 1839 RRAsQEANL 1840RRASsPFRF 1841 RRASsPFRK 1842 RRASsPFRL 1843 RRASsPFRM 1844RRASsPFRR 1845 RRAsVFVKF 1846 RRAsVFVKK 1847 RRAsVFVKL 1848RRAsVFVKM 1849 RRAsVFVKR 1850 RRDsIVAEF 1851 RRDsIVAEK

1852 RRDsIVAEL 1853 RRDsIVAER 1854 RRDsIVAEY 1855 RRDsLQKPGL 1856RRFsFEVTL 1857 RRFsFKF 1858 RRFsFKK 1859 RRFsFKKSF 1860 RRFsFKKSK1861 RRFsFKKSL 1862 RRFsFKKSM 1863 RRFsFKKSR 1864 RRFsFKL 1865RRFsFKM 1866 RRFsFKR 1867 RRFsGTAVY 1868 RRFsGTVRF 1869 RRFsGTVRK1870 RRFsGTVRL 1871 RRFsGTVRM 1872 RRFsGTVRR 1873 RRFsIATLR 1874RRFsLTTLR 1875 RRFsPDDKYSF 1876 RRFsPDDKYSK 1877 RRFsPDDKYSL 1878RRFsPDDKYSM 1879 RRFsPPRRF 1880 RRFsPPRRK 1881 RRFsPPRRL 1882RRFsPPRRm 1883 RRFsPPRRM 1884 RRFsPPRRR 1885 RRFsPPRRY 1886RRFsRLENRY 1887 RRFsRSDEL 1888 RRFsRsPIF 1889 RRFsRSPIF 1890RRFsRsPIK 1891 RRFsRSPIK 1892 RRFsRsPIL 1893 RRFsRSPIL 1894RRFsRSPIM 1895 RRFsRsPIR 1896 RRFsRGPIR 1897 RRFSRsPIR 1898RRFsRsPIRF 1899 RRFsRSPIRF 1900 RRFsRsPIRK 1901 RRFsRSPIRK 1902RRFsRsPIRL 1903 RRFsRSPIRL 1904 RRFsRsPIRR 1905 RRFsRSPIRR 1906RRFsRsPIRY 1907 RRFsRSPIRY 1908 RRFsRsPIY 1909 RRFsRSPIY 1910RRFsRSPK 1911 RRFSsPPRRM 1912 RRFsVSTLR 1913 RRFsVTTMR 1914RRFtPPSPAF 1915 RRFtPPSPAK 1916 RRFtPPSPAR 1917 RRFtPPSPAY 1918RRGsFEVTL 1919 RRHsASNLHAL 1920 RRIDIsPSTF 1921 RRIDIsPSTK 1922RRIDIsPSTLR 1923 RRIDIsPSTLRK 1924 RRIDIsPSTR 1925 RRIDIsPSTY 1926RRIsDPEVF 1927 RRIsDPQVF 1928 RRIsGVDRF 1929 RRIsGVDRK 1930RRIsGVDRL 1931 RRIsGVDRM 1932 RRIsGVDRR 1933 RRIsGVDRY 1934RRIsGVDRYF 1935 RRIsGVDRYK 1936 RRIsGVDRYL 1937 RRIsGVDRYR 1938RRIsGVDRYY 1939 RRIsPAPQR 1940 RRIsQIQQL 1941 RRKsOVAEF 1942RRKsOVAEK 1943 RRKsPPPSF 1944 RRKsPPPSK 1945 RRKsPPPSL 1946RRKsPPPSM 1947 RRKsPPPSR 1948 RRKsQLDSF 1949 RRKsQLDSK 1950RRKsQLDSL 1951 RRKsQLDSM 1952 RRKsQLDSR 1953 RRKsQLDSY 1954RRKsQVAEF 1955 RRKsQVAEK 1956 RRKsQVAEL 1957 RRKsQVAEM 1958RRKsQVAER 1959 RRKsQVAEV 1960 RRKsQVAEY 1961 RRLGsPHRF 1962RRLGsPHRK 1963 RRLGsPHRL 1964 RRLGsPHRM 1965 RRLGsPHRR 1966RRLsADIRF 1967 RRLsADIRK 1968 RRLsADIRL 1969 RRLsADIRM 1970RRLsADIRR 1971 RRLsADIRY 1972 RRLsDSPVF 1973 RRLsELLRY 1974RRLsERETR 1975 RRLsESSAL 1976 RRLsFLVSF

1977 RRLsFLVSK 1978 RRLsFLVSL 1979 RRLsFLVSM 1980 RRLsFLVSR 1981RRLsFLVSY 1982 RRLsGGSHSF 1983 RRLsGGSHSK 1984 RRLsGGSHSL 1985RRLsGGSHSM 1986 RRLsGGSHSR 1987 RRLsGGSHSY 1988 RRLsGPLHTF 1989RRLsGPLHTK 1990 RRLsGPLHTL 1991 RRLsGPLHTM 1992 RRLsGPLHTR 1993RRLsGPLHTV 1994 RRLsGPLHTY 1995 RRLsLFLNV 1996 RRLsNLPTF 1997RRLsNLPTK 1998 RRLsNLPTR 1999 RRLsNLPTV 2000 RRLsNLPTY 2001RRLsPAPCF 2002 RRLsPAPQK 2003 RRLsPAPQL 2004 RRLsPAPQM 2005RRLsPKASQVF 2006 RRLs PKASQVK 2007 RRLsPKASQVL 2008 RRLsPKASQVM2009 RRLsPKASQVR 2010 RRLsPVPVPF 2011 RRLsPVPVPK 2012 RRLsPVPVPL2013 RRLsPVPVPM 2014 RRLsPVPVPR 2015 RRLsRELCK 2016 RRLsRELQF 2017RRLsRELQL 2018 RRLsRELQM 2019 RRLsRELQR 2020 RRLsRKLSL 2021RRLsVERIF 2022 RRLsVERIK 2023 RRLsVERIM 2024 RRLsVERIR 2025RRLsYVLFI 2026 RRLTHLsF 2027 RRLTHLsK 2028 RRLTHLsL 2029 RRLTHLsM2030 RRLTHLsR 2031 RRMsFQKP 2032 RRMsLLSVF 2033 RRMsLLSVK 2034RRMsLLSVL 2035 RRMsLLSVM 2036 RRMsLLSVR 2037 RRmsLLSVV 2038RRMsLLSVV 2039 RRMsLLSVY 2040 RRMsLLSW 2041 RRMsLSVM 2042 RRMsPIKPL2043 RRMsPKAOR 2044 RRMsPKAQF 2045 RRMsPKAQK 2046 RRMsPKAQL 2047RRMsPKAQM 2048 RRMsPKPF 2049 RRMsPKPK 2050 RRMsPKPM 2051 RRMsPKPR2052 RRNsAPVSV 2053 RRNsINRNF 2054 RRNsNPVIAEF 2055 RRNsNPVIAEK2056 RRNsNPVIAEL 2057 RRNsNPVIAEM 2058 RRNsNPVIAER 2059 RRNsSERTF2060 RRNsSERTK 2061 RRNsSERTL 2062 RRNsSERTM 2063 RRNsSERTR 2064RRNsSERTY 2065 RRNsSIVGF 2066 RRNsSIVGK 2067 RRNsSIVGL 2068RRNsSIVGM 2069 RRNsSIVGR 2070 RRNsSIVGY 2071 RRNsVFQQGF 2072RRNsVFQQGK 2073 RRNsVFQQGL 2074 RRNsVFQQGM 2075 RRNsVFQQGR 2076RRNsVFQQGY 2077 RRPsIAPVL 2078 RRPsLLSEF 2079 RRPsLVHGF 2080RRPsLVHGK 2081 RRPsLVHGL 2082 RRPsLVHGM 2083 RRPsLVHGR 2084RRPsLVHGY 2085 RRPsVFERF 2086 RRPsVFERK 2087 RRPsVFERL 2088RRPsVFERM 2089 RRPsVFERR 2090 RRPsVFERY 2091 RRPsYRKIF 2092RRPsYRKIK 2093 RRPsYRKIL 2094 RRPsYRKIM 2095 RRPsYRKIR 2096RRPsYRKIY 2097 RRPsYTLGF 2098 RRPsYTLGK 2099 RRPsYTLGL 2100RRPsYTLGM 2101 RRPsYTLGR 2102 RRPsYTLGV

2103 RRPsYTLGY 2104 RRCsKVEAL 2105 RRRsLERLL 2106 RRsFLVSY 2107RRSFsLE 2108 RRSsFLQ 2109 RRssFLQLF 2110 RRssFLQVF 2111 RRSsFLQVF2112 RRSsFLQVK 2113 RRSsFLQVL 2114 RRssFLQVM 2115 RRSsFLQVM 2116RRSsFLQVR 2117 RRssFLQW 2118 RRSsFLQVY 2119 RRSsIGLRF 2120RRSsIGLRK 2121 RRSsIGLRL 2122 RRSsIGLRM 2123 RRSsIGLRR 2124RRSsIGLRV 2125 RRSsIGLRY 2126 RRsSIQSTF 2127 RRSsIQSTF 2128RRSsIQSTK 2129 RRSsIQSTL 2130 RRSsIQSTM 2131 RRSsIQSTR 2132RRSsIQSTY 2133 RRSsLDAEIDSF 2134 RRSsLDAEIDSL 2135 RRSsLDAEIDSM2136 RRGsLDAEIDSV 2137 RRsSQSWSF 2138 RRSsQSWSF 2139 RRSsQSWSK 2140RRsSQSWSL 2141 RRSsQSWSL 2142 RRsSQSWSM 2143 RRSsQSWSM 2144RRSsQSWSR 2145 RRsSQSWSV 2146 RRSsQSWSY 2147 RRSsSVAQV 2148RRSsTASLVKF 2149 RRSsTASLVKK 2150 RRSsTASLVKL 2151 RRSsTASLVKM 2152RRSsTASLVKR 2153 RRsSVDLGF 2154 RRSsVDLGF 2155 RRsSVDLGK 2156RRSsVDLGK 2157 RRsSVDLGL 2158 RRSsVDLGL 2159 RRsSVDLGM 2160RRSsVDLGM 2161 RRsSVDLGR 2162 RRSsVDLGR 2163 RRsSVDLGY 2164RRSsVDLGY 2165 RRSsVKVEA 2166 RRSsVKVEF 2167 RRSsVKVEK 2168RRSsVKVEL 2169 RRSsVKVEM 2170 RRSsVKVER 2171 RRSsVKVEY 2172RRTsPITRF 2173 RRTsPITRK 2174 RRTsPITRL 2175 RRTsPITRM 2176RRTsPITRR 2177 RRWQRSsF 2178 RRWQRSsK 2179 RRWQRSsL 2180 RRWQRSsM2181 RRWQRSsR 2182 RRWQRSsY 2183 RRWQRSsL 2184 RRYsGKTEF 2185RRYsGKTEK 2186 RRYsGKTEL 2187 RRYsGKTER 2188 RRYsGKTEY 2189RRYsGNMEF 2190 RRYsGNMEK 2191 RRYsGNMEL 2192 RRYsGNMEM 2193RRYsGNMER 2194 RRYsKFFDL 2195 RRYsPPIER 2196 RRYsPPIQ 2197RRYsPPIQF 2198 RRYsPPIQK 2199 RRYsPPIQL 2200 RRYsPPIQM 2201RRYsPPIQR 2202 RRYsPPIQY 2203 RRYsRsPYSF 2204 RRYsRSPYSF 2205RRYSRsPYSF 2206 RRYsRsPYSK 2207 RRYsRSPYSK 2208 RRYSRsPYSK 2209RRYsRsPYSL 2210 RRYsRSPYSL 2211 RRYSRsPYSL 2212 RRYsRsPYSM 2213RRYsRSPYSM 2214 RRYSRsPYSM 2215 RRYsRsPYSR 2216 RRYsRSPYSR 2217RRYSRsPYSR 2218 RRYtNRVVTK 2219 RRYtNRVVTL 2220 RRYtNRVVTM 2221RRYtNRVVTR 2222 RSAsFSRKV 2223 RSAsPDDDLGSSN 2224 RSAsSATQVHK 2225RSAsSATQVHY 2226 RSDPSKsPGSLRY 2227 RSEsPKIDL

2228 RSEsPKIDY 2229 RSEsRAQAV 2230 RSEsRAQAY 2231 RSEsVGENL 2232RSEsVGENY 2233 RSEsYVEL 2234 RSEsYVELSQY 2235 RSEPSKsPGSLRY 2236RSEsKDRKF 2237 RSEsKDRKL 2238 RSEsKDRKM 2239 RSEsKDRKV 2240RSEsPKIDL 2241 RSEsPKIDY 2242 RSEsPPAEL 2243 RSEsRAQAV 2244RSEsRAQAY 2245 RSEsVGENL 2246 RSEsVGENY 2247 RSEsYVELSQY 2248RSFsPTMKV 2249 RSGsLERKF 2250 RSGsLERKL 2251 RSGsLERKM 2252RSGsLERKV 2253 RSHSsPASL 2254 RSIsVGENL 2255 RSLsESYEL 2256RSLsPGGAA 2257 RSLsPGGAF 2258 RSLsPGGAL 2259 RSLsPGGAM 2260RSLsPGGAV 2261 RSLsPLLF 2262 RSLsPLLL 2263 RSLsPLLM 2264 RSLsPLLV2265 RSLsQELVGV 2266 RSLsVEIVK 2267 RSLsVEIVY 2268 RSMsMPVAH 2269RSMsMPVAK 2270 RsPEDEYELLMPHRISSH 2271 RSRRsPLLK 2272 RSRRsPLLY2273 RSRsPLEL 2274 RSRsPPPVSK 2275 RSRsPPPVSY 2276 RSRsPRPAF 2277RSRsPRPAI 2278 RSRsPRPAL 2279 RSRsPRPAM 2280 RSRsPRPAV 2281RSRsPRPAX 2282 RSRTsPITRR 2283 RSRTsPITRY 2284 RSSsLIRHK 2285RSSsLIRHY 2286 RSVsLSMRK 2287 RSVsLSMRY 2288 RsWKYNQSISLRRP 2289RSYsGSRsK 2290 RSYsGSRsR 2291 RSYsGSRsY 2292 RSYsPDHRQK 2293RSYsPDHRQY 2294 RSYsPERSK 2295 RSYsPERSY 2296 RSYsPRNSR 2297RSYsPRNSY 2298 RSYSRsFSK 2299 RSYsRSFSR 2300 RSYSRsFSR 2301RSYSRsFSY 2302 RSYsYPRQK 2303 RSYsYPRQY 2304 RSYVTTSTRTYsLG 2305RTAsFAVRK 2306 RTAsFAVRY 2307 RTAsLIIKV 2308 RTAsPPPPPK 2309RTDPSKsPGSLRY 2310 RTDsPKIDL 2311 RTDsPKIDY 2312 RTDsRAQAV 2313RTDsRAQAY 2314 RTDsYVELSQY 2315 RTEPSKsPGSLRY 2316 RTEsDSGLKF 2317RTEsDSGLKK 2318 RTEsDSGLKL 2319 RTEsDSGLKM 2320 RTEsDSGLKV 2321RTEsPKIDL 2322 RTEsPKIDY 2323 RTEsRAQAV 2324 RTEsRAQAY 2325RTEsYVELSQY 2326 RTFsLDTIL 2327 RTFsPTYGF 2328 RTFsPTYGL 2329RTFsPTYGM 2330 RTFsPTYGV 2331 RTHsLLLLL 2332 RTLsHISEA 2333RTLsHISEV 2334 RTLsPEIITV 2335 RTMsEAALVRK 2336 RTNsPGFQK 2337RTPsDVKEL 2338 RTPsFLKKNK 2339 RTPsFLKKNY 2340 RTRsLSSLREK 2341RTRsLSSLREY 2342 RTRsPSPTF 2343 RTRsPSPTL 2344 RTRsPSPTM 2345RTRsPSPTV 2346 RTSsFALNL 2347 RTSsFTEQL 2348 RTSsFTFQN 2349RTSSFtFQN 2350 RTSsPLFNK 2351 RTYKsPLRH 2352 RTYKsPLRK 2353RTYKsPLRY

2354 RTYsGPMNK 2355 RTYsGPMNKV 2356 RTYsHGTYR 2357 RVAsFAVRK 2358RVAsFAVRY 2359 RVAsPLVHK 2360 RVAsPLVHY 2361 RVAsPPPPPK 2362RVAsPPPPPY 2363 RVAsPTSGV 2364 RVAsPTSGVK 2365 RVAsPTSGVKK 2366RVAsPTSGVKR 2367 RVAsPTSGVY 2368 RVDsPSHGL 2369 RVGsLVLNL 2370RVIsGVLQL 2371 RVKLPsGSKK 2372 RVKsPGsGHVK 2373 RVKsPGsGHVY 2374RVKsPISLK 2375 RVKsPSPKSER 2376 RVKsPSPKSEY 2377 RVKtPTSQSYK 2378RVKtPTSQSYR 2379 RVKtPTSQSYY 2380 RVKTtPLRR 2381 RVKTtPLRY 2382RVLDRSPsRSAK 2383 RVLDRSPsRSAY 2384 RVLHsPPAV 2385 RVLsGVVTK 2386RVLsPLIIK 2387 RVPsLLVLL 2388 RVPsSTLKK 2389 RVPsSTLKY 2390RVRKLPsTTL 2391 RVRQsPLATK 2392 RVRQsPLATR 2393 RVRQsPLATY 2394RVRRsSFLNAK 2395 RVRsLSSLREK 2396 RVRsLSSLREY 2397 RVRsPTRSF 2398RVRsPTRSL 2399 RVRsPTRSM 2400 RVRsPTRSP 2401 RVRsPTRSV 2402RVSsPISKK 2403 RVSsPISKY 2404 RVSsRFSSK 2405 RVSsRFSSR 2406RVSsRFSSY 2407 RVSsVKLISK 2408 RVSsVKLISY 2409 RVTsAEIKL 2410RWsLSMRK 2411 RWsLSMRY 2412 RVWEDRPSsA 2413 RVWsPPRVHKV 2414RVYQyIQSR 2415 RVYQyIQSRFK 2416 RVYQyIQSRFY 2417 RVYQyIQSRK 2418RVYQyIQSRY 2419 RVYsPYNHK 2420 RVYsPYNHR 2421 RVYsPYNHY 2422RVYSRsFSK 2423 RVYSRsFSY 2424 RYPsNLQLF 2425 RYQtQPVTL 2426SAARESHPHGVKRSAsPDDDLG 2427 SARGsPTRPNPPVR 2428 SARRtPVSY 2429SDDEKMPDLE 2430 sDFHAERAAREK 2431 SDmPRAHsF 2432 SDMPRAHsF 2433SEFKAMDsI 2434 SEGsLHRKF 2435 SEGsLHRKW 2436 SEGsLHRKY 2437SELsPGRSV 2438 SFDsGSVRL 2439 SGGAQsPLRYLHVL 2440sGGDDDWTHLSSKEVDPST 2441 sGGDDDWTHLSSKEVDPSTG 2442sGGDDDWTHLSSKEVDPSTGE 2443 sGGDDDWTHLSSKEVDPSTGEL 2444sGGDDDWTHLSSKEVDPSTGELQ 2445 SGPKPLFRRMsSLVGPTQ 2446 SIDsPQKL 2447SIDsPQKY 2448 SILsFVSGL 2449 SIMsFHIDL 2450 SImsPEIQL 2451SIMsPEIQL 2452 SIPtVSGQI 2453 SISsMEVNV 2454 SISStPPAV 2455SKEDKNGHDGDTHQEDDGEKsD 2456 SKRGyIGL 2457 SKtVATFIL 2458 SLAsLTEKI2459 SLDSEDYsL 2460 SLCsLGDVFL 2461 SLCsPSYVLY 2462 SLEsPSYVLY 2463SLFGGsVKL 2464 SLFKRLYsL 2465 SLFsGDEENA 2466 SLFsGSYSSL 2467SLFsPQNTL 2468 SLFsPRRNK 2469 SLFsPRRNY 2470 SLFsSEESNL 2471SLFsSEESNLGA 2472 SLHDIQLsL 2473 SLKsPVTVK 2474 SLLAsPGHISV 2475SLLHTSRsL 2476 SLLNKSsPVK 2477 SLLNKSsPVKK 2478 SLLNKSsPVKY

2479 SLLsLHVDL 2480 SLLTsPPKA 2481 SLLTsPPKV 2482 SLMsGTLESL 2483SLMsPGRKK 2484 SLMsPGRRY 2485 SLCPRSHsV 2486 SLQsLETSV 2487SLRRsVLMK 2488 SLRRsVLMY 2489 SLSsLLVKL 2490 SLtRSPPRV 2491SLTRsPPRV 2492 SLVDGyFRL 2493 SLYDRPAsY 2494 SLYsPVKKK 2495SMFsPRRNK 2496 SMKsPVTVK 2497 SMLNKSsPVK 2498 SMLNKSsPVKK 2499SMLsQEIQTL 2500 SMLTsPPKA 2501 SMLTsPPKV 2502 SMMsPGRRK 2503SMQPRSHsV 2504 SMRRsVLMK 2505 SMSsLSREV 2506 SMtRSPPRV 2507SMTRsPPRV 2508 SMYsPVKKK 2509 SNFKsPVKTIR 2510 SPAASISRLsGEQVDGKG2511 SPAsPKISF 2512 SPAsPKISL 2513 SPAsPKISM 2514 SPAsPKISV 2515SPDsSQSSL 2516 sPEDEYELLMPHRISSH 2517 SPEDEYELLMPHRIsSH 2518SPEKAGRRsSF 2519 SPEKAGRRsSL 2520 SPEKAGRRsSM 2521 SPEKAGRRsSV 2522sPERPFLAILGGAKVADK 2523 SPERPFLAILGGAKVADKIQ 2524 SPFKRQLsF 2525SPFKRQLsL 2526 SPFKRQLsM 2527 SPFKRQLsV 2528 SPFLsKRSL 2529SPGLARKRsF 2530 SPGLARKRsL 2531 SPGLARKRsM 2532 SPGLARKRsV 2533SPGsPRPAF 2534 SPGsPRPAL 2535 SPGsPRPAM 2536 SPGsPRPAV 2537SPKsPGLKA 2538 SPKsPGLKF 2539 SPKsPGLKL 2540 SPKsPGLKM 2541SPKsPGLKV 2542 SPKsPTAAF 2543 SPKsPTAAL 2544 SPKsPTAAM 2545SPKsPTAAV 2546 SPLTKSIsL 2547 sPPFPVPVYTRQAPKQVIK 2548 SPRAPVsPLKF2549 SPRERsPAL 2550 SPRGEAsSL 2551 SPRGEASsL 2552 SPRPPNsPSI 2553SPRRsLGLAL 2554 SPRRsRSIsF 2555 SPRRsRSISF 2556 SPRRsRSIsL 2557SPRRsRSISL 2558 SPRRsRSIsM 2559 SPKRsRSISM 2560 SPRRsRSIsV 2561SPRRsRSISV 2562 SPRsITSTF 2563 SPRsITSTL 2564 SPRsTTSTM 2565SPRsITSTP 2566 SPRsITSTV 2567 SPRsPDRTL 2568 SPRsPGKPF 2569SPRsPGKPL 2570 SPRsPGKPM 2571 SPRsPGKPV 2572 SPRsPGRSF 2573SPRsPGRSI 2574 SPRsPGRSL 2575 SPRsPGRSM 2576 SPRsPGRSV 2577SPRsPGRSX 2578 SPRsPSGLR 2579 SPRsPSTTYF 2580 SPRsPSTTYL 2581SPRSPsTTYL 2582 SPRsPSTTYM 2583 SPRsPSTTYV 2584 SPRssQLV 2585SPRtPVsPVKF 2586 SPRTPVsPVKF 2587 SPRtPVsPVKL 2588 SPRTPVsPVKL 2589SPRtPVsPVKM 2590 SPRTPVsPVKM 2591 SPRtPVsPVKV 2592 SPRTPVsPVKV 2593SPSsPSVRRQF 2594 SPSsPSVRRQL 2595 SPSsPSVRRQM 2596 SPSsPSVRRQV 2597SPSTSRSGGsSRF 2598 SPSTSRSGGsSRL 2599 SPSTSRSGGsSRM 2600SPSTSRSGGsSRV 2601 sPTRPNPPVRNLH 2602 SPVsPMKEL 2603 SPVsTRPLEP2604 SPVStRPLEP

2605 SPWHQsF 2606 SPWHQsL 2607 SPVVHQsM 2608 SPVVHQsV 2609SQIsPKSWGV 2610 SRDKHsEY 2611 SREKHsEI 2612 SREKHsEl 2613 SRFNRRVsV2614 SRLTHLsF 2615 SRLTHLsK 2616 SRLTHLsL 2617 SRLTHLsM 2618SRLTHLsR 2619 SRLTHLsY 2620 SRMsPKAQF 2621 SRMsPKAQK 2622 SRMsPKAQL2623 SRMsPKAQM 2624 SRMsPKAQR 2625 SRMsPKAQY 2626 SRsSRSPYSR 2627SRSsSVLsL 2628 SRSSsVLSL 2629 SRSSSVLsL 2630 SRTsPITRF 2631SRTsPITRK 2632 SRTsPITRL 2633 SRTsPITRM 2634 SRTsPITRR 2635SRTsPITRY 2636 SRWsGSHQF 2637 SRWsGSHQK 2638 SRWsGSHQR 2639SRWsGSHQY 2640 SRYsRsPYSF 2641 SRYsRSPYSF 2642 SRYSRsPYSF 2643SRYsRsPYSK 2644 GRYsRSPYSK 2645 SRYSRsPYSK 2646 SRYsRsPYSL 2647SRYsRSPYSL 2648 SRYSRsPYSL 2649 SRYsRsPYSM 2650 SRYsRSPYSM 2651SRYSRsPYSM 2652 SRYsRsPYSR 2653 SRYsRSPYSR 2654 SRYSRsPYSR 2655SRYsRsPYSY 2656 SRYsRSPYSY 2657 SRYSRsPYSY 2658 SRYsRtsPYSR 2659SSDIsPTRL 2660 SSDIsPTRY 2661 SSDKHsEY 2662 SSDPASQLsY 2663SSDsETLRY 2664 SSDsPQKL 2665 SSDsPQKY 2666 SSDsPSYVLY 2667SSDsPTNHFF 2668 SSEIsPTRY 2669 SSEKHsEY 2670 SSEPASQLsY 2671SSEsETLRY 2672 SSEsPQKL 2673 SSEsPQKY 2674 SSEsPSYVLY 2675SSEsPTNHFY 2676 SSNGKMASRRsEEKEAG 2677 SSNGKMASRRsEEKEAGEI 2678GSPIMRKKVSL 2679 sSPPFPVPVYTRQAPKQVIK 2680 SSsPTHAKSAHV 2681SSsWRILGSKQSEHRP 2682 STDIsPTRL 2683 STDIsPTRY 2684 STDKHsEY 2685STDPASQLsY 2686 STDsETLRY 2687 STDsPQKY 2688 STDsPSYVLY 2689STDsPTNHFY 2690 STEIsPTRL 2691 STEIsPTRY 2692 STEKHsEY 2693STEPASQLsY 2694 STEsETLRY 2695 STEsPQKY 2696 STEsPSYVLY 2697STEsPTNHFY 2698 STIQNsPTKK 2699 sTMSLNIITV 2700 STMsLNIITV 2701SVDIsPIRL 2702 SVDIsPTRL 2703 SVDIsPTRY 2704 SVFsPSFGL 2705SVGsDYYIQL 2706 SVKPRRTsL 2707 SVKsPVTVK 2708 SVKsPVTVY 2709 SVLsPSFQL 2710 SVMDsPKKL 2711 SVRRsVLMK 2712 SVRRsVLMY 2713 SVRsLSLSL2714 SVYSGDFGNLEV 2715 SVYsPVKKK 2716 SVYsPVKKY 2717 sYIEHIFEI 2718SYPsPVATSY 2719 sYQKVIELF 2720 TDKYsKMM 2721 TEAsPESML 2722THKGEIRGASTPFQFRAssP 2723 TIGEKKEPsDKSVDS 2724 TKDKYMASRGQKAKsMEG2725 TKsVKALSSLHGDD 2726 TKsVKALSSLHGDDQ 2727 TKsVKALSSLHGDDQD 2728TLAsPSVFKST 2729 TLAsPSVFKSV

2730 TLLAsPMLK 2731 TLMERTVSL 2732 TLSsPPPGL 2733 TMAsPGKDNY 2734TMAsPSVFKST 2735 TMAsPSVFKSV 2736 TMDsPGKDNY 2737 TMEsPGKDNY 2738TMMsPSQFL 2739 TPAQPQRRsF 2740 TPAQPQRRsL 2741 TPAQPQRRsM 2742TPAQPQRRsV 2743 TPDPSKFFSQLsSEHGGDV 2744 tPDPSKFFSQLSSEHGGDVQ 2745TPIsPGRASGF 2746 TPIsPGRASGL 2747 TPIsPGRASGM 2748 TPISPGRASGV 2749TPMKKHLsL 2750 TPRsPPLGF 2751 TPRsPPLGL 2752 TPRsPPLGLF 2753TPRsPPLGLI 2754 TPRsPPLGLL 2755 TPRsPPLGLM 2756 TPRsPPLGLV 2757TPRsPPLGM 2758 TPRsPPLGV 2759 TQSSGKsSV 2760 TRKtPESFL 2761TRLsPAKIVLF 2762 TRLsPAKIVLK 2763 TRLsPAKIVLR 2764 TRLsPAKIVLY 2765TSAsPGKDNY 2766 TSDsPGKDNY 2767 TSDtPDYLLKY 2768 TSEsPGKDNY 2769TSEtPDYLLKY 2770 TTAsPGKDNY 2771 TTDsPGKDNY 2772 TTDtPDYLLKY 2773TTEsPGKDNY 2774 TTEtPDYLLKY 2775 TTKsVKALSSLHG 2776 TTKsVKALSSLHGDD2777 TTKsVKALSSLHGDDQ 2778 TTKsVKALSSLHGDDQD 2779TTKsVKALSSLHGDDQDS 2780 TTKsVKALSSLHGDDQDsED 2781TTKSVKALSSLHGDDQDsED 2782 TTKsVKALSSLHGDDQDsEDE 2783TTKSVKALSSLHGDDQDsEDE 2784 TVFsPTLPAA 2785 TVMsNSSVIHL 2786 VAKRLsL2787 VAMPVKKSPRRSsSDEQGLSYSSLKNV 2788 VIDsQELSKV 2789 VLDsPASKK2790 VLFPEsPARA 2791 VLFRtPLASV 2792 VLFsSPPQM 2793 VLFSsPPQM 2794VLIENVAsL 2795 VLIGsPKKV 2796 VLIGsPKKY 2797 VLKGsRSSEL 2798VLKGsRSSEV 2799 VLKSRKssVTEE 2800 VLKVMIGsPK 2801 VLKVMIGsPKK 2802VLKVMIGsPKKK 2803 VLLsPVPEL 2804 VLLsPVPEV 2805 VLMK(sPs)PAL 2806VLMK(sPs)PAV 2807 VLQtPPYVK 2808 VLQtPPYVKK 2809 VLQtPPYVKY 2810VLSDVIPsI 2811 VLSSLtPAKV 2812 VLWDTPsI 2813 VLYsPQMAL 2814VMFRtPLASV 2815 VMIGsKKV 2816 VMIGsPKKV 2817 VMIGsPKKY 2818VMKVMIGsPK 2819 VMKVMIGsPKK 2820 VMKVMIGsPKKK 2821 VMKVMIGsPKKY2822 VMLsPVPEL 2823 VMLsPVPEV 2824 VMQtPPYVK 2825 VMQtPPYVKK 2826VPHHGFEDWsQIR 2827 VPKSGRSSsL 2828 VPKsPAFAL 2829 VPLIRKKsL 2830VPNAPPAYEKLsAEQSPPPY 2831 VPREVLRLsF 2832 VPREVLRLsL 2833VPREVLRLsM 2834 VPREVLRLsV 2835 VPRPERRsSL 2836 VPRsPKHAHSSSF 2837VPRsPKHAHSSSL 2838 VPRsPKHAHSSSM 2839 VPRsPKHAHSSSV 2840 VPStPKSSL2841 VPTsPKSSL 2842 VPVsPGQQL 2843 VRAsKDLAQ 2844 VRQsVTSFPDADAFHHQ2845 VSKVMIGsPKKV 2846 VSKVMIGsPKKY 2847 VTQtPPYVKK 2848 VTQtPPYVKY2849 WDsPGQEVL 2850 VYTyIQSRF 2851 WTHLsSKEVDPS 2852 WTHLsSKEVDPSTG2853 YARsVHEEF 2854 YAVPRRGsL 2855 YAYDGKDyI

2856 YEGsPIKV 2857 YEKLsAEQSPPP 2858 YFsPFRPY 2859 yIQSRF 2860YLAsLEKKL 2861 YLDsGIHSG 2862 YLDsGIHsGA 2863 YLDsGIHSGA 2864YLDsGIHsGV 2865 YLDsGIHSGV 2866 yLGLDVPV 2867 YLGsISTLVTL 2868YLIHsPMSL 2869 YLLsPLNTL 2870 YLLsPTKLPSI 2871 YLLsPTKLPSV 2872yLQSRYYRA 2873 YLQsRYYRA 2874 YLSDsDTEAKL 2875 YMDsGIHsGA 2876YMDsGIHSGA 2877 YMDsGIHsGV 2878 YMDsGIHSGV 2879 YPDPHsPFAV 2880YPGGRRsSL 2881 YPLsPAKVNQY 2882 YPLsPTKISEY 2883 YPLsPTKISQY 2884YPRsEDEVEGVM 2885 YPRsFDEVEGF 2886 YPRsFDEVEGL 2887 YPRsFDEVEGM2888 YPRsFDEVEGV 2889 YPRsFDEVEGVF 2890 YPRsFDEVEGVL 2891YPRsFDEVEGVM 2892 YPRsFDEVEGVV 2893 YPSFRRsSL 2894 YPSsPRKAL 2895YPSsPRKF 2896 YPSsPRKL 2897 YPSsPRKM 2898 YPSsPRKV 2899 YPYEFsPVKM2900 YQLsPTKLPSI 2901 YQLsPTKLPSV 2902 YQRPFsPSAY 2903 YQRsFDEVEGF2904 YQRsFDEVEGL 2905 YQRsFDEVEGM 2906 YQRsFDEVEGV 2907YQRsFDEVEGVF 2908 YQRsFDEVEGVL 2909 YQRsFDEVEGVM 2910 YQRsFDEVEGVV2911 YRYsPQSFL 2912 YTAGtPYKV 2913 YYTAGSSsPTHAKSAHV 8808RLLsAAENFL Lowercase s, t, and y indicate phosphorylated serine,phosphorylated threonine, and phosphorylated tyrosine,respectively. Lowercase c indicates that the cysteine is present ina cysteine-cysteine disulfide bond. Lowercase m indicates oxidizedmethionine. (AcS) indicates an N-terminally acetylated serine.(sLss) indicates that at least one serine residue in the amino acidsequence SLSS is phosphorylated. (sPs) indicates that at least oneserine residue in the amino acid sequence SPS isphosphorylated.

TABLE-US-00003 TABLE 3 Amino acid sequences of exemplaryMHC-binding peptides SEQ ID NO Amino Acid Sequence 2914 ALTtsAHSV2915 ALTtSAHSV 2916 ALTTsAHSV 2917 APP(sts)AAAL 2918 APPsTSAAAL2919 APPsTsAAAL 2920 APPStSAAAL 2921 APPSTsAAAL 2922 APPstSAAAL2923 APPStsAAAL 2924 APP<s>TSAAAL 2925 APPS<t>SAAAL2926 APPST<s>AAAL 2927 APPS<t>sAAAL 2928APP<s><t>SAAAL 2929 APP<s>T<s>AAAL 2930APPS<t><s>AAAL 2931 APRG<n>VISL 2932 APRtNGVAM2933 APTsAAAL 2934 APTsASNVM 2935 APTSAsNVM 2936 APVsASASV 2937APVsSKSSL 2938 EP(sst)VVSL 2939 EPsSTVVSL 2940 EPSsTVVSL 2941EPSStVVSL 2942 GLSsLAEEAA 2943 HP(sss)AAVL.sup.(i) 2944HP(sst)ASTAL 2945 HPMsTASQV 2946 HPssTAAVL 2947 HPsStAAVL 2948HPSstAAVL 2949 HPsSTASTAL 2950 HPSsTASTAL 2951 HPSStASTAL 2952HPTtVASY 2953 IPIsLHTSL 2954 IPTsSVLSL 2955 IPVsKPLSL 2956IPV<s>KPLSL 2957 IPVsSHNSL 2958 IPVssHNSL 2959IPV<s>SHNSL 2960 IPV[s]SHNSL 2961 KPPtSQSSVL 2962KPP<t>SQSSVL 2963 KPPTsQSSVL 2964 KPPT<s>QSSVL 2965KPPV<s>FFSL 2966 KPTLY<n>VSL 2967 LPRN(st)MM 2968LPRNstMM 2969 LPTsLPSSL 2970 MPVRPT<t>NTF 2971(diMe)MPVRPT<t>NTF 2972 MPVtSSSFF 2973 NPVsLPSL 2974PPS<t>SAAAL 2975 PPST<s>AAAL 2976 RPP(sss)QQL 2977RPPItQSSL 2978 (Me)RPPItQSSL 2979 (diME)RPPItQSSL 2980(diME)RPPI[t]QSSL 2981 RPPQ<s>SSVSL 2982 RPPsSSQQL 2983RPPSsSQQL 2984 RPPSSsQQL 2985 RPPVtKASSF 2986 RPVtASITTM 2987TPASsRAQTL 2988 TPAsSSSAL 2989 TPIsQAQKL 2990 TPVsSANMM 2991VLTsNVQTI 2992 VPAsSTSTL 2993 VPAtHGQVTY 2994 VPtTSSSL 2995VPTtSSSL 2996 VPTTsSSL 2997 VPVsGTQGL 2998 VPVsNQSSL 2999 VPVsSASEL3000 VPVsVGPSL Lowercase s and t indicate O-GlcNAcylated serine andO-GlnNAcylated threonine, respectively. (sts), (sss), (ts), (sst),and (st) indicates at least one of the serine or threonine residuesis modifed with O-GlnNAc. (i) indicates that two GlnNAc moeitieswere detected, but could not be assigned to specific amino acids.(Me) indicates methylation of the following arginine. (diMe)indicates asymmetric di-methylation of the following arginine.<n> indicates hexose-GlcNAcylated asparagine. <s>indicates hexose-GlcNAcylated serine. <t> indicateshexose-GlcNAcylated threonine. [s] indicates acetyl-GlcNAcylatedserine. [t] indicates acetyl-GlcNAcylated threonine.

TABLE-US-00004 TABLE 4 Amino acid sequences of exemplary antigenicpolypeptides SEQ ID NO Amino Acid Sequence 3001(AcS)AARESHPHGVKRSAsPDDDLGFFRKNLLRLTG 3002 AAEsPSFLFFRKNLLRLTG 3003AASNFKsPVKTIRFFRKNLLRLTG 3004 ADLsPEREVFFRKNLLRLTG 3005AEDEIGtPRKFFFRKNLLRLTG 3006 AEDEIGtPRKYFFRKNLLRLTG 3007AEEEIGtPRKFFFRKNLLRLTG 3008 AEEEIGtPRKWFFRKNLLRLTG 3009AEEEIGtPRKYFFRKNLLRLTG 3010 AENARSAsFFFRKNLLRLTG 3011AENsPTRQQFFFRKNLLRLTG 3012 AENsPTRQQWFFRKNLLRLTG 3013AENsPTRQQYFFRKNLLRLTG 3014 AENsSSRELFFRKNLLRLTG 3015AEQGsPRVSYFFRKNLLRLTG 3016 AESsPTAGKKFFFRKNLLRLTG 3017AESsPTAGKKLFFRKNLLRLTG 3018 AESsPTAGKKWFFRKNLLRLTG 3019AESsPTAGKKYFFRKNLLRLTG 3020 AGDsPGSQFFFRKNLLRLTG 3021AILsPAFKVFFRKNLLRLTG 3022 AIMRsPQMVFFRKNLLRLTG 3023AIsDLQQLFFRKNLLRLTG 3024 AKLsETISFFRKNLLRLTG 3025ALAAsPHAVFFRKNLLRLTG 3026 ALDsGASLLHLFFRKNLLRLTG 3027ALDsGASLLHVFFRKNLLRLTG 3028 ALGNtPPFLFFRKNLLRLTG 3029ALGsRESLATIFFRKNLLRLTG 3030 ALGsRESLATVFFRKNLLRLTG 3031ALIHQsLGLFFRKNLLRLTG 3032 ALIHQsLGVFFRKNLLRLTG 3033ALLGSKsPDPYRLFFRKNLLRLTG 3034 ALLGSKsPDPYRVFFRKNLLRLTG 3035ALLsLLKRVFFRKNLLRLTG 3036 ALMGsPQLVFFRKNLLRLTG 3037ALMGsPQLVAAFFRKNLLRLTG 3038 ALRSsPIMRKFFRKNLLRLTG 3039ALRSsPIMRYFFRKNLLRLTG 3040 ALVsPPALHNAFFRKNLLRLTG 3041APRRYsSSMFFRKNLLRLTG 3042 ALVsPPALHNVFFRKNLLRLTG 3043ALYsGVHKKFFRKNLLRLTG 3044 ALYsGVHKYFFRKNLLRLTG 3045ALYsPAQPSLFFRKNLLRLTG 3046 ALYtPQAPYFFRKNLLRLTG 3047ALYtPQAPYFFRKNLLRLTG 3048 AMAAsPHAVFFRKNLLRLTG 3049AMDsGASLLHLFFRKNLLRLIG 3050 AMDsGASLLHVFFRKNLLRLIG 3051AMGsRESLATIFFRKNLLRLTG 3052 AMGsRESLATVFFRKNLLRLIG 3053AMLGSKsPDPYRLFFRKNLLRLIG 3054 AMLGSKsPDPYRVFFRKNLLRLIG 3055AMPGsPVEVFFRKNLLRLIG 3056 AMRSsPIMRKFFRKNLLRLTG 3057AMVsPPALHNAFFRKNLLRLIG 3058 AMVsPPALHNVFFRKNLLRLIG 3059AMYsGVHKKFFRKNLLRLIG 3060 APDsPRAFLFFRKNLLRLTG 3061APLARASsLFFRKNLLRLTG 3062 APPAYEKLsFFRKNLLRLTG 3063APPAYEKLsAEQFFRKNLLRLTG 3064 APPAYEKLsAEQSPPFFRKNLLRLTG 3065APPAYEKLsAEQSPPPFFRKNLLRLTG 3066 APPAYEKLsAEQSPPPYFFRKNLLRLTG 3067APPPLVPAPRPSsPPRGPGPARADRFFRKNLLRLTG 3068 APRAPsASPLALFFRKNLLRLTG3069 APRDRRAVsFFFRKNLLRLTG 3070 APRKGsFSALFFRKNLLRLTG 3071APRKGsFSALFFFRKNLLRLTG 3072 APRKGsFSALLFFRKNLLRLTG 3073APRKGsFSALMFFRKNLLRLTG 3074 APRKGsFSALVFFRKNLLRLTG 3075APRNGsGVALFFRKNLLRLTG 3076 APRRYsSSFFFRKNLLRLTG 3077APRRYsSSLFFRKNLLRLTG 3078 APRRYsSSMFFRKNLLRLTG 3079APRRYsSSVFFRKNLLRLTG 3080 APRsPPPSRFFFRKNLLRLTG 3081APRsPPPSRLFFRKNLLRLTG 3082 APRsPPPSRMFFRKNLLRLTG 3083APRsPPPSRPFFRKNLLRLTG 3084 APRsPPPSRVFFRKNLLRLTG 3085APSLFHLNtLFFRKNLLRLTG 3086 APSSARAsPLLFFRKNLLRLTG 3087APSTYAHLsPAKFFRKNLLRLTG 3088 APSTYAHLsPAKTPPPPFFRKNLLRLTG 3089APSVRsLSLFFRKNLLRLTG 3090 APSVRSLsLFFRKNLLRLTG 3091ARFsPDDKYSFFFRKNLLRLTG 3092 ARFsPDDKYSKFFRKNLLRLTG 3093ARFsPDDKYSLFFRKNLLRLTG 3094 ARFsPDDKYSMFFRKNLLRLTG 3095ARFsPDDKYSRFFRKNLLRLTG 3096 ARFsPDDKYSYFFRKNLLRLTG 3097ASDEIGtPRKFFRKNLLRLTG 3098 ASDEIGtPRKYFFRKNLLRLTG 3099ASEEIGtPRKFFFRKNLLRLTG 3100 ASEEIGtPRKYFFRKNLLRLTG 3101AsISRLsGEQVDGKGFFRKNLLRLTG 3102 AsISRLSGEQVDGKGFFRKNLLRLTG 3103ASISRLsGEQVDGKGFFRKNLLRLTG 3104 AsIsRLSGEQVDGKGQFFRKNLLRLTG 3105AsISRLSGEQVDKGKGFFRKNLLRLTG 3106 ASKAsPTLDFTERFFRKNLLRLTG 3107ASKMTQPQSKSAFPLSRKNGsGsLDGFFRKNLLRLTG 3108 AsLGFVFFFRKNLLRLTG 3109AsPTIEAQGTSPAHDNFFRKNLLRLTG 3110 AsPTIEAQGTSPAHDNIFFRKNLLRLTG 3111AsPTIEAQGTSPAHDNIAFFRKNLLRLTG 3112 AtAGPRLGFFFRKNLLRLTG 3113AtAGPRLGWFFRKNLLRLTG 3114 AtAGPRLGYFFRKNLLRLTG 3115ATDEIGtPRKFFFRKNLLRLTG 3116 ATDEIGtPRKYFFRKNLLRLTG 3117ATEEIGtPRKFFFRKNLLRLTG 3118 ATEEIGtPRKYFFRKNLLRLTG 3119ATWsGSEFEVFFRKNLLRLTG 3120 ATYtPQAPKFFRKNLLRLTG 3121ATYtPQAPKYFFRKNLLRLTG 3122 AVIHQsLGLFFRKNLLRLTG

3123 AVIHQsLGVFFRKNLLRLTG 3124 AVRPTRLsLFFRKNLLRLTG 3125AVVsPPALHNAFFRKNLLRLTG 3126 AVVsPPALHNVFFRKNLLRLTG 3127AYEKLsAEQSPPFFRKNLLRLTG 3128 DAKKsPLALFFRKNLLRLTG 3129DDDWTHLsSKEVDPFFRKNLLRLTG 3130 DDDWTHLsSKEVDPSFFRKNLLRLTG 3131DDDWTHLsSKEVDPSTFFRKNLLRLTG 3132 DDDWTHLsSKEVDPSTGFFRKNLLRLT 3133DDWTHLsSKEVDPSFFRKNLLRLTG 3134 DEFERIKtFFFRKNLLRLTG 3135DEFERIKtWFFRKNLLRLTG 3136 DEFERIKtYFFRKNLLRLTG 3137DEISHRAsFFFRKNLLRLTG 3138 DEISHRAsWFFRKNLLRLTG 3139DEISHRAsYFFRKNLLRLTG 3140 DERLRINsFFFRKNLLRLTG 3141DERLRINsLFFRKNLLRLTG 3142 DERLRINsWFFRKNLLRLTG 3143DERLRINsYFFRKNLLRLTG 3144 DKLsVIAEDSESGKQFFRKNLLRLTG 3145DKLsVIAEDSESGKQNFFRKNLLRLTG 3146 DKLsVIAEDSESGKQNPFFRKNLLRLTG 3147DKLsVIAEDSESGKQNPGFFRKNLLRLTG 3148 DKLsVIAEDSESGKQNPGDSFFRKNLLRLTG3149 DLKRRsmSIFFRKNLLRLTG 3150 DLKRRsMSIFFRKNLLRLTG 3151DLKSSKAsLFFRKNLLRLTG 3152 DLRtVEKELFFRKNLLRLTG 3153DLsEEKFLFFRKNLLRLTG 3154 DLsEEKFVFFRKNLLRLTG 3155DLVPLsPLKKFFRKNLLRLTG 3156 DLWKItKVMDFFRKNLLRLTG 3157DMVPLsPLKKFFRKNLLRLTG 3158 DPTRRFFKVtPPPGSGPQFFRKNLLRLTG 3159DQFERIKtLFFRKNLLRLTG 3160 DQISHRAsLFFRKNLLRLTG 3161DSDPLsPLKYFFRKNLLRLTG 3162 DSEPLsPLKYFFRKNLLRLTG 3163DSsEEKFLFFRKNLLRLTG 3164 DSsEEKFVFFRKNLLRLTG 3165DSVPLsPLKYFFRKNLLRLTG 3166 DTDPLsPLKYFFRKNLLRLTG 3167DTEPLsPLKYFFRKNLLRLTG 3168 DTVPLsPLKYFFRKNLLRLTG 3169DWTHLsSKEVDPSFFRKNLLRLTG 3170 DWTHLsSKEVDPSTGFFRKNLLRLTG 3171EEGsPTMVEKGLEPGVFTLFFRKNLLRLTG 3172 EELsPTAKFFFRKNLLRLTG 3173EELsPTAKFFFRKNLLRLTG 3174 EEMPENALPsDEDDKDPNDPYRALFFRKNLLRLTG 3175EERRsPPAPFFRKNLLRLTG 3176 EEsSDDGKKFFFRKNLLRLTG 3177EEsSDDGKKFFFRKNLLRLTG 3178 EEsSDDGKKWFFRKNLLRLTG 3179EESsDDGKKWFFRKNLLRLTG 3180 EEsSDDGKKYFFRKNLLRLTG 3181EESsDDGKKYFFRKNLLRLTG 3182 EGEEPTVYsDEEEPKDESARKNDFFRK 3183EGsPTMVEKGLEPGVFTLFFRKNLLRLTG 3184 ELFSsPPAVFFRKNLLRLTG 3185ELKKsPTSLKFFRKNLLRLTG 3186 ELKKsPTSLYFFRKNLLRLTG 3187ELLMPHRIsSHFFFRKNLLRLTG 3188 ELLMPHRIsSHFLFFRKNLLRLTG 3189ELRISGsVQLFFRKNLLRLTG 3190 EMKKsPTSLKFFRKNLLRLTG 3191EPAsPAAsISRLsGEQVDGKGFFRKNLLRLTG 3192EPAsPAAsISRLSGEQVDGKGFFRKNLLRLTG 3193 EPKRRsARFFFRKNLLRLTG 3194EPKRRsARLFFRKNLLRLTG 3195 EPKRRsARMFFRKNLLRLTG 3196EPKRRsARVFFRKNLLRLTG 3197 EPRsPSHSFFFRKNLLRLTG 3198EPRsPSHSLFFRKNLLRLTG 3199 EPRsPSHSMFFRKNLLRLTG 3200EPRsPSHSVFFRKNLLRLTG 3201 ERsPLLSQETAGQKPFFRKNLLRLTG 3202ERsPLLSQETAGQKPLFFRKNLLRLTG 3203 ESDsLPRYFFRKNLLRLTG 3204ESEsLPRYFFRKNLLRLTG 3205 ESsVRSQEDQLSRFFRKNLLRLTG 3206ESsVRSQEDQLSRRFFRKNLLRLTG 3207 ETDsLPRYFFRKNLLRLTG 3208ETEsLPRYFFRKNLLRLTG 3209 FDKHTLGDsDNESFFRKNLLRLTG 3210FEDDDsNEKLFFRKNLLRLTG 3211 FIEsPSKLFFRKNLLRLTG 3212FIEsPSKYFFRKNLLRLTG 3213 FIGsPTTPAGLFFRKNLLRLTG 3214FKMPQEKsPGYSFFRKNLLRLTG 3215 FKsPVKTIRFFRKNLLRLTG 3216FKtQPVTFFFRKNLLRLTG 3217 FLDNsFEKVFFRKNLLRLTG 3218FLDRPPtPLFIFFRKNLLRLTG 3219 FLDsLRDLIFFRKNLLRLTG 3220FLDtPIAKVFFRKNLLRLTG 3221 FLFDKPVsPLLLFFRKNLLRLTG 3222FLGVRPKsAFFRKNLLRLTG 3223 FLIIRtVLQLFFRKNLLRLTG 3224FLITGGGKGsGFSLFFRKNLLRLTG 3225 FLLsQNFDDEFFRKNLLRLTG 3226FLYsGKETYFFRKNLLRLTG 3227 FPHsLLSVFFFRKNLLRLTG 3228FPHsLLSVIFFRKNLLRLTG 3229 FPHsLLSVIFFRKNLLRLTG 3230FPHsLLSVLFFRKNLLRLTG 3231 FPHsLLSVMFFRKNLLRLTG 3232FPHsLLSVVFFRKNLLRLTG 3233 FPIsPVRFFFRKNLLRLTG 3234FPIsPVRLFFRKNLLRLTG 3235 FPIsPVRMFFRKNLLRLTG 3236FPIsPVRVFFRKNLLRLTG 3237 FPLDsPKTLVLFFRKNLLRLTG 3238FPRRHsVTLFFRKNLLRLTG 3239 FPRsPTKSSFFFRKNLLRLTG 3240FPRsPTKSSLFFRKNLLRLTG 3241 FPRsPTKSSLDFFFRKNLLRLTG 3242FPRsPTKSSLDLFFRKNLLRLTG 3243 FPRsPTKSSLDMFFRKNLLRLTG 3244FPRsPTKSSLDVFFRKNLLRLTG 3245 FPRsPTKSSMFFRKNLLRLTG 3246FPRsPTKSSVFFRKNLLRLTG 3247 FRFsGRTEYFFRKNLLRLTG 3248FRGRYRsPYFFRKNLLRLTG

3249 FRKsMVEHYFFRKNLLRLTG 3250 FRRsPIKSSLDYFFRKNLLRLTG 3251FRRsPTKSSFFFRKNLLRLTG 3252 FRRsPTKSSLFFRKNLLRLTG 3253FRRsPTKSSLDFFRKNLLRLTG 3254 FRRsPTKSSLDFFFRKNLLRLTG 3255FRRsPTKSSLDLFFRKNLLRLTG 3256 FRRsPTKSSLDMFFRKNLLRLTG 3257FRRsPTKSSLDVFFRKNLLRLTG 3258 FRRsPTKSSLDYFFRKNLLRLTG 3259FRRsPTKSSMFFRKNLLRLTG 3260 FRRsPTKSSVFFRKNLLRLTG 3261FRsPTKSSLDFFFRKNLLRLTG 3262 FRsPTKSSLDLFFRKNLLRLTG 3263FRsPTKSSLDMFFRKNLLRLTG 3264 FRsPTKSSLDVFFRKNLLRLTG 3265FRYsGKTEFFFRKNLLRLTG 3266 FRYsGKTEKFFRKNLLRLTG 3267FRYsGKTELFFRKNLLRLTG 3268 FRYsGKTEMFFRKNLLRLTG 3269FRYsGKTERFFRKNLLRLTG 3270 FRYsGKTEYFFRKNLLRLTG 3271FSDsHEGFSYFFRKNLLRLTG 3272 FSEsHEGFSYFFRKNLLRLTG 3273FSEsPSKLFFRKNLLRLTG 3274 FSEsPSKYFFRKNLLRLTG 3275FSIsPVRFFFRKNLLRLTG 3276 FSIsPVRLFFRKNLLRLTG 3277FSIsPVRMFFRKNLLRLTG 3278 FSIsPVRVFFRKNLLRLTG 3279FSsSHEGFSYFFRKNLLRLTG 3280 FSSsHEGFSYFFRKNLLRLTG 3281FTDsHEGFSYFFRKNLLRLTG 3282 FTEsHEGFSYFFRKNLLRLTG 3283FTEsPSKLFFRKNLLRLTG 3284 FTEsPSKYFFRKNLLRLTG 3285FTKsPYQEFFFRKNLLRLTG 3286 FTsSHEGFSYFFRKNLLRLTG 3287FVSKVMIGsPKKVFFRKNLLRLTG 3288 GALsPSLLHSLFFRKNLLRLTG 3289GAQPGRHsFFFRKNLLRLTG 3290 GAQPGRHsLFFRKNLLRLTG 3291GAQPGRHsVFFRKNLLRLTG 3292 GDDDWTHLsSKEVDFFRKNLLRLTG 3293GDDDWTHLsSKEVDPFFRKNLLRLTG 3294 GDDDWTHLsSKEVDPSFFRKNLLRLTG 3295GDDDWTHLsSKEVDPSTFFRKNLLRLTG 3296 GDDDWTHLsSKEVDPSTGFFRKNLLRLTG3297 GEAsPSHIIFFRKNLLRLTG 3298 GEEsSDDGKKFFFRKNLLRLTG 3299GEEsSDDGKKWFFRKNLLRLTG 3300 GEEsSDDGKMKYFFRKNLLRLTG 3301GEEsSDIDGKKFFFRKNLLRLTG 3302 GEIsPQREVFFRKNLLRLTG 3303GERsPLLSQETAGQKPFFRKNLLRLTG 3304 GERsPLLSQETAGQKPLFFRKNLLRLTG 3305GETsPRTKIFFRKNLLRLTG 3306 GGDDDWTHLsSKEVDPSFFRKNLLRLTG 3307GGDDDWTHLsSKEVDPSTGFFRKNLLRLTG 3308 GGSFGGRSSGsPFFRKNLLRLTG 3309GGSFGGRSSGsVFFRKNLLRLTG 3310 GIDsPSSSVFFRKNLLRLTG 3311GIMsPLAKKFFRKNLLRLTG 3312 GLAPtPPSMFFRKNLLRLTG 3313GLDsGFHSVFFRKNLLRLTG 3314 GLDsLDQVEIFFRKNLLRLTG 3315GLGELLRsLFFRKNLLRLTG 3316 GLIRSRsFIFKFFRKNLLRLTG 3317GLIRSRsFIFYFFRKNLLRLTG 3318 GLIsPELRHLFFRKNLLRLTG 3319GLIsPNVQLFFRKNLLRLTG 3320 GLIsPVWGAFFRKNLLRLTG 3321GLItPGGFSSVFFRKNLLRLTG 3322 GLLDsPTSIFFRKNLLRLTG 3323GLLGSpARLFFRKNLLRLTG 3324 GLLGsPVRAFFRKNLLRLTG 3325GLLGsPVRVFFRKNLLRLTG 3326 GLLsPARLYAIFFRKNLLRLTG 3327GLLsPARLYAVFFRKNLLRLTG 3328 GLLsPRFVDVFFRKNLLRLTG 3329GLLsPRHSLFFRKNLLRLTG 3330 GLSFGGRSSGsPFFRKNLLRLTG 3331GLSFGGRSSGsVFFRKNLLRLTG 3332 GMLGsPVRVFFRKNLLRLTG 3333GMLsPARLYAIFFRKNLLRLTG 3334 GMLsPARLYAVFFRKNLLRLTG 3335GMLsPGKSIEVFFRKNLLRLTG 3336 GPKPLFRRMsSFFRKNLLRLTG 3337GPKPLFRRMsSLFFRKNLLRLTG 3338 GPKPLFRRMsSLVFFRKNLLRLTG 3339GPKPLFRRMsSLVGFFRKNLLRLTG 3340 GPKPLFRRMsSLVGPFFRKNLLRLTG 3341GPKPLFRRMsSLVGPTFFRKNLLRLTG 3342 GPKPLFRRMsSLVGPTQFFRKNLLRLTG 3343GPKPLFRRMsSLVGPTQSFFRKNLLRLTG 3344 GPPYQRRGsLFFRKNLLRLTG 3345GPQPGRHsFFFRKNLLRLTG 3346 GPQPGRHsLFFRKNLLRLTG 3347GPQPGRHsVFFRKNLLRLTG 3348 GPRPGsPSAFFFRKNLLRLTG 3349GPRPGsPSALFFRKNLLRLTG 3350 GPRPGsPSAMFFRKNLLRLTG 3351GPRPGsPSAVFFRKNLLRLTG 3352 GPRSAsLLFFRKNLLRLTG 3353GPRsASLLSFFFRKNLLRLTG 3354 GPRSAsLLsFFFRKNLLRLTG 3355GPRSASLLsFFFRKNLLRLTG 3356 GPRsAsLLSLFFRKNLLRLTG 3357GPRsASLLSLFFRKNLLRLTG 3358 GPRSAsLLsLFFRKNLLRLTG 3359GPRSAsLLSLFFRKNLLRLTG 3360 GPRSASLLsLFFRKNLLRLTG 3361GPRsASLLSMFFRKNLLRLTG 3362 GPRSAsLLsMFFRKNLLRLTG 3363GPRSASLLsMFFRKNLLRLTG 3364 GPRsASLLSVFFRKNLLRLTG 3365GPRSAsLLsVFFRKNLLRLTG 3366 GPRSASLLsVFFRKNLLRLTG 3367GPRsPKAPPFFRKNLLRLTG 3368 GPRsPPVTLFFRKNLLRLTG 3369GQLsPGVQFFFRKNLLRLTG 3370 GRKsPPPSKFFRKNLLRLTG 3371GRKsPPPSKFFRKNLLRLTG 3372 GRKsPPPSLFFRKNLLRLTG 3373GRKsPPPSMFFRKNLLRLTG

3374 GRKsPPPSRFFRKNLLRLTG 3375 GRKsPPPSYFFRKNLLRLTG 3376GRLGsPHRFFFRKNLLRLTG 3377 GRLGsPHRKFFRKNLLRLTG 3378GRLGsPHRLFFRKNLLRLTG 3379 GRLGsPHRMFFRKNLLRLTG 3380GRLGsPHRRFFRKNLLRLTG 3381 GRLGsPHRYFFRKNLLRLTG 3382GRLsPAYSLFFRKNLLRLTG 3383 GRLsPKASQVFFFRKNLLRLTG 3384GRLsPKASQVKFFRKNLLRLTG 3385 GRLsPKASQVLFFRKNLLRLTG 3386GRLsPKASQVMFFRKNLLRLTG 3387 GRLsPKASQVRFFRKNLLRLTG 3388GRLsPKASQVYFFRKNLLRLTG 3389 GRLsPVPVPFFFRKNLLRLTG 3390GRLsPVPVPKFFRKNLLRLTG 3391 GRLsPVPVPLFFRKNLLRLTG 3392GRLsPVPVPMFFRKNLLRLTG 3393 GRLsPVPVPRFFRKNLLRLTG 3394GRLsPVPVPYFFRKNLLRLTG 3395 GRQsPSFKLFFRKNLLRLTG 3396GRsSPPPGYFFRKNLLRLTG 3397 GRSsTASLVKFFFRKNLLRLTG 3398GRSsTASLVKKFFRKNLLRLTG 3399 GRSsTASLVKKKFFRKNLLRLTG 3400GRSsTASLVKLFFRKNLLRLTG 3401 GRSsTASLVKMFFRKNLLRLTG 3402GRSsTASLVKRFFRKNLLRLTG 3403 GRSsTASLVKYFFRKNLLRLTG 3404GRtGLPDLFFRKNLLRLTG 3405 GSALGGGGAGLSGRASGGAQsPLRYLHVFFRKNLLRLTG3406 GSDsSDDGKKYFFRKNLLRLTG 3407 GSEsSDDGKKYFFRKNLLRLTG 3408GsPHYFSPFFFRKNLLRLTG 3409 GsPHYFSPFRPYFFRKNLLRLTG 3410GsPTMVEKGLEPGVFTLFFRKNLLRLTG 3411 GsQLAVMMYLFFRKNLLRLTG 3412GTDsSDDGKKYFFRKNLLRLTG 3413 GTEsSDDGKKYFFRKNLLRLTG 3414GTIRSRsFIFKFFRKNLLRLTG 3415 GTIRSRsFIFYFFRKNLLRLTG 3416GtLPKYFFRKNLLRLTG 3417 GtLRRSDSQQAVKFFRKNLLRLTG 3418GtLRRSDSQQAVKSFFRKNLLRLTG 3419 GtLRRSDSQQAVKSPPFFRKNLLRLTG 3420GVAsPTITVFFRKNLLRLTG 3421 GVVsPTFELFFRKNLLRLTG 3422HEKKAYsFFFRKNLLRLTG 3423 HKGEIRGASTPFQFRAssPFFRKNLLRLTG 3424HLHsPQHKLFFRKNLLRLTG 3425 HPKRSVsLFFRKNLLRLTG 3426HPRsPNVLFFRKNLLRLTG 3427 HPRsPNVLSFFFRKNLLRLTG 3428HPRsPNVLSLFFRKNLLRLTG 3429 HPRsPNVLSMFFRKNLLRLTG 3430HPRsPNVLSVFFRKNLLRLTG 3431 HPRsPTPTFFFRKNLLRLTG 3432HPRSPtPTFFFRKNLLRLTG 3433 HPRsPTPTLFFRKNLLRLTG 3434HPRSPtPTLFFRKNLLRLTG 3435 HPRsPTPTMFFRKNLLRLTG 3436HPRSPtPTMFFRKNLLRLTG 3437 HPRSPtPTVFFRKNLLRLTG 3438HPsSPTPTVFFRKNLLRLTG 3439 HRLsPVKGEFFFRKNLLRLTG 3440HRLsPVKGEKFFRKNLLRLTG 3441 HRLsPVKGERFFRKNLLRLTG 3442HRLsPVKGEYFFRKNLLRLTG 3443 HRNsMKVFLFFRKNLLRLTG 3444HRNsNPVIAEFFFRKNLLRLTG 3445 HRNsNPVIAEKFFRKNLLRLTG 3446HRNsNPVIAELFFRKNLLRLTG 3447 HRNsNPVIAERFFRKNLLRLTG 3448HRNsNPVIAEYFFRKNLLRLTG 3449 HRYsTPHAFFFRKNLLRLTG 3450HTAsPTGMMKFFRKNLLRLTG 3451 HVYtPSTTKFFRKNLLRLTG 3452IEKIyIMKADTVIVGFFRKNLLRLTG 3453 IIEtPHKEIFFRKNLLRLTG 3454IIEtPHKEYFFRKNLLRLTG 3455 IISsPLKGYFFRKNLLRLTG 3456IISsPLTGKFFRKNLLRLTG 3457 ILDRtPEKLFFRKNLLRLTG 3458ILDRtPEKVFFRKNLLRLTG 3459 ILDsGIYRIFFRKNLLRLTG 3460ILDsGIYRVFFRKNLLRLTG 3461 ILKPRRsLFFRKNLLRLTG 3462ILKsPEIQRAFFRKNLLRLTG 3463 ILKsPEIQRVFFRKNLLRLTG 3464ILQtPQFQMFFRKNLLRLTG 3465 ILQVsIPSLFFRKNLLRLTG 3466IMDRtPEKLFFRKNLLRLTG 3467 IMDRtPEKVFFRKNLLRLTG 3468IMDsGIYRIFFRKNLLRLTG 3469 IMDsGIYRVFFRKNLLRLTG 3470IMKsPEIQRAFFRKNLLRLTG 3471 IMKsPEIQVRFFRKNLLRLTG 3472INKERRSsLFFRKNLLRLTG 3473 IPVgSSHNSLFFRKNLLRLTG 3474IQFsPPFPGAFFRKNLLRLTG 3475 ISDGtLKYFFRKNLLRLTG 3476ISDGtPLKYFFRKNLLRLTG 3477 ISDSAHtDYFFRKNLLRLTG 3478ISDsMHSLYFFRKNLLRLTG 3479 ISDtPHKEIFFRKNLLRLTG 3480ISDtPHKEYFFRKNLLRLTG 3481 ISEGtLKYFFRKNLLRLTG 3482ISEGtPLKYFFRKNLLRLTG 3483 ISESAHtDYFFRKNLLRLTG 3484ISEsMHSLYFFRKNLLRLTG 3485 ISEtPHKEIFFRKNLLRLTG 3486ISEtPHKEYFFRKNLLRLTG 3487 ISFSAHtDYFFRKNLLRLIG 3488ISSsMHSLYFFRKNLLRLTG 3489 IStDRDPLFFRKNLLRLTG 3490IStDRDPYFFRKNLLRLIG 3491 ITDGtLKYFFRKNLLRLTG 3492ITDGtPLKYFFRKNLLRLTG 3493 ITDSAHtDYFFRKNLLRLTG 3494ITDsMHSLYFFRKNLLRLTG 3495 ITDtPHKEIFFRKNLLRLTG 3496ITDtPHKEYFFRKNLLRLTG 3497 ITEGtLKYFFRKNLLRLTG 3498ITEGtPLKYFFRKNLLRLTG 3499 ITESAHtDYFFRKNLLRLTG

3500 ITEsMHSLYFFRKNLLRLTG 3501 ITEtPHKEIFFRKNLLRLTG 3502ITEtPHKEYFFRKNLLRLTG 3503 ITQGtLKYFFRKNLLRLTG 3504ITQGtPLKKFFRKNLLRLTG 3505 ITQGtPLKYFFRKNLLRLTG 3506ITtDRDPLFFRKNLLRLTG 3507 ITtDRDPYFFRKNLLRLTG 3508IVLsDSEVIQLFFRKNLLRLTG 3509 IVRyHQLFFRKNLLRLTG 3510IVtDRDPLFFRKNLLRLTG 3511 IVtDRDPYFFRKNLLRLTG 3512IYQyIQSRFFFRKNLLRLTG 3513 KAFsPVRFFRKNLLRLTG 3514KAFsPVRSVFFRKNLLRLTG 3515 KAKsPAPGLFFRKNLLRLTG 3516KAKsPAPGVFFRKNLLRLTG 3517 KARsPGRAFFFRKNLLRLTG 3518KARsPGRALFFRKNLLRLTG 3519 KARsPGRAMFFRKNLLRLTG 3520KARsPGRAVFFRKNLLRLTG 3521 KASPKRLsLFFRKNLLRLTG 3522KAVsLFLcYFFRKNLLRLTG 3523 KAVsLFLCYFFRKNLLRLTG 3524KEGEEPTVYsDEEEPKDESARKNDFFRKNLLRLTG 3525 KEKsPFRETFFRKNLLRLTG 3526KELARQIsFFFRKNLLRLTG 3527 KEMsPTRQFFFRKNLLRLTG 3528KEmsPTRQLFFRKNLLRLTG 3529 KEMsPTRQLFFRKNLLRLTG 3530KEMsPTRQWFFRKNLLRLTG 3531 KEMsPTRQYFFRKNLLRLTG 3532KESsPLSSRKIFFRKNLLRLTG 3533 KFRPPPLsLFFRKNLLRLTG 3534KGIsSSSLKEKFFRKNLLRLTG 3535 KIAsEIAQLFFRKNLLRLTG 3536KIDIVsSQKVFFRKNLLRLTG 3537 KIDsPTKVKKFFRKNLLRLTG 3538KIEKIyIMKADTVIVGFFRKNLLRLTG 3539 KIEsLENLYLFFRKNLLRLTG 3540KIFsGVFVKFFRKNLLRLTG 3541 KIFsGVFVKVFFRKNLLRLTG 3542KIFsKQQGKFFRKNLLRLTG 3543 KIFsKQQGYFFRKNLLRLTG 3544KIGsIIFQVFFRKNLLRLTG 3545 KIKsFEVVFFFRKNLLRLTG 3546KIRSsPREAKFFRKNLLRLTG 3547 KIRSsPREAYFFRKNLLRLTG 3548KIRTsPTFRFFRKNLLRLTG 3549 KIRTsPTFYFFRKNLLRLTG 3550KLAsLEREASVFFRKNLLRLTG 3551 KLAsLLHQVFFRKNLLRLTG 3552KLAsPEKLAGLFFRKNLLRLTG 3553 KLAsPELERLFFRKNLLRLTG 3554KLAsPELERVFFRKNLLRLTG 3555 KLDIVsSQKVFFRKNLLRLTG 3556KLDsFLDMQVFFRKNLLRLTG 3557 KLDsPRVTVFFRKNLLRLTG 3558KLDsPTKVKKFFRKNLLRLTG 3559 KLDsPTKVKYFFRKNLLRLTG 3560KLFPDtPLALFFRKNLLRLTG 3561 KLFPDtPLAVFFRKNLLRLTG 3562KLFsGTVRKFFRKNLLRLTG 3563 KLFsGVFVKVFFRKNLLRLTG 3564KLFsKQQGKFFRKNLLRLTG 3565 KLFsKQQGYFFRKNLLRLTG 3566KLFsPAHKKFFRKNLLRLTG 3567 KLFsPAHKYFFRKNLLRLTG 3568KLFsPSKEAELFFRKNLLRLTG 3569 KLFsPSKEAEVFFRKNLLRLTG 3570KLHGsLARAGKFFRKNLLRLTG 3571 KLHGsLARAGYFFRKNLLRLTG 3572KLIDIVsSQKVFFRKNLLRLTG 3573 KLIDRTEsLFFRKNLLRLTG 3574KLIDVsSQKVFFRKNLLRLTG 3575 KLIsSSSLKEKFFRKNLLRLTG 3576KLIsSSSLKEYFFRKNLLRLTG 3577 KLKDRLPsIFFRKNLLRLTG 3578KLKsNPDFLKFFRKNLLRLTG 3579 KLKsNPDFLKKFFRKNLLRLTG 3580KLKsNPDFLKYFFRKNLLRLTG 3581 KLKsPAPGLFFRKNLLRLTG 3582KLKsPAPGVFFRKNLLRLTG 3583 KLKsQEIFLFFRKNLLRLTG 3584KLKSsPLIEKKFFRKNLLRLTG 3585 KLKSsPLIEKYFFRKNLLRLTG 3586KLKtPLVAKFFRKNLLRLTG 3587 KLKtPLVARFFRKNLLRLTG 3588KLLDFGSLsNLQVFFRKNLLRLTG 3589 KLLQFYPsLFFRKNLLRLTG 3590KLLQFYPsVFFRKNLLRLTG 3591 KLLsPSDEKLFFRKNLLRLTG 3592KLLsPSNEKLFFRKNLLRLTG 3593 KLLsPSNEKVFFRKNLLRLTG 3594KLLSSAQRtLFFRKNLLRLTG 3595 KLLSSAQRtVFFRKNLLRLTG 3596KLLsTEEMELFFRKNLLRLTG 3597 KLLsTEEMEVFFRKNLLRLTG 3598KLLsVERIKFFRKNLLRLTG 3599 KLLtPIKEKFFRKNLLRLTG 3600KLLtPIKEYFFRKNLLRLTG 3601 KLMAPDIsLFFRKNLLRLTG 3602KLMAPDIsVFFRKNLLRLTG 3603 KLMIDRTEsVFFRKNLLRLTG 3604KLMsDVEDVFFRKNLLRLTG 3605 KLMsPKADVFFRKNLLRLTG 3606KLMsPKADVKLFFRKNLLRLTG 3607 KLMsPKADVKVFFRKNLLRLTG 3608KLPDsPALAFFRKNLLRLTG 3609 KLPDsPALAKFFRKNLLRLTG 3610KLPDsPALAKKFFRKNLLRLTG 3611 KLPDsPALAKYFFRKNLLRLTG 3612KLPDsPALAYFFRKNLLRLTG 3613 KLPsPAPARKFFRKNLLRLTG 3614KLPTsPLKMKFFRKNLLRLTG 3615 KLPTsPLKMYFFRKNLLRLTG 3616KLPTtPVKAKFFRKNLLRLTG 3617 KLPTtPVKAYFFRKNLLRLTG 3618KLQEFLQtLFFRKNLLRLTG 3619 KLQVtSLSVFFRKNLLRLTG 3620KLRsPFLQKFFRKNLLRLTG 3621 KLRsPFLQYFFRKNLLRLTG 3622KLRSsPREAKFFRKNLLRLTG 3623 KLRTsPTFKFFRKNLLRLTG 3624KLsGDQPAARFFRKNLLRLTG

3625 KLSGLsFFFRKNLLRLTG 3626 KLSsLGNLKFFRKNLLRLTG 3627KLSsLGNLKKFFRKNLLRLTG 3628 KLSsLGNLKYFFRKNLLRLTG 3629KLSsPRGGMKFFRKNLLRLTG 3630 KLSsPRGGMKKFFRKNLLRLTG 3631KLSsPRGGMKYFFRKNLLRLTG 3632 KLsVIAEDSESGKQNFFRKNLLRLTG 3633KLsVIAEDSESGKQNPFFRKNLLRLTG 3634 KLsVIAEDSESGKQNPGFFRKNLLRLTG 3635KLVSFHDDsDEDLFFRKNLLRLTG 3636 KLYsEIDIKVFFRKNLLRLTG 3637KLYsGNMEKFFRKNLLRLTG 3638 KMAsLLHQVFFRKNLLRLTG 3639KMAsPELERLFFRKNLLRLTG 3640 KMAsPELERVFFRKNLLRLTG 3641KMDIVsSQKVFFRKNLLRLTG 3642 KMDsFLDMQLFFRKNLLRLTG 3643KMDsFLDMQVFFRKNLLRLTG 3644 KMDsPRVTVFFRKNLLRLTG 3645KMDsPTKVKKFFRKNLLRLTG 3646 KMFPDtPLALFFRKNLLRLTG 3647KMFPDtPLAVFFRKNLLRLTG 3648 KMFsGTVRKFFRKNLLRLTG 3649KMFsGVFVKVFFRKNLLRLTG 3650 KMFsKQQGKFFRKNLLRLTG 3651KMFsPAHKKFFRKNLLRLTG 3652 KMFsPSKEAELFFRKNLLRLTG 3653KMFsPSKEAEVFFRKNLLRLTG 3654 KMHGsLARAGKFFRKNLLRLTG 3655KMIDIVsSQKVFFRKNLLRLTG 3656 KMIDRTEsLFFRKNLLRLTG 3657KMIsSSSLKEKFFRKNLLRLTG 3658 KMKsNPDFLKFFRKNLLRLTG 3659KMKsNPDFLKKFFRKNLLRLTG 3660 KMKsNPDFLKYFFRKNLLRLTG 3661KMKSsPLIEKKFFRKNLLRLTG 3662 KMKtPLVAKFFRKNLLRLTG 3663KMKtPLVARFFRKNLLRLTG 3664 KMLDFGSLsNLOVFFRKNLLRLTG 3665KMLDFGSLsNLQVFFRKNLLRLTG 3666 KMLQFYPsLFFRKNLLRLTG 3667KMLsPSNEKLFFRKNLLRLTG 3668 KMLsPSNEKVFFRKNLLRLTG 3669KMLSSAQRtLFFRKNLLRLTG 3670 KMLSSAQRtVFFRKNLLRLTG 3671KMLsVERIKFFRKNLLRLTG 3672 KMLtPIKEKFFRKNLLRLTG 3673KKMAPDIsVFFRKNLLRLIG 3674 KM:MsPKADVKLFFRKNLLRLTG 3675KM:MsPKADVKVFFRKNLLRLTG 3676 KMPTsPLKMKFFRKNLLRLTG 3677KMPTtPVKAKFFRKNLLRLTG 3678 KMPTtPVKAYFFRKNLLRLTG 3679KMRsPFLQKFFRKNLLRLTG 3680 KMRSsPREAKFFRKNLLRLTG 3681KMRTsPTFKFFRKNLLRLTG 3682 KMSsLGNLKFFRKNLLRLTG 3683KMSsLGNLKKFFRKNLLRLTG 3684 KMSsLGNLKYFFRKNLLRLTG 3685KMSsPRGGMKFFRKNLLRLTG 3686 KMSsPRGGMKKFFRKNLLRLTG 3687KMYsEIDIKVFFRKNLLRLTG 3688 KMYsGNMEKFFRKNLLRLTG 3689KNRsWKYNFFRKNLLRLTG 3690 KNRsWKYNQFFRKNLLRLTG 3691KNRsWKYNQSISLRFFRKNLLRLTG 3692 KNRsWKYNQSISLRRPFFRKNLLRLTG 3693KPAsPARRFFFRKNLLRLTG 3694 KPAsPARRLFFRKNLLRLTG 3695KPAsPARRMFFRKNLLRLTG 3696 KPAsPARRVFFRKNLLRLTG 3697KPAsPKFIVTFFFRKNLLRLTG 3698 KPAsPKFIVTLFFRKNLLRLTG 3699KPAsPKFIVTMFFRKNLLRLTG 3700 KPAsPKFIVTVFFRKNLLRLTG 3701KPEsRRSSLFFRKNLLRLTG 3702 KPEsRRsSLLFFRKNLLRLTG 3703KPEsRRSsLLFFRKNLLRLTG 3704 KPEsRRSSLLFFRKNLLRLTG 3705KPLIRsQSLFFRKNLLRLTG 3706 KPLIRSQsLFFRKNLLRLTG 3707KPPHsPLVFFFRKNLLRLTG 3708 KPPHsPLVLFFRKNLLRLTG 3709KPPHsPLVMFFRKNLLRLTG 3710 KPPHsPLVVFFRKNLLRLTG 3711KPPsPEHQSFFFRKNLLRLTG 3712 KPPsPEHQSLFFRKNLLRLTG 3713KPPsPEHQSMFFRKNLLRLTG 3714 KPPsPEHQSVFFRKNLLRLTG 3715KPPsPSPIEFFFRKNLLRLTG 3716 KPPsPSPIELFFRKNLLRLTG 3717KPPsPSPIEMFFRKNLLRLTG 3718 KPPsPSPIEVFFRKNLLRLTG 3719KPPtPGASFFFRKNLLRLTG 3720 KPPtPGASLFFRKNLLRLTG 3721KPPtPGASMFFRKNLLRLTG 3722 KPPtPGASVFFRKNLLRLTG 3723KPPYRSHsFFFRKNLLRLTG 3724 KPPYRSHsLFFRKNLLRLTG 3725KPPYRSHsMFFRKNLLRLTG 3726 KPPYRSHsVFFRKNLLRLTG 3727KPQTRGKtFFFRKNLLRLTG 3728 KPQTRGKtLFFRKNLLRLTG 3729KPQTRGKtMFFRKNLLRLTG 3730 KPQTRGKtVFFRKNLLRLTG 3731KPRPLsMDLFFRKNLLRLTG 3732 KPRPPPLsFFFRKNLLRLTG 3733KPRPPPLsLFFRKNLLRLTG 3734 KPRPPPLsMFFRKNLLRLTG 3735KPRPPPLsPFFRKNLLRLTG 3736 KPRPPPLsVFFRKNLLRLTG 3737KPRRFsRsLFFRKNLLRLTG 3738 KPRRFsRSLFFRKNLLRLTG 3739KPRsPDHVFFFRKNLLRLTG 3740 KPRsPDHVLFFRKNLLRLTG 3741KPRsPDHVMFFRKNLLRLTG 3742 KPRsPDHVVFFRKNLLRLTG 3743KPRsPFSKIFFRKNLLRLTG 3744 KPRsPPRAFFFRKNLLRLTG 3745KPRsPPRALFFRKNLLRLTG 3746 KPRsPPRALFFFRKNLLRLTG 3747KPRsPPRALLFFRKNLLRLTG 3748 KPRsPPRALMFFRKNLLRLTG 3749KPRsPPRALVFFRKNLLRLTG 3750 KPRsPPRALVFFFRKNLLRLTG

3751 KPRsPPRALVLFFRKNLLRLTG 3752 KPRsPPRALVLFFFRKNLLRLTG 3753KPRsPPRALVLLFFRKNLLRLTG 3754 KPRsPPRALVLMFFRKNLLRLTG 3755KPRsPPRALVLPFFRKNLLRLTG 3756 KPRsPPRALVLVFFRKNLLRLTG 3757KPRsPPRALVMFFRKNLLRLTG 3758 KPRsPPRALVVFFRKNLLRLTG 3759KPRsPPRAMFFRKNLLRLTG 3760 KPRsPPRAVFFRKNLLRLTG 3761KPRsPVVEFFFRKNLLRLTG 3762 KPRsPVVELFFRKNLLRLTG 3763KPRsPVVEMFFRKNLLRLTG 3764 KPRsPVVEVFFRKNLLRLTG 3765KPSsPRGSLFFRKNLLRLTG 3766 KPSsPRGSLLFFRKNLLRLTG 3767KPVsPKSGTLFFRKNLLRLTG 3768 KPYsPLASFFFRKNLLRLTG 3769KPYsPLASLFFRKNLLRLTG 3770 KPYsPLASMFFRKNLLRLTG 3771KPYsPLASVFFRKNLLRLTG 3772 KQDsLVINLFFRKNLLRLTG 3773KRAsFAKSFFFRKNLLRLTG 3774 KRAsFAKSKFFRKNLLRLTG 3775KRAsFAKSLFFRKNLLRLTG 3776 KRAsFAKSMFFRKNLLRLTG 3777KRAsFAKSRFFRKNLLRLTG 3778 KRAsFAKSVFFRKNLLRLTG 3779KRAsFAKSYFFRKNLLRLTG 3780 KRAsGQAFEFFFRKNLLRLTG 3781KRAsGQAFEKFFRKNLLRLTG 3782 KRAsGQAFELFFRKNLLRLTG 3783KRAsGQAFERFFRKNLLRLTG 3784 KRAsGQAFEYFFRKNLLRLTG 3785KRASsPFRFFFRKNLLRLTG 3786 KRASsPFRKFFRKNLLRLTG 3787KRASsPFRLFFRKNLLRLTG 3788 KRASsPFRMFFRKNLLRLTG 3789KRASsPFRRFFRKNLLRLTG 3790 KRASsPFRYFFRKNLLRLTG 3791KRAsVFVKFFFRKNLLRLTG 3792 KRAsVFVKKFFRKNLLRLTG 3793KRAsVFVKLFFRKNLLRLTG 3794 KRAsVFVKMFFRKNLLRLTG 3795KRAsVFVKRFFRKNLLRLTG 3796 KRAsVFVKYFFRKNLLRLTG 3797KRAsYILRLFFRKNLLRLTG 3798 KRFsFKFFFRKNLLRLTG 3799KRFsFKKFFRKNLLRLTG 3800 KRFsFKKsFFFRKNLLRLTG 3801KRFsFKKSFFFRKNLLRLTG 3802 KRFsFKKSKFFRKNLLRLTG 3803KRFsFKKSLFFRKNLLRLTG 3804 KRFsFKKSMFFRKNLLRLTG 3805KRFsFKKSRFFRKNLLRLTG 3806 KRFsFKKSYFFRKNLLRLTG 3807KRFsFKLFFRKNLLRLTG 3808 KRFsFKMFFRKNLLRLTG 3809 KRFsFKRFFRKNLLRLTG3810 KRFsFKsSFFFRKNLLRLTG 3811 KRFsFKYFFRKNLLRLTG 3812KRFsGTVRFFFRKNLLRLTG 3813 KRFsGTVRKFFRKNLLRLTG 3814KRFsGTVRLFFRKNLLRLTG 3815 KRFsGTVRMFFRKNLLRLTG 3816KRFsGTVRRFFRKNLLRLTG 3817 KRFsGTVRYFFRKNLLRLTG 3818KRIVIsPKPFFFRKNLLRLTG 3819 KRKsFTSLYFFRKNLLRLTG 3820KRLEKsPSFFFRKNLLRLTG 3821 KRLEKSPsFFFRKNLLRLTG 3822KRLsPAPQFFFRKNLLRLTG 3823 KRLsPAPQKFFRKNLLRLTG 3824KRLsPAPQLFFRKNLLRLTG 3825 KRLsPAPQMFFRKNLLRLTG 3826KRLsPAPQRFFRKNLLRLTG 3827 KRLsPAPQYFFRKNLLRLTG 3828KRLsTSPVRLFFRKNLLRLTG 3829 KRLsVERIFFFRKNLLRLTG 3830KRLsVERIKFFRKNLLRLTG 3831 KRLsVERILFFRKNLLRLTG 3832KRLsVERIMFFRKNLLRLTG 3833 KRLsVERIRFFRKNLLRLTG 3834KRLsVERIYFFRKNLLRLTG 3835 KRMsPKEFFFRKNLLRLTG 3836KRMsPKEKFFRKNLLRLTG 3837 KRMsPKELFFRKNLLRLTG 3838KRMsPKERFFRKNLLRLTG 3839 KRMsPKEYFFRKNLLRLTG 3840KRmsPKPELFFRKNLLRLTG 3841 KRMsPKPELFFRKNLLRLTG 3842KRMsPKPFFFRKNLLRLTG 3843 KRMsPKPKFFRKNLLRLTG 3844KRMsPKPLFFRKNLLRLTG 3845 KRMsPKPMFFRKNLLRLTG 3846KRMsPKPRFFRKNLLRLTG 3847 KRMsPKPYFFRKNLLRLTG 3848KRPEsPPSIFFRKNLLRLTG 3849 KRWQsPVTKFFRKNLLRLTG 3850KRYsEPVSLFFRKNLLRLTG 3851 KRYsGNMEFFFRKNLLRLTG 3852KRYsGNMEKFFRKNLLRLTG 3853 KRYsGNMELFFRKNLLRLTG 3854KRYsGNMEMFFRKNLLRLTG 3855 KRYsGNMERFFRKNLLRLTG 3856KRYsGNmEYFFRKNLLRLTG 3857 KRYsGNMEYFFRKNLLRLTG 3858KRYsRALYLFFRKNLLRLTG 3859 KSDsRQERYFFRKNLLRLTG 3860KSEsRQERYFFRKNLLRLTG 3861 KSGELLAtWFFRKNLLRLTG 3862KSKsNPDFLKKFFRKNLLRLTG 3863 KSKsNPFLKKFFRKNLLRLTG 3864KSKtPLVAKFFRKNLLRLTG 3865 KSKtPLVARFFRKNLLRLTG 3866KSKtPLVAYFFRKNLLRLTG 3867 KsLVRLLLLFFRKNLLRLTG 3868KSSsLGNLKKFFRKNLLRLTG 3869 KsVKALSSLHGDDQFFRKNLLRLTG 3870KsVKALSSLHGDDQDFFRKNLLRLTG 3871 KsVKALSSLHGDDQDsEDEFFRKNLLRLTG 3872KSVKALSSLHGDDQDsEDEFFRKNLLRLTG 3873 KTDsRQEYRFFRKNLLRLTG 3874KTEsRQERYFFRKNLLRLTG 3875 KtLSPGKNGVVKFFRKNLLRLTG

3876 KtLSPGKNGVVYFFRKNLLRLTG 3877 KTMsGTFLLFFRKNLLRLTG 3878KTMsPSQMIMFFRKNLLRLTG 3879 KTPTsPLKMKFFRKNLLRLTG 3880KTPTsPLKMYFFRKNLLRLTG 3881 KTWKGsIGLFFRKNLLRLTG 3882KVAsLLHQVFFRKNLLRLTG 3883 KVDsPVIFFFRKNLLRLTG 3884KVHGsLARAGKFFRKNLLRLTG 3885 KVHGsLARAGYFFRKNLLRLTG 3886KVKSsPLIEKKFFRKNLLRLTG 3887 KVKsSPLIEKLFFRKNLLRLTG 3888KVKSsPLIEKLFFRKNLLRLTG 3889 KVKSsPLIEKYFFRKNLLRLTG 3890KVLsKEFHLFFRKNLLRLTG 3891 KVLSPtAAKFFRKNLLRLTG 3892KVLsSLVTLFFRKNLLRLTG 3893 KVLsTEEMELFFRKNLLRLTG 3894KVLStEEMELFFRKNLLRLTG 3895 KVLtPIKeKFFRKNLLRLTG 3896KVLtPIKEKFFRKNLLRLTG 3897 KVLtPIKEYFFRKNLLRLTG 3898KVPDsPALAKFFRKNLLRLTG 3899 KVPDsPALAKKFFRKNLLRLTG 3900KVPDsPALAKYFFRKNLLRLTG 3901 KVPDsPALAYFFRKNLLRLTG 3902KVPTsPLKMYFFRKNLLRLTG 3903 KVQsLRRALFFRKNLLRLTG 3904KVQVtSLSVFFRKNLLRLTG 3905 KVYsSSEFLFFRKNLLRLTG 3906KYIsGPHELFFRKNLLRLTG 3907 KYsPGKLRGNFFRKNLLRLTG 3908LGGGGAGLSGRASGGAQsPLRYLHVFFRKNLLRLTG 3909 LKLsYLTWVFFRKNLLRLTG 3910LLAsPGHISVFFRKNLLRLTG 3911 LLDPSRSYsYFFRKNLLRLTG 3912LLDtPVKTQYFFRKNLLRLTG 3913 LLFsPVTSLFFRKNLLRLTG 3914LLFsPVTSVFFRKNLLRLTG 3915 LLLsEEVELFFRKNLLRLTG 3916LLNKSsPVKFFRKNLLRLTG 3917 LLNKSsPVKKFFRKNLLRLTG 3918LLNKSsPVKYFFRKNLLRLTG 3919 LMFsPVTSLFFRKNLLRLTG 3920LMFsPVTSVFFRKNLLRLTG 3921 LMFsVTSIFFRKNLLRLTG 3922LMFsVTSLFFRKNLLRLTG 3923 LMNKSsPVKFFRKNLLRLTG 3924LMNKSsPVKKFFRKNLLRLTG 3925 LMNKSsPVKYFFRKNLLRLTG 3926LPAsPHQFFFRKNLLRLTG 3927 LPAsPHQLFFRKNLLRLTG 3928LPAsPHQMFFRKNLLRLTG 3929 LPAsPHQVFFRKNLLRLTG 3930LPAsPRARFFFRKNLLRLTG 3931 LPAsPRARLFFRKNLLRLTG 3932LPAsPRARMFFRKNLLRLTG 3933 LPAsPRARVFFRKNLLRLTG 3934LPIFSRLsFFFRKNLLRLTG 3935 LPIFSRLsIFFRKNLLRLTG 3936LPIFSRLsLFFRKNLLRLTG 3937 LPIFSRLsMFFRKNLLRLTG 3938LPIFSRLsVFFRKNLLRLTG 3939 LPKGLsASLFFRKNLLRLTG 3940LPKGLSAsLFFRKNLLRLTG 3941 LPKsPPYTAFFFRKNLLRLTG 3942LPKsPPYTALFFRKNLLRLTG 3943 LPKsPPYTAMFFRKNLLRLTG 3944LPKsPPYTAVFFRKNLLRLTG 3945 LPRGSsPSVFFFRKNLLRLTG 3946LPRGsSPSVLFFRKNLLRLTG 3947 LPRGSsPSVLFFRKNLLRLTG 3948LPRGSsPSVMFFRKNLLRLTG 3949 LPRGSsPSVVFFRKNLLRLTG 3950LPRmIsHSELFFRKNLLRLTG 3951 LPRMIsHSELFFRKNLLRLTG 3952LPRPAsPALFFRKNLLRLTG 3953 LPRSSsMAAFFRKNLLRLTG 3954LPRSSsMAAGLFFRKNLLRLTG 3955 LPRtPRPELFFRKNLLRLTG 3956LPVsPRLQLFFRKNLLRLTG 3957 LQLsPLKGLSLFFRKNLLRLTG 3958LQNItENQLFFRKNLLRLTG 3959 LSDPSRSYsYFFRKNLLRLTG 3960LSDsDTEAKLFFRKNLLRLTG 3961 LSDsDTEAKYFFRKNLLRLTG 3962LSDtPVKTQYFFRKNLLRLTG 3963 LSEPSRSYsYFFRKNLLRLTG 3964LSEsDTEAKLFFRKNLLRLTG 3965 LSEsDTEAKYFFRKNLLRLTG 3966LSEtPVKTQYFFRKNLLRLTG 3967 LSKFRMPQPSSGREsPRHFFRKNLLRLTG 3968LSSsVIRELFFRKNLLRLTG 3969 LTDPSRSYsYFFRKNLLRLTG 3970LTDPSsPTISSYFFRKNLLRLTG 3971 LTDsDTEAKLFFRKNLLRLTG 3972LTDsDTEAKYFFRKNLLRLTG 3973 LTDtPVKTQYFFRKNLLRLTG 3974LTEPSRSYsYFFRKNLLRLTG 3975 LTEsDTEAKLFFRKNLLRLTG 3976LTEsDTEAKYFFRKNLLRLTG 3977 LTEtPVKTOYFFRKNLLRLTG 3978LTEtPVKTQYFFRKNLLRLTG 3979 MLAEsPSVPRLFFRKNLLRLTG 3980MLAEsPSVPRVFFRKNLLRLTG 3981 MLRsPPRVSKFFRKNLLRLTG 3982MMRsPPRVSKFFRKNLLRLTG 3983 MPRPsIKKAQNSQAARQFFRKNLLRLTG 3984MPRQPsAIRMFFRKNLLRLTG 3985 MPRQPsATRFFFRKNLLRLTG 3986MPRQPsATRLFFRKNLLRLTG 3987 MPRQPsATRMFFRKNLLRLTG 3988MPRQPsATRVFFRKNLLRLTG 3989 MRLsEWLQLFFRKNLLRLTG 3990MRLsRELQFFFRKNLLRLTG 3991 MRLsRELQKFFRKNLLRLTG 3992MRLsRELQLFFRKNLLRLTG 3993 MRLsRELQMFFRKNLLRLTG 3994MRLsRELQRFFRKNLLRLTG 3995 MRLsRELQYFFRKNLLRLTG 3996MSDtYRLKYFFRKNLLRLTG 3997 MSEtYRLKYFFRKNLLRLTG 3998MTDtYRLKYFFRKNLLRLTG 3999 MTEtYRLKYFFRKNLLRLTG 4000MTRsPPRVSKFFRKNLLRLTG 4001 MTRsPPRVSYFFRKNLLRLTG

4002 NAPPAYEKLsAEFFRKNLLRLTG 4003 NFKsPVKTIRFFRKNLLRLTG 4004NLELSKFRMPQPSSGREsPRHFFRKNLLRLTG 4005 NLGsRNHVQLFFRKNLLRLTG 4006NLLsPDGKMISVFFRKNLLRLTG 4007 NLVERKNsKFFRKNLLRLTG 4008NLVERKNsLFFRKNLLRLTG 4009 NMDsPGPMLFFRKNLLRLTG 4010NMVERKNsKFFRKNLLRLTG 4011 NMVERKNsLFFRKNLLRLTG 4012NRAMRRVsSVPSRFFRKNLLRLTG 4013 NRAMRRVsSVPSRAQFFRKNLLRLTG 4014NRsWKYNQSISLRFFRKNLLRLTG 4015 NRsWKYNQSISLRRPFFRKNLLRLTG 4016NRYtNRVVTFFFRKNLLRLTG 4017 NRYtNRVVTKFFRKNLLRLTG 4018NRYtNRVVTLFFRKNLLRLTG 4019 NRYtNRVVTMFFRKNLLRLTG 4020NRYtNRVVTRFFRKNLLRLTG 4021 NRYtNRVVTYFFRKNLLRLTG 4022NSDsPLRYFFRKNLLRLTG 4023 NSEsPLRYFFRKNLLRLTG 4024NTDsPLRYFFRKNLLRLTG 4025 NTEsPLRYFFRKNLLRLTG 4026NYVERKNsKFFRKNLLRLTG 4027 NYVERKNsLFFRKNLLRLTG 4028NYVERKNsYFFRKNLLRLTG 4029 PARsPVTEIFFRKNLLRLTG 4030PAYEKLsAEFFRKNLLRLTG 4031 PAYEKLsAEQSPFFRKNLLRLTG 4032PmVTLsLNLFFRKNLLRLTG 4033 PMVTLsLNLFFRKNLLRLTG 4034PNAPPAYEKLsAFFRKNLLRLTG 4035 PPAYEKLsAFFRKNLLRLTG 4036PPAYEKLsAEQSFFRKNLLRLTG 4037 PPLPEDSIKVIRNMRAAsPPAFFRKNLLRLTG 4038PYDPALGsPSRFFRKNLLRLTG 4039 QAASNFKsPVKTIRFFRKNLLRLTG 4040QLDsPQRALYFFRKNLLRLTG 4041 QLEsPQRALYFFRKNLLRLTG 4042QLFsPKKGQKFFRKNLLRLTG 4043 QMFsPKKGQKFFRKNLLRLTG 4044QPQRRsLRLFFRKNLLRLTG 4045 QPRsPGPDYSFFFRKNLLRLTG 4046QPRsPGPDYSLFFRKNLLRLTG 4047 QPRsPGPDYSMFFRKNLLRLTG 4048QPRsPGPDYSVFFRKNLLRLTG 4049 QPRtPsPLVFFFRKNLLRLTG 4050QPRtPSPLVFFFRKNLLRLTG 4051 QPRtPsPLVLFFRKNLLRLTG 4052QPRtPSPLVLFFRKNLLRLTG 4053 QPRtPsPLVMFFRKNLLRLTG 4054QPRtPSPLVMFFRKNLLRLTG 4055 QPRtPsPLVVFFRKNLLRLTG 4056QPRtPSPLVVFFRKNLLRLTG 4057 QPSFPsVLPAFFRKNLLRLTG 4058QRLsPLSAAYFFRKNLLRLTG 4059 QSDsPQRALYFFRKNLLRLTG 4060QSEsPQRALYFFRKNLLRLTG 4061 QTDsPQRALYFFRKNLLRLTG 4062QTEsPQRALYFFRKNLLRLTG 4063 QVAMPVKKSPRRSsSDEQGLSYSSLKNVFFRKNLLRLTG4064 QVFsPKKGQKFFRKNLLRLTG 4065 QVFsPKKGQYFFRKNLLRLTG 4066RADsPVHMFFRKNLLRLTG 4067 RAFsFSKTPKFFRKNLLRLTG 4068RAFsFSKTPYFFRKNLLRLTG 4069 RAFsVKFEVFFRKNLLRLTG 4070RAHsEPLALFFRKNLLRLTG 4071 RAHsSPASLFFRKNLLRLTG 4072RAHSsPASLFFRKNLLRLTG 4073 RAKsPISLKFFRKNLLRLTG 4074RAKsPISLYFFRKNLLRLTG 4075 RAPsPSSRFFFRKNLLRLTG 4076RAPsPSSRLFFRKNLLRLTG 4077 RAPsPSSRMFFRKNLLRLTG 4078RAPsPSSRVFFRKNLLRLTG 4079 RARGIsPIVFFFRKNLLRLTG 4080RASsDIVsLFFRKNLLRLTG 4081 RASsDIVSLFFRKNLLRLTG 4082RASsLSITVFFRKNLLRLTG 4083 REAPsPLmIFFRKNLLRLTG 4084REAPsPLMIFFRKNLLRLTG 4085 REAsPAPLAFFRKNLLRLTG 4086REAsPRLRVFFRKNLLRLTG 4087 REAsPSRLSVFFRKNLLRLTG 4088REDsTPGKVFLFFRKNLLRLTG 4089 REIMGtPEYLFFRKNLLRLTG 4090REKsPGRmLFFRKNLLRLTG 4091 REKsPGRMLFFRKNLLRLTG 4092REKsPLFQFFFRKNLLRLTG 4093 REKsPLFQWFFRKNLLRLTG 4094REKsPLFQYFFRKNLLRLTG 4095 RELARKGsLFFRKNLLRLTG 4096RELsPLISLFFRKNLLRLTG 4097 REPsPLPELFFRKNLLRLTG 4098RERsPSPSFFFRKNLLRLTG 4099 RESsPTRRLFFRKNLLRLTG 4100REVsPAPAVFFRKNLLRLTG 4101 REYGsTSSIFFRKNLLRLTG 4102RFKtQPVTFFFRKNLLRLTG 4103 RGDGYGtFFFRKNLLRLTG 4104TGDsPKIDLFFRKNLLRLTG 4105 RIDsKDSASELFFRKNLLRLTG 4106RIGsPLSPKFFRKNLLRLTG 4107 RISsGVVTKFFRKNLLRLTG 4108RILsGVVTYFFRKNLLRLTG 4109 RILsPSMAKSFFRKNLLRLTG 4110RILsPSMASYFFRKNLLRLTG 4111 RINsFEEHVFFRKNLLRLTG 4112RIQsKLYRAFFRKNLLRLTG 4113 RIQyIQSRFFFRKNLLRLTG 4114RIQyIQSRFYFFRKNLLRLTG 4115 RIsHELDSFFRKNLLRLTG 4116RITsLIVHVFFRKNLLRLTG 4117 RIVQyIQSRFFRKNLLRLTG 4118RIYQyIQFFRKNLLRLTG 4119 RIYQyIQSKFFRKNLLRLTG 4120RIYQyIQSRFFRKNLLRLTG 4121 RIYQyIQSRFFFRKNLLRLTG 4122RIYQyIQSRFKFFRKNLLRLTG 4123 RIYQyIQSRFYFFRKNLLRLTG 4124RIYQyIQSRKFFRKNLLRLTG 4125 RIYQyIQSRYFFRKNLLRLTG 4126RIYQyIQSYFFRKNLLRLTG

4127 RIYQyLQSRFFFRKNLLRLTG 4128 RIYQyLQSRFYFFRKNLLRLTG 4129RKLRsLEQLFFRKNLLRLTG 4130 RKLsVILIKFFRKNLLRLTG 4131RKLsVILILFFRKNLLRLTG 4132 RKLsVILIYFFRKNLLRLTG 4133RKPsIVTKYFFRKNLLRLTG 4134 RKSsIIIRMFFRKNLLRLTG 4135RLAsASRALFFRKNLLRLTG 4136 RLAsFAVRKFFRKNLLRLTG 4137RLAsFAVRYFFRKNLLRLTG 4138 RLAsIELPSMFFRKNLLRLTG 4139RLAsIELPSMAVFFRKNLLRLTG 4140 RLAsIELPSVFFRKNLLRLTG 4141RLAsLNAEALFFRKNLLRLTG 4142 RLAsLNAEAVFFRKNLLRLTG 4143RLAsLQSEVFFRKNLLRLTG 4144 RLAsLSISVFFRKNLLRLTG 4145RLAsPLVHKFFRKNLLRLTG 4146 RLAsPLVHYFFRKNLLRLTG 4147RLAsPPPPPKFFRKNLLRLTG 4148 RLAsPPPPPYFFRKNLLRLTG 4149RLAsPTSGVFFRKNLLRLTG 4150 RLAsPTSGVKFFRKNLLRLTG 4151RLAsPTSGVKKFFRKNLLRLTG 4152 RLAsPTSGVKRFFRKNLLRLTG 4153RLAsPTSGVKYFFRKNLLRLTG 4154 RLAsRPLLLFFRKNLLRLTG 4155RLAsSATQVHKFFRKNLLRLTG 4156 RLAsYLDKVFFRKNLLRLTG 4157RLAsYLDRVFFRKNLLRLTG 4158 RLDsTPGKVFLFFRKNLLRLTG 4159RLDsTPGKVFVFFRKNLLRLTG 4160 RLDsYLRAPFFRKNLLRLTG 4161RLDsYVRFFRKNLLRLTG 4162 RLDsYVRSFFRKNLLRLTG 4163RLDsYVRSLFFRKNLLRLTG 4164 RLDsYVRSVFFRKNLLRLTG 4165RLDtGPQSLFFRKNLLRLTG 4166 RLEsANRRLFFRKNLLRLTG 4167RLFsFSKTPKFFRKNLLRLTG 4168 RLFsKELFFRKNLLRLTG 4169RLFsKELRFFRKNLLRLTG 4170 RLFsKELRCFFRKNLLRLTG 4171RLFsKELRVFFRKNLLRLTG 4172 RLFSLsNPSLFFRKNLLRLTG 4173RLFsPTYGLFFRKNLLRLTG 4174 RLFsPTYGVFFRKNLLRLTG 4175RLFsQGQDVFFRKNLLRLTG 4176 RLFVGsIPKFFRKNLLRLTG 4177RLGsFHELLLFFRKNLLRLTG 4178 RLIsFKAEVFFRKNLLRLTG 4179RLIsPYKKKFFRKNLLRLTG 4180 RLIsQDVKLFFRKNLLRLTG 4181RLIsQDVKVFFRKNLLRLTG 4182 RLKLPsGSKFFRKNLLRLTG 4183RLKLPsGSKKFFRKNLLRLTG 4184 RLKLPsGSKYFFRKNLLRLTG 4185RLKsDERPVHIFFRKNLLRLTG 4186 RLKsPFRKKFFRKNLLRLTG 4187RLKsPGsGHVKFFRKNLLRLTG 4188 RLKsPISLKFFRKNLLRLTG 4189RLKsPISLYFFRKNLLRLTG 4190 RLKsPSPKSEKFFRKNLLRLTG 4191RLKsPSPKSERFFRKNLLRLTG 4192 RLKtPTSQSYKFFRKNLLRLTG 4193RLKtPTSQSYRFFRKNLLRLTG 4194 RLKTtPLRKFFRKNLLRLTG 4195RLKTtPLRRFFRKNLLRLTG 4196 RLLDPsSPLALFFRKNLLRLTG 4197RLLDPSsPLALFFRKNLLRLTG 4198 RLLDRSPsRSAKFFRKNLLRLTG 4199RLLDRSPsRSAYFFRKNLLRLTG 4200 RLLsDGQQHLFFRKNLLRLTG 4201RLLsDLEELFFRKNLLRLTG 4202 RLLsDQTRLFFRKNLLRLTG 4203RLLsFQRYLFFRKNLLRLTG 4204 RLLsGVVTKFFRKNLLRLTG 4205RLLsGVVTYFFRKNLLRLTG 4206 RLLsHISEAFFRKNLLRLTG 4207RLLsHISEVFFRKNLLRLTG 4208 RLLsPLSSAFFRKNLLRLTG 4209RLLsPLSSARLFFRKNLLRLTG 4210 RLLsPLSSVFFRKNLLRLTG 4211RLLsPQQPALFFRKNLLRLTG 4212 RLLsPRPSLFFRKNLLRLTG 4213RLLsPRPSLLFFRKNLLRLTG 4214 RLLsPSMASKFFRKNLLRLTG 4215RLLsSGVSEIFFRKNLLRLTG 4216 RLLsSGVSEVFFRKNLLRLTG 4217RLLsTDAEAVFFRKNLLRLTG 4218 RLLsVEIVKFFRKNLLRLTG 4219RLLsVEIVYFFRKNLLRLTG 4220 RLLsVHDFDFFFRKNLLRLTG 4221RLLsVILIKFFRKNLLRLTG 4222 RLMsMPVAKFFRKNLLRLTG 4223RLMsMPVAYFFRKNLLRLTG 4224 RLNtSDFQKLFFRKNLLRLTG 4225RLPNRIPsLFFRKNLLRLTG 4226 RLPsFLKKNKFFRKNLLRLTG 4227RLPsLVHGYFFRKNLLRLTG 4228 RLPsSTLKKFFRKNLLRLTG 4229RLPsSTLKRFFRKNLLRLTG 4230 RLPsSTLKYFFRKNLLRLTG 4231RLQsLIKNIFFRKNLLRLTG 4232 RLQsTSERLFFRKNLLRLTG 4233RLQsTSERVFFRKNLLRLTG 4234 RLR(sLss)PTVTLFFRKNLLRLTG 4235RLR(sLss)PTVTVFFRKNLLRLTG 4236 RLRQsPLATKFFRKNLLRLTG 4237RLRQsPLATRFFRKNLLRLTG 4238 RLRQsPLATYFFRKNLLRLTG 4239RLRRsPLLKFFRKNLLRLTG 4240 RLRsAGAAQKFFRKNLLRLTG 4241RLRsLSSLREKFFRKNLLRLTG 4242 RLRsPPPVSKFFRKNLLRLTG 4243RLRsYEDMIFFRKNLLRLTG 4244 RLRTsPITRKFFRKNLLRLTG 4245RLRTsPITRRFFRKNLLRLTG 4246 RLSDtPPLLFFRKNLLRLTG 4247RLSsLIRHKFFRKNLLRLTG 4248 RLSsLRASTSKFFRKNLLRLTG 4249RLSsPISKKFFRKNLLRLTG 4250 RLSsPISKRFFRKNLLRLTG 4251RLSsPISKYFFRKNLLRLTG 4252 RLsSPLHFVFFRKNLLRLTG

4253 RLSsPLHFVFFRKNLLRLTG 4254 RLSsPVLHKFFRKNLLRLTG 4255RLSsPVLHRFFRKNLLRLTG 4256 RLSsPVLHYFFRKNLLRLTG 4257RLSsRFSSKFFRKNLLRLTG 4258 RLSsRFSSRFFRKNLLRLTG 4259RLSsRFSSYFFRKNLLRLTG 4260 RLSsRYSQKFFRKNLLRLTG 4261RLSsRYSQYFFRKNLLRLTG 4262 RLSsVKLISKFFRKNLLRLTG 4263RLSsVKLISYFFRKNLLRLTG 4264 RLTFsPTYGVFFRKNLLRLTG 4265RLVsLSMRKFFRKNLLRLTG 4266 RLVsLSMRYFFRKNLLRLTG 4267RLYKsPLRHFFRKNLLRLTG 4268 RLYKsPLRKFFRKNLLRLTG 4269RLYQyIQSKFFRKNLLRLTG 4270 RLYQyIQSRFFRKNLLRLTG 4271RLYQyIQSRFKFFRKNLLRLTG 4272 RLYQyIQSRFYFFRKNLLRLTG 4273RLYQyIQSYFFRKNLLRLTG 4274 RLYQylOSKFFRKNLLRLTG 4275RLYQyLQSRFFFRKNLLRLIG 4276 RLYQyLQSRFKFFRKNLLRLIG 4277RLYQyLQSRFYFFRKNLLRLTG 4278 RLYQyLQSRKFFRKNLLRLIG 4279RLYsGPMNKVFFRKNLLRLTG 4280 RLYsGSRsKFFRKNLLRLTG 4281RLYsGSRsRFFRKNLLRLTG 4282 RLYsGSRsYFFRKNLLRLTG 4283RLYsKSRDKFFRKNLLRLTG 4284 RLYsPDHRQKFFRKNLLRLTG 4285RLYsPERSKFFRKNLLRLTG 4286 RLYsPRNSKFFRKNLLRLTG 4287RLYsPYNHKFFRKNLLRLTG 4288 RLYsPYNHRFFRKNLLRLTG 4289RLYsPYNHYFFRKNLLRLTG 4290 RLYSRsFSKFFRKNLLRLTG 4291RLYSRsFSYFFRKNLLRLTG 4292 RLYsYPRQKFFRKNLLRLTG 4293RLYVTTSTRTYsLGFFRKNLLRLTG 4294 RLYVTTSTRTYsLKFFRKNLLRLTG 4295RLYVTTSTRTYsLYFFRKNLLRLTG 4296 RMAsPPPPPKFFRKNLLRLTG 4297RMAsPTSGVFFRKNLLRLTG 4298 RMAsPTSGVKFFRKNLLRLTG 4299RMAsPTSGVKKFFRKNLLRLTG 4300 RMAsPTSGVKRFFRKNLLRLTG 4301RMAsPTSGVKYFFRKNLLRLTG 4302 RMAsSATQVHKFFRKNLLRLTG 4303RMDsTPGKVFLFFRKNLLRLTG 4304 RMDsTPGKVFVFFRKNLLRLTG 4305RMDsYVRSLFFRKNLLRLTG 4306 RMDsYVRSVFFRKNLLRLTG 4307RMFPtPPSLFFRKNLLRLTG 4308 RMFsFSKTPKFFRKNLLRLTG 4309RMFsKELRCFFRKNLLRLTG 4310 RMFsKELRVFFRKNLLRLTG 4311RMFsPMEEKFFRKNLLRLTG 4312 RMFsPMEEKELLFFRKNLLRLTG 4313RMFsPTYGLFFRKNLLRLTG 4314 RMFsPTYGVFFRKNLLRLTG 4315RMIsPYKKKFFRKNLLRLTG 4316 RMIsQDVKLFFRKNLLRLTG 4317RMIsQDVKVFFRKNLLRLTG 4318 RMIsTGSELFFRKNLLRLTG 4319RMKLPsGSKFFRKNLLRLTG 4320 RMKLPsGSKKFFRKNLLRLTG 4321RMKLPsGSKYFFRKNLLRLTG 4322 RMKsPFRKKFFRKNLLRLTG 4323RMKsPGsGHVKFFRKNLLRLTG 4324 RMKsPSPKSEKFFRKNLLRLTG 4325RMKtPTSQSYKFFRKNLLRLTG 4326 RMKtPTSQSYRFFRKNLLRLTG 4327RMKTtPLRKFFRKNLLRLTG 4328 RMKTtPLRRFFRKNLLRLTG 4329RMLDRSPsRSAKFFRKNLLRLTG 4330 RMLDRSPsRSAYFFRKNLLRLTG 4331RMLsHISEAFFRKNLLRLTG 4332 RMLsHISEVFFRKNLLRLTG 4333RMLsLRDQRLFFRKNLLRLTG 4334 RMLsPLSSAFFRKNLLRLTG 4335RMLsPLSSVFFRKNLLRLTG 4336 RMLsPSMASKFFRKNLLRLTG 4337RMLsSGVSEIFFRKNLLRLTG 4338 RMLsSGVSEVFFRKNLLRLTG 4339RMLsVILIKFFRKNLLRLTG 4340 RMPsFLKKNKFFRKNLLRLTG 4341RMPsSTLKKFFRKNLLRLTG 4342 RMPsSTLKRFFRKNLLRLTG 4343RMQsTSERLFFRKNLLRLTG 4344 RMQsTSERVFFRKNLLRLTG 4345RMRQsPLATKFFRKNLLRLTG 4346 RMRQsPLATRFFRKNLLRLTG 4347RMRRsPLLKFFRKNLLRLTG 4348 RMRsAGAAQKFFRKNLLRLTG 4349RMRsLSSLREKFFRKNLLRLTG 4350 RMRsPPPVSKFFRKNLLRLTG 4351RMRTsPITRKFFRKNLLRLTG 4352 RMRTsPITRRFFRKNLLRLTG 4353RMSsLIRHKFFRKNLLRLTG 4354 RMSsPISKKFFRKNLLRLTG 4355RMSsPISKRFFRKNLLRLTG 4356 RMSsPLHFVFFRKNLLRLTG 4357RMSsPVLHKFFRKNLLRLTG 4358 RMSsRYSQKFFRKNLLRLTG 4359RMSsVKLISKFFRKNLLRLTG 4360 RMSsVKLISYFFRKNLLRLTG 4361RMVsLSMRKFFRKNLLRLTG 4362 RMVsLSMRYFFRKNLLRLTG 4363RMYKsPLRHFFRKNLLRLTG 4364 RMYKsPLRKFFRKNLLRLTG 4365RMYQyIQSKFFRKNLLRLTG 4366 RMYQyIQSRFFRKNLLRLTG 4367RMYQyLQSRFFFRKNLLRLIG 4368 RMYQyLQSRFKFFRKNLLRLIG 4369RMYQyLQSRFYFFRKNLLRLIG 4370 RMYQyLQSRKFFRKNLLRLIG 4371RMYsFDDVLFFRKNLLRLTG 4372 RMYsGSRsKFFRKNLLRLTG 4373RMYsGSRsRFFRKNLLRLTG 4374 RMYsKSRDHFFRKNLLRLTG 4375RMYsKSRDKFFRKNLLRLTG 4376 RMYsKSRDYFFRKNLLRLTG 4377RMYsPDHRQKFFRKNLLRLTG

4378 RMYsPERSKFFRKNLLRLTG 4379 RMYsPIIYQAFFRKNLLRLTG 4380RMYsPIPPSLFFRKNLLRLTG 4381 RMYsPRNSKFFRKNLLRLTG 4382RMYsPYNHKFFRKNLLRLTG 4383 RMYsPYNHRFFRKNLLRLTG 4384RMYsYPRQKFFRKNLLRLTG 4385 RMYVTTSTRTYsLGFFRKNLLRLTG 4386RMYVTTSTRTYsLKFFRKNLLRLTG 4387 RMYVTTSTRTYsLYFFRKNLLRLTG 4388RNLsSPFIFFFRKNLLRLTG 4389 RPAFFsPSLFFRKNLLRLTG 4390RPAKsMDSFFFRKNLLRLTG 4391 RPAKsMDSLFFRKNLLRLTG 4392RPAKsMDSMFFRKNLLRLTG 4393 RPAKsMDVFFRKNLLRLTG 4394RPAsAGAMFFFRKNLLRLTG 4395 RPAsAGAmLFFRKNLLRLTG 4396RPAsAGAMLFFRKNLLRLTG 4397 RPAsAGAMMFFRKNLLRLTG 4398RPAsAGAMVFFRKNLLRLTG 4399 RPAsARAQPGFFFRKNLLRLTG 4400RPAsARAQPGLFFRKNLLRLTG 4401 RPAsARAQPGMFFRKNLLRLTG 4402RPAsARAQPGVFFRKNLLRLTG 4403 RPAsEARAPGLFFRKNLLRLTG 4404RPAsPAAKFFFRKNLLRLTG 4405 RPAsPAAKLFFRKNLLRLTG 4406RPAsPAAKMFFRKNLLRLTG 4407 RPAsPAAKVFFRKNLLRLTG 4408RPAsPEPELFFRKNLLRLTG 4409 RPAsPGPSLFFRKNLLRLTG 4410RPAsPKRAKIFFRKNLLRLTG 4411 RPAsPKRAKLFFRKNLLRLTG 4412RPAsPKRAKXFFRKNLLRLTG 4413 RPAsPKRAQIFFRKNLLRLTG 4414RPAsPKRAQLFFRKNLLRLTG 4415 RPAsPKRAQXFFRKNLLRLTG 4416RPAsPQRAKIFFRKNLLRLTG 4417 RPAsPQRAKLFFRKNLLRLTG 4418RPAsPQRAKXFFRKNLLRLTG 4419 RPAsPQRAQIFFRKNLLRLTG 4420RPAsPQRAQLFFRKNLLRLTG 4421 RPAsPQRAQXFFRKNLLRLTG 4422RPAsPSLQLFFRKNLLRLTG 4423 RPAsPSLQLLFFRKNLLRLTG 4424RPAsPtAIRRIGSVTSRQTFFRKNLLRLTG 4425 RPAsRFEVLFFRKNLLRLTG 4426RPAsYKKKSMLFFRKNLLRLTG 4427 RPAtGGPGVAFFRKNLLRLTG 4428RPAtGGPGVFFFRKNLLRLTG 4429 RPAtGGPGVLFFRKNLLRLTG 4430RPAtGGPGVMFFRKNLLRLTG 4431 RPAtGGPGVVFFRKNLLRLTG 4432RPAtPTSQFFFRKNLLRLTG 4433 RPAtPTSQLFFRKNLLRLTG 4434RPAtPTSQMFFRKNLLRLTG 4435 RPAtPTSQVFFRKNLLRLTG 4436RPDsAHKMLFFRKNLLRLTG 4437 RPDsPTRPTLFFRKNLLRLTG 4438RPDsRLGKTEFFFRKNLLRLTG 4439 RPDsRLGKTELFFRKNLLRLTG 4440RPDsRLGKTEMFFRKNLLRLTG 4441 RPDsRLGKTEVFFRKNLLRLTG 4442RPDVAKRLsLFFRKNLLRLTG 4443 RPEsDSGLKFFFRKNLLRLTG 4444RPEsDSGLKLFFRKNLLRLTG 4445 RPEsDSGLKMFFRKNLLRLTG 4446RPEsDSGLKVFFRKNLLRLTG 4447 RPEsKDRKFFFRKNLLRLTG 4448RPEsKDRKLFFRKNLLRLTG 4449 RPEsKDRKMFFRKNLLRLTG 4450RPEsKDRKVFFRKNLLRLTG 4451 RPFARsHSFFFRKNLLRLTG 4452RPFARSHsFFFRKNLLRLTG 4453 RPFHGISTVsLFFRKNLLRLTG 4454RPFsPREAFFFRKNLLRLTG 4455 RPFsPREALFFRKNLLRLTG 4456RPFsPREAMFFRKNLLRLTG 4457 RPFsPREAVFFRKNLLRLTG 4458RPGsLERKFFFRKNLLRLTG 4459 RPGsLERKLFFRKNLLRLTG 4460RPGsLERKMFFRKNLLRLTG 4461 RPGsLERKVFFRKNLLRLTG 4462RPGsRQAGLFFRKNLLRLTG 4463 RPGsRqAGLFFRKNLLRLTG 4464RPHsPEKAFFFRKNLLRLTG 4465 RPHsPEKALFFRKNLLRLTG 4466RPHsPEKAMFFRKNLLRLTG 4467 RPHsPEKAVFFRKNLLRLTG 4468RPHtPTGIYMFFRKNLLRLTG 4469 RPHtPTPGIYMFFRKNLLRLTG 4470RPIsPGLSFFFRKNLLRLTG 4471 RPIsPGLSLFFRKNLLRLTG 4472RPIsPGLSMFFRKNLLRLTG 4473 RPIsPGLSVFFRKNLLRLTG 4474RPIsPGLSYFFRKNLLRLTG 4475 RPIsPPHTYFFRKNLLRLTG 4476RPIsPRIGALFFRKNLLRLTG 4477 RPItPPRNSAFFRKNLLRLTG 4478RPItPPRNSFFFRKNLLRLTG 4479 RPItPPRNSLFFRKNLLRLTG 4480RPItPPRNSMFFRKNLLRLTG 4481 RPItPPRNSVFFRKNLLRLTG 4482RPKLSsPAFFFRKNLLRLTG 4483 RPKLSsPALFFRKNLLRLTG 4484RPKLSsPAMFFRKNLLRLTG 4485 RPKLSsPAVFFRKNLLRLTG 4486RPKPSSsPFFFRKNLLRLTG 4487 RPKPSSsPLFFRKNLLRLTG 4488RPKPSSsPMFFRKNLLRLTG 4489 RPKPSSsPVFFRKNLLRLTG 4490RPKsNIVLFFFRKNLLRLTG 4491 RPKsNIVLLFFRKNLLRLTG 4492RPKsNIVLMFFRKNLLRLTG 4493 RPKsNIVLVFFRKNLLRLTG 4494RPKsPLSKmFFRKNLLRLTG 4495 RPKsPLSKMFFRKNLLRLTG 4496RPKsQVAEFFFRKNLLRLTG 4497 RPKsQVAELFFRKNLLRLTG 4498RPKsQVAEMFFRKNLLRLTG 4499 RPKsQVAEVFFRKNLLRLTG 4500RPKsVDFDSLFFRKNLLRLTG 4501 RPKtPPVVIFFRKNLLRLTG 4502RPLsLLLALFFRKNLLRLTG 4503 RPLsPGGAFFFRKNLLRLTG

4504 RPLsPGGALFFRKNLLRLTG 4505 RPLsPGGAMFFRKNLLRLTG 4506RPLsPGGAVFFRKNLLRLTG 4507 RPLsPLLFFFRKNLLRLTG 4508RPLsPLLLFFRKNLLRLTG 4509 RPLsPLLMFFRKNLLRLTG 4510RPLsPLLVFFRKNLLRLTG 4511 RPLsVVYVLFFRKNLLRLTG 4512RPMsESPHMFFRKNLLRLTG 4513 RPNsPSPTAFFFRKNLLRLTG 4514RPNsPSPTALFFRKNLLRLTG 4515 RPNsPSPTAMFFRKNLLRLTG 4516RPNsPSPTAVFFRKNLLRLTG 4517 RPPIgTQSSLFFRKNLLRLTG 4518RPPPPPDtPFFFRKNLLRLTG 4519 RPPPPPDtPLFFRKNLLRLTG 4520RPPPPPDtPMFFRKNLLRLTG 4521 RPPPPPDtPPFFRKNLLRLTG 4522RPPPPPDtPVFFRKNLLRLTG 4523 RPPsPGPVFFFRKNLLRLTG 4524RPPsPGPVLFFRKNLLRLTG 4525 RPPsPGPVMFFRKNLLRLTG 4526RPPsPGPVVFFRKNLLRLTG 4527 RPPsPSSRFFFRKNLLRLTG 4528RPPsPSSRLFFRKNLLRLTG 4529 RPPsPSSRMFFRKNLLRLTG 4530RPPsPSSRVFFRKNLLRLTG 4531 RPPsSEFLDFFFRKNLLRLTG 4532RPPsSEFLDLFFRKNLLRLTG 4533 RPPsSEFLDMFFRKNLLRLTG 4534RPPsSEFLDVFFRKNLLRLTG 4535 RPQKTQsIIFFRKNLLRLTG 4536RPQRAtSNVFFFRKNLLRLTG 4537 RPQRATsNVFFFRKNLLRLTG 4538RPQRAtSNVLFFRKNLLRLTG 4539 RPQRATsNVLFFRKNLLRLTG 4540RPQRAtSNVMFFRKNLLRLTG 4541 RPQRATsNVMFFRKNLLRLIG 4542RPQRAtSNVVFFRKNLLRLTG 4543 RPQRATsNVVFFRKNLLRLTG 4544RPR(sLss)PTVTLFFRKNLLRLTG 4545 RPR(sLss)PTVTVFFRKNLLRLTG 4546RPRAAtVVFFRKNLLRLTG 4547 RPRAAtVVAFFRKNLLRLTG 4548RPRAAtWFFRKNLLRLTG 4549 RPRAAtWAFFRKNLLRLTG 4550RPRANsGGVDFFFRKNLLRLTG 4551 RPRANsGGVDLFFRKNLLRLTG 4552RPRANsGGVDMFFRKNLLRLTG 4553 RPRANsGGVDVFFRKNLLRLTG 4554RPRARsVDALFFRKNLLRLTG 4555 RPRDtRRISLFFRKNLLRLTG 4556RPRGsESLLFFRKNLLRLTG 4557 RPRGsQSLFFFRKNLLRLTG 4558RPRGsQSLLFFRKNLLRLTG 4559 RPRGsQSLMFFRKNLLRLTG 4560RPRGsQSLVFFRKNLLRLTG 4561 RPRIPsPIGFFFRKNLLRLTG 4562RPRLSsTNSSRFFFRKNLLRLTG 4563 RPRPAsSPALFFRKNLLRLTG 4564RPRPHsAPSFFFRKNLLRLTG 4565 RPRPHsAPSLFFRKNLLRLTG 4566RPRPHsAPSMFFRKNLLRLTG 4567 RPRPHsAPSVFFRKNLLRLTG 4568RPRPSsAHVGLFFRKNLLRLTG 4569 RPRPsSVLFFRKNLLRLTG 4570RPRPsSVLRTLFFRKNLLRLTG 4571 RPRPVsPSSFFFRKNLLRLTG 4572RPRPVsPSSLFFRKNLLRLTG 4573 RPRPVsPSSLLFFRKNLLRLTG 4574RPRPVsPSSMFFRKNLLRLTG 4575 RPRPVsPSSVFFRKNLLRLTG 4576RPRRsSTQFFFRKNLLRLTG 4577 RPRRsSTQLFFRKNLLRLTG 4578RPRRsSTQMFFRKNLLRLTG 4579 RPRRsSTQVFFRKNLLRLTG 4580RPRsAVEQLFFRKNLLRLTG 4581 RPRsAVLFFFRKNLLRLTG 4582RPRsAVLLFFRKNLLRLTG 4583 RPRsAVLMFFRKNLLRLTG 4584RPRsAVLVFFRKNLLRLTG 4585 RPRSGsTGSSLFFRKNLLRLTG 4586RPRsISVEEFFFRKNLLRLTG 4587 RPRsISVEELFFRKNLLRLTG 4588RPRsISVEEMFFRKNLLRLTG 4589 RPRsISVEEVFFRKNLLRLTG 4590RPRsLEVTFFFRKNLLRLTG 4591 RPRsLEVTIFFRKNLLRLTG 4592RPRsLEVTLFFRKNLLRLTG 4593 RPRsLEVTMFFRKNLLRLTG 4594RPRsLEVTVFFRKNLLRLTG 4595 RPRSLsSPTVFFRKNLLRLTG 4596RPRSLsSPTVTFFFRKNLLRLTG 4597 RPRSLsSPTVTLFFRKNLLRLTG 4598RPRSLsSPTVTMFFRKNLLRLTG 4599 RPRSLsSPTVTVFFRKNLLRLTG 4600RPRsMTVSAFFRKNLLRLTG 4601 RPRsMVRSFFFRKNLLRLTG 4602RPRsPAARFFFRKNLLRLTG 4603 RPRsPAARLFFRKNLLRLTG 4604RPRsPAARMFFRKNLLRLTG 4605 RPRsPAARVFFRKNLLRLTG 4606RPRsPGSNSKVFFRKNLLRLTG 4607 RPRsPNMQDLFFRKNLLRLTG 4608RPRsPPGGPFFRKNLLRLTG 4609 RPRsPPPRAFFFRKNLLRLTG 4610RPRsPPPRALFFRKNLLRLTG 4611 RPRsPPPRAMFFRKNLLRLTG 4612RPRsPPPRAPFFRKNLLRLTG 4613 RPRsPPPRAVFFRKNLLRLTG 4614RPRsPPSSPFFRKNLLRLTG 4615 RPRsPRENSFFFRKNLLRLTG 4616RPRsPRENSIFFRKNLLRLTG 4617 RPRsPRENSLFFRKNLLRLTG 4618RPRsPRENSMFFRKNLLRLTG 4619 RPRsPRENSVFFRKNLLRLTG 4620RPRsPRPPPFFRKNLLRLTG 4621 RPRsPRQNLIFFRKNLLRLTG 4622RPRsPRQNSFFFRKNLLRLTG 4623 RPRsPRQNSIFFRKNLLRLTG 4624RPRsPRQNSMFFRKNLLRLTG 4625 RPRsPRQNSVFFRKNLLRLTG 4626RPRsPSPIFFFRKNLLRLTG 4627 RPRsPSPILFFRKNLLRLTG 4628RPRsPSPIMFFRKNLLRLTG

4629 RPRsPSPISFFRKNLLRLTG 4630 RPRSPsPISFFRKNLLRLTG 4631RPRsPSPIVFFRKNLLRLTG 4632 RPRsPTGFFFRKNLLRLTG 4633RPRsPTGLFFRKNLLRLTG 4634 RPRsPTGMFFRKNLLRLTG 4635RPRsPTGPFFRKNLLRLTG 4636 RPRsPTGPsNSFFFRKNLLRLTG 4637RPRsPTGPSNSFFFRKNLLRLTG 4638 RPRsPTGPSNSFLFFRKNLLRLTG 4639RPRsPTGPsNSLFFRKNLLRLTG 4640 RPRsPTGPsNSMFFRKNLLRLTG 4641RPRsPTGPsNSVFFRKNLLRLTG 4642 RPRsPTGVFFRKNLLRLTG 4643RPRsPTRSFFFRKNLLRLTG 4644 RPRsPTRSLFFRKNLLRLTG 4645RPRsPTRSMFFRKNLLRLTG 4646 RPRsPTRSVFFRKNLLRLTG 4647RPRsPWGKLFFRKNLLRLTG 4648 RPRsQYNTKLFFRKNLLRLTG 4649RPRSTsQSIVSLFFRKNLLRLTG 4650 RPRtPLRSLFFRKNLLRLTG 4651RPSGRREsFFFRKNLLRLTG 4652 RPSGRREsLFFRKNLLRLTG 4653RPSGRREsMFFRKNLLRLTG 4654 RPSGRREsVFFRKNLLRLTG 4655RPsNPQLFFRKNLLRLTG 4656 RPSRSsPGFFFRKNLLRLTG 4657RPSRSsPGLFFRKNLLRLTG 4658 RPSRSsPGMFFRKNLLRLTG 4659RPSRSsPGVFFRKNLLRLTG 4660 RPSsGFYELFFRKNLLRLTG 4661RPSsLDAEIDSFFFRKNLLRLTG 4662 RPSsLDAEIDSLFFRKNLLRLTG 4663RPSsLDAEIDSMFFRKNLLRLTG 4664 RPSsLDAEIDSVFFRKNLLRLTG 4665RPSsLPDFFFRKNLLRLTG 4666 RPSsLPDLFFRKNLLRLTG 4667RPSsLPDMFFRKNLLRLTG 4668 RPSsLPDVFFRKNLLRLTG 4669RPsSPALYFFFRKNLLRLTG 4670 RPSsPALYFFFRKNLLRLTG 4671RPsSPALYLFFRKNLLRLTG 4672 RPsSPALYMFFRKNLLRLTG 4673RPsSPALYVFFRKNLLRLTG 4674 RPStPKSDSEFFFRKNLLRLTG 4675RPStPKSDSELFFRKNLLRLTG 4676 RPStPKSDSEMFFRKNLLRLTG 4677RPStPKSDSEVFFRKNLLRLTG 4678 RPTKIGRRsLFFRKNLLRLTG 4679RPTsFADELFFRKNLLRLTG 4680 RPTsPIQIMFFRKNLLRLTG 4681RPTsRLNRFFFRKNLLRLTG 4682 RPTsRLNRLFFRKNLLRLTG 4683RPTsRLNRMFFRKNLLRLTG 4684 RPTsRLNRVFFRKNLLRLTG 4685RPVsPFQEFFFRKNLLRLTG 4686 RPVsPFQELFFRKNLLRLTG 4687RPVsPFQEMFFRKNLLRLTG 4688 RPVsPFQEVFFRKNLLRLTG 4689RPVsPGKDFFFRKNLLRLTG 4690 RPVsPGKDIFFRKNLLRLTG 4691RPVsPGKDLFFRKNLLRLTG 4692 RPVsPGKDMFFRKNLLRLTG 4693RPVsPGKDVFFRKNLLRLTG 4694 RPVSPsSLLFFRKNLLRLTG 4695RPVsTDFAQYFFRKNLLRLTG 4696 RPVtPVSDFFFRKNLLRLTG 4697RPVtPVSDLFFRKNLLRLTG 4698 RPVtPVSDMFFRKNLLRLTG 4699RPVtPVSDVFFRKNLLRLTG 4700 RPWsNSRGLFFRKNLLRLTG 4701RPWsPAVSAFFRKNLLRLTG 4702 RPWsPAVSFFFRKNLLRLTG 4703RPWsPAVSLFFRKNLLRLTG 4704 RPWsPAVSMFFRKNLLRLTG 4705RPWsPAVSVFFRKNLLRLTG 4706 RPYsPPFFSFFFRKNLLRLTG 4707RPYsPPFFSLFFRKNLLRLTG 4708 RPYsPPFFSMFFRKNLLRLTG 4709RPYsPPFFSVFFRKNLLRLTG 4710 RPYSPsQALFFRKNLLRLTG 4711RPYsPSQYALFFRKNLLRLTG 4712 RPYSPsQYALFFRKNLLRLTG 4713RPYsQVNVLFFRKNLLRLTG 4714 RQAsIELPSMFFRKNLLRLTG 4715RQAsIELPSMAVFFRKNLLRLTG 4716 RQAsIELPSVFFRKNLLRLTG 4717RQAsLSISVFFRKNLLRLTG 4718 RQAsPLVHKFFRKNLLRLTG 4719RQAsPLVHRFFRKNLLRLTG 4720 RQAsPLVHYFFRKNLLRLTG 4721RQDsTPGKVFLFFRKNLLRLTG 4722 RQDStPGKVFLFFRKNLLRLTG 4723RQDsTPGKVFVFFRKNLLRLTG 4724 RQIsFKAEVFFRKNLLRLTG 4725RQIsQDVKLFFRKNLLRLTG 4726 RQIsQDVKVFFRKNLLRLTG 4727RQKsPLFQFFFRKNLLRLTG 4728 RQLsALHRAFFRKNLLRLTG 4729RQLsLEGSGLGVFFRKNLLRLTG 4730 RQLsSGVSEIFFRKNLLRLTG 4731RQLsSGVSEVFFRKNLLRLTG 4732 RQSsSRFNLFFRKNLLRLTG 4733RRAsFAKSFFFRKNLLRLTG 4734 RRAsFAKSKFFRKNLLRLTG 4735RRAsFAKSLFFRKNLLRLTG 4736 RRAsFAKSMFFRKNLLRLTG 4737RRAsFAKSRFFRKNLLRLTG 4738 RRAsIITKYFFRKNLLRLTG 4739RRAsLSEIGFFFRKNLLRLTG 4740 RRAsLSEIGKFFRKNLLRLTG 4741RRAsLSEIGYFFRKNLLRLTG 4742 RRAsQEANLFFRKNLLRLTG 4743RRASsPFRFFFRKNLLRLTG 4744 RRASsPFRKFFRKNLLRLTG 4745RRASsPFRLFFRKNLLRLTG 4746 RRASsPFRMFFRKNLLRLTG 4747RRASsPFRRFFRKNLLRLTG 4748 RRAsVFVKFFFRKNLLRLTG 4749RRAsVFVKKFFRKNLLRLTG 4750 RRAsVFVKLFFRKNLLRLTG 4751RRAsVFVKMFFRKNLLRLTG 4752 RRAsVFVKRFFRKNLLRLTG 4753RRDsIVAEFFFRKNLLRLTG 4754 RRDsIVAEKFFRKNLLRLTG

4755 RRDsIVAELFFRKNLLRLTG 4756 RRDsIVAERFFRKNLLRLTG 4757RRDsIVAEYFFRKNLLRLTG 4758 RRDsLQKPGLFFRKNLLRLTG 4759RRFsFEVTLFFRKNLLRLTG 4760 RRFsFKFFFRKNLLRLTG 4761RRFsFKKFFRKNLLRLTG 4762 RRFsFKKSFFFRKNLLRLTG 4763RRFsFKKSKFFRKNLLRLTG 4764 RRFsFKKSLFFRKNLLRLTG 4765RRFsFKKSMFFRKNLLRLTG 4766 RRFsFKKSRFFRKNLLRLTG 4767RRFsFKLFFRKNLLRLTG 4768 RRFsFKMFFRKNLLRLTG 4769 RRFsFKRFFRKNLLRLTG4770 RRFsGTAVYFFRKNLLRLTG 4771 RRFsGTVRFFFRKNLLRLTG 4772RRFsGTVRKFFRKNLLRLTG 4773 RRFsGTVRLFFRKNLLRLTG 4774RRFsGTVRMFFRKNLLRLTG 4775 RRFsGTVRRFFRKNLLRLTG 4776RRFsIATLRFFRKNLLRLTG 4777 RRFsLTTLRFFRKNLLRLTG 4778RRFsPDDKYSFFFRKNLLRLTG 4779 RRFsPDDKYSKFFRKNLLRLTG 4780RRFsPDDKYSLFFRKNLLRLTG 4781 RRFsPDDKYSMFFRKNLLRLTG 4782RRFsPPRRFFFRKNLLRLTG 4783 RRFsPPRRKFFRKNLLRLTG 4784RRFsPPRRLFFRKNLLRLTG 4785 RRFsPPRRmFFRKNLLRLTG 4786RRFsPPRRMFFRKNLLRLTG 4787 RRFsPPRRRFFRKNLLRLTG 4788RRFsPPRRYFFRKNLLRLTG 4789 RRFsRLENRYFFRKNLLRLTG 4790RRFsRSDELFFRKNLLRLTG 4791 RRFsRsPIFFFRKNLLRLTG 4792RRFsRSPIFFFRKNLLRLTG 4793 RRFsRsPIKFFRKNLLRLTG 4794RRFsRSPIKFFRKNLLRLTG 4795 RRFsRsPILFFRKNLLRLTG 4796RRFsRSPILFFRKNLLRLTG 4797 RRFsRSPIMFFRKNLLRLTG 4798RRFsRsPIRFFRKNLLRLTG 4799 RRFsRSPIRFFRKNLLRLTG 4800RRFSRsPIRFFRKNLLRLTG 4801 RRFsRsPIRFFFRKNLLRLTG 4802RRFsRSPIRFFFRKNLLRLTG 4803 RRFsRsPIRKFFRKNLLRLTG 4804RRFsRSPIRKFFRKNLLRLTG 4805 RRFsRsPIRLFFRKNLLRLTG 4806RRFsRSPIRLFFRKNLLRLTG 4807 RRFsRsPIRRFFRKNLLRLTG 4808RRFsRSPIRRFFRKNLLRLTG 4809 RRFsRsPIRYFFRKNLLRLTG 4810RRFsRSPIRYFFRKNLLRLTG 4811 RRFsRsPIYFFRKNLLRLTG 4812RRFsRSPIYFFRKNLLRLTG 4813 RRFsRSPKFFRKNLLRLTG 4814RRFSsPPRRMFFRKNLLRLTG 4815 RRFsVSTLRFFRKNLLRLTG 4816RRFsVTTMRFFRKNLLRLTG 4817 RRFtPPSPAFFFRKNLLRLTG 4818RRFtPPSPAKFFRKNLLRLTG 4819 RRFtPPSPARFFRKNLLRLTG 4820RRFtPPSPAYFFRKNLLRLTG 4821 RRGsFEVTLFFRKNLLRLTG 4822RRHsASNLHALFFRKNLLRLTG 4823 RRIDIsPSTFFFRKNLLRLTG 4824RRIDIsPSTKFFRKNLLRLTG 4825 RRIDIsPSTLRFFRKNLLRLTG 4826RRIDIsPSTLRKFFRKNLLRLTG 4827 RRIDIsPSTRFFRKNLLRLTG 4828RRIDIsPSTYFFRKNLLRLTG 4829 RRIsDPEVFFFRKNLLRLTG 4830RRIsDPQVFFFRKNLLRLTG 4831 RRIsGVDRFFFRKNLLRLTG 4832RRIsGVDRKFFRKNLLRLTG 4833 RRIsGVDRLFFRKNLLRLTG 4834RRIsGVDRMFFRKNLLRLTG 4835 RRIsGVDRRFFRKNLLRLTG 4836RRIsGVDRYFFRKNLLRLTG 4837 RRIsGVDRYFFFRKNLLRLTG 4838RRIsGVDRYKFFRKNLLRLTG 4839 RRIsGVDRYLFFRKNLLRLTG 4840RRIsGVDRYRFFRKNLLRLTG 4841 RRIsGVDRYYFFRKNLLRLTG 4842RRIsPAPQRFFRKNLLRLTG 4843 RRIsQIQQLFFRKNLLRLTG 4844RRKsOVAEFFFRKNLLRLTG 4845 RRKsOVAEKFFRKNLLRLTG 4846RRKsPPPSFFFRKNLLRLTG 4847 RRKsPPPSKFFRKNLLRLTG 4848RRKsPPPSLFFRKNLLRLTG 4849 RRKsPPPSMFFRKNLLRLTG 4850RRKsPPPSRFFRKNLLRLTG 4851 RRKsQLDSFFFRKNLLRLTG 4852RRKsQLDSKFFRKNLLRLTG 4853 RRKsQLDSLFFRKNLLRLTG 4854RRKsQLDSMFFRKNLLRLTG 4855 RRKsQLDSRFFRKNLLRLTG 4856RRKsQLDSYFFRKNLLRLTG 4857 RRKsQVAEFFFRKNLLRLTG 4858RRKsQVAEKFFRKNLLRLTG 4859 RRKsQVAELFFRKNLLRLTG 4860RRKsQVAEMFFRKNLLRLTG 4861 RRKsQVAERFFRKNLLRLTG 4862RRKsQVAEVFFRKNLLRLTG 4863 RRKsQVAEYFFRKNLLRLTG 4864RRLGsPHRFFFRKNLLRLTG 4865 RRLGsPHRKFFRKNLLRLTG 4866RRLGsPHRLFFRKNLLRLTG 4867 RRLGsPHRMFFRKNLLRLTG 4868RRLGsPHRRFFRKNLLRLTG 4869 RRLsADIRFFFRKNLLRLTG 4870RRLsADIRKFFRKNLLRLTG 4871 RRLsADIRLFFRKNLLRLTG 4872RRLsADIRMFFRKNLLRLTG 4873 RRLsADIRRFFRKNLLRLTG 4874RRLsADIRYFFRKNLLRLTG 4875 RRLsDSPVFFFRKNLLRLTG 4876RRLsELLRYFFRKNLLRLTG 4877 RRLsERETRFFRKNLLRLTG 4878RRLsESSALFFRKNLLRLTG 4879 RRLsFLVSFFFRKNLLRLTG

4880 RRLsFLVSKFFRKNLLRLTG 4881 RRLsFLVSLFFRKNLLRLTG 4882RRLsFLVSMFFRKNLLRLTG 4883 RRLsFLVSRFFRKNLLRLTG 4884RRLsFLVSYFFRKNLLRLTG 4885 RRLsGGSHSFFFRKNLLRLTG 4886RRLsGGSHSKFFRKNLLRLTG 4887 RRLsGGSHSLFFRKNLLRLTG 4888RRLsGGSHSMFFRKNLLRLTG 4889 RRLsGGSHSRFFRKNLLRLTG 4890RRLsGGSHSYFFRKNLLRLTG 4891 RRLsGPLHTFFFRKNLLRLTG 4892RRLsGPLHTKFFRKNLLRLTG 4893 RRLsGPLHTLFFRKNLLRLTG 4894RRLsGPLHTMFFRKNLLRLTG 4895 RRLsGPLHTRFFRKNLLRLTG 4896RRLsGPLHTVFFRKNLLRLTG 4897 RRLsGPLHTYFFRKNLLRLTG 4898RRLsLFLNVFFRKNLLRLTG 4899 RRLsNLPTFFFRKNLLRLTG 4900RRLsNLPTKFFRKNLLRLTG 4901 RRLsNLPTRFFRKNLLRLTG 4902RRLsNLPTVFFRKNLLRLTG 4903 RRLsNLPTYFFRKNLLRLTG 4904RRLsPAPOFFFRKNLLRLTG 4905 RRLsPAPQKFFRKNLLRLTG 4906RRLsPAPQLFFRKNLLRLTG 4907 RRLsPAPQMFFRKNLLRLTG 4908RRLsPKASQVFFFRKNLLRLTG 4909 RRLsPKASQVKFFRKNLLRLTG 4910RRLsPKASQVLFFRKNLLRLTG 4911 RRLsPKASQVMFFRKNLLRLTG 4912RRLsPKASQVRFFRKNLLRLTG 4913 RRLsPVPVPFFFRKNLLRLTG 4914RRLsPVPVPKFFRKNLLRLTG 4915 RRLsPVPVPLFFRKNLLRLTG 4916RRLsPVPVPMFFRKNLLRLTG 4917 RRLsPVPVPRFFRKNLLRLTG 4918RRLsRELOKFFRKNLLRLTG 4919 RRLsRELQFFFRKNLLRLTG 4920RRLsRELQLFFRKNLLRLTG 4921 RRLsRELQMFFRKNLLRLTG 4922RRLsRELQRFFRKNLLRLTG 4923 RRLsRKLSLFFRKNLLRLTG 4924RRLsVERIFFFRKNLLRLTG 4925 RRLsVERIKFFRKNLLRLTG 4926RRLsVERIMFFRKNLLRLTG 4927 RRLsVERIRFFRKNLLRLTG 4928RRLsYVLFIFFRKNLLRLTG 4929 RRLTHLsFFFRKNLLRLTG 4930RRLTHLsKFFRKNLLRLTG 4931 RRLTHLsLFFRKNLLRLTG 4932RRLTHLsMFFRKNLLRLTG 4933 RRLTHLsRFFRKNLLRLTG 4934RRMsFQKPFFRKNLLRLTG 4935 RRMsLLSVFFFRKNLLRLTG 4936RRMsLLSVKFFRKNLLRLTG 4937 RRMsLLSVLFFRKNLLRLTG 4938RRMsLLSVMFFRKNLLRLTG 4939 RRMsLLSVRFFRKNLLRLTG 4940RRmsLLSVVFFRKNLLRLTG 4941 RRMsLLSVVFFRKNLLRLTG 4942RRMsLLSVYFFRKNLLRLTG 4943 RRMsLLSWFFRKNLLRLTG 4944RRMsLSVMFFRKNLLRLTG 4945 RRMsPIKPLFFRKNLLRLTG 4946RRMsPKAORFFRKNLLRLTG 4947 RRMsPKAQFFFRKNLLRLTG 4948RRMsPKAQKFFRKNLLRLTG 4949 RRMsPKAQLFFRKNLLRLTG 4950RRMsPKAQMFFRKNLLRLTG 4951 RRMsPKPFFFRKNLLRLTG 4952RRMsPKPKFFRKNLLRLTG 4953 RRMsPKPMFFRKNLLRLTG 4954RRMsPKPRFFRKNLLRLTG 4955 RRNsAPVSVFFRKNLLRLTG 4956RRNsINRNFFFRKNLLRLTG 4957 RRNsNPVIAEFFFRKNLLRLTG 4958RRNsNPVIAEKFFRKNLLRLTG 4959 RRNsNPVIAELFFRKNLLRLTG 4960RRNsNPVIAEMFFRKNLLRLTG 4961 RRNsNPVIAERFFRKNLLRLTG 4962RRNsSERTFFFRKNLLRLTG 4963 RRNsSERTKFFRKNLLRLTG 4964RRNsSERTLFFRKNLLRLTG 4965 RRNsSERTMFFRKNLLRLTG 4966RRNsSERTRFFRKNLLRLTG 4967 RRNsSERTYFFRKNLLRLTG 4968RRNsSIVGFFFRKNLLRLTG 4969 RRNsSIVGKFFRKNLLRLTG 4970RRNsSIVGLFFRKNLLRLTG 4971 RRNsSIVGMFFRKNLLRLTG 4972RRNsSIVGRFFRKNLLRLTG 4973 RRNsSIVGYFFRKNLLRLTG 4974RRNsVFQQGFFFRKNLLRLTG 4975 RRNsVFQQGKFFRKNLLRLTG 4976RRNsVFQQGLFFRKNLLRLTG 4977 RRNsVFQQGMFFRKNLLRLTG 4978RRNsVFQQGRFFRKNLLRLTG 4979 RRNsVFQQGYFFRKNLLRLTG 4980RRPsIAPVLFFRKNLLRLTG 4981 RRPsLLSEFFFRKNLLRLTG 4982RRPsLVHGFFFRKNLLRLTG 4983 RRPsLVHGKFFRKNLLRLTG 4984RRPsLVHGLFFRKNLLRLTG 4985 RRPsLVHGMFFRKNLLRLTG 4986RRPsLVHGRFFRKNLLRLTG 4987 RRPsLVHGYFFRKNLLRLTG 4988RRPsVFERFFFRKNLLRLTG 4989 RRPsVFERKFFRKNLLRLTG 4990RRPsVFERLFFRKNLLRLTG 4991 RRPsVFERMFFRKNLLRLTG 4992RRPsVFERRFFRKNLLRLTG 4993 RRPsVFERYFFRKNLLRLTG 4994RRPsYRKIFFFRKNLLRLTG 4995 RRPsYRKIKFFRKNLLRLTG 4996RRPsYRKILFFRKNLLRLTG 4997 RRPsYRKIMFFRKNLLRLTG 4998RRPsYRKIRFFRKNLLRLTG 4999 RRPsYRKIYFFRKNLLRLTG 5000RRPsYTLGFFFRKNLLRLTG 5001 RRPsYTLGKFFRKNLLRLTG 5002RRPsYTLGLFFRKNLLRLTG 5003 RRPsYTLGMFFRKNLLRLTG 5004RRPsYTLGRFFRKNLLRLTG 5005 RRPsYTLGVFFRKNLLRLTG

5006 RRPsYTLGYFFRKNLLRLTG 5007 RRQsKVEALFFRKNLLRLTG 5008RRRsLERLLFFRKNLLRLTG 5009 RRsFLVSYFFRKNLLRLTG 5010RRSFsLEFFRKNLLRLTG 5011 RRSsFLQFFRKNLLRLTG 5012RRssFLQLFFFRKNLLRLTG 5013 RRssFLQVFFFRKNLLRLTG 5014RRSsFLQVFFFRKNLLRLTG 5015 RRSsFLQVKFFRKNLLRLTG 5016RRSsFLQVLFFRKNLLRLTG 5017 RRssFLQVMFFRKNLLRLTG 5018RRSsFLQVMFFRKNLLRLTG 5019 RRSsFLQVRFFRKNLLRLTG 5020RRssFLQVVFFRKNLLRLTG 5021 RRSsFLQVYFFRKNLLRLTG 5022RRSsIGLRFFFRKNLLRLTG 5023 RRSsIGLRKFFRKNLLRLTG 5024RRSsIGLRLFFRKNLLRLTG 5025 RRSsIGLRMFFRKNLLRLTG 5026RRSsIGLRRFFRKNLLRLTG 5027 RRSsIGLRVFFRKNLLRLTG 5028RRSsIGLRYFFRKNLLRLTG 5029 RRsSIQSTFFFRKNLLRLTG 5030RRSsIQSTFFFRKNLLRLTG 5031 RRSsIQSTKFFRKNLLRLTG 5032RRSsIQSTLFFRKNLLRLTG 5033 RRSsIQSTMFFRKNLLRLTG 5034RRSsIQSTRFFRKNLLRLTG 5035 RRSsIQSTYFFRKNLLRLTG 5036RRSsLDAEIDSFFFRKNLLRLTG 5037 RRSsLDAEIDSLFFRKNLLRLTG 5038RRSsLDAEIDSMFFRKNLLRLTG 5039 RRSsLDAEIDSVFFRKNLLRLTG 5040RRsSQSWSFFFRKNLLRLTG 5041 RRSsQSWSFFFRKNLLRLTG 5042RRSsQSWSKFFRKNLLRLTG 5043 RRsSQSWSLFFRKNLLRLTG 5044RRSsQSWSLFFRKNLLRLTG 5045 RRsSQSWSMFFRKNLLRLTG 5046RRSsQSWSMFFRKNLLRLTG 5047 RRSsQSWSRFFRKNLLRLTG 5048RRsSQSWSVFFRKNLLRLTG 5049 RRSsQSWSYFFRKNLLRLTG 5050RRSsSVAQVFFRKNLLRLTG 5051 RRSsTASLVKFFFRKNLLRLTG 5052RRSsTASLVKKFFRKNLLRLTG 5053 RRSsTASLVKLFFRKNLLRLTG 5054RRSsTASLVKMFFRKNLLRLTG 5055 RRSsTASLVKRFFRKNLLRLTG 5056RRsSVDLGFFFRKNLLRLTG 5057 RRSsVDLGFFFRKNLLRLTG 5058RRsSVDLGKFFRKNLLRLTG 5059 RRSsVDLGKFFRKNLLRLTG 5060RRsSVDLGLFFRKNLLRLTG 5061 RRSsVDLGLFFRKNLLRLTG 5062RRsSVDLGMFFRKNLLRLTG 5063 RRSsVDLGMFFRKNLLRLTG 5064RRsSVDLGRFFRKNLLRLTG 5065 RRSsVDLGRFFRKNLLRLTG 5066RRsSVDLGYFFRKNLLRLTG 5067 RRSsVDLGYFFRKNLLRLTG 5068RRSsVKVEAFFRKNLLRLTG 5069 RRSsVKVEFFFRKNLLRLTG 5070RRSsVKVEKFFRKNLLRLTG 5071 RRSsVKVELFFRKNLLRLTG 5072RRSsVKVEMFFRKNLLRLTG 5073 RRSsVKVERFFRKNLLRLTG 5074RRSsVKVEYFFRKNLLRLTG 5075 RRTsPITRFFFRKNLLRLTG 5076RRTsPITRKFFRKNLLRLTG 5077 RRTsPITRLFFRKNLLRLTG 5078RRTsPITRMFFRKNLLRLTG 5079 RRTsPITRRFFRKNLLRLTG 5080RRVVQRSsFFFRKNLLRLTG 5081 RRVVQRSsKFFRKNLLRLTG 5082RRVVQRSsLFFRKNLLRLTG 5083 RRVVQRSsMFFRKNLLRLTG 5084RRVVQRSsRFFRKNLLRLTG 5085 RRVVQRSsYFFRKNLLRLTG 5086RRWQRSsLFFRKNLLRLTG 5087 RRYsGKTEFFFRKNLLRLTG 5088RRYsGKTEKFFRKNLLRLTG 5089 RRYsGKTELFFRKNLLRLTG 5090RRYsGKTERFFRKNLLRLTG 5091 RRYsGKTEYFFRKNLLRLTG 5092RRYsGNMEFFFRKNLLRLTG 5093 RRYsGNMEKFFRKNLLRLTG 5094RRYsGNMELFFRKNLLRLTG 5095 RRYsGNMEMFFRKNLLRLTG 5096RRYsGNMERFFRKNLLRLTG 5097 RRYsKFFDLFFRKNLLRLTG 5098RRYsPPIERFFRKNLLRLTG 5099 RRYsPPIQFFRKNLLRLTG 5100RRYsPPIQFFFRKNLLRLTG 5101 RRYsPPIQKFFRKNLLRLTG 5102RRYsPPIQLFFRKNLLRLTG 5103 RRYsPPIQMFFRKNLLRLTG 5104RRYsPPIQRFFRKNLLRLTG 5105 RRYsPPIQYFFRKNLLRLTG 5106RRYsRsPYSFFFRKNLLRLTG 5107 RRYsRSPYSFFFRKNLLRLTG 5108RRYSRsPYSFFFRKNLLRLTG 5109 RRYsRsPYSKFFRKNLLRLTG 5110RRYsRSPYSKFFRKNLLRLTG 5111 RRYSRsPYSKFFRKNLLRLTG 5112RRYsRsPYSLFFRKNLLRLTG 5113 RRYsRSPYSLFFRKNLLRLTG 5114RRYSRsPYSLFFRKNLLRLTG 5115 RRYsRsPYSMFFRKNLLRLTG 5116RRYsRSPYSMFFRKNLLRLTG 5117 RRYSRsPYSMFFRKNLLRLTG 5118RRYsRsPYSRFFRKNLLRLTG 5119 RRYsRSPYSRFFRKNLLRLTG 5120RRYSRsPYSRFFRKNLLRLTG 5121 RRYtNRVVTKFFRKNLLRLTG 5122RRYtNRVVTLFFRKNLLRLTG 5123 RRYtNRVVTMFFRKNLLRLTG 5124RRYtNRVVTRFFRKNLLRLTG 5125 RSAsFSRKVFFRKNLLRLTG 5126RSAsPDDDLGSSNFFRKNLLRLTG 5127 RSAsSATQVHKFFRKNLLRLTG 5128RSAsSATQVHYFFRKNLLRLTG 5129 RSDPSKsPGSLRYFFRKNLLRLTG 5130RSDsPKIDLFFRKNLLRLTG

5131 RSDsPKIDYFFRKNLLRLTG 5132 RSDsRAQAVFFRKNLLRLTG 5133RSDsRAQAYFFRKNLLRLTG 5134 RSDsVGENLFFRKNLLRLTG 5135RSDsVGENYFFRKNLLRLTG 5136 RSDsYVELFFRKNLLRLTG 5137RSDsYVELSQYFFRKNLLRLTG 5138 RSEPSKsPGSLRYFFRKNLLRLTG 5139RSEsKDRKFFFRKNLLRLTG 5140 RSEsKDRKLFFRKNLLRLTG 5141RSEsKDRKMFFRKNLLRLTG 5142 RSEsKDRKVFFRKNLLRLTG 5143RSEsPKIDLFFRKNLLRLTG 5144 RSEsPKIDYFFRKNLLRLTG 5145RSEsPPAELFFRKNLLRLTG 5146 RSEsRAQAVFFRKNLLRLTG 5147RSEsRAQAYFFRKNLLRLTG 5148 RSEsVGENLFFRKNLLRLTG 5149RSEsVGENYFFRKNLLRLTG 5150 RSEsYVELSQYFFRKNLLRLTG 5151RSFsPTMKVFFRKNLLRLTG 5152 RSGsLERKFFFRKNLLRLTG 5153RSGsLERKLFFRKNLLRLTG 5154 RSGsLERKMFFRKNLLRLTG 5155RSGsLERKVFFRKNLLRLTG 5156 RSHSsPASLFFRKNLLRLTG 5157RSIsVGENLFFRKNLLRLTG 5158 RSLsESYELFFRKNLLRLTG 5159RSLsPGGAAFFRKNLLRLTG 5160 RSLsPGGAFFFRKNLLRLTG 5161RSLsPGGALFFRKNLLRLTG 5162 RSLsPGGAMFFRKNLLRLTG 5163RSLsPGGAVFFRKNLLRLTG 5164 RSLsPLLFFFRKNLLRLTG 5165RSLsPLLLFFRKNLLRLTG 5166 RSLsPLLMFFRKNLLRLTG 5167RSLsPLLVFFRKNLLRLTG 5168 RSLsQELVGVFFRKNLLRLTG 5169RSLsVEIVKFFRKNLLRLTG 5170 RSLsVEIVYFFRKNLLRLTG 5171RSMsMPVAHFFRKNLLRLTG 5172 RSMsMPVAKFFRKNLLRLTG 5173RsPEDEYELLMPHRISSHFFRKNLLRLTG 5174 RSRRsPLLKFFRKNLLRLTG 5175RSRRsPLLYFFRKNLLRLTG 5176 RSRsPLELFFRKNLLRLTG 5177RSRsPPPVSKFFRKNLLRLTG 5178 RSRsPPPVSYFFRKNLLRLTG 5179RSRsPRPAFFFRKNLLRLTG 5180 RSRsPRPAIFFRKNLLRLTG 5181RSRsPRPALFFRKNLLRLTG 5182 RSRsPRPAMFFRKNLLRLTG 5183RSRsPRPAVFFRKNLLRLTG 5184 RSRsPRPAXFFRKNLLRLTG 5185RSRTsPITRRFFRKNLLRLTG 5186 RSRTsPITRYFFRKNLLRLTG 5187RSSsLIRHKFFRKNLLRLTG 5188 RSSsLIRHYFFRKNLLRLTG 5189RSVsLSMRKFFRKNLLRLTG 5190 RSVsLSMRYFFRKNLLRLTG 5191RsWKYNQSISLRRPFFRKNLLRLTG 5192 RSYsGSRsKFFRKNLLRLTG 5193RSYsGSRsRFFRKNLLRLTG 5194 RSYsGSRsYFFRKNLLRLTG 5195RSYsPDHRQKFFRKNLLRLTG 5196 RSYsPDHRQYFFRKNLLRLTG 5197RSYsPERSKFFRKNLLRLTG 5198 RSYsPERSYFFRKNLLRLTG 5199RSYsPRNSRFFRKNLLRLTG 5200 RSYsPRNSYFFRKNLLRLTG 5201RSYSRsFSKFFRKNLLRLTG 5202 RSYsRSFSRFFRKNLLRLTG 5203RSYSRsFSRFFRKNLLRLTG 5204 RSYSRsFSYFFRKNLLRLTG 5205RSYsYPRQKFFRKNLLRLTG 5206 RSYsYPRQYFFRKNLLRLTG 5207RSYVTTSTRTYsLGFFRKNLLRLTG 5208 RTAsFAVRKFFRKNLLRLTG 5209RTAsFAVRYFFRKNLLRLTG 5210 RTAsLIIKVFFRKNLLRLTG 5211RTAsPPPPPKFFRKNLLRLTG 5212 RTDPSKsPGSLRYFFRKNLLRLTG 5213RTDsPKIDLFFRKNLLRLTG 5214 RTDsPKIDYFFRKNLLRLTG 5215RTDsRAQAVFFRKNLLRLTG 5216 RTDsRAQAYFFRKNLLRLTG 5217RTDsYVELSQYFFRKNLLRLTG 5218 RTEPSKsPGSLRYFFRKNLLRLTG 5219RTEsDSGLKFFFRKNLLRLTG 5220 RTEsDSGLKKFFRKNLLRLTG 5221RTEsDSGLKLFFRKNLLRLTG 5222 RTEsDSGLKMFFRKNLLRLTG 5223RTEsDSGLKVFFRKNLLRLTG 5224 RTEsPKIDLFFRKNLLRLTG 5225RTEsPKIDYFFRKNLLRLTG 5226 RTEsRAQAVFFRKNLLRLTG 5227RTEsRAQAYFFRKNLLRLTG 5228 RTEsYVELSQYFFRKNLLRLTG 5229RTFsLDTILFFRKNLLRLTG 5230 RTFsPTYGFFFRKNLLRLTG 5231RTFsPTYGLFFRKNLLRLTG 5232 RTFsPTYGMFFRKNLLRLTG 5233RTFsPTYGVFFRKNLLRLTG 5234 RTHsLLLLLFFRKNLLRLTG 5235RTLsHISEAFFRKNLLRLTG 5236 RTLsHISEVFFRKNLLRLTG 5237RTLsPEIITVFFRKNLLRLTG 5238 RTMsEAALVRKFFRKNLLRLTG 5239RTNsPGFQKFFRKNLLRLTG 5240 RTPsDVKELFFRKNLLRLTG 5241RTPsFLKKNKFFRKNLLRLTG 5242 RTPsFLKKNYFFRKNLLRLTG 5243RTRsLSSLREKFFRKNLLRLTG 5244 RTRsLSSLREYFFRKNLLRLTG 5245RTRsPSPTFFFRKNLLRLTG 5246 RTRsPSPTLFFRKNLLRLTG 5247RTRsPSPTMFFRKNLLRLTG 5248 RTRsPSPTVFFRKNLLRLTG 5249RTSsFALNLFFRKNLLRLTG 5250 RTSsFTEQLFFRKNLLRLTG 5251RTSsFTFQNFFRKNLLRLTG 5252 RTSSFtFQNFFRKNLLRLTG 5253RTSsPLFNKFFRKNLLRLTG 5254 RTYKsPLRHFFRKNLLRLTG 5255RTYKsPLRKFFRKNLLRLTG 5256 RTYKsPLRYFFRKNLLRLTG

5257 RTYsGPMNKFFRKNLLRLTG 5258 RTYsGPMNKVFFRKNLLRLTG 5259RTYsHGTYRFFRKNLLRLTG 5260 RVAsFAVRKFFRKNLLRLTG 5261RVAsFAVRYFFRKNLLRLTG 5262 RVAsPLVHKFFRKNLLRLTG 5263RVAsPLVHYFFRKNLLRLTG 5264 RVAsPPPPPKFFRKNLLRLTG 5265RVAsPPPPPYFFRKNLLRLTG 5266 RVAsPTSGVFFRKNLLRLTG 5267RVAsPTSGVKFFRKNLLRLTG 5268 RVAsPTSGVKKFFRKNLLRLTG 5269RVAsPTSGVKRFFRKNLLRLTG 5270 RVAsPTSGVYFFRKNLLRLTG 5271RVDsPSHGLFFRKNLLRLTG 5272 RVGsLVLNLFFRKNLLRLTG 5273RVIsGVLQLFFRKNLLRLTG 5274 RVKLPsGSKKFFRKNLLRLTG 5275RVKsPGsGHVKFFRKNLLRLTG 5276 RVKsPGsGHVYFFRKNLLRLTG 5277RVKsPISLKFFRKNLLRLTG 5278 RVKsPSPKSERFFRKNLLRLTG 5279RVKsPSPKSEYFFRKNLLRLTG 5280 RVKtPTSQSYKFFRKNLLRLTG 5281RVKtPTSQSYRFFRKNLLRLTG 5282 RVKtPTSQSYYFFRKNLLRLTG 5283RVKTtPLRRFFRKNLLRLTG 5284 RVKTtPLRYFFRKNLLRLTG 5285RVLDRSPsRSAKFFRKNLLRLTG 5286 RVLDRSPsRSAYFFRKNLLRLTG 5287RVLHsPPAVFFRKNLLRLTG 5288 RVLsGVVTKFFRKNLLRLTG 5289RVLsPLIIKFFRKNLLRLTG 5290 RVPsLLVLLFFRKNLLRLTG 5291RVPsSTLKKFFRKNLLRLTG 5292 RVPsSTLKYFFRKNLLRLTG 5293RVRKLPsTTLFFRKNLLRLTG 5294 RVRQsPLATKFFRKNLLRLTG 5295RVRQsPLATRFFRKNLLRLTG 5296 RVRQsPLATYFFRKNLLRLTG 5297RVRRsSFLNAKFFRKNLLRLTG 5298 RVRsLSSLREKFFRKNLLRLTG 5299RVRsLSSLREYFFRKNLLRLTG 5300 RVRsPTRSFFFRKNLLRLTG 5301RVRsPTRSLFFRKNLLRLTG 5302 RVRsPTRSMFFRKNLLRLTG 5303RVRsPTRSPFFRKNLLRLTG 5304 RVRsPTRSVFFRKNLLRLTG 5305RVSsPISKKFFRKNLLRLTG 5306 RVSsPISKYFFRKNLLRLTG 5307RVSsRFSSKFFRKNLLRLTG 5308 RVSsRFSSRFFRKNLLRLTG 5309RVSsRFSSYFFRKNLLRLTG 5310 RVSsVKLISKFFRKNLLRLTG 5311RVSsVKLISYFFRKNLLRLTG 5312 RVTsAEIKLFFRKNLLRLTG 5313RVVsLSMRKFFRKNLLRLTG 5314 RVVsLSMRYFFRKNLLRLTG 5315RVWEDRPSsAFFRKNLLRLTG 5316 RVWsPPRVHKVFFRKNLLRLTG 5317RVYQyIQSRFFRKNLLRLTG 5318 RVYQyIQSRFKFFRKNLLRLTG 5319RVYQyIQSRFYFFRKNLLRLTG 5320 RVYQyIQSRKFFRKNLLRLTG 5321RVYQyIQSRYFFRKNLLRLTG 5322 RVYsPYNHKFFRKNLLRLTG 5323RVYsPYNHRFFRKNLLRLTG 5324 RVYsPYNHYFFRKNLLRLTG 5325RVYSRsFSKFFRKNLLRLTG 5326 RVYSRsFSYFFRKNLLRLTG 5327RYPsNLQLFFFRKNLLRLTG 5328 RYQtQPVTLFFRKNLLRLTG 5329SAARESHPHGVKRSAsPDDDLGFFRKNLLRLTG 5330 SARGsPTRPNPPVRFFRKNLLRLTG5331 SARRtPVSYFFRKNLLRLTG 5332 sDDEKMPDLEFFRKNLLRLTG 5333sDFHAERAAREKFFRKNLLRLTG 5334 SDmPRAHsFFFRKNLLRLTG 5335SDMPRAHsFFFRKNLLRLTG 5336 SEFKAMDsIFFRKNLLRLTG 5337SEGsLHRKFFFRKNLLRLTG 5338 SEGsLHRKWFFRKNLLRLTG 5339SEGsLHRKYFFRKNLLRLTG 5340 SELsPGRSVFFRKNLLRLTG 5341SFDsGSVRLFFRKNLLRLTG 5342 SGGAQsPLRYLHVLFFRKNLLRLTG 5343sGGDDDWTHLSSKEVDPSTFFRKNLLRLTG 5344 sGGDDDWTHLSSKEVDPSTGFFRKNLLRLTG5345 sGGDDDWTHLSSKEVDPSTGEFFRKNLLRLTG 5346sGGDDDWTHLSSKEVDPSTGELFFRKNLLRLTG 5347sGGDDDWTHLSSKEVDPSTGELQFFRKNLLRLTG 5348SGPKPLFRRMsSLVGPTQFFRKNLLRLTG 5349 SIDsPQKLFFRKNLLRLTG 5350SIDsPQKYFFRKNLLRLTG 5351 SILsFVSGLFFRKNLLRLTG 5352SIMsFHIDLFFRKNLLRLTG 5353 SImsPEIQLFFRKNLLRLTG 5354SIMsPEIQLFFRKNLLRLTG 5355 SIPtVSGQIFFRKNLLRLTG 5356SISsMEVNVFFRKNLLRLIG 5357 SISStPPAVFFRKNLLRLTG 5358SKEDKNGHDGDTHQEDDGEKsDFFRKNLLRLTG 5359 SKRGyIGLFFRKNLLRLTG 5360SKtVATFILFFRKNLLRLTG 5361 SLAsLTE,KIFFRKNLLRLTG 5362SLDSEDYsLFFRKNLLRLTG 5363 SLDsLGDVFLFFRKNLLRLTG 5364SLDsPSYVLYFFRKNLLRLTG 5365 SLEsPSYVLYFFRKNLLRLTG 5366SLFGGsVKLFFRKNLLRLTG 5367 SLFKRLYsLFFRKNLLRLTG 5368SLFsGDEENAFFRKNLLRLTG 5369 SLFsGSYSSLFFRKNLLRLTG 5370SLFsPQNTLFFRKNLLRLTG 5371 SLFsPRRNKFFRKNLLRLTG 5372SLFsPRRNYFFRKNLLRLTG 5373 SLFsSEESNLFFRKNLLRLTG 5374SLFsSEESNLGAFFRKNLLRLTG 5375 SLHDIQLsLFFRKNLLRLTG 5376SLKsPVTVKFFRKNLLRLTG 5377 SLLAsPGHISVFFRKNLLRLTG 5379SLLNKSsPVKFFRKNLLRLTG 5380 SLLNKSsPVKKFFRKNLLRLTG 5381SLLNKSsPVKYFFRKNLLRLTG 5382 SLLsLHVDLFFRKNLLRLTG

5383 SLLTsPPKAFFRKNLLRLTG 5384 SLLTsPPKVFFRKNLLRLTG 5385SLMsGTLESLFFRKNLLRLTG 5386 SLMsPGRRKFFRKNLLRLTG 5387SLMsPGRRYFFRKNLLRLTG 5388 SLQPRSHsVFFRKNLLRLTG 5389SLQsLETSVFFRKNLLRLTG 5390 SLRRsVLMKFFRKNLLRLTG 5391SLRRsVLMYFFRKNLLRLTG 5392 SLSsLLVKLFFRKNLLRLTG 5393SLtRSPPRVFFRKNLLRLTG 5394 SLTRsPPRVFFRKNLLRLTG 5395SLVDGyFRLFFRKNLLRLTG 5396 SLYDRPAsYFFRKNLLRLTG 5397SLYsPVKKKFFRKNLLRLTG 5398 SMFsPRRNKFFRKNLLRLTG 5399SMKsPVTVKFFRKNLLRLTG 5400 SMLNKSsPVKFFRKNLLRLTG 5401SMLNKSsPVKKFFRKNLLRLTG 5402 SMLsQEIQTLFFRKNLLRLTG 5403SMLTsPPKAFFRKNLLRLTG 5404 SMLTsPPKVFFRKNLLRLTG 5405SMMsPGRRKFFRKNLLRLTG 5406 SMQPRSHsVFFRKNLLRLTG 5407SMRRsVLMKFFRKNLLRLTG 5408 SMSsLSREVFFRKNLLRLTG 5409SMtRSPPRVFFRKNLLRLTG 5410 SMTRsPPRVFFRKNLLRLTG 5411SMYsPVKKKFFRKNLLRLTG 5412 SNFKsPVKTIRFFRKNLLRLTG 5413SPAASISRLsGEQVDGKGFFRKNLLRLTG 5414 SPAsPKISFFFRKNLLRLTG 5415SPAsPKISLFFRKNLLRLTG 5416 SPAsPKISMFFRKNLLRLTG 5417SPAsPKISVFFRKNLLRLTG 5418 SPDsSQSSLFFRKNLLRLTG 5419sPEDEYELLMPHRISSHFFRKNLLRLTG 5420 SPEDEYELLMPHRIsSHFFRKNLLRLTG 5421SPEKAGRRsSFFFRKNLLRLTG 5422 SPEKAGRRsSLFFRKNLLRLTG 5423SPEKAGRRsSMFFRKNLLRLTG 5424 SPEKAGRRsSVFFRKNLLRLTG 5425sPERPFLATLGGAKVADKFFRKNLLRLTG 5426 sPERPFLATLGGAKVADKIQFFRKNLLRLTG5427 SPFKRQLsFFFRKNLLRLTG 5428 SPFKRQLsLFFRKNLLRLTG 5429SPFKRQLsMFFRKNLLRLTG 5430 SPFKRQLsVFFRKNLLRLTG 5431SPFLsKRSLFFRKNLLRLTG 5432 SPGLARKRsFFFRKNLLRLTG 5433SPGLARKRsLFFRKNLLRLTG 5434 SPGLARKRsMFFRKNLLRLTG 5435SPGLARKRsVFFRKNLLRLTG 5436 SPGsPRPAFFFRKNLLRLTG 5437SPGsPRPALFFRKNLLRLTG 5438 SPGsPRPAMFFRKNLLRLTG 5439SPGsPRPAVFFRKNLLRLTG 5440 SPKsPGLKAFFRKNLLRLTG 5441SPKsPGLKFFFRKNLLRLTG 5442 SPKsPGLKLFFRKNLLRLTG 5443SPKsPGLKMFFRKNLLRLTG 5444 SPKsPGLKVFFRKNLLRLTG 5445SPKsPTAAFFFRKNLLRLTG 5446 SPKsPTAALFFRKNLLRLTG 5447SPKsPTAAMFFRKNLLRLTG 5448 SPKsPTAAVFFRKNLLRLTG 5449SPLTKSIsLFFRKNLLRLTG 5450 sPPFPVPVYTRQAPKQVIKFFRKNLLRLTG 5451SPRAPVsPLKFFFRKNLLRLTG 5452 SPRERsPALFFRKNLLRLTG 5453SPRGEAsSLFFRKNLLRLTG 5454 SPRGEASsLFFRKNLLRLTG 5455SPRPPNsPSIFFRKNLLRLTG 5456 SPRRsLGLALFFRKNLLRLTG 5457SPRRsRSIsFFFRKNLLRLTG 5458 SPRRsRSISFFFRKNLLRLTG 5459SPRRsRSIsLFFRKNLLRLTG 5460 SPRRsRSISLFFRKNLLRLTG 5461SPRRsRSIsMFFRKNLLRLTG 5462 SPRRsRSISMFFRKNLLRLTG 5463SPRRsRSIsVFFRKNLLRLTG 5464 SPRRsRSISVFFRKNLLRLTG 5465SPRsITSTFFFRKNLLRLTG 5466 SPRsITSTLFFRKNLLRLTG 5467SPRsITSTMFFRKNLLRLTG 5468 SPRsITSTPFFRKNLLRLTG 5469SPRsITSTVFFRKNLLRLTG 5470 SPRsPDRTLFFRKNLLRLTG 5471SPRsPGKPFFFRKNLLRLTG 5472 SPRsPGKPLFFRKNLLRLTG 5473SPRsPGKPMFFRKNLLRLTG 5474 SPRsPGKPVFFRKNLLRLTG 5475SPRsPGRSFFFRKNLLRLTG 5476 SPRsPGRSIFFRKNLLRLTG 5477SPRsPGRSLFFRKNLLRLTG 5478 SPRsPGRSMFFRKNLLRLTG 5479SPRsPGRSVFFRKNLLRLTG 5480 SPRsPGRSXFFRKNLLRLTG 5481SPRsPSGLRFFRKNLLRLTG 5482 SPRsPSTTYFFFRKNLLRLTG 5483SPRsPSTTYLFFRKNLLRLTG 5484 SPRSPsTTYLFFRKNLLRLTG 5485SPRsPSTTYMFFRKNLLRLTG 5486 SPRsPSTTYVFFRKNLLRLTG 5487SPRssQLVFFRKNLLRLTG 5488 SPRtPVsPVKFFFRKNLLRLTG 5489SPRTPVsPVKFFFRKNLLRLTG 5490 SPRtPVsPVKLFFRKNLLRLTG 5491SPRTPVsPVKLFFRKNLLRLTG 5492 SPRtPVsPVKMFFRKNLLRLTG 5493SPRTPVsPVKMFFRKNLLRLTG 5494 SPRtPVsPVKVFFRKNLLRLTG 5495SPRTPVsPVKVFFRKNLLRLTG 5496 SPSsPSVRRQFFFRKNLLRLTG 5497SPSsPSVRRQLFFRKNLLRLTG 5498 SPSsPSVRRQMFFRKNLLRLTG 5499SPSsPSVRRQVFFRKNLLRLTG 5500 SPSTSRSGGsSRFFFRKNLLRLTG 5501SPSTSRSGGsSRLFFRKNLLRLTG 5502 SPSTSRSGGsSRMFFRKNLLRLTG 5503SPSTSRSGGsSRVFFRKNLLRLTG 5504 sPTRPNPPVRNLHFFRKNLLRLTG 5505SPVsPMKELFFRKNLLRLTG 5506 SPVsTRPLEPFFRKNLLRLTG 5507SPVStRPLEPFFRKNLLRLTG 5508 SPVVHQsFFFRKNLLRLTG

5509 SPVVHQsLFFRKNLLRLTG 5510 SPVVHQsMFFRKNLLRLTG 5511SPVVHQsVFFRKNLLRLTG 5512 SQIsPKSWGVFFRKNLLRLTG 5513SRDKHsEYFFRKNLLRLTG 5514 SREKHsEIFFRKNLLRLTG 5515SREKHsElFFRKNLLRLTG 5516 SRFNRRVsVFFRKNLLRLTG 5517SRLTHLsFFFRKNLLRLTG 5518 SRLTHLsKFFRKNLLRLTG 5519SRLTHLsLFFRKNLLRLTG 5520 SRLTHLsMFFRKNLLRLTG 5521SRLTHLsRFFRKNLLRLTG 5522 SRLTHLsYFFRKNLLRLTG 5523SRMsPKAQFFFRKNLLRLTG 5524 SRMsPKAQKFFRKNLLRLTG 5525SRMsPKAQLFFRKNLLRLTG 5526 SRMsPKAQMFFRKNLLRLTG 5527SRMsPKAQRFFRKNLLRLTG 5528 SRMsPKAQYFFRKNLLRLTG 5529SRsSRSPYSRFFRKNLLRLTG 5530 SRSsSVLsLFFRKNLLRLTG 5531SRSSsVLSLFFRKNLLRLTG 5532 SRSSSVLsLFFRKNLLRLTG 5533SRTsPITRFFFRKNLLRLTG 5534 SRTsPITRKFFRKNLLRLTG 5535SRTsPITRLFFRKNLLRLTG 5536 SRTsPITRMFFRKNLLRLTG 5537SRTsPITRRFFRKNLLRLTG 5538 SRTsPITRYFFRKNLLRLTG 5539SRWsGSHQFFFRKNLLRLTG 5540 SRWsGSHQKFFRKNLLRLTG 5541SRWsGSHQRFFRKNLLRLTG 5542 SRWsGSHQYFFRKNLLRLTG 5543SRYsRsPYSFFFRKNLLRLTG 5544 SRYsRSPYSFFFRKNLLRLTG 5545SRYSRsPYSFFFRKNLLRLTG 5546 SRYsRsPYSKFFRKNLLRLTG 5547SRYsRSPYSKFFRKNLLRLTG 5548 SRYSRsPYSKFFRKNLLRLTG 5549SRYsRsPYSLFFRKNLLRLTG 5550 SRYsRSPYSLFFRKNLLRLTG 5551SRYSRsPYSLFFRKNLLRLTG 5552 SRYsRsPYSMFFRKNLLRLTG 5553SRYsRSPYSMFFRKNLLRLTG 5554 SRYSRsPYSMFFRKNLLRLTG 5555SRYsRsPYSRFFRKNLLRLTG 5556 SRYsRSPYSRFFRKNLLRLTG 5557SRYSRsPYSRFFRKNLLRLTG 5558 SRYsRsPYSYFFRKNLLRLTG 5559SRYsRSPYSYFFRKNLLRLTG 5560 SRYSRsPYSYFFRKNLLRLTG 5561SRYsRtsPYSRFFRKNLLRLTG 5562 SSDIsPTRLFFRKNLLRLTG 5563SSDIsPTRYFFRKNLLRLTG 5564 SSDKHsEYFFRKNLLRLTG 5565SSDPASQLsYFFRKNLLRLTG 5566 SSDsETLRYFFRKNLLRLTG 5567SSDsPQKLFFRKNLLRLTG 5568 SSDsPQKYFFRKNLLRLTG 5569SSDsPSYVLYFFRKNLLRLTG 5570 SSDsPTNHFFFFRKNLLRLTG 5571SSEIsPTRYFFRKNLLRLTG 5572 SSEKHsEYFFRKNLLRLTG 5573SSEPASQLsYFFRKNLLRLTG 5574 SSEsETLRYFFRKNLLRLTG 5575SSEsPQKLFFRKNLLRLTG 5576 SSEsPQKYFFRKNLLRLTG 5577SSEsPSYVLYFFRKNLLRLTG 5578 SSEsPTNHFYFFRKNLLRLTG 5579SSNGMKASRRsEEKEAGFFRKNLLRLTG 5580 SSNGKMASRRsEEKEAGEIFFRKNLLRLTG5581 SsPIMRKKVSLFFRKNLLRLTG 5582 sSPPFPVPVYTRQAPKQVIKFFRKNLLRLTG5583 SSsPTHAKSAHVFFRKNLLRLTG 5584 SSsWRILGSKQSEHRPFFRKNLLRLTG 5585STDIsPTRLFFRKNLLRLTG 5586 STDIsPTRYFFRKNLLRLTG 5587STDKHsEYFFRKNLLRLTG 5588 STDPASQLsYFFRKNLLRLTG 5589STDsETLRYFFRKNLLRLTG 5590 STDsPQKYFFRKNLLRLTG 5591STDsPSYVLYFFRKNLLRLTG 5592 STDsPTNHFYFFRKNLLRLTG 5593STEIsPTRLFFRKNLLRLTG 5594 STEIsPTRYFFRKNLLRLTG 5595STEKHsEYFFRKNLLRLTG 5596 STEPASQLsYFFRKNLLRLTG 5597STEsETLRYFFRKNLLRLTG 5598 STEsPQKYFFRKNLLRLTG 5599STEsPSYVLYFFRKNLLRLTG 5600 STEsPTNHFYFFRKNLLRLTG 5601STIQNsPTKKFFRKNLLRLTG 5602 sTMSLNIITVFFRKNLLRLTG 5603STMsLNIITVFFRKNLLRLTG 5604 SVDIsPIRLFFRKNLLRLTG 5605SVDIsPTRLFFRKNLLRLTG 5606 SVDIsPTRYFFRKNLLRLTG 5607SVFsPSFGLFFRKNLLRLTG 5608 SVGsDYYIQLFFRKNLLRLTG 5609SVKPRRTsLFFRKNLLRLTG 5610 SVKsPVTVKFFRKNLLRLTG 5611SVKsPVTVYFFRKNLLRLTG 5612 SVLsPSFQLFFRKNLLRLTG 5613SVMDsPKKLFFRKNLLRLTG 5614 SVRRsVLMKFFRKNLLRLTG 5615SVRRsVLMYFFRKNLLRLTG 5616 SVRsLSLSLFFRKNLLRLTG 5617SVYsGDFGNLEVFFRKNLLRLTG 5618 SVYsPVKKKFFRKNLLRLTG 5619SVYsPVKKYFFRKNLLRLTG 5620 sYIEHIFEIFFRKNLLRLTG 5621SYPsPVATSYFFRKNLLRLTG 5622 sYQKVIELFFFRKNLLRLTG 5623TDKYsKKMFFRKNLLRLIG 5624 TEAsPESMLFFRKNLLRLTG 5625THKGEIRGASTPFQFRAssPFFRKNLLRLTG 5626 TIGEKKEPsDKSVDSFFRKNLLRLTG5627 TKDKYMASRGQKAKsMEGFFRKNLLRLTG 5628 TKsVKALSSLHGDDFFRKNLLRLTG5629 TKsVKALSSLHGDDQFFRKNLLRLTG 5630 TKsVKALSSLHGDDQDFFRKNLLRLTG5631 TLAsPSVFKSTFFRKNLLRLTG 5632 TLAsPSVFKSVFFRKNLLRLTG 5633TLLAsPMLKFFRKNLLRLTG

5634 TLMERTVsLFFRKNLLRLTG 5635 TLSsPPPGLFFRKNLLRLTG 5636TMAsPGKDNYFFRKNLLRLTG 5637 TMAsPSVFKSTFFRKNLLRLTG 5638TMAsPSVFKSVFFRKNLLRLTG 5639 TMDsPGKDNYFFRKNLLRLTG 5640TMEsPGKDNYFFRKNLLRLTG 5641 TMMsPSQFLFFRKNLLRLTG 5642TPAQPQRRsFFFRKNLLRLTG 5643 TPAQPQRRsLFFRKNLLRLTG 5644TPAQPQRRsMFFRKNLLRLTG 5645 TPAQPQRRsVFFRKNLLRLTG 5646TPDPSKFFSQLsSEHGGDVFFRKNLLRLTG 5647 tPDPSKFFSQLSSEHGGDVQFFRKNLLRLTG5648 TPIsPGRASGFFFRKNLLRLTG 5649 TPIsPGRASGLFFRKNLLRLTG 5650TPIsPGRASGMFFRKNLLRLTG 5651 TPIsPGRASGVFFRKNLLRLTG 5652TPMKKHLsLFFRKNLLRLTG 5653 TPRsPPLGFFFRKNLLRLTG 5654TPRsPPLGLFFRKNLLRLTG 5655 TPRsPPLGLFFFRKNLLRLTG 5656TPRsPPLGLIFFRKNLLRLTG 5657 TPRsPPLGLLFFRKNLLRLTG 5658TPRsPPLGLMFFRKNLLRLTG 5659 TPRsPPLGLVFFRKNLLRLTG 5660TPRsPPLGMFFRKNLLRLTG 5661 TPRsPPLGVFFRKNLLRLTG 5662TQSSGKsSVFFRKNLLRLTG 5663 TRKtPESFLFFRKNLLRLTG 5664TRLsPAKIVLFFFRKNLLRLTG 5665 TRLsPAKIVLKFFRKNLLRLTG 5666TRLsPAKIVLRFFRKNLLRLTG 5667 TRLsPAKIVLYFFRKNLLRLTG 5668TSAsPGKDNYFFRKNLLRLTG 5669 TSDsPGKDNYFFRKNLLRLTG 5670TSDtPDYLLKYFFRKNLLRLTG 5671 TSEsPGKDNYFFRKNLLRLTG 5672TSEtPDYLLKYFFRKNLLRLTG 5673 TTAsPGKDNYFFRKNLLRLTG 5674TTDsPGKDNYFFRKNLLRLTG 5675 TTDtPDYLLKYFFRKNLLRLTG 5676TTEsPGKDNYFFRKNLLRLTG 5677 TTEtPDYLLKYFFRKNLLRLTG 5678TTKsVKALSSLHGFFRKNLLRLTG 5679 TTKsVKALSSLHGDDFFRKNLLRLTG 5680TTKsVKALSSLHGDDQFFRKNLLRLTG 5681 TKKsVKALSSHLGDDQDFFRKNLLRLTG 5682TTKsVKALSSLHGDDQDSFFRKNLLRLTG 5683 TTKsVKALSSLHGDDQDsEDFFRKNLLRLTG5684 TTKSVKALSSHGDDQDsEDFFRKNLLRLTG 5685TTKsVKALSSLHGDDQDsEDEFFRKNLLRLTG 5686TTKSVKALSSHGDDQSsEDEFFRKNLLRLTG 5687 TVFsPTLPAAFFRKNLLRLTG 5688TVMsNSSVIHLFFRKNLLRLTG 5689 VAKRLsLFFRKNLLRLTG 5690VAMPVKKSPRRSsSDEQGLSYSSLKNVFFRKNLLRLTG 5691 VIDsQELSKVFFRKNLLRLTG5692 VLDsPASKKFFRKNLLRLTG 5693 VLFPEsPARAFFRKNLLRLTG 5694VLFRtPLASVFFRKNLLRLTG 5695 VLFsSPPQMFFRKNLLRLTG 5696VLFSsPPQMFFRKNLLRLTG 5697 VLIENVAsLFFRKNLLRLTG 5698VLIGsPKKVFFRKNLLRLTG 5699 VLIGsPKKYFFRKNLLRLTG 5700VLKGsRSSELFFRKNLLRLTG 5701 VLKGsRSSEVFFRKNLLRLTG 5702VLKSRKssVTEEFFRKNLLRLTG 5703 VLKVMIGsPKFFRKNLLRLTG 5704VLKVMIGsPKKFFRKNLLRLTG 5705 VLKVMIGsPKKKFFRKNLLRLTG 5706VLLsPVPELFFRKNLLRLTG 5707 VLLsPVPEVFFRKNLLRLTG 5708VLMK(sPs)PALFFRKNLLRLTG 5709 VLMK(sPs)PAVFFRKNLLRLTG 5710VLQtPPYVKFFRKNLLRLTG 5711 VLQtPPYVKKFFRKNLLRLTG 5712VLQtPPYVKYFFRKNLLRLTG 5713 VLSDVIPsIFFRKNLLRLTG 5714VLSSLtPAKVFFRKNLLRLTG 5715 VLVVDTPsIFFRKNLLRLTG 5716VLYsPQMALFFRKNLLRLTG 5717 VMFRtPLASVFFRKNLLRLTG 5718VMIGsKKVFFRKNLLRLTG 5719 VMIGsPKKVFFRKNLLRLTG 5720VMIGsPKKYFFRKNLLRLTG 5721 VMKVMIGsPKFFRKNLLRLTG 5722VMKVMIGsPKKFFRKNLLRLTG 5723 VMKVMIGsPKKKFFRKNLLRLTG 5724VMKVMIGsPKKYFFRKNLLRLTG 5725 VMLsPVPELFFRKNLLRLTG 5726VMLsPVPEVFFRKNLLRLTG 5727 VMQtPPYVKFFRKNLLRLTG 5728VMQtPPYVKKFFRKNLLRLTG 5729 VPHHGFEDWsQIRFFRKNLLRLTG 5730VPKSGRSSsLFFRKNLLRLTG 5731 VPKsPAFALFFRKNLLRLTG 5732VPLIRKKsLFFRKNLLRLTG 5733 VPNAPPAYEKLsAEQSPPPYFFRKNLLRLTG 5734VPREVLRLsFFFRKNLLRLTG 5735 VPREVLRLsLFFRKNLLRLTG 5736VPREVLRLsMFFRKNLLRLTG 5737 VPREVLRLsVFFRKNLLRLTG 5738VPRPERRsSLFFRKNLLRLTG 5739 VPRsPKHAHSSSFFFRKNLLRLTG 5740VPRsPKHAHSSSLFFRKNLLRLTG 5741 VPRsPKHAHSSSMFFRKNLLRLTG 5742VPRsPKHAHSSSVFFRKNLLRLTG 5743 VPStPKSSLFFRKNLLRLTG 5744VPTsPKSSLFFRKNLLRLTG 5745 VPVsPGQQLFFRKNLLRLTG 5746VRAsKDLAQFFRKNLLRLTG 5747 VRQsVTSFPDADAFHHQFFRKNLLRLTG 5748VSKVMIGsPKKVFFRKNLLRLTG 5749 VSKVMIGsPKKYFFRKNLLRLTG 5750VTQtPPYVKKFFRKNLLRLTG 5751 VTQtPPYVKYFFRKNLLRLTG 5752VVDsPGQEVLFFRKNLLRLTG 5753 VYTyIQSRFFFRKNLLRLTG 5754WTHLsSKEVDPSFFRKNLLRLTG 5755 WTHLsSKEVDPSTGFFRKNLLRLTG 5756YARsVHEEFFFRKNLLRLTG 5757 YAVPRRGsLFFRKNLLRLTG 5758YAYDGKDyIFFRKNLLRLTG 5759 YEGsPIKVFFRKNLLRLTG

5760 YEKLsAEQSPPPFFRKNLLRLTG 5761 YFsPFRPYFFRKNLLRLTG 5762yIQSRFFFRKNLLRLTG 5763 YLAsLEKKLFFRKNLLRLTG 5764YLDsGIHSGFFRKNLLRLTG 5765 YLDsGIHsGAFFRKNLLRLTG 5766YLDsGIHSGAFFRKNLLRLTG 5767 YLDsGIHsGVFFRKNLLRLTG 5768YLDsGIHSGVFFRKNLLRLTG 5769 yLGLDVPVFFRKNLLRLTG 5770YLGsISTLVTLFFRKNLLRLTG 5771 YLIHsPMSLFFRKNLLRLTG 5772YLLsPLNTLFFRKNLLRLTG 5773 YLLsPTKLPSIFFRKNLLRLTG 5774YLLsPTKLPSVFFRKNLLRLTG 5775 yLQSRYYRAFFRKNLLRLTG 5776YLQsRYYRAFFRKNLLRLTG 5777 YLSDsDTEAKLFFRKNLLRLTG 5778YMDsGIHsGAFFRKNLLRLTG 5779 YMDsGIHSGAFFRKNLLRLTG 5780YMDsGIHsGVFFRKNLLRLTG 5781 YMDsGIHSGVFFRKNLLRLTG 5782YPDPHsPFAVFFRKNLLRLTG 5783 YPGGRRsSLFFRKNLLRLTG 5784YPLsPAKVNQYFFRKNLLRLTG 5785 YPLsPTKISEYFFRKNLLRLTG 5786YPLsPTKISQYFFRKNLLRLTG 5787 YPRsEDEVEGVMFFRKNLLRLIG 5788YPRsFDEVEGFFFRKNLLRLTG 5789 YPRsFDEVEGLFFRKNLLRLTG 5790YPRsFDEVEGMFFRKNLLRLTG 5791 YPRsFDEVEGVFFRKNLLRLTG 5792YPRsFDEVEGVFFFRKNLLRLTG 5793 YPRsFDEVEGVLFFRKNLLRLTG 5794YPRsFDEVEGVMFFRKNLLRLTG 5795 YPRsFDEVEGVVFFRKNLLRLTG 5796YPSFRRsSLFFRKNLLRLTG 5797 YPSsPRKALFFRKNLLRLTG 5798YPSsPRKFFFRKNLLRLTG 5799 YPSsPRKLFFRKNLLRLTG 5800YPSsPRKMFFRKNLLRLTG 5801 YPSsPRKVFFRKNLLRLTG 5802YPYEFsPVKMFFRKNLLRLTG 5803 YQLsPTKLPSIFFRKNLLRLTG 5804YQLsPTKLPSVFFRKNLLRLTG 5805 YQRPFsPSAYFFRKNLLRLTG 5806YQRsFDEVEGFFFRKNLLRLTG 5807 YQRsFDEVEGLFFRKNLLRLTG 5808YQRsFDEVEGMFFRKNLLRLTG 5809 YQRsFDEVEGVFFRKNLLRLTG 5810YQRsFDEVEGVFFFRKNLLRLTG 5811 YQRsFDEVEGVLFFRKNLLRLTG 5812YQRsFDEVEGVMFFRKNLLRLTG 5813 YQRsFDEVEGVVFFRKNLLRLTG 5814YRYsPQSFLFFRKNLLRLTG 5815 YTAGtPYKVFFRKNLLRLTG 5816YYTAGSSsPTHAKSAHVFFRKNLLRLTG 8809 RLLsAAENFLFFRKNLLRLTG Lowercases, t, and y indicate phosphorylated serine, phosphorylatedthreonine, and phosphorylated tyrosine, respectively. Lowercase cindicates that the cysteine is present in a cysteine--cysteinedisulfide bond. Lowercase m indicates oxidized methionine. (AcS)indicates an N-terminally acetylated serine. (sLss) indicates thatat least one serine residue in the amino acid sequence. SLSS isphosphorylated. (sPs) indicates that at least one serine residue inthe amino acid sequence SPS is phosphorylated.

TABLE-US-00005 TABLE 5 Amino acid sequences of exemplary antigenicpolypeptides SEQ ID NO Amino Acid Sequence 5817(AcS)AARESHPHGVKRSAsPDDDLGFFRKNWLRLTW 5818 AAEsPSFLFFRKNWLRLTW 5819AASNFKsPVKTIRFFRKNWLRLTW 5820 ADLsPEREVFFRKNWLRLTW 5821AEDEIGtPRKFFFRKNWLRLTW 5822 AEDEIGtPRKYFFRKNWLRLTW 5823AEEEIGtPRKFFFRKNWLRLTW 5824 AEEEIGtPRKWFFRKNWLRLTW 5825AEEEIGtPRKYFFRKNWLRLTW 5826 AENARSAsFFFRKNWLRLTW 5827AENsPTRQQFFFRKNWLRLTW 5828 AENsPTRQQWFFRKNWLRLTW 5829AENsPTRQQYFFRKNWLRLTW 5830 AENsSSRELFFRKNWLRLTW 5831AEQGsPRVSYFFRKNWLRLTW 5832 AESsPTAGKKFFFRKNWLRLTW 5833AESsPTAGKKLFFRKNWLRLTW 5834 AESsPTAGKKWFFRKNWLRLTW 5835AESsPTAGKKYFFRKNWLRLTW 5836 AGDsPGSQFFFRKNWLRLTW 5837AILsPAFKVFFRKNWLRLTW 5838 AIMRsPQMVFFRKNWLRLTW 5839AIsDLQQLFFRKNWLRLTW 5840 AKLsETISFFRKNWLRLTW 5841ALAAsPHAVFFRKNWLRLTW 5842 ALDsGASLLHLFFRKNWLRLTW 5843ALDsGASLLHVFFRKNWLRLTW 5844 ALGNtPPFLFFRKNWLRLTW 5845ALGsRESLATIFFRKNWLRLTW 5846 ALGsRESLATVFFRKNWLRLTW 5847ALIHQsLGLFFRKNWLRLTW 5848 ALIHQsLGVFFRKNWLRLTW 5849ALLGSKsPDPYRLFFRKNWLRLTW 5850 ALLGSKsPDPYRVFFRKNWLRLTW 5851ALLsLLKRVFFRKNWLRLTW 5852 ALMGsPQLVFFRKNWLRLTW 5853ALMGsPQLVAAFFRKNWLRLTW 5854 ALRSsPIMRKFFRKNWLRLTW 5855ALRSsPIMRYFFRKNWLRLTW 5856 ALVsPPALHNAFFRKNWLRLTW 5857ALVsPPALHNVFFRKNWLRLTW 5858 ALYsGVHKKFFRKNWLRLTW 5859ALYsGVHKYFFRKNWLRLTW 5860 ALYsPAQPSLFFRKNWLRLTW 5861ALYsPAQPSVFFRKNWLRLTW 5862 ALYtPQAPKFFRKNWLRLTW 5863ALYtPQAPYFFRKNWLRLTW 5864 AMAAsPHAVFFRKNWLRLTW 5865AMDsGASLLHLFFRKNWLRLTW 5866 AMDsGASLLHVFFRKNWLRLTW 5867AMGsRESLATIFFRKNWLRLTW 5868 AMGsRESLATVFFRKNWLRLTW 5869AMLGSKsPDPYRLFFRKNWLRLTW 5870 AMLGSKsPDPYRVFFRKNWLRLTW 5871AMPGsPVEVFFRKNWLRLTW 5872 AMRSsPIMRKFFRKNWLRLTW 5873AMVsPPALHNAFFRKNWLRLTW 5874 AMVsPPALHNVFFRKNWLRLTW 5875AMYsGVHKKFFRKNWLRLTW 5876 APDsPRAFLFFRKNWLRLTW 5877APLARASsLFFRKNWLRLTW 5878 APPAYEKLsFFRKNWLRLTW 5879APPAYEKLsAEQFFRKNWLRLTW 5880 APPAYEKLsAEQSPPFFRKNWLRLTW 5881APPAYEKLsAEQSPPPFFRKNWLRLTW 5882 APPAYEKLsAEQSPPPYFFRKNWLRLTW 5883APPPLVPAPRPSsPPRGPGPARADRFFRKNWLRLTW 5884 APRAPsASPLALFFRKNWLRLTW5885 APRDRRAVsFFFRKNWLRLTW 5886 APRKGsFSALFFRKNWLRLTW 5887APRKGsFSALFFFRKNWLRLTW 5888 APRKGsFSALLFFRKNWLRLTW 5889APRKGsFSALMFFRKNWLRLTW 5890 APRKGsFSALVFFRKNWLRLTW 5891APRNGsGVALFFRKNWLRLTW 5892 APRRYsSSFFFRKNWLRLTW 5893APRRYsSSLFFRKNWLRLTW 5894 APRRYsSSMFFRKNWLRLTW 5895APRRYsSSVFFRKNWLRLTW 5896 APRsPPPSRFFFRKNWLRLTW 5897APRsPPPSRLFFRKNWLRLTW 5898 APRsPPPSRMFFRKNWLRLTW 5899APRsPPPSRPFFRKNWLRLTW 5900 APRsPPPSRVFFRKNWLRLTW 5901APSLFHLNtLFFRKNWLRLTW 5902 APSSARAsPLLFFRKNWLRLTW 5903APSTYAHLsPAKFFRKNWLRLTW 5904 APSTYAHLsPAKTPPPPFFRKNWLRLTW 5905APSVRsLSLFFRKNWLRLTW 5906 APSVRSLsLFFRKNWLRLTW 5907ARFsPDDKYSFFFRKNWLRLTW 5908 ARFsPDDKYSKFFRKNWLRLTW 5909ARFsPDDKYSLFFRKNWLRLTW 5910 ARFsPDDKYSMFFRKNWLRLTW 5911ARFsPDDKYSRFFRKNWLRLTW 5912 ARFsPDDKYSYFFRKNWLRLTW 5913ASDEIGtPRKFFFRKNWLRLTW 5914 ASDEIGtPRKYFFRKNWLRLTW 5915ASEEIGtPRKFFFRKNWLRLTW 5916 ASEEIGtPRKYFFRKNWLRLTW 5917AsISRLsGEQVDGKGFFRKNWLRLTW 5918 AsISRLSGEQVDGKGFFRKNWLRLTW 5919ASISRLsGEQVDGKGFFRKNWLRLTW 5920 AsIsRLSGEQVDGKGQFFRKNWLRLTW 5921AsISRLSGEQVDKGKGFFRKNWLRLTW 5922 ASKAsPTLDFTERFFRKNWLRLTW 5923ASKMTQPQSKSAFPLSRKNKGsGsLDGFFRKNWLRLTW 5924 AsLGFVFFFRKNWLRLTW 5925AsPTIEAQGTSPAHDNFFRKNWLRLTW 5926 AsPTIEAQGTSPAHDNIFFRKNWLRLTW 5927AsPTIEAQGTSPAHDNIAFFRKNWLRLTW 5928 AtAGPRLGFFFRKNWLRLTW 5929AtAGPRLGWFFRKNWLRLTW 5930 AtAGPRLGYFFRKNWLRLTW 5931ATDEIGtPRKFFFRKNWLRLTW 5932 ATDEIGtPRKYFFRKNWLRLTW 5933ATEEIGtPRKFFFRKNWLRLTW 5934 ATEEIGtPRKYFFRKNWLRLTW 5935ATWsGSEFEVFFRKNWLRLTW 5936 ATYtPQAPKFFRKNWLRLTW 5937ATYtPQAPKYFFRKNWLRLTW

5938 AVIHQsLGLFFRKNWLRLTW 5939 AVIHQsLGVFFRKNWLRLTW 5940AVRPTRLsLFFRKNWLRLTW 5941 AVVsPPALHNAFFRKNWLRLTW 5942AVVsPPALHNVFFRKNWLRLTW 5943 AYEKLsAEQSPPFFRKNWLRLTW 5944DAKKsPLALFFRKNWLRLTW 5945 DDDWTHLsSKEVDPFFRKNWLRLTW 5946DDDWTHLsSKEVDPSFFRKNWLRLTW 5947 DDDWTHLsSKEVDPSTFFRKNWLRLTW 5948DDDWTHLsSKEVDPSTGFFRKNWLRLTW 5949 DDWTHLsSKEVDPSFFRKNWLRLTW 5950DEFERIKtFFFRKNWLRLTW 5951 DEFERIKtWFFRKNWLRLTW 5952DEFERIKtYFFRKNWLRLTW 5953 DEISHRAsFFFRKNWLRLTW 5954DEISHRAsWFFRKNWLRLTW 5955 DEISHRAsYFFRKNWLRLTW 5956DERLRINsFFFRKNWLRLTW 5957 DERLRINsLFFRKNWLRLTW 5958DERLRINsWFFRKNWLRLTW 5959 DERLRINsYFFRKNWLRLTW 5960DKLsVIAEDSESGKQFFRKNWLRLTW 5961 DKLsVIAEDSESGKQNFFRKNWLRLTW 5962DKLsVIAEDSESGKQNPFFRKNWLRLTW 5963 DKLsVIAEDSESGKQNPGFFRKNWLRLTW5964 DKLsVIAEDSESGKQNPGDSFFRKNWLRLTW 5965 DLKRRsmSIFFRKNWLRLTW 5966DLKRRsMSIFFRKNWLRLTW 5967 DLKSSKAsLFFRKNWLRLTW 5968DLRtVEKELFFRKNWLRLTW 5969 DLsEEKFLFFRKNWLRLTW 5970DLsEEKFVFFRKNWLRLTW 5971 DLVPLsPLKKFFRKNWLRLTW 5972DLWKItKVMDFFRKNWLRLTW 5973 DMVPLsPLKKFFRKNWLRLTW 5974DPTRRFFKVtPPPGSGPQFFRKNWLRLTW 5975 DQFERIKtLFFRKNWLRLTW 5976DQISHRAsLFFRKNWLRLTW 5977 DSDPLsPLKYFFRKNWLRLTW 5978DSEPLsPLKYFFRKNWLRLTW 5979 DSsEEKFLFFRKNWLRLTW 5980DSsEEKFVFFRKNWLRLTW 5981 DSVPLsPLKYFFRKNWLRLTW 5982DTDPLsPLKYFFRKNWLRLTW 5983 DTEPLsPLKYFFRKNWLRLTW 5984DTVPLsPLKYFFRKNWLRLTW 5985 DWTHLsSKEVDPSFFRKNWLRLTW 5986DWTHLsSKEVDPSTGFFRKNWLRLTW 5987 EEGsPTMVEKGLEPGVFTLFFRKNWLRLTW 5988EELsPTAKFFFRKNWLRLTW 5989 EELsPTKAFFFRKNWLRLTW 5990EEMPENALPsDEDDKDPNDPYRALFFRKNWLRLTW 5991 EERRsPPAPFFRKNWLRLTW 5992EEsSDDGKKFFFRKNWLRLTW 5993 EESsDDGKKFFFRKNWLRLTW 5994EEsSDDGKKWFFRKNWLRLTW 5995 EESsDDGKKWFFRKNWLRLTW 5996EEsSDDGKKYFFRKNWLRLTW 5997 EESsDDGKKYFFRKNWLRLTW 5998EGEEPTVYsDEEEPKDESARKNDFFRKNWLRLTW 5999EGsPTMVEKGLEPGVFTLFFRKNWLRLTW 6000 ELFSsPPAVFFRKNWLRLTW 6001ELKKsPTSLKFFRKNWLRLTW 6002 ELKKsPTSLYFFRKNWLRLTW 6003ELLMPHRIsSHFFFRKNWLRLTW 6004 ELLMPHRIsSHFLFFRKNWLRLTW 6005ELRISGsVQLFFRKNWLRLTW 6006 EMKKsPTSLKFFRKNWLRLTW 6007EPAsPAAsISRLsGEQVDGKGFFRKNWLRLTW 6008EPAsPAAsISRLSGEQVDGKGFFRKNWLRLTW 6009 EPKRRsARFFFRKNWLRLTW 6010EPKRRsARLFFRKNWLRLTW 6011 EPKRRsARMFFRKNWLRLTW 6012EPKRRsARVFFRKNWLRLTW 6013 EPRsPSHSFFFRKNWLRLTW 6014EPRsPSHSLFFRKNWLRLTW 6015 EPRsPSHSMFFRKNWLRLTW 6016EPRsPSHSVFFRKNWLRLTW 6017 ERsPLLSQETAGQKPFFRKNWLRLTW 6018ERsPLLSQETAGQKPLFFRKNWLRLTW 6019 ESDsLPRYFFRKNWLRLTW 6020ESEsLPRYFFRKNWLRLTW 6021 ESsVRSQEDQLSRFFRKNWLRLTW 6022ESsVRSQEDQLSRRFFRKNWLRLTW 6023 ETDsLPRYFFRKNWLRLTW 6024ETEsLPRYFFRKNWLRLTW 6025 FDKHTLGDsDNESFFRKNWLRLTW 6026FEDDDsNEKLFFRKNWLRLTW 6027 FIEsPSKLFFRKNWLRLTW 6028FIEsPSKYFFRKNWLRLTW 6029 FIGsPTTPAGLFFRKNWLRLTW 6030FKMPQEKsPGYSFFRKNWLRLTW 6031 FKsPVKTIRFFRKNWLRLTW 6032FKtQPVTFFFRKNWLRLTW 6033 FLDNsFEKVFFRKNWLRLTW 6034FLDRPPtPLFIFFRKNWLRLTW 6035 FLDsLRDLIFFRKNWLRLTW 6036FLDtPIAKVFFRKNWLRLTW 6037 FLFDKPVsPLLLFFRKNWLRLTW 6038FLGVRPKsAFFRKNWLRLTW 6039 FLIIRtVLQLFFRKNWLRLTW 6040FLITGGGKGsGFSLFFRKNWLRLTW 6041 FLLsQNFDDEFFRKNWLRLTW 6042FLYsGKETKFFRKNWLRLTW 6043 FLYsGKETYFFRKNWLRLTW 6044FPHsLLSVFFFRKNWLRLTW 6045 FPHsLLSVIFFRKNWLRLTW 6046FPHsLLSVLFFRKNWLRLTW 6047 FPHsLLSVMFFRKNWLRLTW 6048FPHsLLSVVFFRKNWLRLTW 6049 FPIsPVRFFFRKNWLRLTW 6050FPIsPVRLFFRKNWLRLTW 6051 FPIsPVRMFFRKNWLRLTW 6052FPIsPVRVFFRKNWLRLTW 6053 FPLDsPKTLVLFFRKNWLRLTW 6054FPRRHsVTLFFRKNWLRLTW 6055 FPRsPTKSSFFFRKNWLRLTW 6056FPRsPTKSSLFFRKNWLRLTW 6057 FPRsPTKSSLDFFFRKNWLRLTW 6058FPRsPTKSSLDLFFRKNWLRLTW 6059 FPRsPTKSSLDMFFRKNWLRLTW 6060FPRsPTKSSLDVFFRKNWLRLTW 6061 FPRsPTKSSMFFRKNWLRLTW 6062FPRsPTKSSVFFRKNWLRLTW 6063 FRFsGRTEYFFRKNWLRLTW

6064 FRGRYRsPYFFRKNWLRLTW 6065 FRKsMVEHYFFRKNWLRLTW 6066FRRsPIKSSLDYFFRKNWLRLTW 6067 FRRsPTKSSFFFRKNWLRLTW 6068FRRsPTKSSLFFRKNWLRLTW 6069 FRRsPTKSSLDFFRKNWLRLTW 6070FRRsPTKSSLDFFFRKNWLRLTW 6071 FRRsPTKSSLDLFFRKNWLRLTW 6072FRRsPTKSSLDMFFRKNWLRLTW 6073 FRRsPTKSSLDVFFRKNWLRLTW 6074FRRsPTKSSLDYFFRKNWLRLTW 6075 FRRsPTKSSMFFRKNWLRLTW 6076FRRsPTKSSVFFRKNWLRLTW 6077 FRsPTKSSLDFFFRKNWLRLTW 6078FRsPTKSSLDLFFRKNWLRLTW 6079 FRsPTKSSLDMFFRKNWLRLTW 6080FRsPTKSSLDVFFRKNWLRLTW 6081 FRYsGKTEFFFRKNWLRLTW 6082FRYsGKTEKFFRKNWLRLTW 6083 FRYsGKTELFFRKNWLRLTW 6084FRYsGKTEMFFRKNWLRLTW 6085 FRYsGKTERFFRKNWLRLTW 6086FRYsGKTEYFFRKNWLRLTW 6087 FSDsHEGFSYFFRKNWLRLTW 6088FSEsHEGFSYFFRKNWLRLTW 6089 FSEsPSKLFFRKNWLRLTW 6090FSEsPSKYFFRKNWLRLTW 6091 FSIsPVRFFFRKNWLRLTW 6092FSIsPVRLFFRKNWLRLTW 6093 FSIsPVRMFFRKNWLRLTW 6094FSIsPVRVFFRKNWLRLTW 6095 FSsSHEGFSYFFRKNWLRLTW 6096FSSsHEGFSYFFRKNWLRLTW 6097 FTDsHEGFSYFFRKNWLRLTW 6098FTEsHEGFSYFFRKNWLRLTW 6099 FTEsPSKLFFRKNWLRLTW 6100FTEsPSKYFFRKNWLRLTW 6101 FTKsPYQEFFFRKNWLRLTW 6102FTsSHEGFSYFFRKNWLRLTW 6103 FVSKVMIGsPKKVFFRKNWLRLTW 6104GALsPSLLHSLFFRKNWLRLTW 6105 GAQPGRHsFFFRKNWLRLTW 6106GAQPGRHsLFFRKNWLRLTW 6107 GAQPGRHsVFFRKNWLRLTW 6108GDDDWTHLsSKEVDFFRKNWLRLTW 6109 GDDDWTHLsSKEVDPFFRKNWLRLTW 6110GDDDWTHLsSKEVDPSFFRKNWLRLTW 6111 GDDDWTHLsSKEVDPSTFFRKNWLRLTW 6112GDDDWTHLsSKEVDPSTGFFRKNWLRLTW 6113 GEAsPSHIIFFRKNWLRLTW 6114GEEsSDDGKKFFFRKNWLRLTW 6115 GEEsSDDGKKWFFRKNWLRLTW 6116GEEsSDDGKKYFFRKNWLRLTW 6117 GEEsSDIDGKKFFFRKNWLRLTW 6118GEIsPQREVFFRKNWLRLTW 6119 GERsPLLSQETAGQKPFFRKNWLRLTW 6120GERsPLLSQETAGQKPLFFRKNWLRLTW 6121 GETsPRTKIFFRKNWLRLTW 6122GGDDDWTHLsSKEVDPSFFRKNWLRLTW 6123 GGDDDWTHLsSKEVDPSTGFFRKNWLRLTW6124 GGSFGGRSSGsPFFRKNWLRLTW 6125 GGSFGGRSSGsVFFRKNWLRLTW 6126GIDsPSSSVFFRKNWLRLTW 6127 GIMsPLAKKFFRKNWLRLTW 6128GLAPtPPSMFFRKNWLRLTW 6129 GLDsGFHSVFFRKNWLRLTW 6130GLDsLDQVEIFFRKNWLRLTW 6131 GLGELLRsLFFRKNWLRLTW 6132GLIRSRsFIFKFFRKNWLRLTW 6133 GLIRSRsFIFYFFRKNWLRLTW 6134GLIsPELRHLFFRKNWLRLTW 6135 GLIsPNVQLFFRKNWLRLTW 6136GLIsPVWGAFFRKNWLRLTW 6137 GLItPGGFSSVFFRKNWLRLTW 6138GLLDsPTSIFFRKNWLRLTW 6139 GLLGsPARLFFRKNWLRLTW 6140GLLGsPVRAFFRKNWLRLTW 6141 GLLGsPVRVFFRKNWLRLTW 6142GLLsPARLYAIFFRKNWLRLTW 6143 GLLsPARLYAVFFRKNWLRLTW 6144GLLsPRFVDVFFRKNWLRLTW 6145 GLLsPRHSLFFRKNWLRLTW 6146GLSFGGRSSGsPFFRKNWLRLTW 6147 GLSFGGRSSGsVFFRKNWLRLTW 6148GMLGsPVRVFFRKNWLRLTW 6149 GMLsPARLYAIFFRKNWLRLTW 6150GMLsPARLYAVFFRKNWLRLTW 6151 GMLsPGKSIEVFFRKNWLRLTW 6152GPKPLFRRMsSFFRKNWLRLTW 6153 GPKPLFRRMsSLFFRKNWLRLTW 6154GPKPLFRRMsSLVFFRKNWLRLTW 6155 GPKPLFRRMsSLVGFFRKNWLRLTW 6156GPKPLFRRMsSLVGPFFRKNWLRLTW 6157 GPKPLFRRMsSLVGPTFFRKNWLRLTW 6158GPKPLFRRMsSLVGPTQFFRKNWLRLTW 6159 GPKPLFRRMsSLVGPTQSFFRKNWLRLTW6160 GPPYQRRGsLFFRKNWLRLTW 6161 GPQPGRHsFFFRKNWLRLTW 6162GPQPGRHsLFFRKNWLRLTW 6163 GPQPGRHsVFFRKNWLRLTW 6164GPRPGsPSAFFFRKNWLRLTW 6165 GPRPGsPSALFFRKNWLRLTW 6166GPRPGsPSAMFFRKNWLRLTW 6167 GPRPGsPSAVFFRKNWLRLTW 6168GPRSAsLLFFRKNWLRLTW 6169 GPRsASLLSFFFRKNWLRLTW 6170GPRSAsLLsFFFRKNWLRLTW 6171 GPRSASLLsFFFRKNWLRLTW 6172GPRsAsLLSLFFRKNWLRLTW 6173 GPRsASLLSLFFRKNWLRLTW 6174GPRSAsLLsLFFRKNWLRLTW 6175 GPRSAsLLSLFFRKNWLRLTW 6176GPRSASLLsLFFRKNWLRLTW 6177 GPRsASLLSMFFRKNWLRLTW 6178GPRSAsLLsMFFRKNWLRLTW 6179 GPRSASLLSMFFRKNWLRLTW 6180GPRsASLLSVFFRKNWLRLTW 6181 GPRSAsLLsVFFRKNWLRLTW 6182GPRSASLLSVFFRKNWLRLTW 6183 GPRsPKAPPFFRKNWLRLTW 6184GPRsPPVTLFFRKNWLRLTW 6185 GQLsPGVQFFFRKNWLRLTW 6186GRKsPPPSFFFRKNWLRLTW 6187 GRKsPPPSKFFRKNWLRLTW 6188GRKsPPPSLFFRKNWLRLTW

6189 GRKsPPPSMFFRKNWLRLTW 6190 GRKsPPPSRFFRKNWLRLTW 6191GRKsPPPSYFFRKNWLRLTW 6192 GRLGsPHRFFFRKNWLRLTW 6193GRLGsPHRKFFRKNWLRLTW 6194 GRLGsPHRLFFRKNWLRLTW 6195GRLGsPHRMFFRKNWLRLTW 6196 GRLGsPHRRFFRKNWLRLTW 6197GRLGsPHRYFFRKNWLRLTW 6198 GRLsPAYSLFFRKNWLRLTW 6199GRLsPKASQVFFFRKNWLRLTW 6200 GRLsPKASQVKFFRKNWLRLTW 6201GRLsPKASQVLFFRKNWLRLTW 6202 GRLsPKASQVMFFRKNWLRLTW 6203GRLsPKASQVRFFRKNWLRLTW 6204 GRLsPKASQVYFFRKNWLRLTW 6205GRLsPVPVPFFFRKNWLRLTW 6206 GRLsPVPVPKFFRKNWLRLTW 6207GRLsPVPVPLFFRKNWLRLTW 6208 GRLsPVPVPMFFRKNWLRLTW 6209GRLsPVPVPRFFRKNWLRLTW 6210 GRLsPVPVPYFFRKNWLRLTW 6211GRQsPSFKLFFRKNWLRLTW 6212 GRsSPPPGYFFRKNWLRLTW 6213GRSsTASLVKFFFRKNWLRLTW 6214 GRSsTASLVKKFFRKNWLRLTW 6215GRSsTASLVKKKFFRKNWLRLTW 6216 GRSsTASLVKLFFRKNWLRLTW 6217GRSSTASLVKMFFRKNWLRLTW 6218 GRSSTASLVKRFFRKNWLRLTW 6219GRSSTASLVKYFFRKNWLRLTW 6220 GRtGLPDLFFRKNWLRLTW 6221GSALGGGGAGLSGRASGGAQsPLRYLHVFFRKNWLRLTW 6222 GSDsSDDGKKYFFRKNWLRLTW6223 GSEsSDDGKKYFFRKNWLRLTW 6224 GsPHYFSPFFFRKNWLRLTW 6225GsPHYFSPFRPYFFRKNWLRLTW 6226 GsPTMVEKGLEPGVFTLFFRKNWLRLTW 6227GsQLAVMMYLFFRKNWLRLTW 6228 GTDsSDDGKKYFFRKNWLRLTW 6229GTEsSDDGKKYFFRKNWLRLTW 6230 GTIRSRsFIFKFFRKNWLRLTW 6231GTIRSRsFIFYFFRKNWLRLTW 6232 GtLPKYFFRKNWLRLTW 6233GtLRRSDSQQAVKFFRKNWLRLTW 6234 GtLRRSDSQQAVKSFFRKNWLRLTW 6235GtLRRSDSQQAVKSPPFFRKNWLRLTW 6236 GVAsPTITVFFRKNWLRLTW 6237GVVsPTFELFFRKNWLRLTW 6238 HEKKAYsFFFRKNWLRLTW 6239HKGEIRGASTPFQFRAsSPFFRKNWLRLTW 6240 HLHsPQHKLFFRKNWLRLTW 6241HPKRSVsLFFRKNWLRLTW 6242 HPRsPNVLFFRKNWLRLTW 6243HPRsPNVLSFFFRKNWLRLTW 6244 HPRsPNVLSLFFRKNWLRLTW 6245HPRsPNVLSMFFRKNWLRLTW 6246 HPRsPNVLSVFFRKNWLRLTW 6247HPRsPTPTFFFRKNWLRLTW 6248 HPRSPtPTFFFRKNWLRLTW 6249HPRsPTPTLFFRKNWLRLTW 6250 HPRSPtPTLFFRKNWLRLTW 6251HPRsPTPTMFFRKNWLRLTW 6252 HPRSPtPTMFFRKNWLRLTW 6253HPRSPtPTVFFRKNWLRLTW 6254 HPsSPTPTVFFRKNWLRLTW 6255HRLsPVKGEFFFRKNWLRLTW 6256 HRLsPVKGEKFFRKNWLRLTW 6257HRLsPVKGERFFRKNWLRLTW 6258 HRLsPVKGEYFFRKNWLRLTW 6259HRNsMKVFLFFRKNWLRLTW 6260 HRNsNPVIAEFFFRKNWLRLTW 6261HRNsNPVIAEKFFRKNWLRLTW 6262 HRNsNPVIAELFFRKNWLRLTW 6263HRNsNPVIAERFFRKNWLRLTW 6264 HRNsNPVIAEYFFRKNWLRLTW 6265HRYsTPHAFFFRKNWLRLTW 6266 HTAsPTGMMKFFRKNWLRLTW 6267HVYtPSTTKFFRKNWLRLTW 6268 IEKIyIMKADTVIVGFFRKNWLRLTW 6269IIEtPHKEIFFRKNWLRLTW 6270 IIEtPHKEYFFRKNWLRLTW 6271IISsPLKGYFFRKNWLRLTW 6272 IISsPLTGKFFRKNWLRLTW 6273ILDRtPEKLFFRKNWLRLTW 6274 ILDRtPEKVFFRKNWLRLTW 6275ILDsGIYRIFFRKNWLRLTW 6276 ILDsGIYRVFFRKNWLRLTW 6277ILKPRRsLFFRKNWLRLTW 6278 ILKsPEIQRAFFRKNWLRLTW 6279ILKsPEIQRVFFRKNWLRLTW 6280 ILQtPQFQMFFRKNWLRLTW 6281ILQVsIPSLFFRKNWLRLTW 6282 IMDRtPEKLFFRKNWLRLTW 6283IMDRtPEKVFFRKNWLRLTW 6284 IMDsGIYRIFFRKNWLRLTW 6285IMDsGIYRVFFRKNWLRLTW 6286 IMKsPEIQRAFFRKNWLRLTW 6287IMKsPEIQRVFFRKNWLRLTW 6288 INKERRSsLFFRKNWLRLTW 6289IPVgSSHNSLFFRKNWLRLTW 6290 IQFsPPFPGAFFRKNWLRLTW 6291ISDGtLKYFFRKNWLRLTW 6292 ISDGtPLKYFFRKNWLRLTW 6293ISDSAHtDYFFRKNWLRLTW 6294 ISDsMHSLYFFRKNWLRLTW 6295ISDtPHKEIFFRKNWLRLTW 6296 ISDtPHKEYFFRKNWLRLTW 6297ISEGtLKYFFRKNWLRLTW 6298 ISEGtPLKYFFRKNWLRLTW 6299ISESAHtDYFFRKNWLRLTW 6300 ISEsMHSLYFFRKNWLRLTW 6301ISEtPHKEIFFRKNWLRLTW 6302 ISEtPHKEYFFRKNWLRLTW 6303ISFSAHtDYFFRKNWLRLTW 6304 ISSsMHSLYFFRKNWLRLTW 6305IStDRDPLFFRKNWLRLTW 6306 IStDRDPYFFRKNWLRLTW 6307ITDGtLKYFFRKNWLRLTW 6308 ITDGtPLKYFFRKNWLRLTW 6309ITDSAHtDYFFRKNWLRLTW 6310 ITDsMHSLYFFRKNWLRLTW 6311ITDtPHKEIFFRKNWLRLTW 6312 ITDtPHKEYFFRKNWLRLTW 6313ITEGtLKYFFRKNWLRLTW 6314 ITEGtPLKYFFRKNWLRLTW

6315 ITESAHtDYFFRKNWLRLTW 6316 ITEsMHSLYFFRKNWLRLTW 6317ITEtPHKEIFFRKNWLRLTW 6318 ITEtPHKEYFFRKNWLRLTW 6319ITQGtLKYFFRKNWLRLTW 6320 ITQGtPLKKFFRKNWLRLTW 6321ITQGtPLKYFFRKNWLRLTW 6322 ITtDRDPLFFRKNWLRLTW 6323ITtDRDPYFFRKNWLRLTW 6324 IVLsDSEVIQLFFRKNWLRLTW 6325IVRyHQLFFRKNWLRLTW 6326 IVtDRDPLFFRKNWLRLTW 6327IVtDRDPYFFRKNWLRLTW 6328 IYQyIQSRFFFRKNWLRLTW 6329KAFsPVRFFRKNWLRLTW 6330 KAFsPVRSVFFRKNWLRLTW 6331KAKsPAPGLFFRKNWLRLTW 6332 KAKsPAPGVFFRKNWLRLTW 6333KARsPGRAFFFRKNWLRLTW 6334 KARsPGRALFFRKNWLRLTW 6335KARsPGRAMFFRKNWLRLTW 6336 KARsPGRAVFFRKNWLRLTW 6337KASPKRLsLFFRKNWLRLTW 6338 KAVsLFLcYFFRKNWLRLTW 6339KAVsLFLCYFFRKNWLRLTW 6340 KEGEEPTVYsDEEEPKDESARKNDFFRKNWLRLTW 6341KEKsPFRETFFRKNWLRLTW 6342 KELARQIsFFFRKNWLRLTW 6343KEMsPTRQFFFRKNWLRLTW 6344 KEmsPTRQLFFRKNWLRLTW 6345KEMSPTRQLFFRKNWLRLTW 6346 KEMsPTRQWFFRKNWLRLTW 6347KEMsPTRQYFFRKNWLRLTW 6348 KESsPLSSRKIFFRKNWLRLTW 6349KFRPPPLsLFFRKNWLRLTW 6350 KGIsSSSLKEKFFRKNWLRLTW 6351KIAsEIAQLFFRKNWLRLTW 6352 KIDIVsSQKVFFRKNWLRLTW 6353KIDsPTKVKKFFRKNWLRLTW 6354 KIEKIyIMKADTVIVGFFRKNWLRLTW 6355KIEsLENLYLFFRKNWLRLTW 6356 KIFsGVFVKFFRKNWLRLTW 6357KIFsGVFVKVFFRKNWLRLTW 6358 KIFsKQQGKFFRKNWLRLTW 6359KIFsKQQGYFFRKNWLRLTW 6360 KIGsIIFQVFFRKNWLRLTW 6361KIKsFEWFFFRKNWLRLTW 6362 KIRSsPREAKFFRKNWLRLTW 6363KIRSsPREAYFFRKNWLRLTW 6364 KIRTsPTFRFFRKNWLRLTW 6365KIRTsPTFYFFRKNWLRLTW 6366 KLAsLEREASVFFRKNWLRLTW 6367KLAsLLHQVFFRKNWLRLTW 6368 KLAsPEKLAGLFFRKNWLRLTW 6369KLAsPELERLFFRKNWLRLTW 6370 KLAsPELERVFFRKNWLRLTW 6371KLDIVsSQKVFFRKNWLRLTW 6372 KLDsFLDMQVFFRKNWLRLTW 6373KLDsPRVTVFFRKNWLRLTW 6374 KLDsPTKVKKFFRKNWLRLTW 6375KLDsPTKVKYFFRKNWLRLTW 6376 KLFPDtPLALFFRKNWLRLTW 6377KLFPDtPLAVFFRKNWLRLTW 6378 KLFsGTVRKFFRKNWLRLTW 6379KLFsGVFVKVFFRKNWLRLTW 6380 KLFsKQQGKFFRKNWLRLTW 6381KLFsKQQGYFFRKNWLRLTW 6382 KLFsPAHKKFFRKNWLRLTW 6383KLFsPAHKYFFRKNWLRLTW 6384 KLFsPSKEAELFFRKNWLRLTW 6385KLFsPSKEAEVFFRKNWLRLTW 6386 KLHGsLARAGKFFRKNWLRLTW 6387KLHGsLARAGYFFRKNWLRLTW 6388 KLIDIVsSQKVFFRKNWLRLTW 6389KLIDRTEsLFFRKNWLRLTW 6390 KLIDVsSQKVFFRKNWLRLTW 6391KLIsSSSLKEKFFRKNWLRLTW 6392 KLIsSSSLKEYFFRKNWLRLTW 6393KLKDRLPsIFFRKNWLRLTW 6394 KLKsNPDFLKFFRKNWLRLTW 6395KLKsNPDFLKKFFRKNWLRLTW 6396 KLKsNPDFLKYFFRKNWLRLTW 6397KLKsPAPGLFFRKNWLRLTW 6398 KLKsPAPGVFFRKNWLRLTW 6399KLKsQEIFLFFRKNWLRLTW 6400 KLKSsPLIEKKFFRKNWLRLTW 6401KLKSsPLIEKYFFRKNWLRLTW 6402 KLKtPLVAKFFRKNWLRLTW 6403KLKtPLVARFFRKNWLRLTW 6404 KLLDFGSLsNLQVFFRKNWLRLTW 6405KLLQFYPsLFFRKNWLRLTW 6406 KLLQFYPsVFFRKNWLRLTW 6407KLLsPSDEKLFFRKNWLRLTW 6408 KLLsPSNEKLFFRKNWLRLTW 6409KLLsPSNEKVFFRKNWLRLTW 6410 KLLSSAQRtLFFRKNWLRLTW 6411KLLSSAQRtVFFRKNWLRLTW 6412 KLLsTEEMELFFRKNWLRLTW 6413KLLsTEEMEVFFRKNWLRLTW 6414 KLLsVERIKFFRKNWLRLTW 6415KLLtPIKEKFFRKNWLRLTW 6416 KLLtPIKEYFFRKNWLRLTW 6417KLMAPDIsLFFRKNWLRLTW 6418 KLMAPDIsVFFRKNWLRLTW 6419KLMIDRTEsVFFRKNWLRLTW 6420 KLMsDVEDVFFRKNWLRLTW 6421KLMsPKADVFFRKNWLRLTW 6422 KLMsPKADVKLFFRKNWLRLTW 6423KLMsPKADVKVFFRKNWLRLTW 6424 KLPDsPALAFFRKNWLRLTW 6425KLPDsPALAKFFRKNWLRLTW 6426 KLPDsPALAKKFFRKNWLRLTW 6427KLPDsPALAKYFFRKNWLRLTW 6428 KLPDsPALAYFFRKNWLRLTW 6429KLPsPAPARKFFRKNWLRLTW 6430 KLPTsPLKMKFFRKNWLRLTW 6431KLPTsPLKMYFFRKNWLRLTW 6432 KLPTtPVKAKFFRKNWLRLTW 6433KLPTtPVKAYFFRKNWLRLTW 6434 KLQEFLQtLFFRKNWLRLTW 6435KLQVtSLSVFFRKNWLRLTW 6436 KLRsPFLQKFFRKNWLRLTW 6437KLRsPFLQYFFRKNWLRLTW 6438 KLRSsPREAKFFRKNWLRLTW 6439KLRTsPTFKFFRKNWLRLTW

6440 KLsGDQPAARFFRKNWLRLTW 6441 KLSGLsFFFRKNWLRLTW 6442KLSsLGNLKFFRKNWLRLTW 6443 KLSsLGNLKKFFRKNWLRLTW 6444KLSsLGNLKYFFRKNWLRLTW 6445 KLSsPRGGMKFFRKNWLRLTW 6446KLSsPRGGMKKFFRKNWLRLTW 6447 KLSsPRGGMKYFFRKNWLRLTW 6448KLsVIAEDSESGKQNFFRKNWLRLTW 6449 KLsVIAEDSESGKQNPFFRKNWLRLTW 6450KLsVIAEDSESGKQNPGFFRKNWLRLTW 6451 KLVSFHDDsDEDLFFRKNWLRLTW 6452KLYsEIDIKVFFRKNWLRLTW 6453 KLYsGNMEKFFRKNWLRLTW 6454KMAsLLHQVFFRKNWLRLTW 6455 KMAsPELERLFFRKNWLRLTW 6456KMAsPELERVFFRKNWLRLTW 6457 KMDIVsSQKVFFRKNWLRLTW 6458KMDsFLDMQLFFRKNWLRLTW 6459 KMDsFLDMQVFFRKNWLRLTW 6460KMDsPRVTVFFRKNWLRLTW 6461 KMDsPTKVKKFFRKNWLRLTW 6462KMFPDtPLALFFRKNWLRLTW 6463 KMFPDtPLAVFFRKNWLRLTW 6464KMFsGTVRKFFRKNWLRLTW 6465 KMFsGVFVKVFFRKNWLRLTW 6466KMFsKQQGKFFRKNWLRLTW 6467 KMFsPAHKKFFRKNWLRLTW 6468KMFsPSKEAELFFRKNWLRLTW 6469 KMFsPSKEAEVFFRKNWLRLTW 6470KMHGsLARAGKFFRKNWLRLTW 6471 KMIDIVsSQKVFFRKNWLRLTW 6472KMIDRTEsLFFRKNWLRLTW 6473 KMIsSSSLKEKFFRKNWLRLTW 6474KMKsNPDFLKFFRKNWLRLTW 6475 KMKsNPDFLKKFFRKNWLRLTW 6476KMKsNPDFLKYFFRKNWLRLTW 6477 KMKSsPLIEKKFFRKNWLRLTW 6478KMKtPLVAKFFRKNWLRLTW 6479 KMKtPLVARFFRKNWLRLTW 6480KMLDFGSLsNLOVFFRKNWLRLTW 6481 KMLDFGSLsNLQVFFRKNWLRLTW 6482KMLQFYPsLFFRKNWLRLTW 6483 KMLsPSNEKLFFRKNWLRLTW 6484KMLsPSNEKVFFRKNWLRLTW 6485 KMLSSAQRtLFFRKNWLRLTW 6486KMLSSAQRtVFFRKNWLRLTW 6487 KMLsVERIKFFRKNWLRLTW 6488KMLtPIKEKFFRKNWLRLTW 6489 KMMAPDIsVFFRKNWLRLTW 6490KMMsPKADVKLFFRKNWLRLTW 6491 KMMsPKADVKVFFRKNWLRLTW 6492KMPTsPLKMKFFRKNWLRLTW 6493 KMPTtPVKAKFFRKNWLRLTW 6494KMPTtPVKAYFFRKNWLRLTW 6495 KMRsPFLQKFFRKNWLRLTW 6496KMRSsPREAKFFRKNWLRLTW 6497 KMRTsPTFKFFRKNWLRLTW 6498KMSsLGNLKFFRKNWLRLTW 6499 KMSsLGNLKKFFRKNWLRLTW 6500KMSsLGNLKYFFRKNWLRLTW 6501 KMSsPRGGMKFFRKNWLRLTW 6502KMSsPRGGMKKFFRKNWLRLTW 6503 KMYsEIDIKVFFRKNWLRLTW 6504KMYsGNMEKFFRKNWLRLTW 6505 KNRsWKYNFFRKNWLRLTW 6506KNRsWKYNQFFRKNWLRLTW 6507 KNRsWKYNQSISLRFFRKNWLRLTW 6508KNRsWKYNQSISLRRPFFRKNWLRLTW 6509 KPAsPARRFFFRKNWLRLTW 6510KPAsPARRLFFRKNWLRLTW 6511 KPAsPARRMFFRKNWLRLTW 6512KPAsPARRVFFRKNWLRLTW 6513 KPAsPKFIVTFFFRKNWLRLTW 6514KPAsPKFIVTLFFRKNWLRLTW 6515 KPAsPKFIVTMFFRKNWLRLTW 6516KPAsPKFIVTVFFRKNWLRLTW 6517 KPEsRRSSLFFRKNWLRLTW 6518KPEsRRsSLLFFRKNWLRLTW 6519 KPEsRRSsLLFFRKNWLRLTW 6520KPESRRSSLLFFRKNWLRLTW 6521 KPLIRsQSLFFRKNWLRLTW 6522KPLIRSQsLFFRKNWLRLTW 6523 KPPHsPLVFFFRKNWLRLTW 6524KPPHsPLVLFFRKNWLRLTW 6525 KPPHsPLVMFFRKNWLRLTW 6526KPPHsPLWFFRKNWLRLTW 6527 KPPsPEHQSFFFRKNWLRLTW 6528KPPsPEHQSLFFRKNWLRLTW 6529 KPPsPEHQSMFFRKNWLRLTW 6530KPPsPEHQSVFFRKNWLRLTW 6531 KPPsPSPIEFFFRKNWLRLTW 6532KPPsPSPIELFFRKNWLRLTW 6533 KPPsPSPIEMFFRKNWLRLTW 6534KPPsPSPIEVFFRKNWLRLTW 6535 KPPtPGASFFFRKNWLRLTW 6536KPPtPGASLFFRKNWLRLTW 6537 KPPtPGASMFFRKNWLRLTW 6538KPPtPGASVFFRKNWLRLTW 6539 KPPYRSHsFFFRKNWLRLTW 6540KPPYRSHsLFFRKNWLRLTW 6541 KPPYRSHsMFFRKNWLRLTW 6542KPPYRSHsVFFRKNWLRLTW 6543 KPQTRGKtFFFRKNWLRLTW 6544KPQTRGKtLFFRKNWLRLTW 6545 KPQTRGKtMFFRKNWLRLTW 6546KPQTRGKtVFFRKNWLRLTW 6547 KPRPLsMDLFFRKNWLRLTW 6548KPRPPPLsFFFRKNWLRLTW 6549 KPRPPPLsLFFRKNWLRLTW 6550KPRPPPLsMFFRKNWLRLTW 6551 KPRPPPLsPFFRKNWLRLTW 6552KPRPPPLsVFFRKNWLRLTW 6553 KPRRFsRsLFFRKNWLRLTW 6554KPRRFsRSLFFRKNWLRLTW 6555 KPRsPDHVFFFRKNWLRLTW 6556KPRsPDHVLFFRKNWLRLTW 6557 KPRsPDHVMFFRKNWLRLTW 6558KPRsPDHWFFRKNWLRLTW 6559 KPRsPFSKIFFRKNWLRLTW 6560KPRsPPRAFFFRKNWLRLTW 6561 KPRsPPRALFFRKNWLRLTW 6562KPRsPPRALFFFRKNWLRLTW 6563 KPRsPPRALLFFRKNWLRLTW 6564KPRsPPRALMFFRKNWLRLTW 6565 KPRsPPRALVFFRKNWLRLTW

6566 KPRsPPRALVFFFRKNWLRLTW 6567 KPRsPPRALVLFFRKNWLRLTW 6568KPRsPPRALVLFFFRKNWLRLTW 6569 KPRsPPRALVLLFFRKNWLRLTW 6570KPRsPPRALVLMFFRKNWLRLTW 6571 KPRsPPRALVLPFFRKNWLRLTW 6572KPRsPPRALVLVFFRKNWLRLTW 6573 KPRsPPRALVMFFRKNWLRLTW 6574KPRsPPRALWFFRKNWLRLTW 6575 KPRsPPRAMFFRKNWLRLTW 6576KPRsPPRAVFFRKNWLRLTW 6577 KPRsPWEFFFRKNWLRLTW 6578KPRsPWELFFRKNWLRLTW 6579 KPRsPWEMFFRKNWLRLTW 6580KPRsPWEVFFRKNWLRLTW 6581 KPSsPRGSLFFRKNWLRLTW 6582KPSsPRGSLLFFRKNWLRLTW 6583 KPVsPKSGTLFFRKNWLRLTW 6584KPYsPLASFFFRKNWLRLTW 6585 KPYsPLASLFFRKNWLRLTW 6586KPYsPLASMFFRKNWLRLTW 6587 KPYsPLASVFFRKNWLRLTW 6588KQDsLVINLFFRKNWLRLTW 6589 KRAsFAKSFFFRKNWLRLTW 6590KRAsFAKSKFFRKNWLRLTW 6591 KRAsFAKSLFFRKNWLRLTW 6592KRAsFAKSMFFRKNWLRLTW 6593 KRAsFAKSRFFRKNWLRLTW 6594KRAsFAKSVFFRKNWLRLTW 6595 KRAsFAKSYFFRKNWLRLTW 6596KRAsGQAFEFFFRKNWLRLTW 6597 KRAsGQAFEKFFRKNWLRLTW 6598KRAsGQAFELFFRKNWLRLTW 6599 KRAsGQAFERFFRKNWLRLTW 6600KRAsGQAFEYFFRKNWLRLTW 6601 KRASsPFRFFFRKNWLRLTW 6602KRASsPFRKFFRKNWLRLTW 6603 KRASsPFRLFFRKNWLRLTW 6604KRASsPFRMFFRKNWLRLTW 6605 KRASsPFRRFFRKNWLRLTW 6606KRASsPFRYFFRKNWLRLTW 6607 KRAsVFVKFFFRKNWLRLTW 6608KRAsVFVKKFFRKNWLRLTW 6609 KRAsVFVKLFFRKNWLRLTW 6610KRAsVFVKMFFRKNWLRLTW 6611 KRAsVFVKRFFRKNWLRLTW 6612KRAsVFVKYFFRKNWLRLTW 6613 KRAsYILRLFFRKNWLRLTW 6614KRFsFKFFFRKNWLRLTW 6615 KRFsFKKFFRKNWLRLTW 6616KRFsFKKsFFFRKNWLRLTW 6617 KRFsFKKSFFFRKNWLRLTW 6618KRFsFKKSKFFRKNWLRLTW 6619 KRFsFKKSLFFRKNWLRLTW 6620KRFsFKKSMFFRKNWLRLTW 6621 KRFsFKKSRFFRKNWLRLTW 6622KRFsFKKSYFFRKNWLRLTW 6623 KRFsFKLFFRKNWLRLTW 6624KRFsFKMFFRKNWLRLTW 6625 KRFsFKRFFRKNWLRLTW 6626KRFsFKsSFFFRKNWLRLTW 6627 KRFsFKYFFRKNWLRLTW 6628KRFsGTVRFFFRKNWLRLTW 6629 KRFsGTVRKFFRKNWLRLTW 6630KRFsGTVRLFFRKNWLRLTW 6631 KRFsGTVRMFFRKNWLRLTW 6632KRFsGTVRRFFRKNWLRLTW 6633 KRFsGTVRYFFRKNWLRLTW 6634KRIVIsPKPFFFRKNWLRLTW 6635 KRKsFTSLYFFRKNWLRLTW 6636KRLEKsPSFFFRKNWLRLTW 6637 KRLEKSPsFFFRKNWLRLTW 6638KRLsPAPQFFFRKNWLRLTW 6639 KRLsPAPQKFFRKNWLRLTW 6640KRLsPAPQLFFRKNWLRLTW 6641 KRLsPAPQMFFRKNWLRLTW 6642KRLsPAPQRFFRKNWLRLTW 6643 KRLsPAPQYFFRKNWLRLTW 6644KRLsTSPVRLFFRKNWLRLTW 6645 KRLsVERIFFFRKNWLRLTW 6646KRLsVERIKFFRKNWLRLTW 6647 KRLsVERILFFRKNWLRLTW 6648KRLsVERIMFFRKNWLRLTW 6649 KRLsVERIRFFRKNWLRLTW 6650KRLsVERIYFFRKNWLRLTW 6651 KRMsPKEFFFRKNWLRLTW 6652KRMsPKEKFFRKNWLRLTW 6653 KRMsPKELFFRKNWLRLTW 6654KRMsPKERFFRKNWLRLTW 6655 KRMsPKEYFFRKNWLRLTW 6656KRmsPKPELFFRKNWLRLTW 6657 KRMsPKPELFFRKNWLRLTW 6658KRMsPKPFFFRKNWLRLTW 6659 KRMsPKPKFFRKNWLRLTW 6660KRMsPKPLFFRKNWLRLTW 6661 KRMsPKPMFFRKNWLRLTW 6662KRMsPKPRFFRKNWLRLTW 6663 KRMsPKPYFFRKNWLRLTW 6664KRPEsPPSIFFRKNWLRLTW 6665 KRWQsPVTKFFRKNWLRLTW 6666KRYsEPVSLFFRKNWLRLTW 6667 KRYsGNMEFFFRKNWLRLTW 6668KRYsGNMEKFFRKNWLRLTW 6669 KRYsGNMELFFRKNWLRLTW 6670KRYsGNMEMFFRKNWLRLTW 6671 KRYsGNMERFFRKNWLRLTW 6672KRYsGNmEYFFRKNWLRLTW 6673 KRYsGNMEYFFRKNWLRLTW 6674KRYsRALYLFFRKNWLRLTW 6675 KSDsRQERYFFRKNWLRLTW 6676KSEsRQERYFFRKNWLRLTW 6677 KSGELLAtWFFRKNWLRLTW 6678KSKsNPDFLKKFFRKNWLRLTW 6679 KSKsNPFLKKFFRKNWLRLTW 6680KSKtPLVAKFFRKNWLRLTW 6681 KSKtPLVARFFRKNWLRLTW 6682KSKtPLVAYFFRKNWLRLTW 6683 KsLVRLLLLFFRKNWLRLTW 6684KSSsLGNLKKFFRKNWLRLTW 6685 KsVKALSSLHGDDQFFRKNWLRLTW 6686KsVKALSSLHGDDQDFFRKNWLRLTW 6687 KsVKALSSLHGDDQDsEDEFFRKNWLRLTW 6688KSVKALSSLHGDDQDsEDEFFRKNWLRLTW 6689 KTDsRQERYFFRKNWLRLTW 6690KTEsRQERYFFRKNWLRLTW

6691 KtLSPGKNGWKFFRKNWLRLTW 6692 KtLSPGKNGWYFFRKNWLRLTW 6693KTMsGTFLLFFRKNWLRLTW 6694 KTMsPSQMIMFFRKNWLRLTW 6695KTPTsPLKMKFFRKNWLRLTW 6696 KTPTsPLKMYFFRKNWLRLTW 6697KTWKGsIGLFFRKNWLRLTW 6698 KVAsLLHQVFFRKNWLRLTW 6699KVDsPVIFFFRKNWLRLTW 6700 KVHGsLARAGKFFRKNWLRLTW 6701KVHGsLARAGYFFRKNWLRLTW 6702 KVKSsPLIEKKFFRKNWLRLTW 6703KVKsSPLIEKLFFRKNWLRLTW 6704 KVKSsPLIEKLFFRKNWLRLTW 6705KVKSsPLIEKYFFRKNWLRLTW 6706 KVLsKEFHLFFRKNWLRLTW 6707KVLSPtAAKFFRKNWLRLTW 6708 KVLsSLVTLFFRKNWLRLTW 6709KVLsTEEMELFFRKNWLRLTW 6710 KVLStEEMELFFRKNWLRLTW 6711KVLtPIKeKFFRKNWLRLTW 6712 KVLtPIKEKFFRKNWLRLTW 6713KVLtPIKEYFFRKNWLRLTW 6714 KVPDsPALAKFFRKNWLRLTW 6715KVPDsPALAKKFFRKNWLRLTW 6716 KVPDsPALAKYFFRKNWLRLTW 6717KVPDsPALAYFFRKNWLRLTW 6718 KVPTsPLKMYFFRKNWLRLTW 6719KVQsLRRALFFRKNWLRLTW 6720 KVQVtSLSVFFRKNWLRLTW 6721KVYsSSEFLFFRKNWLRLTW 6722 KYIsGPHELFFRKNWLRLTW 6723KYsPGKLRGNFFRKNWLRLTW 6724 LGGGGAGLSGRASGGAQsPLRYLHVFFRKNWLRLTW6725 LKLsYLTWVFFRKNWLRLTW 6726 LLAsPGHISVFFRKNWLRLTW 6727LLDPSRSYsYFFRKNWLRLTW 6728 LLDtPVKTQYFFRKNWLRLTW 6729LLFsPVTSLFFRKNWLRLTW 6730 LLFsPVTSVFFRKNWLRLTW 6731LLLsEEVELFFRKNWLRLTW 6732 LLNKSsPVKFFRKNWLRLTW 6733LLNKSsPVKKFFRKNWLRLTW 6734 LLNKSsPVKYFFRKNWLRLTW 6735LMFsPVTSLFFRKNWLRLTW 6736 LMFsPVTSVFFRKNWLRLTW 6737LMFsVTSIFFRKNWLRLTW 6738 LMFsVTSLFFRKNWLRLTW 6739LMNKSsPVKFFRKNWLRLTW 6740 LMNKSsPVKKFFRKNWLRLTW 6741LMNKSsPVKYFFRKNWLRLTW 6742 LPAsPHQFFFRKNWLRLTW 6743LPAsPHQLFFRKNWLRLTW 6744 LPAsPHQMFFRKNWLRLTW 6745LPAsPHQVFFRKNWLRLTW 6746 LPAsPRARFFFRKNWLRLTW 6747LPAsPRARLFFRKNWLRLTW 6748 LPAsPRARMFFRKNWLRLTW 6749LPAsPRARVFFRKNWLRLTW 6750 LPIFSRLsFFFRKNWLRLTW 6751LPIFSRLsIFFRKNWLRLTW 6752 LPIFSRLsLFFRKNWLRLTW 6753LPIFSRLsMFFRKNWLRLTW 6754 LPIFSRLsVFFRKNWLRLTW 6755LPKGLsASLFFRKNWLRLTW 6756 LPKGLSAsLFFRKNWLRLTW 6757LPKsPPYTAFFFRKNWLRLTW 6758 LPKsPPYTALFFRKNWLRLTW 6759LPKsPPYTAMFFRKNWLRLTW 6760 LPKsPPYTAVFFRKNWLRLTW 6761LPRGSsPSVFFFRKNWLRLTW 6762 LPRGsSPSVLFFRKNWLRLTW 6763LPRGSsPSVLFFRKNWLRLTW 6764 LPRGSsPSVMFFRKNWLRLTW 6765LPRGSsPSWFFRKNWLRLTW 6766 LPRmIsHSELFFRKNWLRLTW 6767LPRMIsHSELFFRKNWLRLTW 6768 LPRPAsPALFFRKNWLRLTW 6769LPRSSsMAAFFRKNWLRLTW 6770 LPRSSsMAAGLFFRKNWLRLTW 6771LPRtPRPELFFRKNWLRLTW 6772 LPVsPRLQLFFRKNWLRLTW 6773LQLsPLKGLSLFFRKNWLRLTW 6774 LQNItENQLFFRKNWLRLTW 6775LSDPSRSYsYFFRKNWLRLTW 6776 LSDsDTEAKLFFRKNWLRLTW 6777LSDsDTEAKYFFRKNWLRLTW 6778 LSDtPVKTQYFFRKNWLRLTW 6779LSEPSRSYsYFFRKNWLRLTW 6780 LSEsDTEAKLFFRKNWLRLTW 6781LSEsDTEAKYFFRKNWLRLTW 6782 LSEtPVKTQYFFRKNWLRLTW 6783LSKFRMPQPSSGREsPRHFFRKNWLRLTW 6784 LSSsVIRELFFRKNWLRLTW 6785LTDPSRSYsYFFRKNWLRLTW 6786 LTDPSsPTISSYFFRKNWLRLTW 6787LTDsDTEAKLFFRKNWLRLTW 6788 LTDsDTEAKYFFRKNWLRLTW 6789LTDtPVKTQYFFRKNWLRLTW 6790 LTEPSRSYsYFFRKNWLRLTW 6791LTEsDTEAKLFFRKNWLRLTW 6792 LTEsDTEAKYFFRKNWLRLTW 6793LTEtPVKTOYFFRKNWLRLTW 6794 LTEtPVKTQYFFRKNWLRLTW 6795MLAEsPSVPRLFFRKNWLRLTW 6796 MLAEsPSVPRVFFRKNWLRLTW 6797MLRsPPRVSKFFRKNWLRLTW 6798 MMRsPPRVSKFFRKNWLRLTW 6799MPRPsIKKAQNSQAARQFFRKNWLRLTW 6800 MPRQPsAIRMFFRKNWLRLTW 6801MPRQPsATRFFFRKNWLRLTW 6802 MPRQPsATRLFFRKNWLRLTW 6803MPRQPsATRMFFRKNWLRLTW 6804 MPRQPsATRVFFRKNWLRLTW 6805MRLsEWLQLFFRKNWLRLTW 6806 MRLsRELQFFFRKNWLRLTW 6807MRLsRELQKFFRKNWLRLTW 6808 MRLsRELQLFFRKNWLRLTW 6809MRLsRELQMFFRKNWLRLTW 6810 MRLsRELQRFFRKNWLRLTW 6811MRLsRELQYFFRKNWLRLTW 6812 MSDtYRLKYFFRKNWLRLTW 6813MSEtYRLKYFFRKNWLRLTW 6814 MTDtYRLKYFFRKNWLRLTW 6815MTEtYRLKYFFRKNWLRLTW 6816 MTRsPPRVSKFFRKNWLRLTW

6817 MTRsPPRVSYFFRKNWLRLTW 6818 NAPPAYEKLsAEFFRKNWLRLTW 6819NFKsPVKTIRFFRKNWLRLTW 6820 NLELSKFRMPQPSSGREsPRHFFRKNWLRLTW 6821NLGsRNHVHQLFFRKNWLRLTW 6822 NLLsPDGKMISVFFRKNWLRLTW 6823NLVERKNsKFFRKNWLRLTW 6824 NLVERKNsLFFRKNWLRLTW 6825NMDsPGPMLFFRKNWLRLTW 6826 NMVERKNsKFFRKNWLRLTW 6827NMVERKNsLFFRKNWLRLTW 6828 NRAMRRVsSVPSRFFRKNWLRLTW 6829NRAMRRVsSVPSRAQFFRKNWLRLTW 6830 NRsWKYNQSISLRFFRKNWLRLTW 6831NRsWKYNQSISLRRPFFRKNWLRLTW 6832 NRYtNRWTFFFRKNWLRLTW 6833NRYtNRWTKFFRKNWLRLTW 6834 NRYtNRWTLFFRKNWLRLTW 6835NRYtNRWTMFFRKNWLRLTW 6836 NRYtNRWTRFFRKNWLRLTW 6837NRYtNRWTYFFRKNWLRLTW 6838 NSDsPLRYFFRKNWLRLTW 6839NSEsPLRYFFRKNWLRLTW 6840 NTDsPLRYFFRKNWLRLTW 6841NTEsPLRYFFRKNWLRLTW 6842 NYVERKNsKFFRKNWLRLTW 6843NYVERKNsLFFRKNWLRLTW 6844 NYVERKNsYFFRKNWLRLTW 6845PARsPVTEIFFRKNWLRLTW 6846 PAYEKLsAEFFRKNWLRLTW 6847PAYEKLsAEQSPFFRKNWLRLTW 6848 PmVTLsLNLFFRKNWLRLTW 6849PMVTLsLNLFFRKNWLRLTW 6850 PNAPPAYEKLsAFFRKNWLRLTW 6851PPAYEKLsAFFRKNWLRLTW 6852 PPAYEKLsAEQSFFRKNWLRLTW 6853PPLPEDSIKVIRNMRAAsPPAFFRKNWLRLTW 6854 PYDPALGsPSRFFRKNWLRLTW 6855QAASNFKsPVKTIRFFRKNWLRLTW 6856 QLDsPQRALYFFRKNWLRLTW 6857QLEsPQRALYFFRKNWLRLTW 6858 QLFsPKKGQKFFRKNWLRLTW 6859QMFsPKKGQKFFRKNWLRLTW 6860 QPQRRsLRLFFRKNWLRLTW 6861QPRsPGPDYSFFFRKNWLRLTW 6862 QPRsPGPDYSLFFRKNWLRLTW 6863QPRsPGPDYSMFFRKNWLRLTW 6864 QPRsPGPDYSVFFRKNWLRLTW 6865QPRtPsPLVFFFRKNWLRLTW 6866 QPRtPsPLVFFFRKNWLRLTW 6867QPRtPsPLVLFFRKNWLRLTW 6868 QPRtPsPLVLFFRKNWLRLTW 6869QPRtPsPLVMFFRKNWLRLTW 6870 QPRtPSPLVMFFRKNWLRLTW 6871QPRtPsPLWFFRKNWLRLTW 6872 QPRtPSPLWFFRKNWLRLTW 6873QPSFPsVLPAFFRKNWLRLTW 6874 QRLsPLSAAYFFRKNWLRLTW 6875QSDsPQRALYFFRKNWLRLTW 6876 QSEsPQRALYFFRKNWLRLTW 6877QTDsPQRALYFFRKNWLRLTW 6878 QTEsPQRALYFFRKNWLRLTW 6879QVAMPVKKSPRRSsSDEQGLSYSSLKNVFFRKNWLRLTW 6880 QVFsPKKGQKFFRKNWLRLTW6881 QVFsPKKGQYFFRKNWLRLTW 6882 RADsPVHMFFRKNWLRLTW 6883RAFsFSKTPKFFRKNWLRLTW 6884 RAFsFSKTPYFFRKNWLRLTW 6885RAFsVKFEVFFRKNWLRLTW 6886 RAHsEPLALFFRKNWLRLTW 6887RAHsSPASLFFRKNWLRLTW 6888 RAHSsPASLFFRKNWLRLTW 6889RAKsPISLKFFRKNWLRLTW 6890 RAKsPISLYFFRKNWLRLTW 6891RAPsPSSRFFFRKNWLRLTW 6892 RAPsPSSRLFFRKNWLRLTW 6893RAPsPSSRMFFRKNWLRLTW 6894 RAPsPSSRVFFRKNWLRLTW 6895RARGIsPIVFFFRKNWLRLTW 6896 RASsDIVsLFFRKNWLRLTW 6897RASsDIVSLFFRKNWLRLTW 6898 RASsLSITVFFRKNWLRLTW 6899REAPsPLmIFFRKNWLRLTW 6900 REAPsPLMIFFRKNWLRLTW 6901REAsPAPLAFFRKNWLRLTW 6902 REAsPRLRVFFRKNWLRLTW 6903REAsPSRLSVFFRKNWLRLTW 6904 REDsTPGKVFLFFRKNWLRLTW 6905REIMGtPEYLFFRKNWLRLTW 6906 REKsPGRmLFFRKNWLRLTW 6907REKsPGRMLFFRKNWLRLTW 6908 REKsPLFQFFFRKNWLRLTW 6909REKsPLFQWFFRKNWLRLTW 6910 REKsPLFQYFFRKNWLRLTW 6911RELARKGsLFFRKNWLRLTW 6912 RELsPLISLFFRKNWLRLTW 6913REPsPLPELFFRKNWLRLTW 6914 RERsPSPSFFFRKNWLRLTW 6915RESsPTRRLFFRKNWLRLTW 6916 REVsPAPAVFFRKNWLRLTW 6917REYGsTSSIFFRKNWLRLTW 6918 RFKtQPVTFFFRKNWLRLTW 6919RGDGYGtFFFRKNWLRLTW 6920 RGDsPKIDLFFRKNWLRLTW 6921RIDsKDSASELFFRKNWLRLTW 6922 RIGsPLSPKFFRKNWLRLTW 6923RILsGWTKFFRKNWLRLTW 6924 RILsGWTYFFRKNWLRLTW 6925RILsPSMASKFFRKNWLRLTW 6926 RILsPSMASYFFRKNWLRLTW 6927RINsFEEHVFFRKNWLRLTW 6928 RIQsKLYRAFFRKNWLRLTW 6929RIQyIQSRFFFRKNWLRLTW 6930 RIQyIQSRFYFFRKNWLRLTW 6931RIsHELDSFFRKNWLRLTW 6932 RITsLIVHVFFRKNWLRLTW 6933RIVQyIQSRFFRKNWLRLTW 6934 RIYQyIQFFRKNWLRLTW 6935RIYQyIQSKFFRKNWLRLTW 6936 RIYQyIQSRFFRKNWLRLTW 6937RIYQyIQSRFFFRKNWLRLTW 6938 RIYQyIQSRFKFFRKNWLRLTW 6939RIYQyIQSRFYFFRKNWLRLTW 6940 RIYQyIQSRKFFRKNWLRLTW 6941RIYQyIQSRYFFRKNWLRLTW

6942 RIYQyIQSYFFRKNWLRLTW 6943 RIYQyLQSRFFFRKNWLRLTW 6944RIYQyLQSRFYFFRKNWLRLTW 6945 RKLRsLEQLFFRKNWLRLTW 6946RKLsVILIKFFRKNWLRLTW 6947 RKLsVILILFFRKNWLRLTW 6948RKLsVILIYFFRKNWLRLTW 6949 RKPsIVTKYFFRKNWLRLTW 6950RKSsIIIRMFFRKNWLRLTW 6951 RLAsASRALFFRKNWLRLTW 6952RLAsFAVRKFFRKNWLRLTW 6953 RLAsFAVRYFFRKNWLRLTW 6954RLAsIELPSMFFRKNWLRLTW 6955 RLAsIELPSMAVFFRKNWLRLTW 6956RLAsIELPSVFFRKNWLRLTW 6957 RLAsLNAEALFFRKNWLRLTW 6958RLAsLNAEAVFFRKNWLRLTW 6959 RLAsLQSEVFFRKNWLRLTW 6960RLAsLSISVFFRKNWLRLTW 6961 RLAsPLVHKFFRKNWLRLTW 6962RLAsPLVHYFFRKNWLRLTW 6963 RLAsPPPPPKFFRKNWLRLTW 6964RLAsPPPPPYFFRKNWLRLTW 6965 RLAsPTSGVFFRKNWLRLTW 6966RLAsPTSGVKFFRKNWLRLTW 6967 RLAsPTSGVKKFFRKNWLRLTW 6968RLAsPTSGVKRFFRKNWLRLTW 6969 RLAsPTSGVKYFFRKNWLRLTW 6970RLAsRPLLLFFRKNWLRLTW 6971 RLAsSATQVHKFFRKNWLRLTW 6972RLAsYLDKVFFRKNWLRLTW 6973 RLAsYLDRVFFRKNWLRLTW 6974RLDsTPGKVFLFFRKNWLRLTW 6975 RLDsTPGKVFVFFRKNWLRLTW 6976RLDsYLRAPFFRKNWLRLTW 6977 RLDsYVRFFRKNWLRLTW 6978RLDsYVRSFFRKNWLRLTW 6979 RLDsYVRSLFFRKNWLRLTW 6980RLDsYVRSVFFRKNWLRLTW 6981 RLDtGPQSLFFRKNWLRLTW 6982RLEsANRRLFFRKNWLRLTW 6983 RLFsFSKTPKFFRKNWLRLTW 6984RLFsKELFFRKNWLRLTW 6985 RLFsKELRFFRKNWLRLTW 6986RLFsKELRCFFRKNWLRLTW 6987 RLFsKELRVFFRKNWLRLTW 6988RLFSLsNPSLFFRKNWLRLTW 6989 RLFsPTYGLFFRKNWLRLTW 6990RLFsPTYGVFFRKNWLRLTW 6991 RLFsQGQDVFFRKNWLRLTW 6992RLFVGsIPKFFRKNWLRLTW 6993 RLGsFHELLLFFRKNWLRLTW 6994RLIsFKAEVFFRKNWLRLTW 6995 RLIsPYKKKFFRKNWLRLTW 6996RLIsQDVKLFFRKNWLRLTW 6997 RLIsQDVKVFFRKNWLRLTW 6998RLKLPsGSKFFRKNWLRLTW 6999 RLKLPsGSKKFFRKNWLRLTW 7000RLKLPsGSKYFFRKNWLRLTW 7001 RLKsDERPVHIFFRKNWLRLTW 7002RLKsPFRKKFFRKNWLRLTW 7003 RLKsPGsGHVKFFRKNWLRLTW 7004RLKsPISLKFFRKNWLRLTW 7005 RLKsPISLYFFRKNWLRLTW 7006RLKsPSPKSEKFFRKNWLRLTW 7007 RLKsPSPKSERFFRKNWLRLTW 7008RLKtPTSQSYKFFRKNWLRLTW 7009 RLKtPTSQSYRFFRKNWLRLTW 7010RLKTtPLRKFFRKNWLRLTW 7011 RLKTtPLRRFFRKNWLRLTW 7012RLLDPsSPLALFFRKNWLRLTW 7013 RLLDPSsPLALFFRKNWLRLTW 7014RLLDRSPsRSAKFFRKNWLRLTW 7015 RLLDRSPsRSAYFFRKNWLRLTW 7016RLLsDGQQHLFFRKNWLRLTW 7017 RLLsDLEELFFRKNWLRLTW 7018RLLsDQTRLFFRKNWLRLTW 7019 RLLsFQRYLFFRKNWLRLTW 7020RLLsGWTKFFRKNWLRLTW 7021 RLLsGWTYFFRKNWLRLTW 7022RLLsHISEAFFRKNWLRLTW 7023 RLLsHISEVFFRKNWLRLTW 7024RLLsPLSSAFFRKNWLRLTW 7025 RLLsPLSSARLFFRKNWLRLTW 7026RLLsPLSSVFFRKNWLRLTW 7027 RLLsPQQPALFFRKNWLRLTW 7028RLLsPRPSLFFRKNWLRLTW 7029 RLLsPRPSLLFFRKNWLRLTW 7030RLLsPSMASKFFRKNWLRLTW 7031 RLLsSGVSEIFFRKNWLRLTW 7032RLLsSGVSEVFFRKNWLRLTW 7033 RLLsTDAEAVFFRKNWLRLTW 7034RLLsVEIVKFFRKNWLRLTW 7035 RLLsVEIVYFFRKNWLRLTW 7036RLLsVHDFDFFFRKNWLRLTW 7037 RLLsVILIKFFRKNWLRLTW 7038RLMsMPVAKFFRKNWLRLTW 7039 RLMsMPVAYFFRKNWLRLTW 7040RLNtSDFQKLFFRKNWLRLTW 7041 RLPNRIPsLFFRKNWLRLTW 7042RLPsFLKKNKFFRKNWLRLTW 7043 RLPsLVHGYFFRKNWLRLTW 7044RLPsSTLKKFFRKNWLRLTW 7045 RLPsSTLKRFFRKNWLRLTW 7046RLPsSTLKYFFRKNWLRLTW 7047 RLQsLIKNIFFRKNWLRLTW 7048RLQsTSERLFFRKNWLRLTW 7049 RLQsTSERVFFRKNWLRLTW 7050RLR(sLss)PTVTLFFRKNWLRLTW 7051 RLR(sLss)PTVTVFFRKNWLRLTW 7052RLRQsPLATKFFRKNWLRLTW 7053 RLRQsPLATRFFRKNWLRLTW 7054RLRQsPLATYFFRKNWLRLTW 7055 RLRRsPLLKFFRKNWLRLTW 7056RLRsAGAAQKFFRKNWLRLTW 7057 RLRsLSSLREKFFRKNWLRLTW 7058RLRsPPPVSKFFRKNWLRLTW 7059 RLRsYEDMIFFRKNWLRLTW 7060RLRTsPITRKFFRKNWLRLTW 7061 RLRTsPITRRFFRKNWLRLTW 7062RLSDtPPLLFFRKNWLRLTW 7063 RLSsLIRHKFFRKNWLRLTW 7064RLSsLRASTSKFFRKNWLRLTW 7065 RLSsPISKKFFRKNWLRLTW 7066RLSsPISKRFFRKNWLRLTW 7067 RLSsPISKYFFRKNWLRLTW

7068 RLsSPLHFVFFRKNWLRLTW 7069 RLSsPLHFVFFRKNWLRLTW 7070RLSsPVLHKFFRKNWLRLTW 7071 RLSsPVLHRFFRKNWLRLTW 7072RLSsPVLHYFFRKNWLRLTW 7073 RLSsRFSSKFFRKNWLRLTW 7074RLSsRFSSRFFRKNWLRLTW 7075 RLSsRFSSYFFRKNWLRLTW 7076RLSsRYSQKFFRKNWLRLTW 7077 RLSsRYSQYFFRKNWLRLTW 7078RLSsVKLISKFFRKNWLRLTW 7079 RLSsVKLISYFFRKNWLRLTW 7080RLTFsPTYGVFFRKNWLRLTW 7081 RLVsLSMRKFFRKNWLRLTW 7082RLVsLSMRYFFRKNWLRLTW 7083 RLYKsPLRHFFRKNWLRLTW 7084RLYKsPLRKFFRKNWLRLTW 7085 RLYQyIQSKFFRKNWLRLTW 7086RLYQyIQSRFFRKNWLRLTW 7087 RLYQyIQSRFKFFRKNWLRLTW 7088RLYQyIQSRFYFFRKNWLRLTW 7089 RLYQyIQSYFFRKNWLRLTW 7090RLYQylOSKFFRKNWLRLTW 7091 RLYQyLQSRFFFRKNWLRLTW 7092RLYQyLQSRFKFFRKNWLRLTW 7093 RLYQyLQSRFYFFRKNWLRLTW 7094RLYQyLQSRKFFRKNWLRLTW 7095 RLYsGPMNKVFFRKNWLRLTW 7096RLYsGSRsKFFRKNWLRLTW 7097 RLYsGSRsRFFRKNWLRLTW 7098RLYsGSRsYFFRKNWLRLTW 7099 RLYsKSRDKFFRKNWLRLTW 7100RLYsPDHRQKFFRKNWLRLTW 7101 RLYsPERSKFFRKNWLRLTW 7102RLYsPRNSKFFRKNWLRLTW 7103 RLYSPYNHKFFRKNWLRLTW 7104RLYsPYNHRFFRKNWLRLTW 7105 RLYsPYNHYFFRKNWLRLTW 7106RLYSRsFSKFFRKNWLRLTW 7107 RLYSRsFSYFFRKNWLRLTW 7108RLYsYPRQKFFRKNWLRLTW 7109 RLYVTTSTRTYsLGFFRKNWLRLTW 7110RLYVTTSTRTYsLKFFRKNWLRLTW 7111 RLYVTTSTRTYsLYFFRKNWLRLTW 7112RMAsPPPPPKFFRKNWLRLTW 7113 RMAsPTSGVFFRKNWLRLTW 7114RMAsPTSGVKFFRKNWLRLTW 7115 RMAsPTSGVKKFFRKNWLRLTW 7116RMAsPTSGVKRFFRKNWLRLTW 7117 RMAsPTSGVKYFFRKNWLRLTW 7118RMAsSATQVHKFFRKNWLRLTW 7119 RMDsTPGKVFLFFRKNWLRLTW 7120RMDsTPGKVFVFFRKNWLRLTW 7121 RMDsYVRSLFFRKNWLRLTW 7122RMDsYVRSVFFRKNWLRLTW 7123 RMFPtPPSLFFRKNWLRLTW 7124RMFsFSKTPKFFRKNWLRLTW 7125 RMFsKELRCFFRKNWLRLTW 7126RMFsKELRVFFRKNWLRLTW 7127 RMFsPMEEKFFRKNWLRLTW 7128RMFsPMEEKELLFFRKNWLRLTW 7129 RMFsPTYGLFFRKNWLRLTW 7130RMFsPTYGVFFRKNWLRLTW 7131 RMIsPYKKKFFRKNWLRLTW 7132RMIsQDVKLFFRKNWLRLTW 7133 RMIsQDVKVFFRKNWLRLTW 7134RMIsTGSELFFRKNWLRLTW 7135 RMKLPsGSKFFRKNWLRLTW 7136RMKLPsGSKKFFRKNWLRLTW 7137 RMKLPsGSKYFFRKNWLRLTW 7138RMKsPFRKKFFRKNWLRLTW 7139 RMKsPGsGHVKFFRKNWLRLTW 7140RMKsPSPKSEKFFRKNWLRLTW 7141 RMKtPTSQSYKFFRKNWLRLTW 7142RMKtPTSQSYRFFRKNWLRLTW 7143 RMKTtPLRKFFRKNWLRLTW 7144RMKTtPLRRFFRKNWLRLTW 7145 RMLDRSPsRSAKFFRKNWLRLTW 7146RMLDRSPsRSAYFFRKNWLRLTW 7147 RMLsHISEAFFRKNWLRLTW 7148RMLsHISEVFFRKNWLRLTW 7149 RMLsLRDQRLFFRKNWLRLTW 7150RMLsPLSSAFFRKNWLRLTW 7151 RMLsPLSSVFFRKNWLRLTW 7152RMLsPSMASKFFRKNWLRLTW 7153 RMLsSGVSEIFFRKNWLRLTW 7154RMLsSGVSEVFFRKNWLRLTW 7155 RMLsVILIKFFRKNWLRLTW 7156RMPsFLKKNKFFRKNWLRLTW 7157 RMPsSTLKKFFRKNWLRLTW 7158RMPsSTLKRFFRKNWLRLTW 7159 RMQsTSERLFFRKNWLRLTW 7160RMQsTSERVFFRKNWLRLTW 7161 RMRQsPLATKFFRKNWLRLTW 7162RMRQsPLATRFFRKNWLRLTW 7163 RMRRsPLLKFFRKNWLRLTW 7164RMRsAGAAQKFFRKNWLRLTW 7165 RMRsLSSLREKFFRKNWLRLTW 7166RMRsPPPVSKFFRKNWLRLTW 7167 RMRTsPITRKFFRKNWLRLTW 7168RMRTsPITRRFFRKNWLRLTW 7169 RMSsLIRHKFFRKNWLRLTW 7170RMSsPISKKFFRKNWLRLTW 7171 RMSsPISKRFFRKNWLRLTW 7172RMSsPLHFVFFRKNWLRLTW 7173 RMSsPVLHKFFRKNWLRLTW 7174RMSsRYSQKFFRKNWLRLTW 7175 RMSsVKLISKFFRKNWLRLTW 7176RMSsVKLISYFFRKNWLRLTW 7177 RMVsLSMRKFFRKNWLRLTW 7178RMVsLSMRYFFRKNWLRLTW 7179 RMYKsPLRHFFRKNWLRLTW 7180RMYKsPLRKFFRKNWLRLTW 7181 RMYQyIQSKFFRKNWLRLTW 7182RMYQyIQSRFFRKNWLRLTW 7183 RMYQyLQSRFFFRKNWLRLTW 7184RMYQyLQSRFKFFRKNWLRLTW 7185 RMYQyLQSRFYFFRKNWLRLTW 7186RMYQyLQSRKFFRKNWLRLTW 7187 RMYsFDDVLFFRKNWLRLTW 7188RMYsGSRsKFFRKNWLRLTW 7189 RMYsGSRsRFFRKNWLRLTW 7190RMYsKSRDHFFRKNWLRLTW 7191 RMYsKSRDKFFRKNWLRLTW 7192RMYsKSRDYFFRKNWLRLTW

7193 RMYsPDHRQKFFRKNWLRLTW 7194 RMYsPERSKFFRKNWLRLTW 7195RMYsPIIYQAFFRKNWLRLTW 7196 RMYsPIPPSLFFRKNWLRLTW 7197RMYsPRNSKFFRKNWLRLTW 7198 RMYsPYNHKFFRKNWLRLTW 7199RMYsPYNHRFFRKNWLRLTW 7200 RMYsYPRQKFFRKNWLRLTW 7201RMYVTTSTRTYsLGFFRKNWLRLTW 7202 RMYVTTSTRTYsLKFFRKNWLRLTW 7203RMYVTTSTRTYsLYFFRKNWLRLTW 7204 RNLsSPFIFFFRKNWLRLTW 7205RPAFFsPSLFFRKNWLRLTW 7206 RPAKsMDSFFFRKNWLRLTW 7207RPAKsMDSLFFRKNWLRLTW 7208 RPAKsMDSMFFRKNWLRLTW 7209RPAKsMDVFFRKNWLRLTW 7210 RPAsAGAMFFFRKNWLRLTW 7211RPAsAGAmLFFRKNWLRLTW 7212 RPAsAGAMLFFRKNWLRLTW 7213RPAsAGAMMFFRKNWLRLTW 7214 RPAsAGAMVFFRKNWLRLTW 7215RPAsARAQPGFFFRKNWLRLTW 7216 RPAsARAQPGLFFRKNWLRLTW 7217RPAsARAQPGMFFRKNWLRLTW 7218 RPAsARAQPGVFFRKNWLRLTW 7219RPAsEARAPGLFFRKNWLRLTW 7220 RPAsPAAKFFFRKNWLRLTW 7221RPAsPAAKLFFRKNWLRLTW 7222 RPAsPAAKMFFRKNWLRLTW 7223RPAsPAAKVFFRKNWLRLTW 7224 RPAsPEPELFFRKNWLRLTW 7225RPAsPGPSLFFRKNWLRLTW 7226 RPAsPKRAKIFFRKNWLRLTW 7227RPAsPKRAKLFFRKNWLRLTW 7228 RPAsPKRAKXFFRKNWLRLTW 7229RPAsPKRAQIFFRKNWLRLTW 7230 RPAsPKRAQLFFRKNWLRLTW 7231RPAsPKRAQXFFRKNWLRLTW 7232 RPAsPQRAKIFFRKNWLRLTW 7233RPAsPQRAKLFFRKNWLRLTW 7234 RPAsPQRAKXFFRKNWLRLTW 7235RPAsPQRAQIFFRKNWLRLTW 7236 RPAsPQRAQLFFRKNWLRLTW 7237RPAsPQRAQXFFRKNWLRLTW 7238 RPAsPSLQLFFRKNWLRLTW 7239RPAsPSLQLLFFRKNWLRLTW 7240 RPAsPtAIRRIGSVTSRQTFFRKNWLRLTW 7241RPAsRFEVLFFRKNWLRLTW 7242 RPAsYKKKSMLFFRKNWLRLTW 7243RPAtGGPGVAFFRKNWLRLTW 7244 RPAtGGPGVFFFRKNWLRLTW 7245RPAtGGPGVLFFRKNWLRLTW 7246 RPAtGGPGVMFFRKNWLRLTW 7247RPAtGGPGWFFRKNWLRLTW 7248 RPAtPTSQFFFRKNWLRLTW 7249RPAtPTSQLFFRKNWLRLTW 7250 RPAtPTSQMFFRKNWLRLTW 7251RPAtPTSQVFFRKNWLRLTW 7252 RPDsAHKMLFFRKNWLRLTW 7253RPDsPTRPTLFFRKNWLRLTW 7254 RPDsRLGKTEFFFRKNWLRLTW 7255RPDsRLGKTELFFRKNWLRLTW 7256 RPDsRLGKTEMFFRKNWLRLTW 7257RPDsRLGKTEVFFRKNWLRLTW 7258 RPDVAKRLsLFFRKNWLRLTW 7259RPEsDSGLKFFFRKNWLRLTW 7260 RPEsDSGLKLFFRKNWLRLTW 7261RPEsDSGLKMFFRKNWLRLTW 7262 RPEsDSGLKVFFRKNWLRLTW 7263RPEsKDRKFFFRKNWLRLTW 7264 RPEsKDRKLFFRKNWLRLTW 7265RPEsKDRKMFFRKNWLRLTW 7266 RPEsKDRKVFFRKNWLRLTW 7267RPFARsHSFFFRKNWLRLTW 7268 RPFARSHsFFFRKNWLRLTW 7269RPFHGISTVsLFFRKNWLRLTW 7270 RPFsPREAFFFRKNWLRLTW 7271RPFsPREALFFRKNWLRLTW 7272 RPFsPREAMFFRKNWLRLTW 7273RPFsPREAVFFRKNWLRLTW 7274 RPGsLERKFFFRKNWLRLTW 7275RPGsLERKLFFRKNWLRLTW 7276 RPGsLERKMFFRKNWLRLTW 7277RPGsLERKVFFRKNWLRLTW 7278 RPGsRQAGLFFRKNWLRLTW 7279 RPGsRqAGLFFRKNWLRLTW 7280 RPHsPEKAFFFRKNWLRLTW 7281 RPHsPEKALFFRKNWLRLTW7282 RPHsPEKAMFFRKNWLRLTW 7283 RPHsPEKAVFFRKNWLRLTW 7284RPHtPTGIYMFFRKNWLRLTW 7285 RPHtPTPGIYMFFRKNWLRLTW 7286RPIsPGLSFFFRKNWLRLTW 7287 RPIsPGLSLFFRKNWLRLTW 7288RPIsPGLSMFFRKNWLRLTW 7289 RPIsPGLSVFFRKNWLRLTW 7290RPIsPGLSYFFRKNWLRLTW 7291 RPIsPPHTYFFRKNWLRLTW 7292RPIsPRIGALFFRKNWLRLTW 7293 RPItPPRNSAFFRKNWLRLTW 7294RPItPPRNSFFFRKNWLRLTW 7295 RPItPPRNSLFFRKNWLRLTW 7296RPItPPRNSMFFRKNWLRLTW 7297 RPItPPRNSVFFRKNWLRLTW 7298RPKLSsPAFFFRKNWLRLTW 7299 RPKLSsPALFFRKNWLRLTW 7300RPKLSsPAMFFRKNWLRLTW 7301 RPKLSsPAVFFRKNWLRLTW 7302RPKPSSsPFFFRKNWLRLTW 7303 RPKPSSsPLFFRKNWLRLTW 7304RPKPSSsPMFFRKNWLRLTW 7305 RPKPSSsPVFFRKNWLRLTW 7306RPKsNIVLFFFRKNWLRLTW 7307 RPKsNIVLLFFRKNWLRLTW 7308RPKsNIVLMFFRKNWLRLTW 7309 RPKsNIVLVFFRKNWLRLTW 7310RPKsPLSKmFFRKNWLRLTW 7311 RPKsPLSKMFFRKNWLRLTW 7312RPKsQVAEFFFRKNWLRLTW 7313 RPKsQVAELFFRKNWLRLTW 7314RPKsQVAEMFFRKNWLRLTW 7315 RPKsQVAEVFFRKNWLRLTW 7316RPKsVDFDSLFFRKNWLRLTW 7317 RPKtPPWIFFRKNWLRLTW 7318RPLsLLLALFFRKNWLRLTW

7319 RPLsPGGAFFFRKNWLRLTW 7320 RPLsPGGALFFRKNWLRLTW 7321RPLsPGGAMFFRKNWLRLTW 7322 RPLsPGGAVFFRKNWLRLTW 7323RPLsPLLFFFRKNWLRLTW 7324 RPLsPLLLFFRKNWLRLTW 7325RPLsPLLMFFRKNWLRLTW 7326 RPLsPLLVFFRKNWLRLTW 7327RPLsWYVLFFRKNWLRLTW 7328 RPMsESPHMFFRKNWLRLTW 7329RPNsPSPTAFFFRKNWLRLTW 7330 RPNsPSPTALFFRKNWLRLTW 7331RPNsPSPTAMFFRKNWLRLTW 7332 RPNsPSPTAVFFRKNWLRLTW 7333RPPIgTQSSLFFRKNWLRLTW 7334 RPPPPPDtPFFFRKNWLRLTW 7335RPPPPPDtPLFFRKNWLRLTW 7336 RPPPPPDtPMFFRKNWLRLTW 7337RPPPPPDtPPFFRKNWLRLTW 7338 RPPPPPDtPVFFRKNWLRLTW 7339RPPsPGPVFFFRKNWLRLTW 7340 RPPsPGPVLFFRKNWLRLTW 7341RPPsPGPVMFFRKNWLRLTW 7342 RPPsPGPWFFRKNWLRLTW 7343RPPsPSSRFFFRKNWLRLTW 7344 RPPsPSSRLFFRKNWLRLTW 7345RPPsPSSRMFFRKNWLRLTW 7346 RPPsPSSRVFFRKNWLRLTW 7347RPPsSEFLDFFFRKNWLRLTW 7348 RPPsSEFLDLFFRKNWLRLTW 7349RPPsSEFLDMFFRKNWLRLTW 7350 RPPsSEFLDVFFRKNWLRLTW 7351RPQKTQsIIFFRKNWLRLTW 7352 RPQRAtSNVFFFRKNWLRLTW 7353RPQRATsNVFFFRKNWLRLTW 7354 RPQRAtSNVLFFRKNWLRLTW 7355RPQRATsNVLFFRKNWLRLTW 7356 RPQRAtSNVMFFRKNWLRLTW 7357RPQRATsNVMFFRKNWLRLTW 7358 RPQRAtSNWFFRKNWLRLTW 7359RPQRATsNWFFRKNWLRLTW 7360 RPR(sLss)PTVTLFFRKNWLRLTW 7361RPR(sLss)PTVTVFFRKNWLRLTW 7362 RPRAAtWFFRKNWLRLTW 7363RPRAAtWAFFRKNWLRLTW 7364 RPRAAtWFFRKNWLRLTW 7365RPRAAtWAFFRKNWLRLTW 7366 RPRANsGGVDFFFRKNWLRLTW 7367RPRANsGGVDLFFRKNWLRLTW 7368 RPRANsGGVDMFFRKNWLRLTW 7369RPRANsGGVDVFFRKNWLRLTW 7370 RPRARsVDALFFRKNWLRLTW 7371RPRDtRRISLFFRKNWLRLTW 7372 RPRGsESLLFFRKNWLRLTW 7373RPRGsQSLFFFRKNWLRLTW 7374 RPRGsQSLLFFRKNWLRLTW 7375RPRGsQSLMFFRKNWLRLTW 7376 RPRGsQSLVFFRKNWLRLTW 7377RPRIPsPIGFFFRKNWLRLTW 7378 RPRLSsTNSSRFFFRKNWLRLTW 7379RPRPAsSPALFFRKNWLRLTW 7380 RPRPHsAPSFFFRKNWLRLTW 7381RPRPHsAPSLFFRKNWLRLTW 7382 RPRPHsAPSMFFRKNWLRLTW 7383RPRPHsAPSVFFRKNWLRLTW 7384 RPRPSsAHVGLFFRKNWLRLTW 7385RPRPsSVLFFRKNWLRLTW 7386 RPRPsSVLRTLFFRKNWLRLTW 7387RPRPVsPSSFFFRKNWLRLTW 7388 RPRPVsPSSLFFRKNWLRLTW 7389RPRPVsPSSLLFFRKNWLRLTW 7390 RPRPVsPSSMFFRKNWLRLTW 7391RPRPVsPSSVFFRKNWLRLTW 7392 RPRRsSTQFFFRKNWLRLTW 7393RPRRsSTQLFFRKNWLRLTW 7394 RPRRsSTQMFFRKNWLRLTW 7395RPRRsSTQVFFRKNWLRLTW 7396 RPRsAVEQLFFRKNWLRLTW 7397RPRsAVLFFFRKNWLRLTW 7398 RPRsAVLLFFRKNWLRLTW 7399RPRsAVLMFFRKNWLRLTW 7400 RPRsAVLVFFRKNWLRLTW 7401RPRSGsTGSSLFFRKNWLRLTW 7402 RPRsISVEEFFFRKNWLRLTW 7403RPRsISVEELFFRKNWLRLTW 7404 RPRsISVEEMFFRKNWLRLTW 7405RPRsISVEEVFFRKNWLRLTW 7406 RPRsLEVTFFFRKNWLRLTW 7407RPRsLEVTIFFRKNWLRLTW 7408 RPRsLEVTLFFRKNWLRLTW 7409RPRsLEVTMFFRKNWLRLTW 7410 RPRsLEVTVFFRKNWLRLTW 7411RPRSLsSPTVFFRKNWLRLTW 7412 RPRSLsSPTVTFFFRKNWLRLTW 7413RPRSLsSPTVTLFFRKNWLRLTW 7414 RPRSLsSPTVTMFFRKNWLRLTW 7415RPRSLsSPTVTVFFRKNWLRLTW 7416 RPRsMTVSAFFRKNWLRLTW 7417RPRsMVRSFFFRKNWLRLTW 7418 RPRsPAARFFFRKNWLRLTW 7419RPRsPAARLFFRKNWLRLTW 7420 RPRsPAARMFFRKNWLRLTW 7421RPRsPAARVFFRKNWLRLTW 7422 RPRsPGSNSKVFFRKNWLRLTW 7423RPRsPNMQDLFFRKNWLRLTW 7424 RPRsPPGGPFFRKNWLRLTW 7425RPRsPPPRAFFFRKNWLRLTW 7426 RPRsPPPRALFFRKNWLRLTW 7427RPRsPPPRAMFFRKNWLRLTW 7428 RPRsPPPRAPFFRKNWLRLTW 7429RPRsPPPRAVFFRKNWLRLTW 7430 RPRsPPSSPFFRKNWLRLTW 7431RPRsPRENSFFFRKNWLRLTW 7432 RPRsPRENSIFFRKNWLRLTW 7433RPRsPRENSLFFRKNWLRLTW 7434 RPRsPRENSMFFRKNWLRLTW 7435RPRsPRENSVFFRKNWLRLTW 7436 RPRsPRPPPFFRKNWLRLTW 7437RPRsPRQNLIFFRKNWLRLTW 7438 RPRsPRQNSFFFRKNWLRLTW 7439RPRsPRQNSIFFRKNWLRLTW 7440 RPRsPRQNSMFFRKNWLRLTW 7441RPRsPRQNSVFFRKNWLRLTW 7442 RPRsPSPIFFFRKNWLRLTW 7443RPRsPSPILFFRKNWLRLTW

7444 RPRsPSPIMFFRKNWLRLTW 7445 RPRsPSPISFFRKNWLRLTW 7446RPRSPsPISFFRKNWLRLTW 7447 RPRsPSPIVFFRKNWLRLTW 7448RPRsPTGFFFRKNWLRLTW 7449 RPRsPTGLFFRKNWLRLTW 7450RPRsPTGMFFRKNWLRLTW 7451 RPRsPTGPFFRKNWLRLTW 7452RPRsPTGPsNSFFFRKNWLRLTW 7453 RPRsPTGPSNSFFFRKNWLRLTW 7454RPRsPTGPSNSFLFFRKNWLRLTW 7455 RPRsPTGPsNSLFFRKNWLRLTW 7456RPRsPTGPsNSMFFRKNWLRLTW 7457 RPRsPTGPsNSVFFRKNWLRLTW 7458RPRsPTGVFFRKNWLRLTW 7459 RPRsPTRSFFFRKNWLRLTW 7460RPRsPTRSLFFRKNWLRLTW 7461 RPRsPTRSMFFRKNWLRLTW 7462RPRsPTRSVFFRKNWLRLTW 7463 RPRsPWGKLFFRKNWLRLTW 7464RPRsQYNTKLFFRKNWLRLTW 7465 RPRSTsQSIVSLFFRKNWLRLTW 7466RPRtPLRSLFFRKNWLRLTW 7467 RPSGRREsFFFRKNWLRLTW 7468RPSGRREsLFFRKNWLRLTW 7469 RPSGRREsMFFRKNWLRLTW 7470RPSGRREsVFFRKNWLRLTW 7471 RPsNPQLFFRKNWLRLTW 7472RPSRSsPGFFFRKNWLRLTW 7473 RPSRSsPGLFFRKNWLRLTW 7474RPSRSsPGMFFRKNWLRLTW 7475 RPSRSsPGVFFRKNWLRLTW 7476RPSsGFYELFFRKNWLRLTW 7477 RPSsLDAEIDSFFFRKNWLRLTW 7478RPSsLDAEIDSLFFRKNWLRLTW 7479 RPSsLDAEIDSMFFRKNWLRLTW 7480RPSsLDAEIDSVFFRKNWLRLTW 7481 RPSsLPDFFFRKNWLRLTW 7482RPSsLPDLFFRKNWLRLTW 7483 RPSsLPDMFFRKNWLRLTW 7484RPSsLPDVFFRKNWLRLTW 7485 RPsSPALYFFFRKNWLRLTW 7486RPSsPALYFFFRKNWLRLTW 7487 RPsSPALYLFFRKNWLRLTW 7488RPsSPALYMFFRKNWLRLTW 7489 RPsSPALYVFFRKNWLRLTW 7490RPStPKSDSEFFFRKNWLRLTW 7491 RPStPKSDSELFFRKNWLRLTW 7492RPStPKSDSEMFFRKNWLRLTW 7493 RPStPKSDSEVFFRKNWLRLTW 7494RPTKIGRRsLFFRKNWLRLTW 7495 RPTsFADELFFRKNWLRLTW 7496RPTsPIQIMFFRKNWLRLTW 7497 RPTsRLNRFFFRKNWLRLTW 7498RPTsRLNRLFFRKNWLRLTW 7499 RPTsRLNRMFFRKNWLRLTW 7500RPTsRLNRVFFRKNWLRLTW 7501 RPVsPFQEFFFRKNWLRLTW 7502RPVsPFQELFFRKNWLRLTW 7503 RPVsPFQEMFFRKNWLRLTW 7504RPVsPFQEVFFRKNWLRLTW 7505 RPVsPGKDFFFRKNWLRLTW 7506RPVsPGKDIFFRKNWLRLTW 7507 RPVsPGKDLFFRKNWLRLTW 7508RPVsPGKDMFFRKNWLRLTW 7509 RPVsPGKDVFFRKNWLRLTW 7510RPVSPsSLLFFRKNWLRLTW 7511 RPVsTDFAQYFFRKNWLRLTW 7512RPVtPVSDFFFRKNWLRLTW 7513 RPVtPVSDLFFRKNWLRLTW 7514RPVtPVSDMFFRKNWLRLTW 7515 RPVtPVSDVFFRKNWLRLTW 7516RPWsNSRGLFFRKNWLRLTW 7517 RPWsPAVSAFFRKNWLRLTW 7518RPWsPAVSFFFRKNWLRLTW 7519 RPWsPAVSLFFRKNWLRLTW 7520RPWsPAVSMFFRKNWLRLTW 7521 RPWsPAVSVFFRKNWLRLTW 7522RPYsPPFFSFFFRKNWLRLTW 7523 RPYsPPFFSLFFRKNWLRLTW 7524RPYsPPFFSMFFRKNWLRLTW 7525 RPYsPPFFSVFFRKNWLRLTW 7526RPYSPsQALFFRKNWLRLTW 7527 RPYsPSQYALFFRKNWLRLTW 7528RPYSPsQYALFFRKNWLRLTW 7529 RPYsQVNVLFFRKNWLRLTW 7530RQAsIELPSMFFRKNWLRLTW 7531 RQAsIELPSMAVFFRKNWLRLTW 7532RQAsIELPSVFFRKNWLRLTW 7533 RQAsLSISVFFRKNWLRLTW 7534RQAsPLVHKFFRKNWLRLTW 7535 RQAsPLVHRFFRKNWLRLTW 7536RQAsPLVHYFFRKNWLRLTW 7537 RQDsTPGKVFLFFRKNWLRLTW 7538RQDStPGKVFLFFRKNWLRLTW 7539 RQDsTPGKVFVFFRKNWLRLTW 7540RQIsFKAEVFFRKNWLRLTW 7541 RQIsQDVKLFFRKNWLRLTW 7542RQIsQDVKVFFRKNWLRLTW 7543 RQKsPLFQFFFRKNWLRLTW 7544RQLsALHRAFFRKNWLRLTW 7545 RQLsLEGSGLGVFFRKNWLRLTW 7546RQLsSGVSEIFFRKNWLRLTW 7547 RQLsSGVSEVFFRKNWLRLTW 7548RQSsSRFNLFFRKNWLRLTW 7549 RRAsFAKSFFFRKNWLRLTW 7550RRAsFAKSKFFRKNWLRLTW 7551 RRAsFAKSLFFRKNWLRLTW 7552RRAsFAKSMFFRKNWLRLTW 7553 RRAsFAKSRFFRKNWLRLTW 7554RRAsIITKYFFRKNWLRLTW 7555 RRAsLSEIGFFFRKNWLRLTW 7556RRAsLSEIGKFFRKNWLRLTW 7557 RRAsLSEIGYFFRKNWLRLTW 7558RRAsQEANLFFRKNWLRLTW 7559 RRASsPFRFFFRKNWLRLTW 7560RRASsPFRKFFRKNWLRLTW 7561 RRASsPFRLFFRKNWLRLTW 7562RRASsPFRMFFRKNWLRLTW 7563 RRASsPFRRFFRKNWLRLTW 7564RRAsVFVKFFFRKNWLRLTW 7565 RRAsVFVKKFFRKNWLRLTW 7566RRAsVFVKLFFRKNWLRLTW 7567 RRAsVFVKMFFRKNWLRLTW 7568RRAsVFVKRFFRKNWLRLTW 7569 RRDsIVAEFFFRKNWLRLTW

7570 RRDsIVAEKFFRKNWLRLTW 7571 RRDsIVAELFFRKNWLRLTW 7572RRDsIVAERFFRKNWLRLTW 7573 RRDsIVAEYFFRKNWLRLTW 7574RRDsLQKPGLFFRKNWLRLTW 7575 RRFsFEVTLFFRKNWLRLTW 7576RRFsFKFFFRKNWLRLTW 7577 RRFsFKKFFRKNWLRLTW 7578RRFsFKKSFFFRKNWLRLTW 7579 RRFsFKKSKFFRKNWLRLTW 7580RRFsFKKSLFFRKNWLRLTW 7581 RRFsFKKSMFFRKNWLRLTW 7582RRFsFKKSRFFRKNWLRLTW 7583 RRFsFKLFFRKNWLRLTW 7584RRFsFKMFFRKNWLRLTW 7585 RRFsFKRFFRKNWLRLTW 7586RRFsGTAVYFFRKNWLRLTW 7587 RRFsGTVRFFFRKNWLRLTW 7588RRFsGTVRKFFRKNWLRLTW 7589 RRFsGTVRLFFRKNWLRLTW 7590RRFsGTVRMFFRKNWLRLTW 7591 RRFsGTVRRFFRKNWLRLTW 7592RRFsIATLRFFRKNWLRLTW 7593 RRFsLTTLRFFRKNWLRLTW 7594RRFsPDDKYSFFFRKNWLRLTW 7595 RRFsPDDKYSKFFRKNWLRLTW 7596RRFsPDDKYSLFFRKNWLRLTW 7597 RRFsPDDKYSMFFRKNWLRLTW 7598RRFsPPRRFFFRKNWLRLTW 7599 RRFsPPRRKFFRKNWLRLTW 7600RRFsPPRRLFFRKNWLRLTW 7601 RRFsPPRRmFFRKNWLRLTW 7602RRFsPPRRMFFRKNWLRLTW 7603 RRFsPPRRRFFRKNWLRLTW 7604RRFsPPRRYFFRKNWLRLTW 7605 RRFsRLENRYFFRKNWLRLTW 7606RRFsRSDELFFRKNWLRLTW 7607 RRFsRsPIFFFRKNWLRLTW 7608RRFsRSPIFFFRKNWLRLTW 7609 RRFsRsPIKFFRKNWLRLTW 7610RRFsRSPIKFFRKNWLRLTW 7611 RRFsRsPILFFRKNWLRLTW 7612RRFsRSPILFFRKNWLRLTW 7613 RRFsRSPIMFFRKNWLRLTW 7614RRFsRsPIRFFRKNWLRLTW 7615 RRFsRSPIRFFRKNWLRLTW 7616RRFSRsPIRFFRKNWLRLTW 7617 RRFsRsPIRFFFRKNWLRLTW 7618RRFsRSPIRFFFRKNWLRLTW 7619 RRFsRsPIRKFFRKNWLRLTW 7620RRFsRSPIRKFFRKNWLRLTW 7621 RRFsRsPIRLFFRKNWLRLTW 7622RRFsRSPIRLFFRKNWLRLTW 7623 RRFsRsPIRRFFRKNWLRLTW 7624RRFsRSPIRRFFRKNWLRLTW 7625 RRFsRsPIRYFFRKNWLRLTW 7626RRFsRSPIRYFFRKNWLRLTW 7627 RRFsRsPIYFFRKNWLRLTW 7628RRFsRSPIYFFRKNWLRLTW 7629 RRFsRSPKFFRKNWLRLTW 7630RRFSsPPRRMFFRKNWLRLTW 7631 RRFsVSTLRFFRKNWLRLTW 7632RRFsVTTMRFFRKNWLRLTW 7633 RRFtPPSPAFFFRKNWLRLTW 7634RRFtPPSPAKFFRKNWLRLTW 7635 RRFtPPSPARFFRKNWLRLTW 7636RRFtPPSPAYFFRKNWLRLTW 7637 RRGsFEVTLFFRKNWLRLTW 7638RRHsASNLHALFFRKNWLRLTW 7639 RRIDIsPSTFFFRKNWLRLTW 7640RRIDIsPSTKFFRKNWLRLTW 7641 RRIDIsPSTLRFFRKNWLRLTW 7642RRIDIsPSTLRKFFRKNWLRLTW 7643 RRIDIsPSTRFFRKNWLRLTW 7644RRIDIsPSTYFFRKNWLRLTW 7645 RRIsDPEVFFFRKNWLRLTW 7646RRIsDPQVFFFRKNWLRLTW 7647 RRIsGVDRFFFRKNWLRLTW 7648RRIsGVDRKFFRKNWLRLTW 7649 RRIsGVDRLFFRKNWLRLTW 7650RRIsGVDRMFFRKNWLRLTW 7651 RRIsGVDRRFFRKNWLRLTW 7652RRIsGVDRYFFRKNWLRLTW 7653 RRIsGVDRYFFFRKNWLRLTW 7654RRIsGVDRYKFFRKNWLRLTW 7655 RRIsGVDRYLFFRKNWLRLTW 7656RRIsGVDRYRFFRKNWLRLTW 7657 RRISGVDRYYFFRKNWLRLTW 7658RRISPAPQRFFRKNWLRLTW 7659 RRIsQIQQLFFRKNWLRLTW 7660RRKsOVAEFFFRKNWLRLTW 7661 RRKsOVAEKFFRKNWLRLTW 7662RRKsPPPSFFFRKNWLRLTW 7663 RRKsPPPSKFFRKNWLRLTW 7664RRKsPPPSLFFRKNWLRLTW 7665 RRKsPPPSMFFRKNWLRLTW 7666RRKsPPPSRFFRKNWLRLTW 7667 RRKsQLDSFFFRKNWLRLTW 7668RRKsQLDSKFFRKNWLRLTW 7669 RRKsQLDSLFFRKNWLRLTW 7670RRKsQLDSMFFRKNWLRLTW 7671 RRKsQLDSRFFRKNWLRLTW 7672RRKsQLDSYFFRKNWLRLTW 7673 RRKsQVAEFFFRKNWLRLTW 7674RRKsQVAEKFFRKNWLRLTW 7675 RRKsQVAELFFRKNWLRLTW 7676RRKsQVAEMFFRKNWLRLTW 7677 RRKsQVAERFFRKNWLRLTW 7678RRKsQVAEVFFRKNWLRLTW 7679 RRKsQVAEYFFRKNWLRLTW 7680RRLGsPHRFFFRKNWLRLTW 7681 RRLGsPHRKFFRKNWLRLTW 7682RRLGsPHRLFFRKNWLRLTW 7683 RRLGsPHRMFFRKNWLRLTW 7684RRLGsPHRRFFRKNWLRLTW 7685 RRLsADIRFFFRKNWLRLTW 7686RRLsADIRKFFRKNWLRLTW 7687 RRLsADIRLFFRKNWLRLTW 7688RRLsADIRMFFRKNWLRLTW 7689 RRLsADIRRFFRKNWLRLTW 7690RRLsADIRYFFRKNWLRLTW 7691 RRLsDSPVFFFRKNWLRLTW 7692RRLsELLRYFFRKNWLRLTW 7693 RRLsERETRFFRKNWLRLTW 7694RRLsESSALFFRKNWLRLTW

7695 RRLsFLVSFFFRKNWLRLTW 7696 RRLsFLVSKFFRKNWLRLTW 7697RRLsFLVSLFFRKNWLRLTW 7698 RRLsFLVSMFFRKNWLRLTW 7699RRLsFLVSRFFRKNWLRLTW 7700 RRLsFLVSYFFRKNWLRLTW 7701RRLsGGSHSFFFRKNWLRLTW 7702 RRLsGGSHSKFFRKNWLRLTW 7703RRLsGGSHSLFFRKNWLRLTW 7704 RRLsGGSHSMFFRKNWLRLTW 7705RRLsGGSHSRFFRKNWLRLTW 7706 RRLsGGSHSYFFRKNWLRLTW 7707RRLsGPLHTFFFRKNWLRLTW 7708 RRLsGPLHTKFFRKNWLRLTW 7709RRLsGPLHTLFFRKNWLRLTW 7710 RRLsGPLHTMFFRKNWLRLTW 7711RRLsGPLHTRFFRKNWLRLTW 7712 RRLsGPLHTVFFRKNWLRLTW 7713RRLsGPLHTYFFRKNWLRLTW 7714 RRLsLFLNVFFRKNWLRLTW 7715RRLsNLPTFFFRKNWLRLTW 7716 RRLsNLPTKFFRKNWLRLTW 7717RRLsNLPTRFFRKNWLRLTW 7718 RRLsNLPTVFFRKNWLRLTW 7719RRLsNLPTYFFRKNWLRLTW 7720 RRLsPAPOFFFRKNWLRLTW 7721RRLsPAPQKFFRKNWLRLTW 7722 RRLsPAPQLFFRKNWLRLTW 7723RRLsPAPQMFFRKNWLRLTW 7724 RRLsPKASQVFFFRKNWLRLTW 7725RRLsPKASQVKFFRKNWLRLTW 7726 RRLsPKASQVLFFRKNWLRLTW 7727RRLsPKASQVMFFRKNWLRLTW 7728 RRLsPKASQVRFFRKNWLRLTW 7729RRLsPVPVPFFFRKNWLRLTW 7730 RRLsPVPVPKFFRKNWLRLTW 7731RRLsPVPVPLFFRKNWLRLTW 7732 RRLsPVPVPMFFRKNWLRLTW 7733RRLsPVPVPRFFRKNWLRLTW 7734 RRLsRELOKFFRKNWLRLTW 7735RRLsRELQFFFRKNWLRLTW 7736 RRLsRELQLFFRKNWLRLTW 7737RRLsRELQMFFRKNWLRLTW 7738 RRLsRELQRFFRKNWLRLTW 7739RRLsRKLSLFFRKNWLRLTW 7740 RRLsVERIFFFRKNWLRLTW 7741RRLsVERIKFFRKNWLRLTW 7742 RRLsVERIMFFRKNWLRLTW 7743RRLsVERIRFFRKNWLRLTW 7744 RRLsYVLFIFFRKNWLRLTW 7745RRLTHLsFFFRKNWLRLTW 7746 RRLTHLsKFFRKNWLRLTW 7747RRLTHLsLFFRKNWLRLTW 7748 RRLTHLsMFFRKNWLRLTW 7749RRLTHLsRFFRKNWLRLTW 7750 RRMsFQKPFFRKNWLRLTW 7751RRMsLLSVFFFRKNWLRLTW 7752 RRMsLLSVKFFRKNWLRLTW 7753RRMsLLSVLFFRKNWLRLTW 7754 RRMsLLSVMFFRKNWLRLTW 7755RRMsLLSVRFFRKNWLRLTW 7756 RRmsLLSWFFRKNWLRLTW 7757RRMsLLSWFFRKNWLRLTW 7758 RRMsLLSVYFFRKNWLRLTW 7759RRMsLLSWFFRKNWLRLTW 7760 RRMsLSVMFFRKNWLRLTW 7761RRMsPIKPLFFRKNWLRLTW 7762 RRMsPKAORFFRKNWLRLTW 7763RRMsPKAQFFFRKNWLRLTW 7764 RRMsPKAQKFFRKNWLRLTW 7765RRMsPKAQLFFRKNWLRLTW 7766 RRMsPKAQMFFRKNWLRLTW 7767RRMsPKPFFFRKNWLRLTW 7768 RRMsPKPKFFRKNWLRLTW 7769RRMsPKPMFFRKNWLRLTW 7770 RRMsPKPRFFRKNWLRLTW 7771RRNsAPVSVFFRKNWLRLTW 7772 RRNsINRNFFFRKNWLRLTW 7773RRNsNPVIAEFFFRKNWLRLTW 7774 RRNsNPVIAEKFFRKNWLRLTW 7775RRNsNPVIAELFFRKNWLRLTW 7776 RRNsNPVIAEMFFRKNWLRLTW 7777RRNsNPVIAERFFRKNWLRLTW 7778 RRNsSERTFFFRKNWLRLTW 7779RRNsSERTKFFRKNWLRLTW 7780 RRNsSERTLFFRKNWLRLTW 7781RRNsSERTMFFRKNWLRLTW 7782 RRNsSERTRFFRKNWLRLTW 7783RRNsSERTYFFRKNWLRLTW 7784 RRNsSIVGFFFRKNWLRLTW 7785RRNsSIVGKFFRKNWLRLTW 7786 RRNsSIVGLFFRKNWLRLTW 7787RRNsSIVGMFFRKNWLRLTW 7788 RRNsSIVGRFFRKNWLRLTW 7789RRNsSIVGYFFRKNWLRLTW 7790 RRNsVFQQGFFFRKNWLRLTW 7791RRNsVFQQGKFFRKNWLRLTW 7792 RRNsVFQQGLFFRKNWLRLTW 7793RRNsVFQQGMFFRKNWLRLTW 7794 RRNsVFQQGRFFRKNWLRLTW 7795RRNsVFQQGYFFRKNWLRLTW 7796 RRPsIAPVLFFRKNWLRLTW 7797RRPsLLSEFFFRKNWLRLTW 7798 RRPsLVHGFFFRKNWLRLTW 7799RRPsLVHGKFFRKNWLRLTW 7800 RRPsLVHGLFFRKNWLRLTW 7801RRPsLVHGMFFRKNWLRLTW 7802 RRPsLVHGRFFRKNWLRLTW 7803RRPsLVHGYFFRKNWLRLTW 7804 RRPsVFERFFFRKNWLRLTW 7805RRPsVFERKFFRKNWLRLTW 7806 RRPsVFERLFFRKNWLRLTW 7807RRPsVFERMFFRKNWLRLTW 7808 RRPsVFERRFFRKNWLRLTW 7809RRPsVFERYFFRKNWLRLTW 7810 RRPsYRKIFFFRKNWLRLTW 7811RRPsYRKIKFFRKNWLRLTW 7812 RRPsYRKILFFRKNWLRLTW 7813RRPsYRKIMFFRKNWLRLTW 7814 RRPsYRKIRFFRKNWLRLTW 7815RRPsYRKIYFFRKNWLRLTW 7816 RRPsYTLGFFFRKNWLRLTW 7817RRPsYTLGKFFRKNWLRLTW 7818 RRPsYTLGLFFRKNWLRLTW 7819RRPsYTLGMFFRKNWLRLTW 7820 RRPsYTLGRFFRKNWLRLTW

7821 RRPsYTLGVFFRKNWLRLTW 7822 RRPsYTLGYFFRKNWLRLTW 7823RRQsKVEALFFRKNWLRLTW 7824 RRRsLERLLFFRKNWLRLTW 7825RRsFLVSYFFRKNWLRLTW 7826 RRSFsLEFFRKNWLRLTW 7827 RRSsFLQFFRKNWLRLTW7828 RRssFLQLFFFRKNWLRLTW 7829 RRssFLQVFFFRKNWLRLTW 7830RRSsFLQVFFFRKNWLRLTW 7831 RRSsFLQVKFFRKNWLRLTW 7832RRSsFLQVLFFRKNWLRLTW 7833 RRssFLQVMFFRKNWLRLTW 7834RRSsFLQVMFFRKNWLRLTW 7835 RRSsFLQVRFFRKNWLRLTW 7836RRssFLQWFFRKNWLRLTW 7837 RRSsFLQVYFFRKNWLRLTW 7838RRSsIGLRFFFRKNWLRLTW 7839 RRSsIGLRKFFRKNWLRLTW 7840RRSsIGLRLFFRKNWLRLTW 7841 RRSsIGLRMFFRKNWLRLTW 7842RRSsIGLRRFFRKNWLRLTW 7843 RRSsIGLRVFFRKNWLRLTW 7844RRSsIGLRYFFRKNWLRLTW 7845 RRsSIQSTFFFRKNWLRLTW 7846RRSsIQSTFFFRKNWLRLTW 7847 RRSsIQSTKFFRKNWLRLTW 7848RRSsIQSTLFFRKNWLRLTW 7849 RRSsIQSTMFFRKNWLRLTW 7850RRSsIQSTRFFRKNWLRLTW 7851 RRSsIQSTYFFRKNWLRLTW 7852RRSsLDAEIDSFFFRKNWLRLTW 7853 RRSsLDAEIDSLFFRKNWLRLTW 7854RRSsLDAEIDSMFFRKNWLRLTW 7855 RRSsLDAEIDSVFFRKNWLRLTW 7856RRsSQSWSFFFRKNWLRLTW 7857 RRSsQSWSFFFRKNWLRLTW 7858RRSsQSWSKFFRKNWLRLTW 7859 RRsSQSWSLFFRKNWLRLTW 7860RRSsQSWSLFFRKNWLRLTW 7861 RRsSQSWSMFFRKNWLRLTW 7862RRSsQSWSMFFRKNWLRLTW 7863 RRSsQSWSRFFRKNWLRLTW 7864RRsSQSWSVFFRKNWLRLTW 7865 RRSsQSWSYFFRKNWLRLTW 7866RRSsSVAQVFFRKNWLRLTW 7867 RRSsTASLVKFFFRKNWLRLTW 7868RRSsTASLVKKFFRKNWLRLTW 7869 RRSsTASLVKLFFRKNWLRLTW 7870RRSsTASLVKMFFRKNWLRLTW 7871 RRSsTASLVKRFFRKNWLRLTW 7872RRsSVDLGFFFRKNWLRLTW 7873 RRSsVDLGFFFRKNWLRLTW 7874RRsSVDLGKFFRKNWLRLTW 7875 RRSsVDLGKFFRKNWLRLTW 7876RRsSVDLGLFFRKNWLRLTW 7877 RRSsVDLGLFFRKNWLRLTW 7878RRsSVDLGMFFRKNWLRLTW 7879 RRSsVDLGMFFRKNWLRLTW 7880RRsSVDLGRFFRKNWLRLTW 7881 RRSsVDLGRFFRKNWLRLTW 7882RRsSVDLGYFFRKNWLRLTW 7883 RRSsVDLGYFFRKNWLRLTW 7884RRSsVKVEAFFRKNWLRLTW 7885 RRSsVKVEFFFRKNWLRLTW 7886RRSsVKVEKFFRKNWLRLTW 7887 RRSsVKVELFFRKNWLRLTW 7888RRSsVKVEMFFRKNWLRLTW 7889 RRSsVKVERFFRKNWLRLTW 7890RRSsVKVEYFFRKNWLRLTW 7891 RRTsPITRFFFRKNWLRLTW 7892RRTsPITRKFFRKNWLRLTW 7893 RRTsPITRLFFRKNWLRLTW 7894RRTsPITRMFFRKNWLRLTW 7895 RRTsPITRRFFRKNWLRLTW 7896RRWQRSsFFFRKNWLRLTW 7897 RRWQRSsKFFRKNWLRLTW 7898RRWQRSsLFFRKNWLRLTW 7899 RRWQRSsMFFRKNWLRLTW 7900RRWQRSsRFFRKNWLRLTW 7901 RRWQRSsYFFRKNWLRLTW 7902RRWQRSsLFFRKNWLRLTW 7903 RRYsGKTEFFFRKNWLRLTW 7904RRYsGKTEKFFRKNWLRLTW 7905 RRYsGKTELFFRKNWLRLTW 7906RRYsGKTERFFRKNWLRLTW 7907 RRYsGKTEYFFRKNWLRLTW 7908RRYsGNMEFFFRKNWLRLTW 7909 RRYsGNMEKFFRKNWLRLTW 7910RRYsGNMELFFRKNWLRLTW 7911 RRYsGNMEMFFRKNWLRLTW 7912RRYsGNMERFFRKNWLRLTW 7913 RRYsKFFDLFFRKNWLRLTW 7914RRYsPPIERFFRKNWLRLTW 7915 RRYsPPIQFFRKNWLRLTW 7916RRYsPPIQFFFRKNWLRLTW 7917 RRYsPPIQKFFRKNWLRLTW 7918RRYsPPIQLFFRKNWLRLTW 7919 RRYsPPIQMFFRKNWLRLTW 7920RRYsPPIQRFFRKNWLRLTW 7921 RRYsPPIQYFFRKNWLRLTW 7922RRYsRsPYSFFFRKNWLRLTW 7923 RRYsRSPYSFFFRKNWLRLTW 7924RRYSRsPYSFFFRKNWLRLTW 7925 RRYsRsPYSKFFRKNWLRLTW 7926RRYsRSPYSKFFRKNWLRLTW 7927 RRYSRsPYSKFFRKNWLRLTW 7928RRYsRsPYSLFFRKNWLRLTW 7929 RRYsRSPYSLFFRKNWLRLTW 7930RRYSRsPYSLFFRKNWLRLTW 7931 RRYsRsPYSMFFRKNWLRLTW 7932RRYsRSPYSMFFRKNWLRLTW 7933 RRYSRsPYSMFFRKNWLRLTW 7934RRYsRsPYSRFFRKNWLRLTW 7935 RRYsRSPYSRFFRKNWLRLTW 7936RRYSRsPYSRFFRKNWLRLTW 7937 RRYtNRWTKFFRKNWLRLTW 7938RRYtNRWTLFFRKNWLRLTW 7939 RRYtNRWTMFFRKNWLRLTW 7940RRYtNRWTRFFRKNWLRLTW 7941 RSAsFSRKVFFRKNWLRLTW 7942RSAsPDDDLGSSNFFRKNWLRLTW 7943 RSAsSATQVHKFFRKNWLRLTW 7944RSAsSATQVHYFFRKNWLRLTW 7945 RSDPSKsPGSLRYFFRKNWLRLTW

7946 RSDsPKIDLFFRKNWLRLTW 7947 RSDsPKIDYFFRKNWLRLTW 7948RSDsRAQAVFFRKNWLRLTW 7949 RSDsRAQAYFFRKNWLRLTW 7950RSDsVGENLFFRKNWLRLTW 7951 RSDsVGENYFFRKNWLRLTW 7952RSDsYVELFFRKNWLRLTW 7953 RSDsYVELSQYFFRKNWLRLTW 7954RSEPSKsPGSLRYFFRKNWLRLTW 7955 RSEsKDRKFFFRKNWLRLTW 7956RSEsKDRKLFFRKNWLRLTW 7957 RSEsKDRKMFFRKNWLRLTW 7958RSEsKDRKVFFRKNWLRLTW 7959 RSEsPKIDLFFRKNWLRLTW 7960RSEsPKIDYFFRKNWLRLTW 7961 RSEsPPAELFFRKNWLRLTW 7962RSEsRAQAVFFRKNWLRLTW 7963 RSEsRAQAYFFRKNWLRLTW 7964RSEsVGENLFFRKNWLRLTW 7965 RSEsVGENYFFRKNWLRLTW 7966RSEsYVELSQYFFRKNWLRLTW 7967 RSFsPTMKVFFRKNWLRLTW 7968RSGsLERKFFFRKNWLRLTW 7969 RSGsLERKLFFRKNWLRLTW 7970RSGsLERKMFFRKNWLRLTW 7971 RSGsLERKVFFRKNWLRLTW 7972RSHSsPASLFFRKNWLRLTW 7973 RSIsVGENLFFRKNWLRLTW 7974RSLsESYELFFRKNWLRLTW 7975 RSLsPGGAAFFRKNWLRLTW 7976RSLsPGGAFFFRKNWLRLTW 7977 RSLsPGGALFFRKNWLRLTW 7978RSLsPGGAMFFRKNWLRLTW 7979 RSLsPGGAVFFRKNWLRLTW 7980RSLsPLLFFFRKNWLRLTW 7981 RSLsPLLLFFRKNWLRLTW 7982RSLsPLLMFFRKNWLRLTW 7983 RSLsPLLVFFRKNWLRLTW 7984RSLsQELVGVFFRKNWLRLTW 7985 RSLsVEIVKFFRKNWLRLTW 7986RSLsVEIVYFFRKNWLRLTW 7987 RSMsMPVAHFFRKNWLRLTW 7988RSMsMPVAKFFRKNWLRLTW 7989 RsPEDEYELLMPHRISSHFFRKNWLRLTW 7990RSRRsPLLKFFRKNWLRLTW 7991 RSRRsPLLYFFRKNWLRLTW 7992RSRsPLELFFRKNWLRLTW 7993 RSRsPPPVSKFFRKNWLRLTW 7994RSRsPPPVSYFFRKNWLRLTW 7995 RSRsPRPAFFFRKNWLRLTW 7996RSRsPRPAIFFRKNWLRLTW 7997 RSRsPRPALFFRKNWLRLTW 7998RSRsPRPAMFFRKNWLRLTW 7999 RSRsPRPAVFFRKNWLRLTW 8000RSRsPRPAXFFRKNWLRLTW 8001 RSRTsPITRRFFRKNWLRLTW 8002RSRTsPITRYFFRKNWLRLTW 8003 RSSsLIRHKFFRKNWLRLTW 8004RSSsLIRHYFFRKNWLRLTW 8005 RSVsLSMRKFFRKNWLRLTW 8006RSVsLSMRYFFRKNWLRLTW 8007 RsWKYNQSISLRRPFFRKNWLRLTW 8008RSYsGSRsKFFRKNWLRLTW 8009 RSYsGSRsRFFRKNWLRLTW 8010RSYsGSRsYFFRKNWLRLTW 8011 RSYsPDHRQKFFRKNWLRLTW 8012RSYsPDHRQYFFRKNWLRLTW 8013 RSYsPERSKFFRKNWLRLTW 8014RSYsPERSYFFRKNWLRLTW 8015 RSYsPRNSRFFRKNWLRLTW 8016RSYsPRNSYFFRKNWLRLTW 8017 RSYSRsFSKFFRKNWLRLTW 8018RSYsRSFSRFFRKNWLRLTW 8019 RSYSRsFSRFFRKNWLRLTW 8020RSYSRsFSYFFRKNWLRLTW 8021 RSYsYPRQKFFRKNWLRLTW 8022RSYsYPRQYFFRKNWLRLTW 8023 RSYVTTSTRTYsLGFFRKNWLRLTW 8024RTAsFAVRKFFRKNWLRLTW 8025 RTAsFAVRYFFRKNWLRLTW 8026RTAsLIIKVFFRKNWLRLTW 8027 RTAsPPPPPKFFRKNWLRLTW 8028RTDPSKsPGSLRYFFRKNWLRLTW 8029 RTDsPKIDLFFRKNWLRLTW 8030RTDsPKIDYFFRKNWLRLTW 8031 RTDsRAQAVFFRKNWLRLTW 8032RTDsRAQAYFFRKNWLRLTW 8033 RTDsYVELSQYFFRKNWLRLTW 8034RTEPSKsPGSLRYFFRKNWLRLTW 8035 RTEsDSGLKFFFRKNWLRLTW 8036RTEsDSGLKKFFRKNWLRLTW 8037 RTEsDSGLKLFFRKNWLRLTW 8038RTEsDSGLKMFFRKNWLRLTW 8039 RTEsDSGLKVFFRKNWLRLTW 8040RTEsPKIDLFFRKNWLRLTW 8041 RTEsPKIDYFFRKNWLRLTW 8042RTEsRAQAVFFRKNWLRLTW 8043 RTEsRAQAYFFRKNWLRLTW 8044RTEsYVELSQYFFRKNWLRLTW 8045 RTFsLDTILFFRKNWLRLTW 8046RTFsPTYGFFFRKNWLRLTW 8047 RTFsPTYGLFFRKNWLRLTW 8048RTFsPTYGMFFRKNWLRLTW 8049 RTFsPTYGVFFRKNWLRLTW 8050RTHsLLLLLFFRKNWLRLTW 8051 RTLsHISEAFFRKNWLRLTW 8052RTLsHISEVFFRKNWLRLTW 8053 RTLsPEIITVFFRKNWLRLTW 8054RTMsEAALVRKFFRKNWLRLTW 8055 RTNsPGFQKFFRKNWLRLTW 8056RTPsDVKELFFRKNWLRLTW 8057 RTPsFLKKNKFFRKNWLRLTW 8058RTPsFLKKNYFFRKNWLRLTW 8059 RTRsLSSLREKFFRKNWLRLTW 8060RTRsLSSLREYFFRKNWLRLTW 8061 RTRsPSPTFFFRKNWLRLTW 8062RTRsPSPTLFFRKNWLRLTW 8063 RTRsPSPTMFFRKNWLRLTW 8064RTRsPSPTVFFRKNWLRLTW 8065 RTSsFALNLFFRKNWLRLTW 8066RTSsFTEQLFFRKNWLRLTW 8067 RTSsFTFQNFFRKNWLRLTW 8068RTSSFtFQNFFRKNWLRLTW 8069 RTSsPLFNKFFRKNWLRLTW 8070RTYKsPLRHFFRKNWLRLTW 8071 RTYKsPLRKFFRKNWLRLTW

8072 RTYKsPLRYFFRKNWLRLTW 8073 RTYsGPMNKFFRKNWLRLTW 8074RTYsGPMNKVFFRKNWLRLTW 8075 RTYsHGTYRFFRKNWLRLTW 8076RVAsFAVRKFFRKNWLRLTW 8077 RVAsFAVRYFFRKNWLRLTW 8078RVAsPLVHKFFRKNWLRLTW 8079 RVAsPLVHYFFRKNWLRLTW 8080RVAsPPPPPKFFRKNWLRLTW 8081 RVAsPPPPPYFFRKNWLRLTW 8082RVAsPTSGVFFRKNWLRLTW 8083 RVAsPTSGVKFFRKNWLRLTW 8084RVAsPTSGVKKFFRKNWLRLTW 8085 RVAsPTSGVKRFFRKNWLRLTW 8086RVAsPTSGVYFFRKNWLRLTW 8087 RVDsPSHGLFFRKNWLRLTW 8088RVGsLVLNLFFRKNWLRLTW 8089 RVIsGVLQLFFRKNWLRLTW 8090RVKLPsGSKKFFRKNWLRLTW 8091 RVKsPGsGHVKFFRKNWLRLTW 8092RVKsPGsGHVYFFRKNWLRLTW 8093 RVKsPISLKFFRKNWLRLTW 8094RVKsPSPKSERFFRKNWLRLTW 8095 RVKsPSPKSEYFFRKNWLRLTW 8096RVKtPTSQSYKFFRKNWLRLTW 8097 RVKtPTSQSYRFFRKNWLRLTW 8098RVKtPTSQSYYFFRKNWLRLTW 8099 RVKTtPLRRFFRKNWLRLTW 8100RVKTtPLRYFFRKNWLRLTW 8101 RVLDRSPsRSAKFFRKNWLRLTW 8102RVLDRSPsRSAYFFRKNWLRLTW 8103 RVLHsPPAVFFRKNWLRLTW 8104RVLsGWTKFFRKNWLRLTW 8105 RVLsPLIIKFFRKNWLRLTW 8106RVPsLLVLLFFRKNWLRLTW 8107 RVPsSTLKKFFRKNWLRLTW 8108RVPsSTLKYFFRKNWLRLTW 8109 RVRKLPsTTLFFRKNWLRLTW 8110RVRQsPLATKFFRKNWLRLTW 8111 RVRQsPLATRFFRKNWLRLTW 8112RVRQsPLATYFFRKNWLRLTW 8113 RVRRsSFLNAKFFRKNWLRLTW 8114RVRsLSSLREKFFRKNWLRLTW 8115 RVRsLSSLREYFFRKNWLRLTW 8116RVRsPTRSFFFRKNWLRLTW 8117 RVRsPTRSLFFRKNWLRLTW 8118RVRsPTRSMFFRKNWLRLTW 8119 RVRsPTRSPFFRKNWLRLTW 8120RVRsPTRSVFFRKNWLRLTW 8121 RVSsPISKKFFRKNWLRLTW 8122RVSsPISKYFFRKNWLRLTW 8123 RVSsRFSSKFFRKNWLRLTW 8124RVSsRFSSRFFRKNWLRLTW 8125 RVSsRFSSYFFRKNWLRLTW 8126RVSsVKLISRFFRKNWLRLTW 8127 RVSsVKLISYFFRKNWLRLTW 8128RVTsAEIKLFFRKNWLRLTW 8129 RWsLSMRKFFRKNWLRLTW 8130RWsLSMRYFFRKNWLRLTW 8131 RVWEDRPSsAFFRKNWLRLTW 8132RVWsPPRVHKVFFRKNWLRLTW 8133 RVYQyIQSRFFRKNWLRLTW 8134RVYQyIQSRFKFFRKNWLRLTW 8135 RVYQyIQSRFYFFRKNWLRLTW 8136RVYQyIQSRKFFRKNWLRLTW 8137 RVYQyIQSRYFFRKNWLRLTW 8138RVYsPYNHKFFRKNWLRLTW 8139 RVYsPYNHRFFRKNWLRLTW 8140RVYsPYNHYFFRKNWLRLTW 8141 RVYSRsFSKFFRKNWLRLTW 8142RVYSRsFSYFFRKNWLRLTW 8143 RYPsNLQLFFFRKNWLRLTW 8144RYQtQPVTLFFRKNWLRLTW 8145 SAARESHPHGVKRSAsPDDDLGFFRKNWLRLTW 8146SARGsPTRPNPPVRFFRKNWLRLTW 8147 SARRtPVSYFFRKNWLRLTW 8148sDDEKMPDLEFFRKNWLRLTW 8149 sDFHAERAAREKFFRKNWLRLTW 8150SDmPRAHsFFFRKNWLRLTW 8151 SDMPRAHsFFFRKNWLRLTW 8152SEFKAMDsIFFRKNWLRLTW 8153 SEGsLHRKFFFRKNWLRLTW 8154SEGsLHRKWFFRKNWLRLTW 8155 SEGsLHRKYFFRKNWLRLTW 8156SELsPGRSVFFRKNWLRLTW 8157 SFDsGSVRLFFRKNWLRLTW 8158SGGAQsPLRYLHVLFFRKNWLRLTW 8159 sGGDDDWTHLSSKEVDPSTFFRKNWLRLTW 8160sGGDDDWTHLSSKEVDPSTGFFRKNWLRLTW 8161sGGDDDWTHLSSKEVDPSTGEFFRKNWLRLTW 8162sGGDDDWTHLSSKEVDPSTGELFFRKNWLRLTW 8163sGGDDDWTHLSSKEVDPSTGELQFFRKNWLRLTW 8164SGPKPLFRRMsSLVGPTQFFRKNWLRLTW 8165 SIDsPQKLFFRKNWLRLTW 8166SIDsPQKYFFRKNWLRLTW 8167 SILsFVSGLFFRKNWLRLTW 8168SIMsFHIDLFFRKNWLRLTW 8169 SImsPEIQLFFRKNWLRLTW 8170SIMsPEIQLFFRKNWLRLTW 8171 SIPtVSGQIFFRKNWLRLTW 8172SISsMEVNVFFRKNWLRLTW 8173 SISStPPAVFFRKNWLRLTW 8174SKEDKNGHDGDTHQEDDGEKsDFFRKNWLRLTW 8175 SKRGyIGLFFRKNWLRLTW 8176SKtVATFILFFRKNWLRLTW 8177 SLAsLTEKIFFRKNWLRLTW 8178SLDSEDYsLFFRKNWLRLTW 8179 SLDsLGDVFLFFRKNWLRLTW 8180SLDsPSYVLYFFRKNWLRLTW 8181 SLEsPSYVLYFFRKNWLRLTW 8182SLFGGsVKLFFRKNWLRLTW 8183 SLFKRLYsLFFRKNWLRLTW 8184SLFsGDEENAFFRKNWLRLTW 8185 SLFsGSYSSLFFRKNWLRLTW 8186SLFsPQNTLFFRKNWLRLTW 8187 SLFsPRRNKFFRKNWLRLTW 8188SLFsPRRNYFFRKNWLRLTW 8189 SLFsSEESNLFFRKNWLRLTW 8190SLFsSEESNLGAFFRKNWLRLTW 8191 SLHDIQLsLFFRKNWLRLTW 8192SLKsPVTVKFFRKNWLRLTW 8193 SLLAsPGHISVFFRKNWLRLTW 8194SLLHTSRsLFFRKNWLRLTW 8195 SLLNKSsPVKFFRKNWLRLTW 8196SLLNKSsPVKKFFRKNWLRLTW

8197 SLLNKSsPVKYFFRKNWLRLTW 8198 SLLsLHVDLFFRKNWLRLTW 8199SLLTsPPKAFFRKNWLRLTW 8200 SLLTsPPKVFFRKNWLRLTW 8201SLMsGTLESLFFRKNWLRLTW 8202 SLMsPGRRKFFRKNWLRLTW 8203SLMsPGRRYFFRKNWLRLTW 8204 SLQPRSHsVFFRKNWLRLTW 8205SLQsLETSVFFRKNWLRLTW 8206 SLRRsVLMKFFRKNWLRLTW 8207SLRRsVLMYFFRKNWLRLTW 8208 SLSsLLVKLFFRKNWLRLTW 8209SLtRSPPRVFFRKNWLRLTW 8210 SLTRsPPRVFFRKNWLRLTW 8211SLVDGyFRLFFRKNWLRLTW 8212 SLYDRPAsYFFRKNWLRLTW 8213SLYsPVKKKFFRKNWLRLTW 8214 SMFsPRRNKFFRKNWLRLTW 8215SMKsPVTVKFFRKNWLRLTW 8216 SMLNKSsPVKFFRKNWLRLTW 8217SMLNKSsPVKKFFRKNWLRLTW 8218 SMLsQEIQTLFFRKNWLRLTW 8219SMLTsPPKAFFRKNWLRLTW 8220 SMLTsPPKVFFRKNWLRLTW 8221SMMsPGRRKFFRKNWLRLTW 8222 SMQPRSHsVFFRKNWLRLTW 8223SMRRsVLMKFFRKNWLRLTW 8224 SMSsLSREVFFRKNWLRLTW 8225SMtRSPPRVFFRKNWLRLTW 8226 SMTRsPPRVFFRKNWLRLTW 8227SMYsPVKKKFFRKNWLRLTW 8228 SNFKsPVKTIRFFRKNWLRLTW 8229SPAASISRLsGEQVDGKGFFRKNWLRLTW 8230 SPAsPKISFFFRKNWLRLTW 8231SPAsPKISLFFRKNWLRLTW 8232 SPAsPKISMFFRKNWLRLTW 8233SPAsPKISVFFRKNWLRLTW 8234 SPDsSQSSLFFRKNWLRLTW 8235sPEDEYELLMPHRISSHFFRKNWLRLTW 8236 SPEDEYELLMPHRIsSHFFRKNWLRLTW 8237SPEKAGRRsSFFFRKNWLRLTW 8238 SPEKAGRRsSLFFRKNWLRLTW 8239SPEKAGRRsSMFFRKNWLRLTW 8240 SPEKAGRRsSVFFRKNWLRLTW 8241sPERPFLAILGGAKVADKFFRKNWLRLTW 8242 sPERPFLAILGGAKVADKIQFFRKNWLRLTW8243 SPFKRQLsFFFRKNWLRLTW 8244 SPFKRQLsLFFRKNWLRLTW 8245SPFKRQLsMFFRKNWLRLTW 8246 SPFKRQLsVFFRKNWLRLTW 8247SPFLsKRSLFFRKNWLRLTW 8248 SPGLARKRsFFFRKNWLRLTW 8249SPGLARKRsLFFRKNWLRLTW 8250 SPGLARKRsMFFRKNWLRLTW 8251SPGLARKRsVFFRKNWLRLTW 8252 SPGsPRPAFFFRKNWLRLTW 8253SPGsPRPALFFRKNWLRLTW 8254 SPGsPRPAMFFRKNWLRLTW 8255SPGsPRPAVFFRKNWLRLTW 8256 SPKsPGLKAFFRKNWLRLTW 8257SPKsPGLKFFFRKNWLRLTW 8258 SPKsPGLKLFFRKNWLRLTW 8259SPKsPGLKMFFRKNWLRLTW 8260 SPKsPGLKVFFRKNWLRLTW 8261SPKsPTAAFFFRKNWLRLTW 8262 SPKsPTAALFFRKNWLRLTW 8263SPKsPTAAMFFRKNWLRLTW 8264 SPKsPTAAVFFRKNWLRLTW 8265SPLTKSIsLFFRKNWLRLTW 8266 sPPFPVPVYTRQAPKQVIKFFRKNWLRLTW 8267SPRAPVsPLKFFFRKNWLRLTW 8268 SPRERsPALFFRKNWLRLTW 8269SPRGEAsSLFFRKNWLRLTW 8270 SPRGEASsLFFRKNWLRLTW 8271SPRPPNsPSIFFRKNWLRLTW 8272 SPRRsLGLALFFRKNWLRLTW 8273SPRRsRSISFFFRKNWLRLTW 8274 SPRRsRSISFFFRKNWLRLTW 8275SPRRsRSIsLFFRKNWLRLTW 8276 SPRRsRSISLFFRKNWLRLTW 8277SPRRsRSIsMFFRKNWLRLTW 8278 SPRRsRSISMFFRKNWLRLTW 8279SPRRsRSIsVFFRKNWLRLTW 8280 SPRRsRSISVFFRKNWLRLTW 8281SPRsITSTFFFRKNWLRLTW 8282 SPRsITSTLFFRKNWLRLTW 8283SPRsITSTMFFRKNWLRLTW 8284 SPRsITSTPFFRKNWLRLTW 8285SPRsITSTVFFRKNWLRLTW 8286 SPRsPDRTLFFRKNWLRLTW 8287SPRsPGKPFFFRKNWLRLTW 8288 SPRsPGKPLFFRKNWLRLTW 8289SPRsPGKPMFFRKNWLRLTW 8290 SPRsPGKPVFFRKNWLRLTW 8291SPRsPGRSFFFRKNWLRLTW 8292 SPRsPGRSIFFRKNWLRLTW 8293SPRsPGRSLFFRKNWLRLTW 8294 SPRsPGRSMFFRKNWLRLTW 8295SPRsPGRSVFFRKNWLRLTW 8296 SPRsPGRSXFFRKNWLRLTW 8297SPRsPSGLRFFRKNWLRLTW 8298 SPRsPSTTYFFFRKNWLRLTW 8299SPRsPSTTYLFFRKNWLRLTW 8300 SPRSPsTTYLFFRKNWLRLTW 8301SPRsPSTTYMFFRKNWLRLTW 8302 SPRsPSTTYVFFRKNWLRLTW 8303SPRsSQLVFFRKNWLRLTW 8304 SPRtPVsPVKFFFRKNWLRLTW 8305SPRTPVsPVKFFFRKNWLRLTW 8306 SPRtPVsPVKLFFRKNWLRLTW 8307SPRTPVsPVKLFFRKNWLRLTW 8308 SPRtPVsPVKMFFRKNWLRLTW 8309SPRTPVsPVKMFFRKNWLRLTW 8310 SPRtPVsPVKVFFRKNWLRLTW 8311SPRTPVsPVKVFFRKNWLRLTW 8312 SPSsPSVRRQFFFRKNWLRLTW 8313SPSsPSVRRQLFFRKNWLRLTW 8314 SPSsPSVRRQMFFRKNWLRLTW 8315SPSsPSVRRQVFFRKNWLRLTW 8316 SPSTSRSGGsSRFFFRKNWLRLTW 8317SPSTSRSGGsSRLFFRKNWLRLTW 8318 SPSTSRSGGsSRMFFRKNWLRLTW 8319SPSTSRSGGsSRVFFRKNWLRLTW 8320 sPTRPNPPVRNLHFFRKNWLRLTW 8321SPVsPMKELFFRKNWLRLTW 8322 SPVsTRPLEPFFRKNWLRLTW

8323 SPVStRPLEPFFRKNWLRLTW 8324 SPWHQsFFFRKNWLRLTW 8325SPWHQsLFFRKNWLRLTW 8326 SPWHQsMFFRKNWLRLTW 8327 SPWHQsVFFRKNWLRLTW8328 SQIsPKSWGVFFRKNWLRLTW 8329 SRDKHsEYFFRKNWLRLTW 8330SREKHsEIFFRKNWLRLTW 8331 SREKHsElFFRKNWLRLTW 8332SRFNRRVsVFFRKNWLRLTW 8333 SRLTHLsFFFRKNWLRLTW 8334SRLTHLsKFFRKNWLRLTW 8335 SRLTHLsLFFRKNWLRLTW 8336SRLTHLsMFFRKNWLRLTW 8337 SRLTHLsRFFRKNWLRLTW 8338SRLTHLsYFFRKNWLRLTW 8339 SRMsPKAQFFFRKNWLRLTW 8340SRMsPKAQKFFRKNWLRLTW 8341 SRMsPKAQLFFRKNWLRLTW 8342SRMsPKAQMFFRKNWLRLTW 8343 SRMsPKAQRFFRKNWLRLTW 8344SRMsPKAQYFFRKNWLRLTW 8345 SRsSRSPYSRFFRKNWLRLTW 8346SRSsSVLsLFFRKNWLRLTW 8347 SRSSsVLSLFFRKNWLRLTW 8348SRSSSVLsLFFRKNWLRLTW 8349 SRTsPITRFFFRKNWLRLTW 8350SRTsPITRKFFRKNWLRLTW 8351 SRTsPITRLFFRKNWLRLTW 8352SRTsPITRMFFRKNWLRLTW 8353 SRTsPITRRFFRKNWLRLTW 8354SRTsPITRYFFRKNWLRLTW 8355 SRWsGSHQFFFRKNWLRLTW 8356SRWsGSHQKFFRKNWLRLTW 8357 SRWsGSHQRFFRKNWLRLTW 8358SRWsGSHQYFFRKNWLRLTW 8359 SRYsRsPYSFFFRKNWLRLTW 8360SRYsRSPYSFFFRKNWLRLTW 8361 SRYSRsPYSFFFRKNWLRLTW 8362SRYsRsPYSKFFRKNWLRLTW 8363 SRYsRSPYSFFFRKNWLRLTW 8364SRYSRsPYSFFFRKNWLRLTW 8365 SRYsRsPYSLFFRKNWLRLTW 8366SRYsRSPYSLFFRKNWLRLTW 8367 SRYSRsPYSLFFRKNWLRLTW 8368SRYsRsPYSMFFRKNWLRLTW 8369 SRYsRSPYSMFFRKNWLRLTW 8370SRYSRsPYSMFFRKNWLRLTW 8371 SRYsRsPYSRFFRKNWLRLTW 8372SRYsRSPYSRFFRKNWLRLTW 8373 SRYSRsPYSRFFRKNWLRLTW 8374SRYsRsPYSYFFRKNWLRLTW 8375 SRYsRSPYSYFFRKNWLRLTW 8376SRYSRsPYSYFFRKNWLRLTW 8377 SRYsRtsPYSRFFRKNWLRLTW 8378SSDIsPTRLFFRKNWLRLTW 8379 SSDIsPTRYFFRKNWLRLTW 8380SSDKHsEYFFRKNWLRLTW 8381 SSDPASQLsYFFRKNWLRLTW 8382SSDsETLRYFFRKNWLRLTW 8383 SSDsPQKLFFRKNWLRLTW 8384SSDsPQKYFFRKNWLRLTW 8385 SSDsPSYVLYFFRKNWLRLTW 8386SSDsPTNHFFFFRKNWLRLTW 8387 SSEIsPTRYFFRKNWLRLTW 8388SSEKHsEYFFRKNWLRLTW 8389 SSEPASQLsYFFRKNWLRLTW 8390SSEsETLRYFFRKNWLRLTW 8391 SSEsPQKLFFRKNWLRLTW 8392SSEsPQKYFFRKNWLRLTW 8393 SSEsPSYVLYFFRKNWLRLTW 8394SSEsPTNHFYFFRKNWLRLTW 8395 SSNGKMASRRsEEKEAGFFRKNWLRLTW 8396SSNGKMASRRsEEKEAGEIFFRKNWLRLTW 8397 SsPIMRKKVSLFFRKNWLRLTW 8398sSPPFPVPVYTRQAPKQVIKFFRKNWLRLTW 8399 SSsPTHAKSAHVFFRKNWLRLTW 8400SSsWRILGSKQSEHRPFFRKNWLRLTW 8401 STDIsPTRLFFRKNWLRLTW 8402STDIsPTRYFFRKNWLRLTW 8403 STDKHsEYFFRKNWLRLTW 8404STDPASQLsYFFRKNWLRLTW 8405 STDsETLRYFFRKNWLRLTW 8406STDsPQKYFFRKNWLRLTW 8407 STDsPSYVLYFFRKNWLRLTW 8408STDsPTNHFYFFRKNWLRLTW 8409 STEIsPTRLFFRKNWLRLTW 8410STEIsPTRYFFRKNWLRLTW 8411 STEKHsEYFFRKNWLRLTW 8412STEPASQLsYFFRKNWLRLTW 8413 STEsETLRYFFRKNWLRLTW 8414STEsPQKYFFRKNWLRLTW 8415 STEsPSYVLYFFRKNWLRLTW 8416STEsPTNHFYFFRKNWLRLTW 8417 STIQNsPTKKFFRKNWLRLTW 8418sTMSLNIITVFFRKNWLRLTW 8419 STMsLNIITVFFRKNWLRLTW 8420SVDIsPIRLFFRKNWLRLTW 8421 SVDIsPTRLFFRKNWLRLTW 8422SVDIsPTRYFFRKNWLRLTW 8423 SVFsPSFGLFFRKNWLRLTW 8424SVGsDYYIQLFFRKNWLRLTW 8425 SVKPRRTsLFFRKNWLRLTW 8426SVKsPVTVKFFRKNWLRLTW 8427 SVKsPVTVYFFRKNWLRLTW 8428SVLsPSFQLFFRKNWLRLTW 8429 SVMDsPKKLFFRKNWLRLTW 8430SVRRsVLMKFFRKNWLRLTW 8431 SVRRsVLMYFFRKNWLRLTW 8432SVRsLSLSLFFRKNWLRLTW 8433 SVYsGDFGNLEVFFRKNWLRLTW 8434SVYsPVKKKFFRKNWLRLTW 8435 SVYsPVKKYFFRKNWLRLTW 8436sYIEHIFEIFFRKNWLRLTW 8437 SYPsPVATSYFFRKNWLRLTW 8438sYQKVIELFFFRKNWLRLTW 8439 TDKYsKMMFFRKNWLRLTW 8440TEAsPESMLFFRKNWLRLTW 8441 THKGEIRGASTPFQFRAssPFFRKNWLRLTW 8442TIGEKKEPsDKSVDSFFRKNWLRLTW 8443 TKDKYMASRGQKAKsMEGFFRKNWLRLTW 8444TKsVKALSSLHGDDFFRKNWLRLTW 8445 TKsVKALSSLHGDDQFFRKNWLRLTW 8446TKsVKALSSLHGDDQDFFRKNWLRLTW 8447 TLAsPSVFKSTFFRKNWLRLTW

8448 TLAsPSVFKSVFFRKNWLRLTW 8449 TLLAsPMLKFFRKNWLRLTW 8450TLMERTVsLFFRKNWLRLTW 8451 TLSsPPPGLFFRKNWLRLTW 8452TMAsPGKDNYFFRKNWLRLTW 8453 TMAsPSVFKSTFFRKNWLRLTW 8454TMAsPSVFKSVFFRKNWLRLTW 8455 TMDsPGKDNYFFRKNWLRLTW 8456TMEsPGKDNYFFRKNWLRLTW 8457 TMMsPSQFLFFRKNWLRLTW 8458TPAQPQRRsFFFRKNWLRLTW 8459 TPAQPQRRsLFFRKNWLRLTW 8460TPAQPQRRsMFFRKNWLRLTW 8461 TPAQPQRRsVFFRKNWLRLTW 8462TPDPSKFFSQLsSEHGGDVFFRKNWLRLTW 8463 tPDPSKFFSQLSSEHGGDVQFFRKNWLRLTW8464 TPIsPGRASGFFFRKNWLRLTW 8465 TPIsPGRASGLFFRKNWLRLTW 8466TPIsPGRASGMFFRKNWLRLTW 8467 TPIsPGRASGVFFRKNWLRLTW 8468TPMKKHLsLFFRKNWLRLTW 8469 TPRsPPLGFFFRKNWLRLTW 8470TPRsPPLGLFFRKNWLRLTW 8471 TPRsPPLGLFFFRKNWLRLTW 8472TPRsPPLGLIFFRKNWLRLTW 8473 TPRsPPLGLLFFRKNWLRLTW 8474TPRsPPLGLMFFRKNWLRLTW 8475 TPRsPPLGLVFFRKNWLRLTW 8476TPRsPPLGMFFRKNWLRLTW 8477 TPRsPPLGVFFRKNWLRLTW 8478TQSSGKsSVFFRKNWLRLTW 8479 TRKtPESFLFFRKNWLRLTW 8480TRLsPAKIVLFFFRKNWLRLTW 8481 TRLsPAKIVLKFFRKNWLRLTW 8482TRLsPAKIVLRFFRKNWLRLTW 8483 TRLsPAKIVLYFFRKNWLRLTW 8484TSAsPGKDNYFFRKNWLRLTW 8485 TSDsPGKDNYFFRKNWLRLTW 8486TSDtPDYLLKYFFRKNWLRLTW 8487 TSEsPGKDNYFFRKNWLRLTW 8488TSEtPDYLLKYFFRKNWLRLTW 8489 TTAsPGKDNYFFRKNWLRLTW 8490TTDsPGKDNYFFRKNWLRLTW 8491 TTDtPDYLLKYFFRKNWLRLTW 8492TTEsPGKDNYFFRKNWLRLTW 8493 TTEtPDYLLKYFFRKNWLRLTW 8494TTKsVKALSSLHGFFRKNWLRLTW 8495 TTKsVKALSSLHGDDFFRKNWLRLTW 8496TTKsVKALSSLHGDDQFFRKNWLRLTW 8497 TTKsVKALSSLHGDDQDFFRKNWLRLTW 8498TTKsVKALSSLHGDDQDSFFRKNWLRLTW 8499 TTKsVKALSSLHGDDQDsEDFFRKNWLRLTW8500 TTKSVKALSSLHGDDQDsEDFFRKNWLRLTW 8501TTKsVKALSSLHGDDQDsEDEFFRKNWLRLTW 8502TTKSVKALSSLHGDDQDsEDEFFRKNWLRLTW 8503 TVFsPTLPAAFFRKNWLRLTW 8504TVMsNSSVIHLFFRKNWLRLTW 8505 VAKRLsLFFRKNWLRLTW 8506VAMPVKKSPRRSsSDEQGLSYSSLKNVFFRKNWLRLTW 8507 VIDsQELSKVFFRKNWLRLTW8508 VLDsPASKKFFRKNWLRLTW 8509 VLFPEsPARAFFRKNWLRLTW 8510VLFRtPLASVFFRKNWLRLTW 8511 VLFsSPPQMFFRKNWLRLTW 8512VLFSsPPQMFFRKNWLRLTW 8513 VLIENVAsLFFRKNWLRLTW 8514VLIGsPKKVFFRKNWLRLTW 8515 VLIGsPKKYFFRKNWLRLTW 8516VLKGsRSSELFFRKNWLRLTW 8517 VLKGsRSSEVFFRKNWLRLTW 8518VLKSRKssVTEEFFRKNWLRLTW 8519 VLKVMIGsPKFFRKNWLRLTW 8520VLKVMIGsPKKFFRKNWLRLTW 8521 VLKVMIGsPKKKFFRKNWLRLTW 8522VLLsPVPELFFRKNWLRLTW 8523 VLLsPVPEVFFRKNWLRLTW 8524VLMK(sPs)PALFFRKNWLRLTW 8525 VLMK(sPs)PAVFFRKNWLRLTW 8526VLQtPPYVKFFRKNWLRLTW 8527 VLQtPPYVKKFFRKNWLRLTW 8528VLQtPPYVKYFFRKNWLRLTW 8529 VLSDVIPsIFFRKNWLRLTW 8530VLSSLtPAKVFFRKNWLRLTW 8531 VLWDTPsIFFRKNWLRLTW 8532VLYsPQMALFFRKNWLRLTW 8533 VMFRtPLASVFFRKNWLRLTW 8534VMIGsKKVFFRKNWLRLTW 8535 VMIGsPKKVFFRKNWLRLTW 8536VMIGsPKKYFFRKNWLRLTW 8537 VMKVMIGsPKFFRKNWLRLTW 8538VMKVMIGsPKKFFRKNWLRLTW 8539 VMKVMIGsPKKKFFRKNWLRLTW 8540VMKVMIGsPKKYFFRKNWLRLTW 8541 VMLsPVPELFFRKNWLRLTW 8542VMLsPVPEVFFRKNWLRLTW 8543 VMQtPPYVKFFRKNWLRLTW 8544VMQtPPYVKKFFRKNWLRLTW 8545 VPHHGFEDWsQIRFFRKNWLRLTW 8546VPKSGRSSsLFFRKNWLRLTW 8547 VPKsPAFALFFRKNWLRLTW 8548VPLIRKKsLFFRKNWLRLTW 8549 VPNAPPAYEKLsAEQSPPPYFFRKNWLRLTW 8550VPREVLRLsFFFRKNWLRLTW 8551 VPREVLRLsLFFRKNWLRLTW 8552VPREVLRLsMFFRKNWLRLTW 8553 VPREVLRLsVFFRKNWLRLTW 8554VPRPERRsSLFFRKNWLRLTW 8555 VPRsPKHAHSSSFFFRKNWLRLTW 8556VPRsPKHAHSSSLFFRKNWLRLTW 8557 VPRsPKHAHSSSMFFRKNWLRLTW 8558VPRsPKHAHSSSVFFRKNWLRLTW 8559 VPStPKSSLFFRKNWLRLTW 8560VPTsPKSSLFFRKNWLRLTW 8561 VPVsPGQQLFFRKNWLRLTW 8562VRAsKDLAQFFRKNWLRLTW 8563 VRQsVTSFPDADAFHHQFFRKNWLRLTW 8564VSKVMIGsPKKVFFRKNWLRLTW 8565 VSKVMIGsPKKYFFRKNWLRLTW 8566VTQtPPYVKKFFRKNWLRLTW 8567 VTQtPPYVKYFFRKNWLRLTW 8568WDsPGQEVLFFRKNWLRLTW 8569 VYTyIQSRFFFRKNWLRLTW 8570WTHLsSKEVDPSFFRKNWLRLTW 8571 WTHLsSKEVDPSTGFFRKNWLRLTW 8572YARsVHEEFFFRKNWLRLTW 8573 YAVPRRGsLFFRKNWLRLTW

8574 YAYDGKDyIFFRKNWLRLTW 8575 YEGsPIKVFFRKNWLRLTW 8576YEKLsAEQSPPPFFRKNWLRLTW 8577 YFsPFRPYFFRKNWLRLTW 8578yIQSRFFFRKNWLRLTW 8579 YLAsLEKKLFFRKNWLRLTW 8580YLDsGIHSGFFRKNWLRLTW 8581 YLDsGIHsGAFFRKNWLRLTW 8582YLDsGIHSGAFFRKNWLRLTW 8583 YLDsGIHsGVFFRKNWLRLTW 8584YLDsGIHSGVFFRKNWLRLTW 8585 yLGLDVPVFFRKNWLRLTW 8586YLGsISTLVTLFFRKNWLRLTW 8587 YLIHsPMSLFFRKNWLRLTW 8588YLLsPLNTLFFRKNWLRLTW 8589 YLLsPTKLPSIFFRKNWLRLTW 8590YLLsPTKLPSVFFRKNWLRLTW 8591 yLQSRYYRAFFRKNWLRLTW 8592YLQsRYYRAFFRKNWLRLTW 8593 YLSDsDTEAKLFFRKNWLRLTW 8594YMDsGIHsGAFFRKNWLRLTW 8595 YMDsGIHSGAFFRKNWLRLTW 8596YMDsGIHsGVFFRKNWLRLTW 8597 YMDsGIHSGVFFRKNWLRLTW 8598YPDPHsPFAVFFRKNWLRLTW 8599 YPGGRRsSLFFRKNWLRLTW 8600YPLsPAKVNQYFFRKNWLRLTW 8601 YPLsPTKISEYFFRKNWLRLTW 8602YPLsPTKISQYFFRKNWLRLTW 8603 YPRsEDEVEGVMFFRKNWLRLTW 8604YPRsFDEVEGFFFRKNWLRLTW 8605 YPRsFDEVEGLFFRKNWLRLTW 8606YPRsFDEVEGMFFRKNWLRLTW 8607 YPRsFDEVEGVFFRKNWLRLTW 8608YPRsFDEVEGVFFFRKNWLRLTW 8609 YPRsFDEVEGVLFFRKNWLRLTW 8610YPRsFDEVEGVMFFRKNWLRLTW 8611 YPRsFDEVEGWFFRKNWLRLTW 8612YPSFRRsSLFFRKNWLRLTW 8613 YPSsPRKALFFRKNWLRLTW 8614YPSsPRKFFFRKNWLRLTW 8615 YPSsPRKLFFRKNWLRLTW 8616YPSsPRKMFFRKNWLRLTW 8617 YPSsPRKVFFRKNWLRLTW 8618YPYEFsPVKMFFRKNWLRLTW 8619 YQLsPTKLPSIFFRKNWLRLTW 8620YQLsPTKLPSVFFRKNWLRLTW 8621 YQRPFsPSAYFFRKNWLRLTW 8622YQRsFDEVEGFFFRKNWLRLTW 8623 YQRsFDEVEGLFFRKNWLRLTW 8624YQRsFDEVEGMFFRKNWLRLTW 8625 YQRsFDEVEGVFFRKNWLRLTW 8626YQRsFDEVEGVFFFRKNWLRLTW 8627 YQRsFDEVEGVLFFRKNWLRLTW 8628YQRsFDEVEGVMFFRKNWLRLTW 8629 YQRsFDEVEGWFFRKNWLRLTW 8630YRYsPQSFLFFRKNWLRLTW 8631 YTAGtPYKVFFRKNWLRLTW 8632YYTAGSSsPTHAKSAHVFFRKNWLRLTW 8810 RLLsAAENFLFFRKNWLRLTW Lowercases, t, and y indicate phosphorylated serine, phosphorylatedthreonine, and phosphorylated tyrosine, respectively. Lowercase cindicates that the cysteine is present in a cysteine-cysteinedisulfide bond. Lowercase m indicates oxidized methionine. (AcS)indicates an N-terminally acetylated serine. (sLss) indicates thatat least one serine residue in the amino acid sequence SLSS isphosphorylated. (sPs) indicates that at least one serine residue inthe amino acid sequence SPS is phosphorylated.

TABLE-US-00006 TABLE 6 Amino acid sequences of exemplary antigenicpolypeptides SEQ ID NO Amino Acid Sequence 8633ALTtsAHSVFFRKNLLRLTG 8634 ALTtSAHSVFFRKNLLRLTG 8635ALTTsAHSVFFRKNLLRLTG 8636 APP(sts)AAALFFRKNLLRLTG 8637APPsTSAAALFFRKNLLRLTG 8638 APPsTsAAALFFRKNLLRLTG 8639APPStSAAALFFRKNLLRLTG 8640 APPSTsAAALFFRKNLLRLTG 8641APPstSAAALFFRKNLLRLTG 8642 APPStsAAALFFRKNLLRLTG 8643APP<s>TSAAALFFRKNLLRLTG 8644 APPS<t>SAAALFFRKNLLRLTG8645 APPST<s>AAALFFRKNLLRLTG 8646APPS<t>sAAALFFRKNLLRLTG 8647APP<s><t>SAAALFFRKNLLRLTG 8648APP<s>T<s>AAALFFRKNLLRLTG 8649APPS<t><s>AAALFFRKNLLRLTG 8650APRG<n>VISLFFRKNLLRLIG 8651 APRtNGVAMFFRKNLLRLTG 8652APTsAAALFFRKNLLRLTG 8653 APTsASNVMFFRKNLLRLTG 8654APTSAsNVMFFRKNLLRLTG 8655 APVsASASVFFRKNLLRLTG 8656APVsSKSSLFFRKNLLRLTG 8657 EP(sst)VVSLFFRKNLLRLTG 8658EPsSTVVSLFFRKNLLRLTG 8659 EPSsTVVSLFFRKNLLRLTG 8660EPSStVVSLFFRKNLLRLTG 8661 GLSsLAEEAAFFRKNLLRLTG 8662HP(sss)AAVLFFRKNLLRLTG.sup.(i) 8663 HP(sst)ASTALFFRKNLLRLTG 8664HPMsTASQVFFRKNLLRLTG 8665 HPssTAAVLFFRKNLLRLTG 8666HPsStAAVLFFRKNLLRLTG 8667 HPSstAAVLFFRKNLLRLTG 8668HPsSTASTALFFRKNLLRLTG 8669 HPSsTASTALFFRKNLLRLTG 8670HPSStASTALFFRKNLLRLTG 8671 HPTtVASYFFRKNLLRLTG 8672IPIsLHTSLFFRKNLLRLTG 8673 IPTsSVLSLFFRKNLLRLTG 8674IPVsKPLSLFFRKNLLRLTG 8675 IPV<s>KPLSLFFRKNLLRLTG 8676IPVsSHNSLFFRKNLLRLTG 8677 IPVssHNSLFFRKNLLRLTG 8678IPV<s>SHNSLFFRKNLLRLTG 8679 IPV[s]SHNSLFFRKNLLRLTG 8680KPPtSQSSVLFFRKNLLRLTG 8681 KPP<t>SQSSVLFFRKNLLRLTG 8682KPPTsQSSVLFFRKNLLRLTG 8683 KPPT<s>QSSVLFFRKNLLRLTG 8684KPPV<s>FFSLFFRKNLLRLIG 8685 KPTLY<n>VSLFFRKNLLRLIG 8686LPRN(st)MMFFRKNLLRLTG 8687 LPRNstMMFFRKNLLRLTG 8688LPTsLPSSLFFRKNLLRLTG 8689 MPVRPT<t>NTFFFRKNLLRLTG 8690(diMe)MPVRPT<t>NTFFFRKNLL RLTG 8691 MPVtSSSFFFFRKNLLRLTG 8692NPVsLPSLFFRKNLLRLTG 8693 PPS<t>SAAALFFRKNLLRLTG 8694PPST<s>AAALFFRKNLLRLIG 8695 RPP(sss)QQLFFRKNLLRLTG 8696RPPItQSSLFFRKNLLRLTG 8697 (Me)RPPItQSSLFFRKNLLRLTG 8698(diME)RPPItQSSLFFRKNLLRLT G 8699 (diME)RPPI[t]QSSLFFRKNLLR LTG 8700RPPQ<s>SSVSLFFRKNLLRLTG 8701 RPPsSSQQLFFRKNLLRLTG 8702RPPSsSQQLFFRKNLLRLTG 8703 RPPSSsQQLFFRKNLLRLTG 8704RPPVtKASSFFFRKNLLRLTG 8705 RPVtASITTMFFRKNLLRLTG 8706TPASsRAQTLFFRKNLLRLTG 8707 TPAsSSSALFFRKNLLRLTG 8708TPIsQAQKLFFRKNLLRLTG 8709 TPVsSANMMFFRKNLLRLTG 8710VLTsNVQTIFFRKNLLRLTG 8711 VPAsSTSTLFFRKNLLRLTG 8712VPAtHGQVTYFFRKNLLRLTG 8713 VPtTSSSLFFRKNLLRLTG 8714VPTtSSSLFFRKNLLRLTG 8715 VPTTsSSLFFRKNLLRLTG 8716VPVsGTQGLFFRKNLLRLTG 8717 VPVsNQSSLFFRKNLLRLTG 8718VPVsSASELFFRKNLLRLTG 8719 VPVsVGPSLFFRKNLLRLTG Lowercase s and tindicate O-GlcNAcylated serine and O-GlcNAcylated threonine,respectively. (sts), (sss), (ts), (sst), and (st) indicates atleast one of the serine or threonine residues is modified withO-GlcNAc. .sup.(i)indicates that two GlcNAc moeities were detected,but could not be assigned to specific amino acids. (Me) indicatesmethylation of the following arginine. (diMe) indicates asymmetricdi-methylation of the following arginine. <n> indicateshexose-GlcNAcylated asparagine. <s> indicateshexose-GlcNAcylated serine. <t> indicates hexose-GlcNAcylatedthreonine. [s] indicates acetyl-GlcNAcylated serine. [t] indicatesacetyl-GlcNAcylated threonine.

TABLE-US-00007 TABLE 7 Amino acid sequences of exemplary antigenicpolypeptides SEQ ID NO Amino Acid Sequence 8720ALTtsAHSVFFRKNWLRLTW 8721 ALTtSAHSVFFRKNWLRLTW 8722ALTTsAHSVFFRKNWLRLTW 8723 APP(sts)AAALFFRKNWLRLTW 8724APPsTSAAALFFRKNWLRLTW 8725 APPsTsAAALFFRKNWLRLTW 8726APPStSAAALFFRKNWLRLTW 8727 APPSTsAAALFFRKNWLRLTW 8728APPstSAAALFFRKNWLRLTW 8729 APPStsAAALFFRKNWLRLTW 8730APP<s>TSAAALFFRKNWLRLTW 8731 APPS<t>SAAALFFRKNWLRLTW8732 APPST<s>AAALFFRKNWLRLTW 8733APPS<t>sAAALFFRKNWLRLTW 8734APP<s><t>SAAALFFRKNWLRLTW 8735APP<s>T<s>AAALFFRKNWLRLTW 8736APPS<t><s>AAALFFRKNWLRLTW 8737APRG<n>VISLFFRKNWLRLTW 8738 APRtNGVAMFFRKNWLRLTW 8739APTsAAALFFRKNWLRLTW 8740 APTsASNVMFFRKNWLRLTW 8741APTSAsNVMFFRKNWLRLTW 8742 APVsASASVFFRKNWLRLTW 8743APVsSKSSLFFRKNWLRLTW 8744 EP(sst)VVSLFFRKNWLRLTW 8745EPsSTVVSLFFRKNWLRLTW 8746 EPSsTVVSLFFRKNWLRLTW 8747EPSStVVSLFFRKNWLRLTW 8748 GLSsLAEEAAFFRKNWLRLTW 8749HP(sss)AAVLFFRKNWLRLTW.sup.(i) 8750 HP(sst)ASTALFFRKNWLRLTW 8751HPMsTASQVFFRKNWLRLTW 8752 HPssTAAVLFFRKNWLRLTW 8753HPsStAAVLFFRKNWLRLTW 8754 HPSstAAVLFFRKNWLRLTW 8755HPsSTASTALFFRKNWLRLTW 8756 HPSsTASTALFFRKNWLRLTW 8757HPSStASTALFFRKNWLRLTW 8758 HPTtVASYFFRKNWLRLTW 8759IPIsLHTSLFFRKNWLRLTW 8760 IPTsSVLSLFFRKNWLRLTW 8761IPVsKPLSLFFRKNWLRLTW 8762 IPV<s>KPLSLFFRKNWLRLTW 8763IPVsSHNSLFFRKNWLRLTW 8764 IPVssHNSLFFRKNWLRLTW 8765IPV<s>SHNSLFFRKNWLRLTW 8766 IPV[s]SHNSLFFRKNWLRLTW 8767KPPtSQSSVLFFRKNWLRLTW 8768 KPP<t>SQSSVLFFRKNWLRLTW 8769KPPTsQSSVLFFRKNWLRLTW 8770 KPPT<s>QSSVLFFRKNWLRLTW 8771KPPV<s>FFSLFFRKNWLRLTW 8772 KPTLY<n>VSLFFRKNWLRLTW 8773LPRN(st)MMFFRKNWLRLTW 8774 LPRNstMMFFRKNWLRLTW 8775LPTsLPSSLFFRKNWLRLTW 8776 MPVRPT<t>NIFFFRKNWLRLTW 8777(diMe)MPVRPT<t>NIFFFRKNW LRLTW 8778 MPVtSSSFFFFRKNWLRLTW 8779NPVsLPSLFFRKNWLRLTW 8780 PPS<t>SAAALFFRKNWLRLTW 8781PPST<s>AAALFFRKNWLRLTW 8782 RPP(sss)QQLFFRKNWLRLTW 8783RPPItQSSLFFRKNWLRLTW 8784 (Me)RPPItQSSLFFRKNWLRLTW 8785(diME)RPPItQSSLFFRKNWLRLT W 8786 (diME)RPPI[t]QSSLFFRKNWLR LTW 8787RPPQ<s>SSVSLFFRKNWLRLTW 8788 RPPsSSQQLFFRKNWLRLTW 8789RPPSsSQQLFFRKNWLRLTW 8790 RPPSSsQQLFFRKNWLRLTW 8791RPPVtKASSFFFRKNWLRLTW 8792 RPVtASITTMFFRKNWLRLTW 8793TPASsRAQTLFFRKNWLRLTW 8794 TPAsSSSALFFRKNWLRLTW 8795TPIsQAQKLFFRKNWLRLTW 8796 TPVsSANMMFFRKNWLRLTW 8797VLTsNVQTIFFRKNWLRLTW 8798 VPAsSTSTLFFRKNWLRLTW 8799VPAtHGQVTYFFRKNWLRLTW 8800 VPtTSSSLFFRKNWLRLTW 8801VPTtSSSLFFRKNWLRLTW 8802 VPTTsSSLFFRKNWLRLTW 8803VPVsGTQGLFFRKNWLRLTW 8804 VPVsNQSSLFFRKNWLRLTW 8805VPVsSASELFFRKNWLRLTW 8806 VPVsVGPSLFFRKNWLRLTW Lowercase s and tindicate O-GlcNAcylated serine and O-GlcNAcylated threonine,respectively. (sts), (sss), (ts), (sst), and (st) indicates atleast one of the serine or threonine residues is modified withO-GlcNAc. .sup.(i)indicates that two GlcNAc moeities were detected,but could not be assigned to specific amino acids. (Me) indicatesmethylation of the following arginine. (diMe) indicates asymmetricdi-methylation of the following arginine. <n> indicateshexose-GlcNAcylated asparagine. <s> indicateshexose-GlcNAcylated serine. <t> indicates hexose-GlcNAcylatedthreonine. [s] indicates acetyl-GlcNAcylated serine. [t] indicatesacetyl-GlcNAcylated threonine.

[0024] In certain embodiments, the instant disclosure provides: anantigenic polypeptide comprising an MHC-binding peptide comprisingan amino acid sequence selected from the group consisting of SEQ IDNOs: 98-3000 and 8808; and an HSP-binding peptide comprising theamino acid sequence ofX.sub.1X.sub.2X.sub.3X.sub.4X.sub.5X.sub.6X.sub.7 (SEQ ID NO: 1),wherein X.sub.1 is omitted, N, F, or Q; X.sub.2 is W, L, or F;X.sub.3 is L or I; X.sub.4 is R, L, or K; X.sub.5 is L, W, or I;X.sub.6 is T, L, F, K, R, or W; and X.sub.7 is W, G, K, or F.

[0025] In certain embodiments, the HSP-binding peptide comprisesthe amino acid sequence of: [0026] (a) X.sub.1LX.sub.2LTX.sub.3(SEQ ID NO: 2), wherein X.sub.1 is W or F; X.sub.2 is R or K; andX.sub.3 is W, F, or G; [0027] (b) NX.sub.1LX.sub.2LTX.sub.3 (SEQ IDNO: 3), wherein X.sub.1 is W or F; X.sub.2 is R or K; and X.sub.3is W, F, or G; [0028] (c) WLX.sub.1LTX.sub.2 (SEQ ID NO: 4),wherein X.sub.1 is R or K; and X.sub.2 is W or G; [0029] (d)NWLX.sub.1LTX.sub.2 (SEQ ID NO: 5), wherein X.sub.1 is R or K; andX.sub.2 is W or G; or [0030] (e)NWX.sub.1X.sub.2X.sub.3X.sub.4X.sub.5 (SEQ ID NO: 6), whereinX.sub.1 is L or I; X.sub.2 is L, R, or K; X.sub.3 is L or I;X.sub.4 is T, L, F, K, R, or W; and X.sub.5 is W or K.

[0031] In certain embodiments, the instant disclosure provides: anantigenic polypeptide comprising an WIC-binding peptide comprisingan amino acid sequence selected from the group consisting of SEQ IDNOs: 98-3000 and 8808, optionally wherein the amino acid sequenceof the WIC-binding peptide consists of an amino acid sequenceselected from the group consisting of SEQ ID NOs: 98-3000 and 8808;and an HSP-binding peptide comprising an amino acid sequenceselected from the group consisting of SEQ ID NOs: 1-42, optionallywherein the amino acid sequence of the HSP-binding peptide consistsof an amino acid sequence selected from the group consisting of SEQID NOs: 1-42.

[0032] In certain embodiments, the C-terminus of the WIC-bindingpeptide is linked (either directly or indirectly) to the N-terminusof the HSP-binding peptide. Accordingly, in certain embodiments,the antigenic polypeptide comprises an MHC-binding peptidecomprising an amino acid sequence selected from the groupconsisting of SEQ ID NOs: 98-3000 and 8808, and an HSP-bindingpeptide comprising an amino acid sequence selected from the groupconsisting of SEQ ID NOs: 1-42, wherein the C-terminus of theMHC-binding peptide is linked (either directly or indirectly) tothe N-terminus of the HSP-binding peptide.

[0033] In certain embodiments, the N-terminus of the MHC-bindingpeptide is linked (either directly or indirectly) to the C-terminusof the HSP-binding peptide. Accordingly, in certain embodiments,the antigenic polypeptide comprises an MHC-binding peptidecomprising an amino acid sequence selected from the groupconsisting of SEQ ID NOs: 98-3000 and 8808, and an HSP-bindingpeptide comprising an amino acid sequence selected from the groupconsisting of SEQ ID NOs: 1-42, wherein the N-terminus of theWIC-binding peptide is linked (either directly or indirectly) tothe C-terminus of the HSP-binding peptide.

[0034] In certain embodiments, the MHC-binding peptide is 8 to 50amino acids in length, optionally 8, 9, 10, 11, 12, 13, 14, 15, 16,17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33,34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or50 amino acids in length.

[0035] In certain embodiments, the HSP-binding peptide is 6, 7, 8,9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42,43, 44, 45, 46, 47, 48, 49, or 50 amino acids in length. In certainembodiments, the HSP-binding peptide is less than 7, 8, 9, 10, 11,12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28,29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45,46, 47, 48, 49, or 50 amino acids in length.

[0036] In certain embodiments, the HSP-binding peptide is linked tothe MHC-binding peptide via a chemical linker. Any chemical linkerscan be employed to link the HSP-binding peptide and the WIC-bindingpeptide. Exemplary chemical linkers include moieties generated fromchemical crosslinking (see, e.g., Wong, 1991, Chemistry of ProteinConjugation and Cross-Linking, CRC Press, incorporated herein byreference in its entirety), UV crosslinking, and click chemistryreactions (see, e.g., U.S. Patent Publication 20130266512, which isincorporated by reference herein in its entirety).

[0037] In certain embodiments, the HSP-binding peptide is linked tothe MHC-binding peptide via a peptide linker (e.g., a peptidelinker as disclosed herein). In certain embodiments, the peptidelinker comprises the amino acid sequence of SEQ ID NO: 43 or FR. Incertain embodiments, the amino acid sequence of the peptide linkerconsists of the amino acid sequence of SEQ ID NO: 43 or FR.

[0038] In certain embodiments, the C-terminus of the MHC-bindingpeptide is linked by the peptide linker of SEQ ID NO: 43 or FR tothe N-terminus of the HSP-binding peptide. Accordingly, in certainembodiments, the antigenic polypeptide comprises from N-terminus toC-terminus: an MHC-binding peptide comprising an amino acidsequence selected from the group consisting of SEQ ID NOs: 98-3000and 8808; the peptide linker of SEQ ID NO: 43 or FR; and anHSP-binding peptide comprising an amino acid sequence selected fromthe group consisting of SEQ ID NOs: 1-42. In certain embodiments,the amino acid sequence of the WIC-binding peptide consists of anamino acid sequence selected from the group consisting of SEQ IDNOs: 98-3000 and 8808, and the amino acid sequence of theHSP-binding peptide consists of an amino acid sequence selectedfrom the group consisting of SEQ ID NOs: 1-42.

[0039] In certain embodiments, the antigenic polypeptide comprisesan amino acid sequence selected from the group consisting of SEQ IDNOs: 3001-8806, 8809, and 8810. In certain embodiments, the aminoacid sequence of the antigenic polypeptide consists of an aminoacid sequence selected from the group consisting of SEQ ID NOs:3001-8806, 8809, and 8810. In certain embodiments, the antigenicpolypeptide consists of an amino acid sequence selected from thegroup consisting of SEQ ID NOs: 3001-8806, 8809, and 8810.

[0040] In certain embodiments, the N-terminus of the MHC-bindingpeptide is linked by the peptide linker of SEQ ID NO: 43 or FR tothe C-terminus of the HSP-binding peptide. Accordingly, in certainembodiments the antigenic polypeptide comprises from N-terminus toC-terminus: an HSP-binding peptide comprising an amino acidsequence selected from the group consisting of SEQ ID NOs: 1-42;the peptide linker of SEQ ID NO: 43 or FR; and an WIC-bindingpeptide comprising an amino acid sequence selected from the groupconsisting of SEQ ID NOs: 98-3000 and 8808. In certain embodiments,the amino acid sequence of the MHC-binding peptide consists of anamino acid sequence selected from the group consisting of SEQ IDNOs: 98-3000 and 8808, and the amino acid sequence of theHSP-binding peptide consists of an amino acid sequence selectedfrom the group consisting of SEQ ID NOs: 1-42.

[0041] In certain embodiments, the antigenic polypeptide comprisesan MHC-binding peptide comprising an amino acid sequence selectedfrom the group consisting of SEQ ID NOs: 98-3000 and 8808, andwherein the N-terminus of the MHC-binding peptide is linked to theC-terminus of an amino acid sequence selected from the groupconsisting of SEQ ID NOs: 74-97. In certain embodiments, the aminoacid sequence of the MHC-binding peptide consists of an amino acidsequence selected from the group consisting of SEQ ID NOs: 98-3000and 8808.

[0042] In certain embodiments, the antigenic polypeptide comprisesan MHC-binding peptide comprising an amino acid sequence selectedfrom the group consisting of SEQ ID NOs: 98-3000 and 8808, andwherein the C-terminus of the WIC-binding peptide is linked to theN-terminus of an amino acid sequence selected from the groupconsisting of SEQ ID NOs: 50-67. In certain embodiments, the aminoacid sequence of the MHC-binding peptide consists of an amino acidsequence selected from the group consisting of SEQ ID NOs: 98-3000and 8808.

[0043] In certain embodiments, the antigenic peptides disclosedherein are 8 to 100 amino acids, (e.g., 8, 9, 10, 11, 12, 13, 14,15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48,49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65,66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82,83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99,or 100 amino acids) in length. In certain embodiments, an antigenicpeptide is 8 to 50 amino acids in length.

[0044] In certain embodiments, the antigenic peptides disclosedherein are less than 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20,21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37,38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54,55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71,72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88,89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100 amino acids inlength.

[0045] In certain embodiments, the amino acid sequence of theantigenic polypeptides disclosed herein does not comprise more than8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41,42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58,59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75,76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92,93, 94, 95, 96, 97, 98, 99, or 100 contiguous amino acids of aprotein (e.g., a naturally occurring protein) that comprises anamino acid sequence selected from the group consisting of SEQ IDNO: 98-3000 and 8808.

[0046] In certain embodiments, the instant disclosure provides apolypeptide comprising an amino acid sequence selected from thegroup consisting of SEQ ID NOs: 3001-8806, 8809, and 8810. Incertain embodiments, the polypeptide is 15 to 100 amino acids inlength, optionally, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20,21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37,38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54,55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71,72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88,89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100 amino acids inlength. In certain embodiments, the amino acid sequence of theantigenic polypeptide consists of an amino acid sequence selectedfrom the group consisting of SEQ ID NOs: 3001-8806, 8809, and8810.

[0047] The antigenic polypeptide disclosed herein can comprise oneor more MHC-binding peptides. In certain embodiments, the antigenicpeptide comprises one MHC-binding peptides. In certain embodiments,the antigenic polypeptide comprises two or more (e.g., 3, 4, 5, 6,7, 8, 9, 10, or more) MHC-binding peptides. The two or moreMHC-binding peptides can be linked via a chemical linker or apeptide linker, wherein the peptide linker optionally comprises anamino acid sequence that can be recognized and/or cleaved by aprotease.

[0048] The skilled worker will appreciate that the antigenicpolypeptides disclosed herein also encompass derivatives ofantigenic polypeptides that are modified during or after synthesis.Such modifications include, but are not limited to: glycosylation,acetylation, methylation, phosphorylation (e.g., phosphorylation ofTyr, Ser, Thr, Arg, Lys, or His on a side chain hydroxyl or amine),formylation, or amidation (e.g., amidation of a C-terminal carboxylgroup); derivatization using reactive chemical groups (e.g.,derivatization of: free NH.sub.2, COOH, or OH groups); specificchemical cleavage (e.g., by cyanogen bromide, hydroxylamine,BNPS-Skatole, acid, NaBH.sub.4, or alkali hydrolysis); enzymaticcleavage (e.g., by trypsin, chymotrypsin, papain, V8 protease;oxidation; reduction; etc. Methods for effecting the foregoingmodification to antigenic polypeptides are well known in theart.

[0049] In certain embodiments, the antigenic polypeptide comprisesone or more modified amino acid residues (e.g., in the MHC-bindingpeptide portion of the antigenic polypeptide). In certainembodiments, the antigenic polypeptide comprises a phosphorylatedresidue (e.g., a Tyr, Ser, Thr, Arg, Lys, or His that has beenphosphorylated on a side chain hydroxyl or amine). In certainembodiments, the antigenic polypeptide comprises a phosphomimeticresidue (e.g., a mimetic of a Tyr, Ser, Thr, Arg, Lys, or His aminoacid that has been phosphorylated on a side chain hydroxyl oramine). Non-limiting examples of phosphomimetic groups includeO-boranophospho, borono, O-dithiophospho, phosphoramide,H-phosphonate, alkylphosphonate, phosphorothioate, phosphodithioateand phosphorofluoridate, any of which may be derivatized on Tyr,Thr, Ser, Arg, Lys, or His residues. In certain embodiments, an Aspor Glu residue is used as a phosphomimetic in place of aphospho-Tyr, phospho-Thr, phospho-Ser, phospho-Arg, phospho-Lysand/or phospho-His residue in a peptide. In certain embodiments,the phosphomimetic residue is a non-hydrolyzable analogue of aphosphorylated residue. Accordingly, in certain embodiments, theantigenic polypeptide comprises a phosphopeptide selected from thegroup consisting of SEQ ID NOs: 98-3000 and 8808, wherein aphosphorylated amino acid residue of the phosphopeptide is replacedby a non-hydrolyzable mimetic of the phosphorylated amino acidresidue.

[0050] The skilled worker will further appreciate that, in certainembodiments, the antigenic polypeptides disclosed herein cancomprise one or more natural and/or non-natural amino acids (e.g.,D-amino acids), and amino acid analogues and derivatives (e.g.,disubstituted amino acids, N-alkyl amino acids, lactic acid,4-hydroxyproline, .gamma.-carboxyglutamate,.epsilon.-N,N,N-trimethyllysine, .epsilon.-N-acetyllysine,0-phosphoserine, N-acetylserine, N-formylmethionine,3-methylhistidine, 5-hydroxylysine, .sigma.-N-methylarginine). Incertain embodiments, the antigenic polypeptides disclosed hereincomprise one or more retro-inverso peptides. A "retro-inversopeptide" refers to a peptide with a reversal of the peptidesequence in two or more positions and inversion of thestereochemistry from L to D configuration in chiral amino acids.Thus, a retro-inverso peptide has reversed termini, reverseddirection of peptide bonds, and reversed peptide sequence fromN-to-C-terminus, while approximately maintaining the topology ofthe side chains as in the native peptide sequence. Synthesis ofretro-inverso peptide analogues are described in Bonelli, F. etal., Int J Pept Protein Res. 24(6):553-6 (1984); Verdini, A andViscomi, G. C, J. Chem. Soc. Perkin Trans. 1:697-701 (1985); andU.S. Pat. No. 6,261,569, which are incorporated herein in theirentirety by reference.

6.2.1 Production of Antigenic Polypeptides by ChemicalSynthesis

[0051] Antigenic polypeptides disclosed herein can be synthesizedby standard chemical methods including the use of a peptidesynthesizer. Conventional peptide synthesis or other syntheticprotocols well known in the art can be used.

[0052] In certain embodiments, the polypeptide disclosed hereinconsists of amino acid residues (natural or non-natural) linked bypeptide bonds. Such polypeptides can be synthesized, for example,by solid-phase peptide synthesis using procedures similar to thosedescribed by Merrifield, 1963, J. Am. Chem. Soc., 85:2149,incorporated herein by reference in its entirety. During synthesis,N-.alpha.-protected amino acids having protected side chains areadded stepwise to a growing polypeptide chain linked by itsC-terminal end to an insoluble polymeric support i.e., polystyrenebeads. The polypeptides are synthesized by linking an amino groupof an N-.alpha.-deprotected amino acid to an .alpha.-carboxyl groupof an N-.alpha.-protected amino acid that has been activated byreacting it with a reagent such as dicyclohexylcarbodiimide or2-(6-Chloro-1-H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminiumhexafluorophosphate. The attachment of a free amino group to theactivated carboxyl leads to peptide bond formation. The mostcommonly used N-.alpha.-protecting groups include Boc which is acidlabile and Fmoc which is base labile. Details of appropriatechemistries, resins, protecting groups, protected amino acids andreagents are well known in the art (See, Atherton, et al., 1989,Solid Phase Peptide Synthesis: A Practical Approach, IRL Press, andBodanszky, 1993, Peptide Chemistry, A Practical Textbook, 2nd Ed.,Springer-Verlag, each of which is incorporated herein by referencein its entirety).

[0053] In addition, analogs and derivatives of polypeptides can bechemically synthesized as described supra. If desired, nonclassicalamino acids or chemical amino acid analogs can be introduced as asubstitution or addition into the peptide sequence. Non-classicalamino acids include, but are not limited to, the D-isomers of thecommon amino acids, .alpha.-amino isobutyric acid, 4-aminobutyricacid, hydroxyproline, sarcosine, citrulline, cysteic acid,t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine,.beta.-alanine, designer amino acids such as .beta.-methyl aminoacids, C-.alpha.-methyl amino acids, and N-.alpha.-methyl aminoacids.

[0054] Polypeptides phosphorylated on the side chains of Tyr, Ser,Thr, Arg, Lys, and His can be synthesized in Fmoc solid phasesynthesis using the appropriate side chain protected Fmoc-phosphoamino acid. In this way, polypeptides with a combination ofphosphorylated and non-phosphorylated Tyr, Ser, Thr, Arg, Lys, andHis residues can be synthesized. For example, the method ofStaerkaer et al can be applied (1991, Tetrahedron Letters 32:5389-5392). Other procedures (some for specific amino acids) aredetailed in De Bont et al. (1987, Tray. Chim Pays Bas 106: 641,642), Bannwarth and Trezeciak (1987, Helv. Chim. Acta 70: 175-186),Perich and Johns (1988, Tetrahedron Letters 29: 2369-2372), Kitaset al. (1990, J. Org. Chem. 55:4181-4187), Valerio et al. (1989,Int. J. Peptide Protein Res. 33:428-438), Perich et al. (1991,Tetrahedron Letters 32:4033-4034), Pennington (1994, Meth. Molec.Biol. 35:195-2), and Perich (1997, Methods Enzymol. 289:245-266,Chan et al. (2000, White, Fmoc Solid Phase Peptide Synthesis: APractical Approach, Oxford University Press), Graham et al. (1999,Org. Lett., Vol. 1, No. 5), Russell et al., (2008 Org. Biomol.Chem. (2008, Sep. 21; 6(18):3270-5), each of which is incorporatedherein by reference in its entirety).

[0055] A phosphorylated polypeptide can also be produced by firstculturing a cell transformed with a nucleic acid that encodes theamino acid sequence of the polypeptide. After producing such apolypeptide by cell culture, the hydroxyl groups of the appropriateamino acid are substituted by phosphate groups using organicsynthesis or enzymatic methods with phosphorylation enzymes. Forexample, in the case of serine-specific phosphorylation, serinekinases can be used.

[0056] Phosphopeptide mimetics can also be synthesized, wherein aphosphorylated amino acid residue in a polypeptide is replaced witha phosphomimetic group. Non-limiting examples of phosphomimeticgroups include O-boranophospho, borono, O-dithiophospho,phosphoramide, H-phosphonate, alkylphosphonate, phosphorothioate,phosphodithioate and phosphorofluoridate, any of which may bederivatized on Tyr, Thr, Ser, Arg, Lys, or His residues. In certainembodiments, an Asp or Glu residue is used as a phosphomimetic. Aspor Glu residues can also function as phosphomimetic groups, and beused in place of a phospho-Tyr, phospho-Thr, phospho-Ser,phospho-Arg, phospho-Lys and/or phospho-His residue in apeptide.

[0057] Purification of the resulting peptide is accomplished usingconventional procedures, such as preparative HPLC usingreverse-phase, gel permeation, partition and/or ion exchangechromatography. The choice of appropriate matrices and buffers arewell known in the art and so are not described in detailherein.

6.2.2 Production of Antigenic Polypeptides Using Recombinant DNATechnology

[0058] Polypeptides disclosed herein can also be prepared byrecombinant DNA methods known in the art. A nucleic acid sequenceencoding a polypeptide can be obtained by back translation of theamino acid sequence and synthesized by standard chemical methods,such as the use of an oligonucleotide synthesizer. Alternatively,coding information for polypeptides can be obtained from DNAtemplates using specifically designed oligonucleotide primers andPCR methodologies. Variations and fragments of the polypeptides canbe made by substitutions, insertions or deletions that provide forfunctionally equivalent molecules. Due to the degeneracy ofnucleotide coding sequences, DNA sequences which encode the same ora variant of a polypeptide may be used in the practice of thepresent invention. These include, but are not limited to,nucleotide sequences which are altered by the substitution ofdifferent codons that encode a functionally equivalent amino acidresidue within the sequence, thus producing a silent orconservative change. The nucleic acid encoding a polypeptide can beinserted into an expression vector for propagation and expressionin host cells.

[0059] As the coding sequence for peptides of the lengthcontemplated herein can be synthesized by chemical techniques, forexample, the phosphotriester method of Matteucci et al., J. Am.Chem. Soc. 103:3185 (1981) (incorporated herein by reference in itsentirety), modification can be made simply by substituting theappropriate base(s) for those encoding the native peptide sequence.The coding sequence can then be provided with appropriate linkersand ligated into expression vectors commonly available in the art,and the vectors used to transform suitable hosts to produce thedesired peptide or fusion protein. A number of such vectors andsuitable host systems are now available. For expression of thepeptide or fusion proteins, the coding sequence will be providedwith operably linked start and stop codons, promoter and terminatorregions and usually a replication system to provide an expressionvector for expression in the desired cellular host.

[0060] An expression construct refers to a nucleotide sequenceencoding a polypeptide operably linked with one or more regulatoryregions which enables expression of the peptide in an appropriatehost cell. "Operably-linked" refers to an association in which theregulatory regions and the peptide sequence to be expressed arejoined and positioned in such a way as to permit transcription, andultimately, translation.

[0061] The regulatory regions necessary for transcription of thepeptide can be provided by the expression vector. A translationinitiation codon (ATG) may also be provided if the peptide genesequence lacking its cognate initiation codon is to be expressed.In a compatible host-construct system, cellular transcriptionalfactors, such as RNA polymerase, will bind to the regulatoryregions on the expression construct to effect transcription of thepeptide sequence in the host organism. The precise nature of theregulatory regions needed for gene expression may vary from hostcell to host cell. Generally, a promoter is required which iscapable of binding RNA polymerase and promoting the transcriptionof an operably-associated nucleic acid sequence. Such regulatoryregions may include those 5' non-coding sequences involved withinitiation of transcription and translation, such as the TATA box,capping sequence, CAAT sequence, and the like. The non-codingregion 3' to the coding sequence may contain transcriptionaltermination regulatory sequences, such as terminators andpolyadenylation sites.

[0062] In order to attach DNA sequences with regulatory functions,such as promoters, to the peptide gene sequence or to insert thepeptide gene sequence into the cloning site of a vector, linkers oradapters providing the appropriate compatible restriction sites maybe ligated to the ends of the cDNAs by techniques well known in theart (Wu et al., 1987, Methods in Enzymol 152:343-349, incorporatedherein by reference in its entirety). Cleavage with a restrictionenzyme can be followed by modification to create blunt ends bydigesting back or filling in single-stranded DNA termini beforeligation. Alternatively, a desired restriction enzyme site can beintroduced into a fragment of DNA by amplification of the DNA byuse of PCR with primers containing the desired restriction enzymesite.

[0063] An expression construct comprising a polypeptide codingsequence operably linked with regulatory regions can be directlyintroduced into appropriate host cells for expression andproduction of the peptide without further cloning. The expressionconstructs can also contain DNA sequences that facilitateintegration of the DNA sequence into the genome of the host cell,e.g., via hom*ologous recombination. In this instance, it is notnecessary to use an expression vector comprising a replicationorigin suitable for appropriate host cells in order to propagateand express the peptide in the host cells.

[0064] A variety of expression vectors may be used includingplasmids, cosmids, phage, phagemids or modified viruses. Typically,such expression vectors comprise a functional origin of replicationfor propagation of the vector in an appropriate host cell, one ormore restriction endonuclease sites for insertion of the peptidegene sequence, and one or more selection markers. Expressionvectors may be constructed to carry nucleotide sequences for one ormore of the polypeptides disclosed herein. The expression vectormust be used with a compatible host cell which may be derived froma prokaryotic or eukaryotic organism including but not limited tobacteria, yeasts, insects, mammals and humans. Such host cells canbe transformed to express one or more polypeptides disclosedherein, such as by transformation of the host cell with a singleexpression vector containing a plurality of nucleotide sequencesencoding any of the polypeptides disclosed herein, or bytransformation of the host cell with multiple expression vectorsencoding different polypeptides disclosed herein.

[0065] In bacterial systems, a number of expression vectors may beadvantageously selected to produce polypeptides. For example, whena large quantity of such a protein is to be produced, such as forthe generation of pharmaceutical compositions, vectors that directthe expression of high levels of fusion protein products that arereadily purified may be desirable. Such vectors include the E. coliexpression vector pUR278 (Ruther et al., 1983, EMBO J. 2, 1791,incorporated herein by reference in its entirety), in which thepeptide coding sequence may be ligated individually into the vectorin frame with the lac Z coding region so that a fusion protein isproduced; pIN vectors (Inouye and Inouye, 1985, Nucleic Acids Res.13, 3101-3109; Van Heeke and Schuster, 1989, J. Biol. Chem 264,5503-5509, each of which is incorporated herein by reference in itsentirety); and the like. pGEX vectors may also be used to expressthese peptides as fusion proteins with glutathione S-transferase(GST). In general, such fusion proteins are soluble and can easilybe purified from lysed cells by adsorption to glutathione-agarosebeads followed by elution in the presence of free glutathione. ThepGEX vectors are designed to include thrombin or factor Xa proteasecleavage sites so that the polypeptide can be released from the GSTmoiety.

[0066] Alternatively, for long term, high yield production ofproperly processed peptide complexes, stable expression inmammalian cells is preferred. Cell lines that stably expresspeptide complexes may be engineered by using a vector that containsa selectable marker. By way of example, following the introductionof the expression constructs, engineered cells may be allowed togrow for 1-2 days in an enriched media, and then are switched to aselective media. The selectable marker in the expression constructconfers resistance to the selection and optimally allows cells tostably integrate the expression construct into their chromosomesand to grow in culture and to be expanded into cell lines. Suchcells can be cultured for a long period of time while the peptideis expressed continuously.

[0067] The recombinant cells may be cultured under standardconditions of temperature, incubation time, optical density andmedia composition. However, conditions for growth of recombinantcells may be different from those for expression of thepolypeptides. Modified culture conditions and media may also beused to enhance production of the peptides. For example,recombinant cells containing peptides with their cognate promotersmay be exposed to heat or other environmental stress, or chemicalstress. Any techniques known in the art may be applied to establishthe optimal conditions for producing peptide complexes.

[0068] In one embodiment disclosed herein, a codon encodingmethionine is added at the 5' end of the nucleotide sequenceencoding a polypeptide to provide a signal for initiation oftranslation of the peptide. This methionine may remain attached tothe polypeptide, or the methionine may be removed by the additionof an enzyme or enzymes that can catalyze the cleavage ofmethionine from the peptide. For example, in both prokaryotes andeukaryotes, N-terminal methionine is removed by a methionineaminopeptidase (MAP) (Tsunasawa et al., 1985, J. Biol. Chem. 260,5382-5391, incorporated herein by reference in its entirety).Methionine aminopeptidases have been isolated and cloned fromseveral organisms, including E. coli, yeast, and rat.

[0069] The peptide may be recovered from the bacterial, mammalian,or other host cell types, or from the culture medium, by knownmethods (see, for example, Current Protocols in Immunology, vol. 2,chapter 8, Coligan et al. (ed.), John Wiley & Sons, Inc.;Pathogenic and Clinical Microbiology: A Laboratory Manual byRowland et al., Little Brown & Co., June 1994, incorporatedherein by reference in its entirety).

[0070] Both of the foregoing methods can be used for synthesizing apolypeptide disclosed herein. For example, a peptide comprising theamino acid sequence of the HSP-binding peptide can be synthesizedchemically, and joined to an antigenic peptide, optionally producedby recombinant DNA technology, via a peptide bond.

[0071] Included within the scope disclosed herein are derivativesor analogs of the polypeptides disclosed herein that are modifiedduring or after translation, e.g., by glycosylation, acetylation,phosphorylation, amidation (e.g., of the C-terminal carboxylgroup), or derivatization by known protecting/blocking groups, orproteolytic cleavage. Any of numerous chemical modifications may becarried out by known techniques, including but not limited to,reagents useful for protection or modification of free NH.sub.2--groups, free COOH-- groups, OH-- groups, side groups of Trp-, Tyr-,Phe-, His-, Arg-, or Lys-; specific chemical cleavage by cyanogenbromide, hydroxylamine, BNPS-Skatole, acid, or alkali hydrolysis;enzymatic cleavage by trypsin, chymotrypsin, papain, V8 protease,NaBH.sub.4; acetylation, formylation, oxidation, reduction;metabolic synthesis in the presence of tunicamycin; etc.

6.3 Compositions Comprising Antigenic Polypeptides

[0072] In another aspect, the instant disclosure provides acomposition (e.g., a pharmaceutical composition, a vaccine, or aunit dosage form thereof) comprising one or more antigenicpolypeptide as disclosed herein. In certain embodiments, thecomposition comprises a plurality of the antigenic polypeptidesdisclosed herein. For example, in certain embodiments, thecomposition comprises 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48,49, or 50 different antigenic polypeptides as disclosed herein.

6.3.1 Compositions Comprising Antigenic Polypeptides in Complexwith Stress Proteins

[0073] In certain embodiments, the instant disclosure provides acomposition (e.g., a pharmaceutical composition) comprising one ormore antigenic polypeptides as disclosed herein and a purifiedstress protein. In certain embodiments, at least a portion of thepurified stress protein binds to the antigenic polypeptide in thecomposition. Such compositions are useful as vaccines for thetreatment of a cancer.

[0074] Stress proteins, which are also referred to interchangeablyherein as heat shock proteins (HSPs), useful in the practice of theinstant invention can be selected from among any cellular proteinthat is capable of binding other proteins or peptides and capableof releasing the bound proteins or peptides in the presence ofadenosine triphosphate (ATP) or under acidic conditions. Theintracellular concentration of such protein may increase when acell is exposed to a stressful stimulus. In addition to those heatshock proteins that are induced by stress, the HSP60, HSP70, HSP90,HSP100, sHSPs, and PDI families also include proteins that arerelated to stress-induced HSPs in sequence similarity, for example,having greater than 35% amino acid identity, but whose expressionlevels are not altered by stress. Therefore, stress protein or heatshock protein embraces other proteins, mutants, analogs, andvariants thereof having at least 35% (e.g., at least 40, 45, 50,55, 60, 65, 70, 75, 80, 85, 90, 95, or 99%) amino acid identitywith members of these families whose expression levels in a cellare enhanced in response to a stressful stimulus. Accordingly, incertain embodiments, the stress protein is a member of the hsp60,hsp70, or hsp90 family of stress proteins (e.g., Hsc70, humanHsc70), or a mutant, analog, or variant thereof. In certainembodiments, the stress protein is selected from the groupconsisting of hsc70, hsp70, hsp90, hsp110, grp170, gp96,calreticulin, a mutant thereof, and combinations of two or morethereof. In certain embodiments, the stress protein is Hsc70 (e.g.,human Hsc70). In certain embodiments, the stress protein comprisesthe amino acid sequence of SEQ ID NO: 8807. In certain embodiments,the amino acid sequence of the stress protein consists of the aminoacid sequence of SEQ ID NO: 8807. In certain embodiments, thestress protein is Hsp70 (e.g., human Hsp70). In certainembodiments, the stress protein (e.g., human hsc70) is arecombinant protein.

[0075] Amino acid sequences and nucleotide sequences of naturallyoccurring HSPs are generally available in sequence databases, suchas GenBank. For example, hom*o sapiens heat shock protein HSP70(Heat Shock 70 kDa Protein 1A) has the following identifiers HGNC:5232; Entrez Gene: 3303; Ensembl: ENSG00000204389; OMIM: 140550;UniProtKB: P08107 and NCBI Reference Sequence: NM_005345.5.Computer programs, such as Entrez, can be used to browse thedatabase, and retrieve any amino acid sequence and genetic sequencedata of interest by accession number. These databases can also besearched to identify sequences with various degrees of similaritiesto a query sequence using programs, such as FASTA and BLAST, whichrank the similar sequences by alignment scores and statistics.Nucleotide sequences of non-limiting examples of HSPs that can beused for preparation of the HSP peptide-binding fragments disclosedherein are as follows: human Hsp70, Genbank Accession No.NM_005345, Sargent et al., 1989, Proc. Natl. Acad. Sci. U.S.A.,86:1968-1972; human Hsc70: Genbank Accession Nos. P11142, Y00371;human Hsp90, Genbank Accession No. X15183, Yamazaki et al., Nucl.Acids Res. 17:7108; human gp96: Genbank Accession No. X15187, Makiet al., 1990, Proc. Natl. Acad Sci., 87: 5658-5562; human BiP:Genbank Accession No. M19645; Ting et al., 1988, DNA 7: 275-286;human Hsp27, Genbank Accession No. M24743; Hickey et al., 1986,Nucleic Acids Res. 14:4127-45; mouse Hsp70: Genbank Accession No.M35021, Hunt et al., 1990, Gene, 87:199-204; mouse gp96: GenbankAccession No. M16370, Srivastava et al., 1987, Proc. Natl. Acad.Sci., 85:3807-3811; and mouse BiP: Genbank Accession No. U16277,Haas et al., 1988, Proc. Natl. Acad. Sci. U.S.A., 85: 2250-2254(each of these references is incorporated herein by reference inits entirety).

[0076] In addition to the major stress protein families describedabove, an endoplasmic reticulum resident protein, calreticulin, hasalso been identified as yet another heat shock protein useful foreliciting an immune response when complexed to antigenic molecules(Basu and Srivastava, 1999, J. Exp. Med. 189:797-202; incorporatedherein by reference in its entirety). Other stress proteins thatcan be used in the invention include grp78 (or BiP), proteindisulfide isomerase (PDI), hsp110, and grp170 (Lin et al., 1993,Mol. Biol. Cell, 4:1109-1119; Wang et al., 2001, J. Immunol.,165:490-497, each of which is incorporated herein by reference inits entirety). Many members of these families were foundsubsequently to be induced in response to other stressful stimuliincluding nutrient deprivation, metabolic disruption, oxygenradicals, hypoxia and infection with intracellular pathogens (seeWelch, May 1993, Scientific American 56-64; Young, 1990, Annu. Rev.Immunol. 8:401-420; Craig, 1993, Science 260:1902-1903; Gething, etal., 1992, Nature 355:33-45; and Lindquist, et al., 1988, Annu.Rev. Genetics 22:631-677, each of which is incorporated herein byreference in its entirety). It is contemplated that HSPs/stressproteins belonging to all of these families can be used in thepractice disclosed herein. In certain embodiments, a stress proteinencompasses any chaperone protein that facilitates peptide-WICpresentation. Suitable chaperone proteins include, but are notlimited to, ER chaperones and tapasin (e.g., human tapasin).

[0077] The major stress proteins can accumulate to very high levelsin stressed cells, but they occur at low to moderate levels incells that have not been stressed. For example, the highlyinducible mammalian hsp70 is hardly detectable at normaltemperatures but becomes one of the most actively synthesizedproteins in the cell upon heat shock (Welch, et al., 1985, J. Cell.Biol. 101:1198-1211, incorporated herein by reference in itsentirety). In contrast, hsp90 and hsp60 proteins are abundant atnormal temperatures in most, but not all, mammalian cells and arefurther induced by heat (Lai, et al., 1984, Mol. Cell. Biol.4:2802-10; van Bergen en Henegouwen, et al., 1987, Genes Dev.1:525-31, each of which is incorporated herein by reference in itsentirety).

[0078] In various embodiments, nucleotide sequences encoding heatshock protein within a family or variants of a heat shock proteincan be identified and obtained by hybridization with a probecomprising nucleotide sequence encoding an HSP under conditions oflow to medium stringency. By way of example, procedures using suchconditions of low stringency are as follows (see also Shilo andWeinberg, 1981, Proc. Natl. Acad. Sci. USA 78:6789-6792). Filterscontaining DNA are pretreated for 6 h at 40.degree. C. in asolution containing 35% formamide, 5.times.SSC, 50 mM Tris-HCl (pH7.5), 5 mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA, and 500 .mu.g/mldenatured salmon sperm DNA. Hybridizations are carried out in thesame solution with the following modifications: 0.02% PVP, 0.02%Ficoll, 0.2% BSA, 100 .mu.g/ml salmon sperm DNA, 10% (wt/vol)dextran sulfate. Filters are incubated in hybridization mixture for18-20 h at 40.degree. C., and then washed for 1.5 h at 55.degree.C. in a solution containing 2.times.SSC, 25 mM Tris-HCl (pH 7.4), 5mM EDTA, and 0.1% SDS. The wash solution is replaced with freshsolution and incubated an additional 1.5 h at 60.degree. C. Filtersare blotted dry and exposed for signal detection. If necessary,filters are washed for a third time at 65-68.degree. C. beforesignal detection. Other conditions of low stringency which may beused are well known in the art (e.g., as used for cross-specieshybridizations).

[0079] Where stress proteins are used, peptide-binding fragments ofstress proteins and functionally active derivatives, analogs, andvariants thereof can also be used. Accordingly, in certainembodiments, the stress protein is a full-length HSP. In certainembodiments, the stress protein is a polypeptide comprising adomain of an HSP (e.g., a member of the Hsp60, Hsp70, or Hsp90family, such as Hsc70, particularly human Hsc70), wherein thedomain is capable of being noncovalently associated with a peptide(e.g., an HSP-binding peptide as described herein) to form acomplex and optionally eliciting an immune response, and whereinthe stress protein is not a full-length HSP.

[0080] In certain embodiments, the stress protein is a polypeptidethat is capable of being noncovalently associated with a peptide(e.g., an HSP-binding peptide as described herein) to form acomplex and optionally eliciting an immune response, wherein thestress protein shares a high degree of sequence similarity with awild-type HSP (e.g., a member of the Hsp60, Hsp70, or Hsp90 family,such as Hsc70, particularly human Hsc70). To determine a region ofidentity between two amino acid sequences or nucleic acidsequences, the sequences are aligned for optimal comparisonpurposes (e.g., gaps can be introduced in the sequence of a firstamino acid or nucleic acid sequence for optimal alignment with asecond amino or nucleic acid sequence). The amino acid residues ornucleotides at corresponding amino acid positions or nucleotidepositions are then compared. When a position in the first sequenceis occupied by the same amino acid residue or nucleotide as thecorresponding position in the second sequence, then the moleculesare identical at that position. The percent identity between thetwo sequences is a function of the number of identical positionsshared by the sequences (i.e., % identity=number of identicaloverlapping positions/total number of positions.times.100%). In oneembodiment, the two sequences are the same length.

[0081] The determination of percent identity between two sequencescan also be accomplished using a mathematical algorithm. Anon-limiting example of a mathematical algorithm utilized for thecomparison of two sequences is the algorithm of Karlin andAltschul, 1990, Proc. Natl. Acad. Sci. USA 87:2264-2268, modifiedas in Karlin and Altschul, 1993, Proc. Natl. Acad. Sci. USA90:5873-5877 (each of which is incorporated herein by reference inits entirety). Such an algorithm is incorporated into the NBLASTand XBLAST programs of Altschul, et al., 1990, J. Mol. Biol.215:403-410 (incorporated herein by reference in its entirety).BLAST nucleotide searches can be performed with the NBLAST program,e.g., score=100, wordlength=12 to obtain nucleotide sequenceshom*ologous to a nucleic acid molecule disclosed herein. BLASTprotein searches can be performed with the XBLAST program, e.g.,score=50, wordlength=3 to obtain amino acid sequences hom*ologous toa protein molecule disclosed herein. To obtain gapped alignmentsfor comparison purposes, Gapped BLAST can be utilized as describedin Altschul et al., 1997, Nucleic Acids Res. 25:3389-3402.Alternatively, PSI-Blast can be used to perform an iterated searchwhich detects distant relationships between molecules (Altschul etal., 1997, supra). When utilizing BLAST, Gapped BLAST, andPSI-Blast programs, the default parameters of the respectiveprograms (e.g., XBLAST and NBLAST) can be used. Another example ofa mathematical algorithm utilized for the comparison of sequencesis the algorithm of Myers and Miller, 1988, CABIOS 4:11-17. Such analgorithm is incorporated into the ALIGN program (version 2.0)which is part of the GCG sequence alignment software package. Whenutilizing the ALIGN program for comparing amino acid sequences, aPAM120 weight residue table, a gap length penalty of 12, and a gappenalty of 4 can be used. The percent identity between twosequences can be determined using techniques similar to thosedescribed above, with or without allowing gaps. In calculatingpercent identity, typically only exact matches are counted.

[0082] In certain embodiments, isolated peptide-binding domains ofa stress protein (e.g., Hsp70 or Hsc70) are employed. Thesepeptide-binding domains can be identified by computer modeling ofthe three-dimensional structure of the peptide-binding site of astress protein (e.g., Hsp70 and Hsc70). See for example, thepeptide-binding fragments of HSPs disclosed in United States patentpublication US 2001/0034042 (incorporated herein by reference inits entirety).

[0083] In certain embodiments, the stress protein is a mutatedstress protein which has an affinity for a target polypeptide thatis greater than a native stress protein. Such mutated stressproteins can be useful when the target polypeptide isphosphorylated or is a phosphopeptide mimetic (such asnon-hydrolyzable analogs) or has some other post-translationalmodification.

[0084] The stress proteins can be prepared by purification fromtissues, or by recombinant DNA techniques. HSPs can be purifiedfrom tissues in the presence of ATP or under acidic conditions (pH1 to pH 6.9), for subsequent in vitro complexing to one or morepolypeptides. See Peng, et al., 1997, J. Immunol. Methods,204:13-21; Li and Srivastava, 1993, EMBO J. 12:3143-3151 (each ofthese references is incorporated herein by reference in itsentirety). "Purified" stress proteins are substantially free ofmaterials that are associated with the proteins in a cell, in acell extract, in a cell culture medium, or in an individual. Incertain embodiments, the stress protein purified from a tissue is amixture of different HSPs, for example, hsp70 and hsc70.

[0085] Using the defined amino acid or cDNA sequences of a givenHSP or a peptide-binding domain thereof, one can make a geneticconstruct which is transfected into and expressed in a host cell.The recombinant host cells may contain one or more copies of anucleic acid sequence comprising a sequence that encodes an HSP ora peptide-binding fragment, operably linked with regulatoryregion(s) that drives the expression of the HSP nucleic acidsequence in the host cell. Recombinant DNA techniques can bereadily utilized to generate recombinant HSP genes or fragments ofHSP genes, and standard techniques can be used to express such HSPgene fragments. Any nucleic acid sequence encoding an HSPpeptide-binding domain, including cDNA and genomic DNA, can be usedto prepare the HSPs or peptide-binding fragments disclosed herein.The nucleic acid sequence can be wild-type or a codon-optimizedvariant that encodes the same amino acid sequence. An HSP genefragment containing the peptide-binding domain can be inserted intoan appropriate cloning vector and introduced into host cells sothat many copies of the gene sequence are generated. A large numberof vector-host systems known in the art may be used such as, butnot limited to, bacteriophages such as lambda derivatives, orplasmids such as pBR322, pUC plasmid derivatives, the Bluescriptvectors (Stratagene) or the pET series of vectors (Novagen). Anytechnique for mutagenesis known in the art can be used to modifyindividual nucleotides in a DNA sequence, for purpose of makingamino acid substitution(s) in the expressed peptide sequence, orfor creating/deleting restriction sites to facilitate furthermanipulations.

[0086] The stress proteins may be expressed as fusion proteins tofacilitate recovery and purification from the cells in which theyare expressed. For example, the stress proteins may contain asignal sequence leader peptide to direct its translocation acrossthe endoplasmic reticulum membrane for secretion into culturemedium. Further, the stress protein may contain an affinity labelfused to any portion of the protein not involved in binding to atarget polypeptide, for example, the carboxyl terminus. Theaffinity label can be used to facilitate purification of theprotein, by binding to an affinity partner molecule. A variety ofaffinity labels known in the art may be used, non-limiting examplesof which include the immunoglobulin constant regions, polyhistidinesequence (Petty, 1996, Metal-chelate affinity chromatography, inCurrent Protocols in Molecular Biology, Vol. 2, Ed. Ausubel et al.,Greene Publish. Assoc. & Wiley Interscience, incorporatedherein by reference in its entirety), glutathione S-transferase(GST; Smith, 1993, Methods Mol. Cell Bio. 4:220-229, incorporatedherein by reference in its entirety), the E. coli maltose bindingprotein (Guan et al., 1987, Gene 67:21-30, incorporated herein byreference in its entirety), and various cellulose binding domains(U.S. Pat. Nos. 5,496,934; 5,202,247; 5,137,819; Tomme et al.,1994, Protein Eng. 7:117-123, each of which is incorporated hereinby reference in its entirety).

[0087] Such recombinant stress proteins can be assayed for peptidebinding activity (see, e.g., Klappa et al., 1998, EMBO J.,17:927-935, incorporated herein by reference in its entirety) fortheir ability to elicit an immune response. In certain embodiments,the recombinant stress protein produced in the host cell is of thesame species as the intended recipient of the immunogeniccomposition (e.g., human).

[0088] The stress protein may be bound to the polypeptide(s)non-covalently or covalently. In certain embodiments, the stressprotein is non-covalently bound to the polypeptide. Methods ofpreparing such complexes are set forth infra.

[0089] The molar ratio of total polypeptide(s) to total stressprotein(s) can be any ratio from about 0.01:1 to about 100:1,including but not limited to about 0.01:1, 0.02:1, 0.05:1. 0.1:1.0.2:1, 0.5:1, 1:1, 1.5:1, 2:1, 2.5:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1,9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1,20:1, 30:1, 40:1, 49:1, up to 100:1. In certain embodiments, thecomposition comprises a plurality of complexes each comprising apolypeptide disclosed herein and a stress protein, wherein themolar ratio of the polypeptide to the stress protein in eachcomplex is at least about 1:1 (e.g., about 1.5:1, 2:1, 2.5:1, 3:1,4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1,16:1, 17:1, 18:1, 19:1, 20:1, 30:1, 40:1, 49:1, up to 100:1).

[0090] In certain embodiments, the molar ratio of totalpolypeptide(s) to total stress protein(s) is about 0.5:1 to 5:1. Incertain embodiments, the molar ratio of total polypeptide(s) tototal stress protein(s) is about 1:1 to 2:1. In certainembodiments, the molar ratio of total polypeptide(s) to totalstress protein(s) is about 1:1, 1.25:1, 1.5:1, 2:1, 2.5:1, 3:1,3.5:1, 4:1, 4.5:1, or 5:1. Such ratios, particularly the ratiosclose to 1:1, are advantageous in that the composition does notcomprise a great excess of free peptide(s) that is not bound to astress protein. Since many antigenic peptides comprisingWIC-binding peptides tend to comprise hydrophobic regions, anexcess amount of free peptide(s) may tend to aggregate duringpreparation and storage of the composition. Substantialcomplexation with a stress protein at a molar ratio of totalpolypeptide(s) to total stress protein(s) close to 1:1 (e.g., 1:1,1.25:1, 1.5:1, or 2:1) is enabled by a high binding affinity of thepolypeptide to the stress protein. Accordingly, in certainembodiments, the polypeptide binds to an HSP (e.g., Hsc70, Hsp70,Hsp90, Hsp110, Grp170, Gp96, or Calreticulin) with a K.sub.d lowerthan 10.sup.-3 M, 10.sup.-4 M, 10.sup.-5 M, 10.sup.-6 M, 10.sup.-7M, 10.sup.-8 M, or 10.sup.-9 M. In certain embodiments, thepolypeptide binds to Hsc70 (e.g., human Hsc70) with a K.sub.d of10.sup.-3 M, 10.sup.-4 M, 10.sup.-5 M, 10.sup.-6 M, 10.sup.-7 M,10.sup.-8M, 10.sup.-9M, or lower.

[0091] In certain embodiments, at least 40%, 45%, 50%, 55%, 60%,65%, 70%, 75%, 80%, 85%, 90%, or 95% of the stress protein binds tothe polypeptide in the composition. In certain embodiments,substantially all of the stress protein binds to the polypeptide inthe composition.

[0092] Any number of different polypeptides can be included in asingle composition as disclosed herein. In certain embodiments, thecompositions comprise no more than 100 different polypeptides,e.g., 2-50, 2-30, 2-20, 5-20, 5-15, 5-10, or 10-15 differentpolypeptides.

[0093] In certain embodiments, each of the antigenic polypeptidescomprises the same HSP-binding peptide and a different antigenicpeptide. In certain embodiments, the composition comprises a singlestress protein, wherein the stress protein is capable of binding tothe HSP-binding peptide.

[0094] Pharmaceutical compositions comprising the complexes ofstress proteins and antigenic polypeptides disclosed herein can beformulated to contain one or more pharmaceutically acceptablecarriers or excipients including bulking agents, stabilizingagents, buffering agents, sodium chloride, calcium salts,surfactants, antioxidants, chelating agents, other excipients, andcombinations thereof.

[0095] Bulking agents are preferred in the preparation oflyophilized formulations of the composition. Such bulking agentsform the crystalline portion of the lyophilized product and may beselected from the group consisting of mannitol, glycine, alanine,and hydroxyethyl starch (HES).

[0096] Stabilizing agents may be selected from the group consistingof sucrose, trehalose, raffinose, and arginine. These agents arepreferably present in amounts between 1-4%. Sodium chloride can beincluded in the present formulations preferably in an amount of100-300 mM, or if used without the aforementioned bulking agents,can be included in the formulations in an amount of between 300-500mM NaCl. Calcium salts include calcium chloride, calcium gluconate,calcium glubionate, or calcium gluceptate.

[0097] Buffering agents can be any physiologically acceptablechemical entity or combination of chemical entities which have acapacity to act as buffers, including but not limited to histidine,potassium phosphate, TRIS [tris-(hydroxymethyl)-aminomethane],BIS-Tris Propane(1,3-bis-[tris-(hydroxymethyl)methylamino]-propane), PIPES[piperazine-N,N'-bis-(2-ethanesulfonic acid)], MOPS[3-(N-morpholino)ethanesulfonic acid], HEPES(N-2-hydroxyethyl-piperazine-N'-2-ethanesulfonic acid), IVIES[2-(N-morpholino)ethanesulfonic acid], and ACES(N-2-acetamido-2-aminoethanesulfonic acid). Typically, thebuffering agent is included in a concentration of 10-50 mM.Specific examples of base buffers include (i) PBS; (ii) 10 mMKPO.sub.4, 150 mM NaCl; (iii) 10 mM HEPES, 150 mM NaCl; (iv) 10 mMimidazole, 150 mM NaCl; and (v) 20 mM sodium citrate. Excipientsthat can be used include (i) glycerol (10%, 20%); (ii) Tween 50(0.05%, 0.005%); (iii) 9% sucrose; (iv) 20% sorbitol; (v) 10 mMlysine; or (vi) 0.01 mM dextran sulfate.

[0098] Surfactants, if present, are preferably in a concentrationof 0.1% or less, and may be chosen from the group including but notlimited to polysorbate 20, polysorbate 80, pluronic polyols, andBRIJ 35 (polyoxyethylene 23 laurel ether). Antioxidants, if used,must be compatible for use with a pharmaceutical preparation, andare preferably water soluble. Suitable antioxidants includehom*ocysteine, glutathione, lipoic acid,6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox),methionine, sodium thiosulfate, platinum, glycine-glycine-histidine(tripeptide), and butylatedhydroxytoluene (BHT). Chelating agentsshould preferably bind metals such as copper and iron with greateraffinity than calcium, if a calcium salt is being used in thecomposition. An exemplary chelator is deferoxamine.

[0099] Many formulations known in the art can be used. For example,U.S. Pat. No. 5,763,401 describes a therapeutic formulation,comprising 15-60 mM sucrose, up to 50 mM NaCl, up to 5 mM calciumchloride, 65-400 mM glycine, and up to 50 mM histidine. In someembodiments, the therapeutic formulation is a solution of 9%sucrose in potassium phosphate buffer.

[0100] U.S. Pat. No. 5,733,873 (incorporated herein by reference inits entirety) discloses formulations which include between 0.01-1mg/ml of a surfactant. This patent discloses formulations havingthe following ranges of excipients: polysorbate 20 or 80 in anamount of at least 0.01 mg/ml, preferably 0.02-1.0 mg/ml; at least0.1 M NaCl; at least 0.5 mM calcium salt; and at least 1 mMhistidine. More particularly, the following specific formulationsare also disclosed: (1) 14.7-50-65 mM histidine, 0.31-0.6 M NaCl, 4mM calcium chloride, 0.001-0.02-0.025% polysorbate 80, with orwithout 0.1% PEG 4000 or 19.9 mM sucrose; and (2) 20 mg/mlmannitol, 2.67 mg/ml histidine, 18 mg/ml NaCl, 3.7 mM calciumchloride, and 0.23 mg/ml polysorbate 80.

[0101] The use of low or high concentrations of sodium chloride hasbeen described, for example U.S. Pat. No. 4,877,608 (incorporatedherein by reference in its entirety) teaches formulations withrelatively low concentrations of sodium chloride, such asformulations comprising 0.5 mM-15 mM NaCl, 5 mM calcium chloride,0.2 mM-5 mM histidine, 0.01-10 mM lysine hydrochloride and up to10% maltose, 10% sucrose, or 5% mannitol.

[0102] U.S. Pat. No. 5,605,884 (incorporated herein by reference inits entirety) teaches the use of formulations with relatively highconcentrations of sodium chloride. These formulations include 0.35M-1.2 M NaCl, 1.5-40 mM calcium chloride, 1 mM-50 mM histidine, andup to 10% sugar such as mannitol, sucrose, or maltose. Aformulation comprising 0.45 M NaCl, 2.3 mM calcium chloride, and1.4 mM histidine is exemplified.

[0103] International Patent Application WO 96/22107 (incorporatedherein by reference in its entirety) describes formulations whichinclude the sugar trehalose, for example formulations comprising:(1) 0.1 M NaCl, 15 mM calcium chloride, 15 mM histidine, and 1.27 M(48%) trehalose; or (2) 0.011% calcium chloride, 0.12% histidine,0.002% TRIS, 0.002% Tween 80, 0.004% PEG 3350, 7.5% trehalose; andeither 0.13% or 1.03% NaCl.

[0104] U.S. Pat. No. 5,328,694 (incorporated herein by reference inits entirety) describes a formulation which includes 100-650 mMdisaccharide and 100 mM-1.0 M amino acid, for example (1) 0.9 Msucrose, 0.25 M glycine, 0.25 M lysine, and 3 mM calcium chloride;and (2) 0.7 M sucrose, 0.5 M glycine, and 5 mM calcium chloride.Pharmaceutical compositions can be optionally prepared aslyophilized product, which may then be formulated for oraladministration or reconstituted to a liquid form for parenteraladministration.

[0105] In certain embodiments, the composition stimulates a T-cellresponse against a cell expressing or displaying a polypeptidecomprising one or more of the WIC-binding peptides in a subject towhom the composition is administered. The cell expressing thepolypeptide may be a cell comprising a polynucleotide encoding thepolypeptide, wherein the polynucleotide is in the genome of thecell, in an episomal vector, or in the genome of a virus that hasinfected the cell. The cell displaying the polypeptide may notcomprise a polynucleotide encoding the polypeptide, and may beproduced by contacting the cell with the polypeptide or aderivative thereof.

[0106] In certain embodiments, the composition induces in vitroactivation of T cells in peripheral blood mononuclear cells (PBMCs)isolated from a subject. The in vitro activation of T cellsincludes, without limitation, in vitro proliferation of T cells,production of cytokines (e.g., IFN.gamma.) from T cells, andincreased surface expression of activation markers (e.g., CD25,CD45RO) on T cells.

6.3.2 Preparation of Complexes of Antigenic Polypeptides and StressProteins

[0107] In another aspect, the instant disclosure provides a methodof making complexes of antigenic polypeptides and stress proteins(e.g., for the purposes of making a vaccine), the method comprisingmixing one or more antigenic polypeptides as disclosed herein witha purified stress protein in vitro under suitable conditions suchthat the purified stress protein binds to at least one of theantigenic polypeptides. The method is also referred to as acomplexing reaction herein. In certain embodiments, two or morepurified stress proteins are employed, wherein each purified stressprotein binds to at least one of the antigenic polypeptides. Incertain embodiments, at least a portion of the purified stressprotein binds to the antigenic polypeptide in the composition.

[0108] The stress protein may be bound to the polypeptidenon-covalently or covalently. In certain embodiments, the stressprotein is non-covalently bound to the polypeptide. In variousembodiments, the complexes formed in vitro are optionally purified.Purified complexes of stress proteins and polypeptides aresubstantially free of materials that are associated with suchcomplexes in a cell, or in a cell extract. Where purified stressproteins and purified polypeptides are used in an in vitrocomplexing reaction, the term "purified complex(es)" does notexclude a composition that also comprises free stress proteins andconjugates or peptides not in complexes.

[0109] Any stress proteins described supra may be employed in themethod disclosed herein. In certain embodiments, the stress proteinis selected from the group consisting of Hsc70, Hsp70, Hsp90,Hsp110, Grp170, Gp96, Calreticulin, a mutant thereof, andcombinations of two or more thereof. In one embodiment, the stressprotein is an Hsc70, e.g., a human Hsc70. In another embodiment,the stress protein is an Hsp70, e.g., a human Hsp70. In certainembodiments, the stress protein (e.g., human Hsc70 or human Hsp70)is a recombinant protein.

[0110] Prior to complexing, HSPs can be pretreated with ATP orexposed to acidic conditions to remove any peptides that may benon-covalently associated with the HSP of interest. Acidicconditions are any pH levels below pH 7, including the ranges pH1-pH 2, pH 2-pH 3, pH 3-pH 4, pH 4-pH 5, pH 5-pH 6, and pH 6-pH6.9. When the ATP procedure is used, excess ATP is removed from thepreparation by the addition of apyranase as described by Levy, etal., 1991, Cell 67:265-274 (incorporated herein by reference in itsentirety). When acidic conditions are used, the buffer isreadjusted to neutral pH by the addition of pH modifyingreagents.

[0111] In certain embodiments, prior to complexation with purifiedstress proteins, the polypeptides may be reconstituted from powderin 100% DMSO. Equimolar amounts of the peptides may then be pooledin a solution of 75% DMSO diluted in sterile water.

[0112] In certain embodiments, prior to complexation with purifiedstress proteins, the polypeptides may be reconstituted in neutralwater.

[0113] In certain embodiments, prior to complexation with purifiedstress proteins, the polypeptides may be reconstituted in acidicwater containing HCl or another acid.

[0114] In certain embodiments, prior to complexation with purifiedstress proteins, the polypeptides may be reconstituted in basicwater containing NaOH, or NH.sub.4OH, or another base.

[0115] In certain embodiments, prior to complexation with purifiedstress proteins, the solubility of each polypeptide in water may betested. If a polypeptide is soluble in neutral water, neutral watermay be used as a solvent for the polypeptide. If the polypeptide isnot soluble in neutral water, solubility in acidic water containingHCl, or another acid, e.g., acetic acid, phosphoric acid, orsulfuric acid may be tested. If the polypeptide is soluble inacidic water containing HCl (or another acid), acidic watercontaining HCl (or another acid) may be used as the solvent for thepolypeptide. If the polypeptide is not soluble in acidic watercontaining HCl (or another acid), solubility in basic watercontaining NaOH may be tested. If the polypeptide is soluble inbasic water containing NaOH, basic water containing NaOH may beused as the solvent for the polypeptide. If the polypeptide is notsoluble in basic water containing NaOH, the polypeptide may bedissolved in DMSO. If the polypeptide is not soluble in DMSO thepolypeptide may be excluded. The dissolved polypeptides may then bemixed to make a pool of polypeptides. The dissolved polypeptidesmay be mixed at equal volume. The dissolved polypeptides may bemixed in equimolar amounts.

[0116] The molar ratio of total polypeptide(s) to total stressprotein(s) can be any ratio from 0.01:1 to 100:1, including but notlimited to 0.01:1, 0.02:1, 0.05:1. 0.1:1. 0.2:1, 0.5:1, 1:1, 1.5:1,2:1, 2.5:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1,13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, 20:1, 30:1, 40:1, 49:1,up to 100:1. In certain embodiments, the composition to be preparedcomprises a plurality of complexes each comprising a polypeptidedisclosed herein and a stress protein, and the complexing reactioncomprises mixing the polypeptides with the stress proteins, whereinthe molar ratio of the polypeptide to the stress protein in eachcomplex is at least 1:1 (e.g., about 2:1, 3:1, 4:1, 5:1, 6:1, 7:1,8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1,19:1, 20:1, 30:1, 40:1, 49:1, up to 100:1).

[0117] In certain embodiments, the molar ratio of totalpolypeptide(s) to total stress protein(s) is about 0.5:1 to 5:1. Incertain embodiments, the molar ratio of total polypeptide(s) tototal stress protein(s) is about 1:1, 1.25:1, 1.5:1, 2:1, 2.5:1,3:1, 3.5:1, 4:1, 4.5:1, or 5:1. In certain embodiments, the molarratio of total polypeptide(s) to total stress protein(s) is about1:1, 1.25:1, or 1.5:1. Such ratios, particularly the ratios closeto 1:1, are advantageous in that the composition does not comprisea great excess of free peptide(s) that is not bound to a stressprotein. Since many antigenic peptides comprising WIC-bindingpeptides tend to comprise hydrophobic regions, an excess amount offree peptide(s) may tend to aggregate during preparation andstorage of the composition. Substantial complexation with a stressprotein at a molar ratio of total polypeptide(s) to total stressprotein(s) close to 1:1 (e.g., 1:1, 1.25:1, 1.5:1, or 2:1) isenabled by a high binding affinity of the polypeptide to the stressprotein. Accordingly, in certain embodiments, the polypeptide usedin the complexing reaction binds to an HSP (e.g., Hsc70, Hsp70,Hsp90, Hsp110, Grp170, Gp96, or Calreticulin) with a K.sub.d lowerthan 10.sup.-3 M, 10.sup.-4 M, 10.sup.-5 M, 10.sup.-6 M, 10.sup.-7M, 10.sup.-8 M, or 10.sup.-9 M. In certain embodiments, thepolypeptide binds to Hsc70 (e.g., human Hsc70) with a K.sub.d of10.sup.-3 M, 10.sup.-4 M, 10.sup.-5 M, 10.sup.-6 M, 10.sup.-7 M,10.sup.-8 M, 10.sup.-9 M, or lower.

[0118] The method disclosed herein can be used to prepare acomposition (e.g., a pharmaceutical composition) in bulk (e.g.,greater than or equal to 30 mg, 50 mg, 100 mg, 200 mg, 300 mg, 500mg, or 1 g of total peptide and protein). The prepared compositioncan then be transferred to single-use or multi-use containers, orapportioned to unit dosage forms. Alternatively, the methoddisclosed herein can be used to prepare a composition (e.g., apharmaceutical composition) in a small amount (e.g., less than orequal to 300 .mu.g, 1 mg, 3 mg, 10 mg, 30 mg, or 100 mg of totalpeptide and protein). In certain embodiments, the composition isprepared for single use, optionally in a unit dosage form.

[0119] In certain embodiments, the total amount of thepolypeptide(s) and stress protein in the composition is about 10.mu.g to 600 .mu.g (e.g., about 50 .mu.g, 100 .mu.g, 200 .mu.g, 300.mu.g, 400 .mu.g, or 500 .mu.g, optionally about 120 .mu.g, 240.mu.g, or 480 .mu.g). In certain embodiments, the total amount ofthe polypeptide(s) and stress protein in the composition is about300 .mu.g. Amounts of the stress protein(s) and polypeptide(s) in aunit dosage form are disclosed infra.

[0120] An exemplary protocol for noncovalent complexing of apopulation of polypeptides to a stress protein in vitro is providedherein. The population of polypeptides can comprise a mixture ofthe different polypeptide species disclosed herein. Then, themixture is incubated with the purified and/or pretreated stressprotein for from 15 minutes to 3 hours (e.g., 1 hour) at from4.degree. to 50.degree. C. (e.g., 37.degree. C.) in a suitablebinding buffer, such as phosphate buffered saline pH 7.4 optionallysupplemented with 0.01% Polysorbate 20; a buffer comprising 9%sucrose in potassium phosphate buffer; a buffer comprising 2.7 mMSodium Phosphate Dibasic, 1.5 mM Potassium Phosphate Monobasic, 150mM NaCl, pH 7.2; a buffer containing 20 mM sodium phosphate, pH7.2-7.5, 350-500 mM NaCl, 3 mM MgCl.sub.2 and 1 mM phenyl methylsulfonyl fluoride (PMSF); and the buffer optionally comprising 1 mMADP. Any buffer may be used that is compatible with the stressprotein. The preparations are then optionally purified bycentrifugation through a Centricon 10 assembly (Millipore;Billerica, Mass.) to remove any unbound peptide. The non-covalentassociation of the proteins/peptides with the HSPs can be assayedby High Performance Liquid Chromatography (HPLC), Mass Spectrometry(MS), mixed lymphocyte target cell assay (MLTC), or enzyme-linkedimmunospot (ELISPOT) assay (Taguchi T, et al., J Immunol Methods1990; 128: 65-73, incorporated herein by reference in itsentirety). Once the complexes have been isolated and diluted, theycan be optionally characterized further in animal models using theadministration protocols and excipients described herein (see,e.g., Example 2 infra).

[0121] Complexes of stress proteins and antigenic polypeptides fromseparate covalent and/or non-covalent complexing reactions can beprepared to form a composition before administration to a subject.In certain embodiments, the composition is prepared within 1, 2, 3,4, 5, 6, or 7 days before administration to a subject. In certainembodiments, the composition is prepared within 1, 2, 3, 4, 5, 6,7, or 8 weeks before administration to a subject. In certainembodiments, the composition is prepared within 1, 2, 3, 4, 5, 6,7, 8, 9, 10, 11, or 12 months before administration to a subject.The composition can optionally be stored at about 4.degree. C.,-20.degree. C., or -80.degree. C. after preparation and beforeuse.

[0122] In certain embodiments, the complexes prepared by the methoddisclosed herein are mixed with an adjuvant at bedside just priorto administration to a patient. In certain embodiments, theadjuvant comprises a saponin or an immunostimulatory nucleic acid.In certain embodiments, the adjuvant comprises QS-21. In certainembodiments, the dose of QS-21 is 10 .mu.g, 25 .mu.g, 50 .mu.g, 75.mu.g, 100 .mu.g, 125 .mu.g, 150 .mu.g, 175 .mu.g, or 200 .mu.g. Incertain embodiments, the dose of QS-21 is about 100 .mu.g. Incertain embodiments, the adjuvant comprises a TLR agonist. Incertain embodiments, the TLR agonist is an agonist of TLR4. Incertain embodiments, the TLR agonist is an agonist of TLR7 and/orTLR8. In certain embodiments, the TLR agonist is an agonist ofTLR9. In certain embodiments, the TLR agonist is an agonist ofTLR5.

[0123] As an alternative to making non-covalent complexes of stressproteins and polypeptides, the polypeptides can be covalentlyattached to stress proteins, e.g., by chemical crosslinking or UVcrosslinking. Any chemical crosslinking or UV crosslinking methodsknown in the art (see, e.g., Wong, 1991, Chemistry of ProteinConjugation and Cross-Linking, CRC Press, incorporated herein byreference in its entirety) can be employed. For example,glutaraldehyde crosslinking (see, e.g., Barrios et al., 1992, Eur.J. Immunol. 22: 1365-1372, incorporated herein by reference in itsentirety) may be used. In an exemplary protocol, 1-2 mg ofHSP-peptide complex is cross-linked in the presence of 0.002%glutaraldehyde for 2 hours. Glutaraldehyde is removed by dialysisagainst phosphate buffered saline (PBS) overnight (Lussow et al.,1991, Eur. J. Immunol. 21: 2297-2302, incorporated herein byreference in its entirety).

6.3.3 Vaccines

[0124] In another aspect, the instant disclosure provides a vaccinecomprising the polypeptide compositions (e.g., antigenicpolypeptide compositions) disclosed herein. The vaccine may beprepared by any method that results in a stable, sterile,preferably injectable formulation.

[0125] In certain embodiments, the vaccine comprises one or morecompositions disclosed herein and one or more adjuvants. A varietyof adjuvants may be employed, including, for example, systemicadjuvants and mucosal adjuvants. A systemic adjuvant is an adjuvantthat can be delivered parenterally. Systemic adjuvants includeadjuvants that create a depot effect, adjuvants that stimulate theimmune system, and adjuvants that do both.

[0126] An adjuvant that creates a depot effect is an adjuvant thatcauses the antigen to be slowly released in the body, thusprolonging the exposure of immune cells to the antigen. This classof adjuvants includes alum (e.g., aluminum hydroxide, aluminumphosphate); or emulsion-based formulations including mineral oil,non-mineral oil, water-in-oil or oil-in-water-in oil emulsion,oil-in-water emulsions such as Seppic ISA series of Montanideadjuvants (e.g., Montanide ISA 720, AirLiquide, Paris, France);MF-59 (a squalene-in-water emulsion stabilized with Span 85 andTween 80; Chiron Corporation, Emeryville, Calif.; and PROVAX (anoil-in-water emulsion containing a stabilizing detergent and amicelle-forming agent; IDEC, Pharmaceuticals Corporation, SanDiego, Calif.).

[0127] Other adjuvants stimulate the immune system, for instance,cause an immune cell to produce and secrete cytokines or IgG. Thisclass of adjuvants includes immunostimulatory nucleic acids, suchas CpG oligonucleotides; saponins purified from the bark of the Q.saponaria tree, such as QS-21;poly[di(carboxylatophenoxy)phosphazene (PCPP polymer; VirusResearch Institute, USA); RNA mimetics such aspolyinosinic:polycytidylic acid (poly I:C) or poly I:C stabilizedwith poly-lysine (poly-ICLC [Hiltonol.RTM.; Oncovir, Inc.];derivatives of lipopolysaccharides (LPS) such as monophosphoryllipid A (MPL; Ribi ImmunoChem Research, Inc., Hamilton, Mont.),muramyl dipeptide (MDP; Ribi) and threonyl-muramyl dipeptide(t-MDP; Ribi); OM-174 (a glucosamine disaccharide related to lipidA; OM Pharma SA, Meyrin, Switzerland); and Leishmania elongationfactor (a purified Leishmania protein; Corixa Corporation, Seattle,Wash.).

[0128] Other systemic adjuvants are adjuvants that create a depoteffect and stimulate the immune system. These compounds have bothof the above-identified functions of systemic adjuvants. This classof adjuvants includes but is not limited to ISCOMs(Immunostimulating complexes which contain mixed saponins, lipidsand form virus-sized particles with pores that can hold antigen;CSL, Melbourne, Australia); AS01 which is a liposome basedformulation containing MPL and QS-21 (GlaxoSmithKline, Belgium);AS02 (GlaxoSmithKline, which is an oil-in-water emulsion containingMPL and QS-21: GlaxoSmithKline, Rixensart, Belgium); AS04(GlaxoSmithKline, which contains alum and MPL; GSK, Belgium); AS15which is a liposome based formulation containing CpGoligonucleotides, MPL and QS-21 (GlaxoSmithKline, Belgium);non-ionic block copolymers that form micelles such as CRL 1005(these contain a linear chain of hydrophobic polyoxypropyleneflanked by chains of polyoxyethylene; Vaxcel, Inc., Norcross, Ga.);and Syntex Adjuvant Formulation (SAF, an oil-in-water emulsioncontaining Tween 80 and a nonionic block copolymer; SyntexChemicals, Inc., Boulder, Colo.).

[0129] The mucosal adjuvants useful according to the invention areadjuvants that are capable of inducing a mucosal immune response ina subject when administered to a mucosal surface in conjunctionwith complexes disclosed herein. Mucosal adjuvants include CpGnucleic acids (e.g. PCT published patent application WO 99/61056,incorporated herein by reference in its entirety), bacterialtoxins: e.g., Cholera toxin (CT), CT derivatives including but notlimited to CT B subunit (CTB); CTD53 (Val to Asp); CTK97 (Val toLys); CTK104 (Tyr to Lys); CTD53/K63 (Val to Asp, Ser to Lys);CTH54 (Arg to His); CTN107 (His to Asn); CTE114 (Ser to Glu);CTE112K (Glu to Lys); CTS61F (Ser to Phe); CTS 106 (Pro to Lys);and CTK63 (Ser to Lys), Zonula occludens toxin (zot), Escherichiacoli heat-labile enterotoxin, Labile Toxin (LT), LT derivativesincluding but not limited to LT B subunit (LTB); LT7K (Arg to Lys);LT61F (Ser to Phe); LT112K (Glu to Lys); LT118E (Gly to Glu);LT146E (Arg to Glu); LT192G (Arg to Gly); LTK63 (Ser to Lys); andLTR72 (Ala to Arg), Pertussis toxin, PT. including PT-9K/129G;Toxin derivatives (see below); Lipid A derivatives (e.g.,monophosphoryl lipid A, MPL); Muramyl Dipeptide (MDP) derivatives;bacterial outer membrane proteins (e.g., outer surface protein A(OspA) lipoprotein of Borrelia burgdorferi, outer membrane proteinof Neisseria meningitidis); oil-in-water emulsions (e.g., MF59;aluminum salts (Isaka et al., 1998, 1999); and Saponins (e.g.,QS-21, e.g., QS-21 Stimulon.RTM., Antigenics LLC, Lexington,Mass.), ISCOMs, MF-59 (a squalene-in-water emulsion stabilized withSpan 85 and Tween 80; Chiron Corporation, Emeryville, Calif.); theSeppic ISA series of Montanide adjuvants (e.g., Montanide ISA 720;AirLiquide, Paris, France); PROVAX (an oil-in-water emulsioncontaining a stabilizing detergent and a micelle-forming agent; DECPharmaceuticals Corporation, San Diego, Calif.); Syntext AdjuvantFormulation (SAF; Syntex Chemicals, Inc., Boulder, Colo.); poly[di(carboxylatophenoxy)]phosphazene (PCPP polymer; Virus ResearchInstitute, USA) and Leishmania elongation factor (CorixaCorporation, Seattle, Wash.).

[0130] In certain embodiments, the adjuvant added to thecompositions disclosed herein comprises a saponin and/or animmunostimulatory nucleic acid. In certain embodiments, theadjuvant added to the composition comprises or further comprisesQS-21.

[0131] In certain embodiments, the adjuvant added to thecompositions disclosed herein comprises a Toll-like receptor (TLR)agonist. In certain embodiments, the TLR agonist is an agonist ofTLR4. In certain embodiments, the TLR agonist is an agonist of TLR7and/or TLR8. In certain embodiments, the TLR agonist is an agonistof TLR9. In certain embodiments, the TLR agonist is an agonist ofTLR5.

[0132] The compositions disclosed herein described herein may becombined with an adjuvant in several ways. For example, differentpolypeptides may be mixed together first to form a mixture and thencomplexed with stress protein(s) and/or adjuvant(s) to form acomposition. As another example, different polypeptides may becomplexed individually with a stress protein and/or adjuvant(s),and the resulting batches of complexes may then be mixed to form acomposition.

[0133] The adjuvant can be administered prior to, during, orfollowing administration of the compositions comprising complexesof stress protein and polypeptides. Administration of the adjuvantand the compositions can be at the same or different administrationsites.

6.3.4 Unit Dosage Forms

[0134] In another aspect, the instant disclosure provides a unitdosage form of a composition (e.g., pharmaceutical composition orvaccine) disclosed herein.

[0135] The amounts and concentrations of the polypeptides (e.g.,antigenic polypeptides), stress proteins, and/or adjuvants at whichthe efficacy of a vaccine disclosed herein is effective may varydepending on the chemical nature and the potency of thepolypeptides, stress proteins, and/or adjuvants. Typically, thestarting amounts and concentrations in the vaccine are the onesconventionally used for eliciting the desired immune response,using the conventional routes of administration, e.g.,intramuscular injection. The amounts and concentrations of thepolypeptides (e.g., antigenic polypeptides), conjugates, stressproteins, and/or adjuvants can then be adjusted, e.g., by dilutionusing a diluent, so that an effective immune response is achievedas assessed using standard methods known in the art (e.g.,determined by the antibody or T-cell response to the vaccinerelative to a control formulation).

[0136] In certain embodiments, the total amount of the polypeptidesand stress protein in the composition is about 10 .mu.g to 600.mu.g (e.g., about 50 .mu.g, 100 .mu.g, 200 .mu.g, 300 .mu.g, 400.mu.g, or 500 .mu.g, optionally about 120 .mu.g, 240 .mu.g, or 480.mu.g). In certain embodiments, the total amount of thepolypeptides and stress protein in the composition is about 300.mu.g. In certain embodiments, the amount of the stress protein inthe composition is about 250 .mu.g to 290 .mu.g.

[0137] In certain embodiments, the amount of the stress protein inthe composition is about 10 .mu.g to 600 .mu.g (e.g., about 50.mu.g, 100 .mu.g, 200 .mu.g, 300 .mu.g, 400 .mu.g, or 500 .mu.g,optionally about 120 .mu.g, 240 .mu.g, or 480 .mu.g). In certainembodiments, the amount of the stress protein in the composition isabout 300 .mu.g. The amount of the polypeptide is calculated basedon a designated molar ratio and the molecular weight of thepolypeptides.

[0138] In certain embodiments, the total molar amount of thepolypeptides in the unit dosage form of the composition is about0.1 to 10 nmol (e.g., about 0.1 nmol, 0.5 nmol, 1 nmol, 2 nmol, 3nmol, 4 nmol, 5 nmol, 6 nmol, 7 nmol, 8 nmol, 9 nmol, or 10 nmol).In certain embodiments, the total molar amount of the polypeptidesin the unit dosage form of the composition is about 4 nmol. Incertain embodiments, the total molar amount of the polypeptides inthe unit dosage form of the composition is about 5 nmol.

[0139] The molar ratio of total polypeptides to total stressproteins can be any ratio from about 0.01:1 to about 100:1,including but not limited to about 0.01:1, 0.02:1, 0.05:1. 0.1:1.0.2:1, 0.5:1, 1:1, 1.5:1, 2:1, 2.5:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1,9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1,20:1, 30:1, 40:1, 49:1, up to 100:1. In certain embodiments, thecomposition comprises a plurality of complexes each comprising apolypeptide and a stress protein, wherein the molar ratio of thepolypeptide to the stress protein in each complex is at least about1:1 (e.g., about 1.5:1, 2:1, 2.5:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1,9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1,20:1, 30:1, 40:1, 49:1, up to 100:1). In certain embodiments, themolar ratio of total polypeptide(s) to total stress protein(s) isabout 0.5:1 to 5:1.

[0140] In certain embodiments, the molar ratio of totalpolypeptide(s) to total stress protein(s) is about 1:1 to 2:1. Incertain embodiments, the molar ratio of total polypeptide(s) tototal stress protein(s) is about 1:1, 1.25:1, or 1.5:1. Suchratios, particularly the ratios close to 1:1, are advantageous inthat the composition does not comprise a great excess of freepeptide(s) that is not bound to a stress protein. Since manyantigenic peptides comprising WIC-binding peptides tend to comprisehydrophobic regions, an excess amount of free peptide(s) may tendto aggregate during preparation and storage of the composition.Substantial complexation with a stress protein at a molar ratio oftotal polypeptide(s) to total stress protein(s) close to 1:1 (e.g.,1:1, 1.25:1, 1.5:1, or 2:1) is enabled by a high binding affinityof the polypeptide to the stress protein. Accordingly, in certainembodiments, the polypeptide binds to an HSP (e.g., Hsc70, Hsp70,Hsp90, Hsp110, Grp170, Gp96, or Calreticulin) with a K.sub.d lowerthan 10.sup.-3 M, 10.sup.-4 M, 10.sup.-5 M, 10.sup.-6 M, 10.sup.-7M, 10.sup.-8 M, or 10.sup.-9 M. In certain embodiments, thepolypeptide binds to Hsc70 (e.g., human Hsc70) with a K.sub.d of10.sup.-3 M, 10.sup.-4 M, 10.sup.-5 M, 10.sup.-6 M, 10.sup.-7 M,10.sup.-8 M, 10.sup.-9M, or lower.

[0141] Methods of calculating the amounts of components in the unitdosage form are provided. For example, in certain embodiments, thepolypeptides have an average molecular weight of about 3 kD, andthe molecular weight of Hsc70 is about 71 kD. Assuming in oneembodiment that the total amount of the polypeptides and stressprotein in the composition is 300 .mu.g, and the molar ratio of thepolypeptides to hsc70 is 1.5:1. The molar amount of Hsc70 can becalculated as 300 .mu.g divided by 71 kD+1.5.times.3 kD, resultingin about 4.0 nmol, and the mass amount of Hsc70 can be calculatedby multiplying the molar amount with 71 kD, resulting in about 280kD. The total molar amount of the polypeptides can be calculated as1.5.times.4.0 nmol, resulting in 6.0 nmol. If 10 differentpolypeptides are employed, the molar amount of each polypeptide is0.60 nmol. Assuming in another embodiment that a 300 .mu.g dose ofHsc70 is intended to be included in a unit dosage form, and themolar ratio of polypeptides to Hsc70 is 1.5:1. The total molaramount of the polypeptides can be calculated as 300 .mu.g dividedby 71 kD then times 1.5, resulting in 6.3 nmol. If 10 differentpolypeptides are employed, the molar amount of each polypeptide is0.63 nmol. In cases where one or more of the variables aredifferent from those in the examples, the quantities of the stressproteins and of the polypeptides are scaled accordingly.

[0142] It is further appreciated that the unit dosage form canoptionally comprise one or more adjuvants as disclosed supra. Incertain embodiments, the adjuvant comprises a saponin and/or animmunostimulatory nucleic acid. In certain embodiments, theadjuvant comprises or further comprises QS-21. In certainembodiments, the amount of QS-21 in the unit dosage form ofcomposition is 10 .mu.g, 25 .mu.g, 50 .mu.g, 75 .mu.g, 100 .mu.g,125 .mu.g, 150 .mu.g, 175 .mu.g, or 200 .mu.g. In certainembodiments, the amount of QS-21 in the unit dosage form ofcomposition is 100 .mu.g. In certain embodiments, the adjuvantcomprises a Toll-like receptor (TLR) agonist. In certainembodiments, the TLR agonist is an agonist of TLR4. In certainembodiments, the TLR agonist is an agonist of TLR7 and/or TLR8. Incertain embodiments, the TLR agonist is an agonist of TLR9. Incertain embodiments, the TLR agonist is an agonist of TLR5.

6.4 Methods of Use

[0143] The compositions (e.g., pharmaceutical compositions andvaccines, and unit dosage forms thereof) disclosed herein areparticularly useful for inducing a cellular immune response. Incertain embodiments, stress proteins can deliver antigenicpolypeptides through the cross-presentation pathway in antigenpresenting cells (APCs) (e.g., macrophages and dendritic cells(DCs) via membrane receptors (mainly CD91) or by binding toToll-like receptors, thereby leading to activation of CD8.sup.+ andCD4.sup.+ T cells. Internalization of a stress protein/antigenicpolypeptide complex results in functional maturation of the APCswith chemokine and cytokine production leading to activation ofnatural killer cells (NK), monocytes and Th1 and Th-2-mediatedimmune responses.

[0144] In one aspect, the instant disclosure provides a method ofinducing a cellular immune response to an antigenic peptide in asubject, the method comprising administering to the subject aneffective amount of a composition as disclosed herein. In anotheraspect, the instant disclosure provides a method of treating adisease (e.g., cancer) in a subject, the method comprisingadministering to the subject an effective amount of a compositionas disclosed herein. The compositions disclosed herein can also beused in preparing a medicament or vaccine for the treatment of asubject.

[0145] In various embodiments, such subjects can be an animal,e.g., a mammal, a non-human primate, and a human. The term "animal"includes companion animals, such as cats and dogs; zoo animals;wild animals, including deer, foxes and raccoons; farm animals,livestock and fowl, including horses, cattle, sheep, pigs, turkeys,ducks, and chickens, and laboratory animals, such as rodents,rabbits, and guinea pigs. In certain embodiments, the subject hascancer.

6.4.1 Treatment of Cancer

[0146] The compositions disclosed herein can be used alone or incombination with other therapies for the treatment of cancer. Oneor more of the MHC-binding peptides disclosed herein can be presentin the subject's cancer cells. In certain embodiments, one or moreof the MHC-binding peptides are common to or frequently found inthe type and/or stage of the cancer. In certain embodiments, one ormore MHC-binding peptides are found in greater than 5% of cancers.In certain embodiments, one or more of the WIC-binding peptides arespecific to the cancer of the subject.

[0147] Cancers that can be treated using the compositions disclosedherein include, without limitation, a solid tumor, a hematologicalcancer (e.g., leukemia, lymphoma, myeloma, e.g., multiple myeloma),and a metastatic lesion. In one embodiment, the cancer is a solidtumor. Examples of solid tumors include malignancies, e.g.,sarcomas and carcinomas, e.g., adenocarcinomas of the various organsystems, such as those affecting the lung, breast, ovarian,lymphoid, gastrointestinal (e.g., colon), anal, genitals andgenitourinary tract (e.g., renal, urothelial, bladder cells,prostate), pharynx, CNS (e.g., brain, neural or glial cells), headand neck, skin (e.g., melanoma), and pancreas, as well asadenocarcinomas which include malignancies such as colon cancers,rectal cancer, renal-cell carcinoma, liver cancer, lung cancer(e.g., non-small cell lung cancer or small cell lung cancer),cancer of the small intestine and cancer of the esophagus. Thecancer may be at an early, intermediate, late stage or metastaticcancer. In certain embodiments, the cancer is associated withelevated PD-1 activity (e.g., elevated PD-1 expression).

[0148] In one embodiment, the cancer is chosen from a lung cancer(e.g., lung adenocarcinoma or a non-small cell lung cancer (NSCLC)(e.g., a NSCLC with squamous and/or non-squamous histology, or aNSCLC adenocarcinoma)), a melanoma (e.g., an advanced melanoma), arenal cancer (e.g., a renal cell carcinoma), a liver cancer (e.g.,hepatocellular carcinoma or intrahepatic cholangiocellularcarcinoma), a myeloma (e.g., a multiple myeloma), a prostatecancer, a breast cancer (e.g., a breast cancer that does notexpress one, two or all of estrogen receptor, progesteronereceptor, or Her2/neu, e.g., a triple negative breast cancer), anovarian cancer, a colorectal cancer, a pancreatic cancer, a headand neck cancer (e.g., head and neck squamous cell carcinoma(HNSCC), anal cancer, gastro-esophageal cancer (e.g., esophagealsquamous cell carcinoma), mesothelioma, nasopharyngeal cancer,thyroid cancer, cervical cancer, epithelial cancer, peritonealcancer, or a lymphoproliferative disease (e.g., a post-transplantlymphoproliferative disease). In one embodiment, the cancer isNSCLC. In one embodiment, the cancer is a renal cell carcinoma. Inone embodiment, the cancer is an ovarian cancer, optionally whereinthe ovarian cancer is associated with human papillomavirus (HPV)infection. In a specific embodiment, the ovarian cancer is aplatinum-refractory ovarian cancer.

[0149] In one embodiment, the cancer is a hematological cancer, forexample, a leukemia, a lymphoma, or a myeloma. In one embodiment,the cancer is a leukemia, for example, acute lymphoblastic leukemia(ALL), acute myelogenous leukemia (AML), acute myeloblasticleukemia (AML), chronic lymphocytic leukemia (CLL), chronicmyelogenous leukemia (CML), chronic myeloid leukemia (CML), chronicmyelomonocytic leukemia (CMML), chronic lymphocytic leukemia (CLL),or hairy cell leukemia. In one embodiment, the cancer is alymphoma, for example, B cell lymphoma, diffuse large B-celllymphoma (DLBCL), activated B-cell like (ABC) diffuse large B celllymphoma, germinal center B cell (GCB) diffuse large B celllymphoma, mantle cell lymphoma, Hodgkin lymphoma, non-Hodgkinlymphoma, relapsed non-Hodgkin lymphoma, refractory non-Hodgkinlymphoma, recurrent follicular non-Hodgkin lymphoma, Burkittlymphoma, small lymphocytic lymphoma, follicular lymphoma,lymphoplasmacytic lymphoma, or extranodal marginal zone lymphoma.In one embodiment the cancer is a myeloma, for example, multiplemyeloma.

[0150] In another embodiment, the cancer is chosen from a carcinoma(e.g., advanced or metastatic carcinoma), melanoma or a lungcarcinoma, e.g., a non-small cell lung carcinoma.

[0151] In one embodiment, the cancer is a lung cancer, e.g., a lungadenocarcinoma, non-small cell lung cancer or small cell lungcancer.

[0152] In one embodiment, the cancer is a melanoma, e.g., anadvanced melanoma. In one embodiment, the cancer is an advanced orunresectable melanoma that does not respond to other therapies. Inother embodiments, the cancer is a melanoma with a BRAF mutation(e.g., a BRAF V600 mutation). In yet other embodiments, thecompositions disclosed herein is administered after treatment withan anti-CTLA-4 antibody (e.g., ipilimumab) with or without a BRAFinhibitor (e.g., vemurafenib or dabrafenib).

[0153] In another embodiment, the cancer is a hepatocarcinoma,e.g., an advanced hepatocarcinoma, with or without a viralinfection, e.g., a chronic viral hepatitis.

[0154] In another embodiment, the cancer is a prostate cancer,e.g., an advanced prostate cancer.

[0155] In yet another embodiment, the cancer is a myeloma, e.g.,multiple myeloma.

[0156] In yet another embodiment, the cancer is a renal cancer,e.g., a renal cell carcinoma (RCC) (e.g., a metastatic RCC, clearcell renal cell carcinoma (CCRCC) or kidney papillary cellcarcinoma).

[0157] In yet another embodiment, the cancer is chosen from a lungcancer, a melanoma, a renal cancer, a breast cancer, a colorectalcancer, a leukemia, or a metastatic lesion of the cancer.

[0158] In a particular embodiment, the cancer is AML. In anotherparticular embodiment, the cancer is colorectal cancer.

[0159] The compositions disclosed herein may be administered when acancer is detected, or prior to or during an episode ofrecurrence.

[0160] Administration can begin at the first sign of cancer orrecurrence, followed by boosting doses until at least symptoms aresubstantially abated and for a period thereafter.

[0161] In some embodiments, the compositions can be administered toa subject with cancer who has undergone tumor resection surgerythat results in an insufficient amount of resected tumor tissue(e.g., less than 7 g, less than 6 g, less than 5 g, less than 4 g,less than 3 g, less than 2 g, or less than 1 g of resected tumortissue) for production of a therapeutically effective amount of anautologous cancer vaccine comprising a representative set ofantigens collected from the resected tumor tissue. See, forexample, cancer vaccines described in Expert Opin. Biol. Ther. 2009Febuary; 9(2):179-86; incorporated herein by reference.

[0162] The compositions disclosed herein can also be used forimmunization against recurrence of cancers. Prophylacticadministration of a composition to an individual can conferprotection against a future recurrence of a cancer.

6.4.2 Combination Therapy

[0163] Combination therapy refers to the use of compositionsdisclosed herein, as a first modality, with a second modality totreat cancer. Accordingly, in certain embodiments, the instantdisclosure provides a method of inducing a cellular immune responseto an antigenic peptide in a subject as disclosed herein, or amethod of treating a disease in a subject as disclosed herein, themethod comprising administering to the subject an effective amountof (a) a composition as disclosed herein and (b) a secondmodality.

[0164] In one embodiment, the second modality is a non-HSPmodality, e.g., a modality that does not comprise HSP as acomponent. This approach is commonly termed combination therapy,adjunctive therapy or conjunctive therapy (the terms are usedinterchangeably). With combination therapy, additive potency oradditive therapeutic effect can be observed. Synergistic outcomesare sought where the therapeutic efficacy is greater than additive.The use of combination therapy can also provide better therapeuticprofiles than the administration of either the first or the secondmodality alone.

[0165] The additive or synergistic effect may allow for a reductionin the dosage and/or dosing frequency of either or both modalitiesto mitigate adverse effects. In certain embodiments, the secondmodality administered alone is not clinically adequate to treat thesubject (e.g., the subject is non-responsive or refractory to thesingle modality), such that the subject needs an additionalmodality. In certain embodiments, the subject has responded to thesecond modality, yet suffers from side effects, relapses, developsresistance, etc., such that the subject needs an additionalmodality. Methods disclosed herein comprising administration of thecompositions disclosed herein to such subjects to improve thetherapeutic effectiveness of the second modality. The effectivenessof a treatment modality can be assayed in vivo or in vitro usingmethods known in the art.

[0166] In one embodiment, a lesser amount of the second modality isrequired to produce a therapeutic benefit in a subject. In specificembodiments, a reduction of about 10%, 20%, 30%, 40% and 50% of theamount of second modality can be achieved. The amount of the secondmodality, including amounts in a range that does not produce anyobservable therapeutic benefits, can be determined by dose-responseexperiments conducted in animal models by methods well known in theart.

[0167] In certain embodiments, the second modality comprises a TCR,e.g., a soluble TCR or a cell expressing a TCR. In certainembodiments, the second modality comprises a cell expressing achimeric antigen receptor (CAR). In certain embodiments, the cellexpressing the TCR or CAR is a T cell. In a particular embodiment,the TCR or CAR binds to (e.g., specifically binds to) at least oneWIC-binding epitope in the composition disclosed herein.

[0168] In certain embodiments, the second modality comprises a TCRmimic antibody. In certain embodiments, the TCR mimic antibody isan antibody that specifically binds to a peptide-WIC complex.Non-limiting examples of TCR mimic antibodies are disclosed in U.S.Pat. No. 9,074,000, U.S. Publication Nos. US 2009/0304679 A1 and US2014/0134191 A1, all of which are incorporated herein by referencein their entireties. In a particular embodiment, the TCR mimicantibody binds to (e.g., specifically binds to) at least oneWIC-binding epitope in the composition disclosed herein.

[0169] In certain embodiments, the second modality comprises acheckpoint targeting agent. In certain embodiments, the checkpointtargeting agent is selected from the group consisting of anantagonist anti-CTLA-4 antibody, an antagonist anti-PD-L1 antibody,an antagonist anti-PD-L2 antibody, an antagonist anti-PD-1antibody, an antagonist anti-TIM-3 antibody, an antagonistanti-LAG-3 antibody, an antagonist anti-CEACAM1 antibody, anagonist anti-CD137 antibody, an antagonist anti-TIGIT antibody, anantagonist anti-VISTA antibody, an agonist anti-GITR antibody, andan agonist anti-OX40 antibody.

[0170] In certain embodiments, an anti-PD-1 antibody is used as thesecond modality in methods disclosed herein. In certainembodiments, the anti-PD-1 antibody is nivolumab, also known asBMS-936558 or MDX1106, developed by Bristol-Myers Squibb. Incertain embodiments, the anti-PD-1 antibody is pembrolizumab, alsoknown as lambrolizumab or MK-3475, developed by Merck & Co. Incertain embodiments, the anti-PD-1 antibody is pidilizumab, alsoknown as CT-011, developed by CureTech. In certain embodiments, theanti-PD-1 antibody is MEDI0680, also known as AMP-514, developed byMedimmune. In certain embodiments, the anti-PD-1 antibody is PDR001developed by Novartis Pharmaceuticals. In certain embodiments, theanti-PD-1 antibody is REGN2810 developed by RegeneronPharmaceuticals. In certain embodiments, the anti-PD-1 antibody isPF-06801591 developed by Pfizer. In certain embodiments, theanti-PD-1 antibody is BGB-A317 developed by BeiGene. In certainembodiments, the anti-PD-1 antibody is TSR-042 developed byAnaptysBio and Tesaro. In certain embodiments, the anti-PD-1antibody is SHR-1210 developed by Hengrui.

[0171] Further non-limiting examples of anti-PD-1 antibodies thatmay be used in treatment methods disclosed herein are disclosed inthe following patents and patent applications, all of which areherein incorporated by reference in their entireties for allpurposes: U.S. Pat. Nos. 6,808,710; 7,332,582; 7,488,802;8,008,449; 8,114,845; 8,168,757; 8,354,509; 8,686,119; 8,735,553;8,747,847; 8,779,105; 8,927,697; 8,993,731; 9,102,727; 9,205,148;U.S. Publication No. US 2013/0202623 A1; U.S. Publication No. US2013/0291136 A1; U.S. Publication No. US 2014/0044738 A1; U.S.Publication No. US 2014/0356363 A1; U.S. Publication No. US2016/0075783 A1; and PCT Publication No. WO 2013/033091 A1; PCTPublication No. WO 2015/036394 A1; PCT Publication No. WO2014/179664 A2; PCT Publication No. WO 2014/209804 A1; PCTPublication No. WO 2014/206107 A1; PCT Publication No. WO2015/058573 A1; PCT Publication No. WO 2015/085847 A1; PCTPublication No. WO 2015/200119 A1; PCT Publication No. WO2016/015685 A1; and PCT Publication No. WO 2016/020856 A1.

[0172] In certain embodiments, an anti-PD-L1 antibody is used asthe second modality in methods disclosed herein. In certainembodiments, the anti-PD-L1 antibody is atezolizumab developed byGenentech. In certain embodiments, the anti-PD-L1 antibody isdurvalumab developed by AstraZeneca, Celgene and Medimmune. Incertain embodiments, the anti-PD-L1 antibody is avelumab, alsoknown as MSB0010718C, developed by Merck Serono and Pfizer. Incertain embodiments, the anti-PD-L1 antibody is MDX-1105 developedby Bristol-Myers Squibb. In certain embodiments, the anti-PD-L1antibody is AMP-224 developed by Amplimmune and GSK.

[0173] Non-limiting examples of anti-PD-L1 antibodies that may beused in treatment methods disclosed herein are disclosed in thefollowing patents and patent applications, all of which are hereinincorporated by reference in their entireties for all purposes:U.S. Pat. Nos. 7,943,743; 8,168,179; 8,217,149; 8,552,154;8,779,108; 8,981,063; 9,175,082; U.S. Publication No. US2010/0203056 A1; U.S. Publication No. US 2003/0232323 A1; U.S.Publication No. US 2013/0323249 A1; U.S. Publication No. US2014/0341917 A1; U.S. Publication No. US 2014/0044738 A1; U.S.Publication No. US 2015/0203580 A1; U.S. Publication No. US2015/0225483 A1; U.S. Publication No. US 2015/0346208 A1; U.S.Publication No. US 2015/0355184 A1; and PCT Publication No. WO2014/100079 A1; PCT Publication No. WO 2014/022758 A1; PCTPublication No. WO 2014/055897 A2; PCT Publication No. WO2015/061668 A1; PCT Publication No. WO 2015/109124 A1; PCTPublication No. WO 2015/195163 A1; PCT Publication No. WO2016/000619 A1; and PCT Publication No. WO 2016/030350 A1.

[0174] In certain embodiments, a compound that targets animmunomodulatory enzyme(s) such as IDO(indoleamine-(2,3)-dioxygenase) and/or TDO (tryptophan2,3-dioxygenase) is used as the second modality in methodsdisclosed herein. Therefore, in one embodiment, the compoundtargets an immunomodulatory enzyme(s), such as an inhibitor ofindoleamine-(2,3)-dioxygenase (IDO). In certain embodiments, suchcompound is selected from the group consisting of epacadostat(Incyte Corp; see, e.g., WO 2010/005958 which is hereinincorporated by reference in its entirety), F001287 (FlexusBiosciences/Bristol-Myers Squibb), indoximod (NewLink Genetics),and NLG919 (NewLink Genetics). In one embodiment, the compound isepacadostat. In another embodiment, the compound is F001287. Inanother embodiment, the compound is indoximod. In anotherembodiment, the compound is NLG919. In a specific embodiment, ananti-TIM-3 (e.g., human TIM-3) antibody disclosed herein isadministered to a subject in combination with an IDO inhibitor fortreating cancer. The IDO inhibitor as described herein for use intreating cancer is present in a solid dosage form of apharmaceutical composition such as a tablet, a pill or a capsule,wherein the pharmaceutical composition includes an IDO inhibitorand a pharmaceutically acceptable excipient. As such, the antibodyas described herein and the IDO inhibitor as described herein canbe administered separately, sequentially or concurrently asseparate dosage forms. In one embodiment, the antibody isadministered parenterally, and the IDO inhibitor is administeredorally. In particular embodiments, the inhibitor is selected fromthe group consisting of epacadostat (Incyte Corporation), F001287(Flexus Biosciences/Bristol-Myers Squibb), indoximod (NewLinkGenetics), and NLG919 (NewLink Genetics). Epacadostat has beendescribed in PCT Publication No. WO 2010/005958, which is hereinincorporated by reference in its entirety for all purposes. In oneembodiment, the inhibitor is epacadostat. In another embodiment,the inhibitor is F001287. In another embodiment, the inhibitor isindoximod. In another embodiment, the inhibitor is NLG919.

[0175] In certain embodiments, the second modality comprises adifferent vaccine (e.g., a peptide vaccine, a DNA vaccine, or anRNA vaccine) for treating cancer. In certain embodiments, thevaccine is a heat shock protein-based tumor vaccine or a heat shockprotein-based pathogen vaccine (e.g., a vaccine as described in WO2016/183486, which is incorporated herein by reference in itsentirety). In a specific embodiment, the second modality comprisesa stress protein-based vaccine. For example, in certainembodiments, the second modality comprises a composition asdisclosed herein that is different from the first modality. Incertain embodiments, the second modality comprises a compositionanalogous to those disclosed herein except for having a differentsequence of the HSP-binding peptide. In certain embodiments, thestress protein-based vaccine is derived from a tumor preparation,such that the immunity elicited by the vaccine is specificallydirected against the unique antigenic peptide repertoire expressedby the cancer of each subject.

[0176] In certain embodiments, the second modality comprises one ormore adjuvants, such as the ones disclosed supra that may beincluded in the vaccine formulation disclosed herein. In certainembodiments, the second modality comprises a saponin, animmunostimulatory nucleic acid, and/or QS-21. In certainembodiments, the second modality comprises a Toll-like receptor(TLR) agonist. In certain embodiments, the TLR agonist is anagonist of TLR4. In certain embodiments, the TLR agonist is anagonist of TLR7 and/or TLR8. In certain embodiments, the TLRagonist is an agonist of TLR9. In certain embodiments, the TLRagonist is an agonist of TLR5.

[0177] In certain embodiments, the second modality comprises one ormore of the agents selected from the group consisting oflenalidomide, dexamethasone, interleukin-2, recombinant interferonalfa-2b, and peginterferon alfa-2b.

[0178] In certain embodiments, where the pharmaceutical compositionis used for treating a subject having cancer, the second modalitycomprises a chemotherapeutic or a radiotherapeutic. In certainembodiments, the chemotherapeutic agent is a hypomethylating agent(e.g., azacitidine).

[0179] The composition disclosed herein can be administeredseparately, sequentially, or concurrently from the second modality(e.g., chemotherapeutic, radiotherapeutic, checkpoint targetingagent, IDO inhibitor, vaccine, adjuvant, soluble TCR, cellexpressing a TCR, cell expressing a CAR, and/or TCR mimicantibody), by the same or different delivery routes.

6.4.3 Dosage Regimen

[0180] The dosage of the compositions disclosed herein, and thedosage of any additional treatment modality if combination therapyis to be administered, depends to a large extent on the weight andgeneral state of health of the subject being treated, as well asthe frequency of treatment and the route of administration. Amountseffective for this use will also depend on the stage and severityof the disease and the judgment of the prescribing physician, butgenerally range for the initial immunization (that is, fortherapeutic administration) from about 1.0 .mu.g to about 1000.mu.g (1 mg) (including, for example, 10, 20, 25, 30, 40, 50, 60,70, 80, 90, 100, 150, 200, 240, 250, 300, 350, 400, 450, 500, 550,600, 650, 700, 750, 800, 850, 900, 950, or 1000 .mu.g) of any oneof the compositions disclosed herein for a 70 kg patient, followedby boosting dosages of from about 1.0 .mu.g to about 1000 .mu.g ofthe composition (including, for example, 10, 20, 25, 30, 40, 50,60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550,600, 650, 700, 750, 800, 850, 900, 950, or 1000 .mu.g) pursuant toa boosting regimen over weeks to months depending upon thepatient's response and condition by measuring specific CTL activityin the patient's blood. Regimens for continuing therapy, includingsite, dose and frequency may be guided by the initial response andclinical judgment. Dosage ranges and regimens for adjuvants areknown to those in the art, see, e.g., Vogel and Powell, 1995, ACompendium of Vaccine Adjuvants and Excipients; M. F. Powell, M. J.Newman (eds.), Plenum Press, New York, pages 141-228.

[0181] Preferred adjuvants include QS-21, e.g., QS-21Stimulon.RTM., and CpG oligonucleotides. Exemplary dosage rangesfor QS-21 are 1 .mu.g to 200 .mu.g per administration. In otherembodiments, dosages for QS-21 can be 10, 25, and 50 .mu.g peradministration. In certain embodiments, the adjuvant comprises aToll-like receptor (TLR) agonist. In certain embodiments, the TLRagonist is an agonist of TLR4. In certain embodiments, the TLRagonist is an agonist of TLR7 and/or TLR8. In certain embodiments,the TLR agonist is an agonist of TLR9. In certain embodiments, theTLR agonist is an agonist of TLR5.

[0182] In certain embodiments, the administered amount ofcompositions depends on the route of administration and the type ofHSPs in the compositions. For example, the amount of HSP in thecompositions can range, for example, from 5 to 1000 .mu.g (1 mg)per administration. In certain embodiments, the administered amountof compositions comprising Hsc70-, Hsp70- and/or Gp96-polypeptidecomplexes is, for example, 5, 10, 20, 25, 30, 40, 50, 60, 70, 80,90, 100, 200, 250, 300, 400, 500, 600, 700, 750, 800, 900, or 1000.mu.g. In certain embodiments, the administered amount of thecomposition is in the range of about 10 to 600 .mu.g peradministration and about 5 to 100 .mu.g if the composition isadministered intradermally. In certain embodiments, theadministered amount of the composition is about 5 .mu.g to 600.mu.g, about 5 .mu.g to 300 .mu.g, about 5 .mu.g to 150 .mu.g, orabout 5 .mu.g to 60 .mu.g. In certain embodiments, the administeredamount of the composition is less than 100 .mu.g. In certainembodiments, the administered amount of the composition is about 5.mu.g, 25 .mu.g, 50 .mu.g, 120 .mu.g, 240 .mu.g, or 480 .mu.g. Incertain embodiments, the compositions comprising complexes ofstress proteins and polypeptides are purified.

[0183] In one embodiment of a therapeutic regimen, a dosagesubstantially equivalent to that observed to be effective insmaller non-human animals (e.g., mice or guinea pigs) is effectivefor human administration, optionally subject to a correction factornot exceeding a fifty-fold increase, based on the relative lymphnode sizes in such mammals and in humans. Specifically,interspecies dose-response equivalence for stress proteins (orHSPs) noncovalently bound to or mixed with antigenic molecules fora human dose is estimated as the product of the therapeutic dosageobserved in mice and a single scaling ratio, not exceeding afifty-fold increase. In certain embodiment, the dosages of thecomposition can be much smaller than the dosage estimated byextrapolation.

[0184] The doses recited above can be given once or repeatedly,such as daily, every other day, weekly, biweekly, or monthly, for aperiod up to a year or over a year. Doses are preferably given onceevery 28 days for a period of about 52 weeks or more.

[0185] In one embodiment, the compositions are administered to asubject at reasonably the same time as an additional treatmentmodality or modalities. This method provides that the twoadministrations are performed within a time frame of less than oneminute to about five minutes, or up to about sixty minutes fromeach other, for example, at the same doctor's visit.

[0186] In another embodiment, the compositions and an additionaltreatment modality or modalities are administered concurrently.

[0187] In yet another embodiment the compositions and an additionaltreatment modality or modalities are administered in a sequence andwithin a time interval such that the complexes disclosed herein,and the additional treatment modality or modalities can acttogether to provide an increased benefit than if they wereadministered alone.

[0188] In another embodiment, the compositions and an additionaltreatment modality or modalities are administered sufficientlyclose in time so as to provide the desired therapeutic orprophylactic outcome. Each can be administered simultaneously orseparately, in any appropriate form and by any suitable route. Inone embodiment, the complexes disclosed herein, and the additionaltreatment modality or modalities are administered by differentroutes of administration. In an alternate embodiment, each isadministered by the same route of administration. The compositionscan be administered at the same or different sites, e.g. arm andleg. When administered simultaneously, the compositions and anadditional treatment modality or modalities may or may not beadministered in admixture or at the same site of administration bythe same route of administration.

[0189] In various embodiments, the compositions and an additionaltreatment modality or modalities are administered less than 1 hourapart, at about 1 hour apart, 1 hour to 2 hours apart, 2 hours to 3hours apart, 3 hours to 4 hours apart, 4 hours to 5 hours apart, 5hours to 6 hours apart, 6 hours to 7 hours apart, 7 hours to 8hours apart, 8 hours to 9 hours apart, 9 hours to 10 hours apart,10 hours to 11 hours apart, 11 hours to 12 hours apart, no morethan 24 hours apart or no more than 48 hours apart. In otherembodiments, the compositions and a vaccine composition areadministered 2 to 4 days apart, 4 to 6 days apart, 1 week a part, 1to 2 weeks apart, 2 to 4 weeks apart, one month apart, 1 to 2months apart, or 2 or more months apart. In preferred embodiments,the compositions and an additional treatment modality or modalitiesare administered in a time frame where both are still active. Oneskilled in the art would be able to determine such a time frame bydetermining the half-life of each administered component.

[0190] In certain embodiments, the compositions are administered tothe subject weekly for at least four weeks. In certain embodiments,after the four weekly doses, at least 2 (e.g., 2, 3, 4, 5, 6, 7, 8,9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) further doses ofthe compositions are administered biweekly to the subject. Incertain embodiments, the compositions administered as a boosterthree months after the final weekly or biweekly dose. The boosteradministered every three months can be administered for the life ofthe subject (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 40, 50, or more years). Incertain embodiments, the total number of doses of the compositionsadministered to the subject is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,12, 13, 14, 15, 16, 17, 18, 19, or 20.

[0191] In one embodiment, the compositions and an additionaltreatment modality or modalities are administered within the samepatient visit. In certain embodiments, the compositions areadministered prior to the administration of an additional treatmentmodality or modalities. In an alternate specific embodiment, thecompositions are administered subsequent to the administration ofan additional treatment modality or modalities.

[0192] In certain embodiments, the compositions and an additionaltreatment modality or modalities are cyclically administered to asubject. Cycling therapy involves the administration of thecompositions for a period of time, followed by the administrationof a modality for a period of time and repeating this sequentialadministration. Cycling therapy can reduce the development ofresistance to one or more of the therapies, avoid or reduce theside effects of one of the therapies, and/or improve the efficacyof the treatment. In such embodiments, the disclosure contemplatesthe alternating administration of the compositions followed by theadministration of a modality 4 to 6 days later, preferable 2 to 4days, later, more preferably 1 to 2 days later, wherein such acycle may be repeated as many times as desired. In certainembodiments, the compositions and the modality are alternatelyadministered in a cycle of less than 3 weeks, once every two weeks,once every 10 days or once every week. In certain embodiments, thecompositions are administered to a subject within a time frame ofone hour to twenty-four hours after the administration of amodality. The time frame can be extended further to a few days ormore if a slow- or continuous-release type of modality deliverysystem is used.

6.4.4 Routes of Administration

[0193] The compositions disclosed herein may be administered usingany desired route of administration. Many methods may be used tointroduce the compositions described above, including but notlimited to, oral, intradermal, intramuscular, intraperitoneal,intravenous, subcutaneous, mucosal, intranasal, intra-tumoral, andintra-lymph node routes. Non-mucosal routes of administrationinclude, but are not limited to, intradermal and topicaladministration. Mucosal routes of administration include, but arenot limited to, oral, rectal and nasal administration. Advantagesof intradermal administration include use of lower doses and rapidabsorption, respectively. Advantages of subcutaneous orintramuscular administration include suitability for some insolublesuspensions and oily suspensions, respectively. Preparations formucosal administrations are suitable in various formulations asdescribed below.

[0194] Solubility and the site of the administration are factorswhich should be considered when choosing the route ofadministration of the compositions. The mode of administration canbe varied between multiple routes of administration, includingthose listed above.

[0195] If the compositions are water-soluble, then it may beformulated in an appropriate buffer, for example, phosphatebuffered saline or other physiologically compatible solutions,preferably sterile. Alternatively, if a composition has poorsolubility in aqueous solvents, then it may be formulated with anon-ionic surfactant such as Tween, or polyethylene glycol. Thus,the compositions may be formulated for administration by inhalationor insufflation (either through the mouth or the nose) or oral,buccal, parenteral, or rectal administration.

[0196] For oral administration, the composition may be in liquidform, for example, solutions, syrups or suspensions, or may bepresented as a drug product for reconstitution with water or othersuitable vehicle before use. Such a liquid preparation may beprepared by conventional means with pharmaceutically acceptableadditives such as suspending agents (e.g., sorbitol syrup,cellulose derivatives or hydrogenated edible fats); emulsifyingagents (e.g., lecithin or acacia); non-aqueous vehicles (e.g.,almond oil, oily esters, or fractionated vegetable oils); andpreservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbicacid). The compositions may take the form of, for example, tabletsor capsules prepared by conventional means with pharmaceuticallyacceptable excipients such as binding agents (e.g., pre-gelatinizedmaize starch, polyvinyl pyrrolidone or hydroxypropylmethylcellulose); fillers (e.g., lactose, microcrystallinecellulose or calcium hydrogen phosphate); lubricants (e.g.,magnesium stearate, talc or silica); disintegrants (e.g., potatostarch or sodium starch glycolate); or wetting agents (e.g., sodiumlauryl sulphate). The tablets may be coated by methods well-knownin the art.

[0197] The compositions for oral administration may be suitablyformulated to be released in a controlled and/or timed manner.

[0198] For buccal administration, the compositions may take theform of tablets or lozenges formulated in conventional manner.

[0199] The preparation may be formulated for parenteraladministration by injection, e.g., by bolus injection or continuousinfusion. Formulations for injection may be presented in unitdosage form, e.g., in ampoules or in multi-dose containers, with anadded preservative. The preparation may take such forms assuspensions, solutions or emulsions in oily or aqueous vehicles,and may contain formulatory agents such as suspending, stabilizingand/or dispersing agents. Alternatively, the active ingredient maybe in powder form for constitution with a suitable vehicle, e.g.,sterile pyrogen-free water, before use.

[0200] The preparation may also be formulated in a rectalpreparation such as a suppository or retention enema, e.g.,containing conventional suppository bases such as cocoa butter orother glycerides.

[0201] In addition to the formulations described above, thepreparation may also be formulated as a depot preparation. Suchlong acting formulations may be administered by implantation (forexample, subcutaneously or intramuscularly) or by intramuscularinjection. Thus, for example, the preparation may be formulatedwith suitable polymeric or hydrophobic materials (for example, asemulsion in an acceptable oil) or ion exchange resins, or assparingly soluble derivatives, for example, as a sparingly solublesalt. Liposomes and emulsions are well known examples of deliveryvehicles or carriers for hydrophilic drugs.

[0202] For administration by inhalation, the compositions areconveniently delivered in the form of an aerosol spray presentationfrom pressurized packs or a nebulizer, with the use of a suitablepropellant, e.g., dichlorodifluoromethane, trichlorofluoromethane,dichlorotetrafluoroethane, carbon dioxide or other suitable gas. Inthe case of a pressurized aerosol the dosage unit may be determinedby providing a valve to deliver a metered amount. Capsules andcartridges of, e.g., gelatin for use in an inhaler or insufflatormay be formulated containing a powder mix of the compound and asuitable powder base such as lactose or starch.

6.4.5 Patient (Subject) Evaluation

[0203] Patients treated with the compositions disclosed herein maybe tested for an anti-tumor immune response. In this regard,peripheral blood from patients may be obtained and assayed formarkers of anti-tumor immunity. Using standard laboratoryprocedures, leukocytes may be obtained from the peripheral bloodand assayed for frequency of different immune cell phenotypes, HLAsubtype, and function of anti-tumor immune cells.

[0204] The majority of effector immune cells in the anti-tumorresponse is CD8.sup.+ T cells and thus is HLA class I restricted.Using immunotherapeutic strategies in other tumor types, expansionof CD8+ cells that recognize HLA class I restricted antigens isfound in a majority of patients. However, other cell types areinvolved in the anti-tumor immune response, including, for example,CD4+ T cells, and macrophages and dendritic cells, which may act asantigen-presenting cells. Populations of T cells (CD4+, CD8+, andTreg cells), macrophages, and antigen presenting cells may bedetermined using flow cytometry. HLA typing may be performed usingroutine methods in the art, such as methods described in Boegel etal. Genome Medicine 2012, 4:102 (seq2HLA), or using a TruSight.RTM.HLA sequencing panel (Illumina, Inc.). The HLA subtype of CD8+ Tcells may be determined by a complement-dependent microcytotoxicitytest.

[0205] To determine if there is an increase in anti-tumor T cellresponse, an enzyme linked immunospot assay may be performed toquantify the IFN.gamma.-producing peripheral blood mononuclearcells (PBMC). This technique provides an assay for antigenrecognition and immune cell function. In some embodiments, subjectswho respond clinically to the vaccine may have an increase intumor-specific T cells and/or IFN.gamma.-producing PBMCs. In someembodiments, immune cell frequency is evaluated using flowcytometry. In some embodiments, antigen recognition and immune cellfunction is evaluated using enzyme linked immunospot assays.

[0206] In some embodiments, a panel of assays may be performed tocharacterize the immune response generated to the composition aloneor given in combination with standard of care (e.g., maximalsurgical resection, radiotherapy, and concomitant and adjuvantchemotherapy with temozolomide for glioblastoma multiforme). Insome embodiments, the panel of assays includes one or more of thefollowing tests: whole blood cell count, absolute lymphocyte count,monocyte count, percentage of CD4.sup.+CD3.sup.+ T cells,percentage of CD8.sup.+CD3.sup.+ T cells, percentage ofCD4.sup.+CD25.sup.+FoxP3.sup.+ regulatory T cells and otherphenotyping of PBL surface markers, intracellular cytokine stainingto detect proinflammatory cytokines at the protein level, qPCR todetect cytokines at the mRNA level and CFSE dilution to assay Tcell proliferation.

[0207] In evaluating a subject, a number of other tests may beperformed to determine the overall health of the subject. Forexample, blood samples may be collected from subjects and analyzedfor hematology, coagulation times and serum biochemistry.Hematology for CBC may include red blood cell count, platelets,hematocrit, hemoglobin, white blood cell (WBC) count, plus WBCdifferential to be provided with absolute counts for neutrophils,eosinophils, basophils, lymphocytes, and monocytes. Serumbiochemistry may include albumin, alkaline phosphatase, aspartateamino transferase, alanine amino transferase, total bilirubin, BUN,glucose, creatinine, potassium and sodium. Protime (PT) and partialthromboplastin time (PTT) may also be tested. One or more of thefollowing tests may also be conducted: anti-thyroid(anti-microsomal or thyroglobulin) antibody tests, assessment foranti-nuclear antibody, and rheumatoid factor. Urinalysis may beperformed to evaluated protein, RBC, and WBC levels in urine. Also,a blood draw to determine histocompatibility leukocyte antigen(HLA) status may be performed.

[0208] In some embodiments, radiologic tumor evaluations areperformed one or more times throughout a treatment to evaluatetumor size and status. For example, tumor evaluation scans may beperformed within 30 days prior to surgery, within 48 hours aftersurgery (e.g., to evaluate percentage resection), 1 week (maximum14 days) prior to the first vaccination (e.g., as a baselineevaluation), and approximately every 8 weeks thereafter for aparticular duration. MRI or CT imaging may be used. Typically, thesame imaging modality used for the baseline assessment is used foreach tumor evaluation visit.

6.5 Kits

[0209] Kits are also provided for carrying out the prophylactic andtherapeutic methods disclosed herein. The kits may optionallyfurther comprise instructions on how to use the various componentsof the kits.

[0210] In certain embodiments, the kit comprises a first containercontaining a composition (e.g., composition comprising stressprotein(s) and antigenic polypeptide(s) disclosed herein, and asecond container containing one or more adjuvants. The adjuvant canbe any adjuvant disclosed herein, e.g., a saponin, animmunostimulatory nucleic acid, or QS-21 (e.g., QS-21Stimulon.RTM.). In certain embodiments, the kit further comprises athird container containing an additional treatment modality. Thekit can further comprise an instruction on the indication, dosageregimen, and route of administration of the composition, adjuvant,and additional treatment modality, e.g., as disclosed inherein.

[0211] Alternatively, the kit can comprise the stress protein(s)and antigenic polypeptide(s) of a composition disclosed herein inseparate containers. In certain embodiments, the kit comprises afirst container containing one or more antigenic polypeptidesdisclosed herein, and a second container containing a purifiedstress protein capable of binding to the polypeptide.

[0212] The first container can contain any number of differentpolypeptides. For example, in certain embodiments, the firstcontainer contains no more than 100 different polypeptides, e.g.,2-50, 2-30, 2-20, 5-20, 5-15, 5-10, or 10-15 differentpolypeptides. In certain embodiments, each of the differentpolypeptides comprises the same HSP-binding peptide and a differentantigenic peptide. In certain embodiments, the total amount of thepolypeptide(s) in the first container is a suitable amount for aunit dosage. In certain embodiments, the total amount of thepolypeptide(s) in the first container is about 0.1 to 20 nmol(e.g., 3, 4, 5, or 6 nmol).

[0213] The second container can contain any stress proteindisclosed herein. In certain embodiments, the stress protein isselected from the group consisting of Hsc70, Hsp70, Hsp90, Hsp110,Grp170, Gp96, or Calreticulin, and a mutant or fusion proteinthereof. In certain embodiments, the stress protein is Hsc70 (e.g.,human Hsc70). In certain embodiments, the stress protein is arecombinant protein. In certain embodiments, the total amount ofthe stress protein(s) in the second container is about 10 .mu.g to600 .mu.g (e.g., 120 .mu.g, 240 .mu.g, or 480 .mu.g). In certainembodiments, the total amount of the stress protein(s) in thesecond container is about 50 .mu.g, 100 .mu.g, 200 .mu.g, 300.mu.g, 400 .mu.g, or 500 .mu.g. In certain embodiments, the amountof the stress protein in the composition is about 300 .mu.g. Incertain embodiments, the total molar amount of the stressprotein(s) in the second container is calculated based on the totalmolar amount of the polypeptide(s) in the first container, suchthat the molar ratio of the polypeptide(s) to the stress protein(s)is about 0.5:1 to 5:1 (e.g., about 1:1, 1.25:1, 1.5:1, 2:1, 2.5:1,3:1, 3.5:1, 4:1, 4.5:1, or 5:1). In certain embodiments, the totalamount of the stress protein(s) in the second container is anamount for multiple administrations (e.g., less than or equal to 1mg, 3 mg, 10 mg, 30 mg, or 100 mg).

[0214] In certain embodiments, the kit further comprises aninstruction for preparing a composition from the polypeptide(s) inthe first container and the stress protein(s) in the secondcontainer (e.g., an instruction for the complexing reaction asdisclosed herein).

[0215] In certain embodiments, the kit further comprises a thirdcontainer containing one or more adjuvants. The adjuvant can be anyadjuvant disclosed herein, e.g., a saponin, an immunostimulatorynucleic acid, or QS-21 (e.g., QS-21 Stimulon.RTM.). In certainembodiments, the kit further comprises a fourth containercontaining an additional treatment modality. The kit can furthercomprise an instruction on the indication, dosage regimen, androute of administration of the composition prepared from thepolypeptide(s) and stress protein(s), the adjuvant, and theadditional treatment modality, e.g., as disclosed herein.

[0216] In certain embodiments, the composition, polypeptide(s),stress protein(s), adjuvant(s), and additional treatment modalityin the containers are present in pre-determined amounts effectiveto treat cancers. If desired, the compositions can be presented ina pack or dispenser device which may contain one or more unitdosage forms of the compositions. The pack may, for example,comprise metal or plastic foil, such as a blister pack. The pack ordispenser device may be accompanied by instructions foradministration

7. EXAMPLES

[0217] The examples in this section are offered by way ofillustration, and not by way of limitation.

7.1 Example 1: Phosphopeptide Synthesis

[0218] The antigenic peptides set forth in SEQ ID NOs: 119, 123,125, 133, 134, 221, 247, 281, 296, 355, 407, 410, 417, 419, 421,455, 456, 457, 546, 563, 611, 641, 642, 650, 654, 657, 669, 670,701, 703, 791, 809, 821, 824, 859, 869, 911, 954, 974, 979, 1016,1028, 1032, 1049, 1143, 1148, 1149, 1167, 1176, 1179, 1199, 1217,1218, 1220, 1228, 1232, 1240, 1253, 1254, 1260, 1266, 1267, 1274,1298, 1300, 1314, 1343, 1350, 1468, 1486, 1493, 1534, 1536, 1539,1550, 1552, 1561, 1571, 1574, 1598, 1621, 1651, 1658, 1669, 1670,1683, 1694, 1720, 1735, 1763, 1767, 1779, 1787, 1804, 1811, 1812,1814, 1818, 1822, 1825, 1867, 1918, 1927, 1981, 2078, 2111, 2255,2265, 2328, 2331, 2332, 2355, 2363, 2364, 2386, 2400, 2451, 2453,2454, 2463, 2465, 2467, 2470, 2471, 2472, 2485, 2486, 2505, 2507,2512, 2525, 2557, 2570, 2580, 2706, 2740, 2747, 2751, 2753, 2784,2793, 2803, 2813, 2816, 2863, 2872, 2911, 3124, 3199, 3324, 3360,3553, 3560, 3572, 4052, 4157, 4253, 4477, 4572, 4682, 4690, 4714,4715, 5231, 5266, 5303, 5654, 5656, 5719, 5766, 5842, 6015, 6074,6175, 6176, 6330, 6369, 6630, 6747, 6751, 6768, 6868, 6936, 6947,6973, 6993, 7019, 7069, 7258, 7269, 7271, 7290, 7377, 7388, 7389,7402, 7413, 7454, 7482, 7498, 7523, 7530, 7531, 7586, 7637, 7646,7700, 7797, 7830, 8047, 8082, 8119, 8231, 8244, 8470, 8472, 8808,and 8810 were synthesized using standard Fmoc solid-phase chemicalsynthesis with pre-loaded polystyrene Wang (PS-Wang) resin in aSymphony.RTM.X automatic synthesizer (Gyros Protein TechnologiesInc.RTM.). A sample of the first amino acid loaded resin from theC-terminus was placed in a dry reaction vessel and was charged toeach of the 24 reaction/pre-activation vessels. The synthesizer wasprogrammed to run the complete synthesis cycle using O-(1H-6-Chlorobenzotriazole-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate/N-methylmorpholine HCTU/NMM activationchemistry. The phosphate group was incorporated usingN-.alpha.-Fmoc-O-benzyl-L-phosphoserine,N-.alpha.-Fmoc-O-benzyl-L-phosphothreonine andN-.alpha.-Fmoc-O-benzyl-L-phosphotyrosine for serine, threonine andtyrosine respectively. A 5-fold excess of amino acid, 5-fold excessof activating reagent (HCTU) and 10-fold excess of N-methylmorpholine was used for the peptide coupling reaction. The couplingreaction was performed for 10 min with double coupling cycle forany incomplete coupling throughout the synthesis. These steps wererepeated until the desired sequence was obtained.

[0219] At the end of the peptide synthesis, the resin was washedwith dichloromethane (DCM) and dried. Upon completion ofphosphopeptide assembly, the resin was transferred to a cleavagevessel for cleavage of the peptide from the resin. The cleavagereagent (TFA:DTT:Water:TIS at 88:5:5:2 (v/w/v/v)) was mixed withthe resin and stirred for 4 hours at 25.degree. C. Crude peptideswere isolated from the resin by filtration and evaporated withN.sub.2 gas, followed by precipitation with chilled diethyl etherand storage at 20.degree. C. for 12 hours.

[0220] The precipitated peptides were centrifuged and washed twicewith diethyl ether, dried, dissolved in a 1:1 (v/v) mixture ofacetonitrile and water, and lyophilized to produce a crude drypowder. The crude peptides were analyzed by reverse phase HPLC witha Luna.RTM. C18 analytical column (Phenomenex.RTM., Inc) using awater (0.1% TFA)-acetonitrile (0.1% TFA) gradient. Peptides werefurther purified by prep-HPLC with a preparative Luna.RTM. C18column (Phenomenex.RTM., Inc) using a water (0.1% TFA)-acetonitrile(0.1% TFA) gradient. Purified fractions were analyzed usinganalytical HPLC and pure fractions were pooled for subsequentlyophilization. Peptide purity was tested using an analyticalLuna.RTM. C18-column (Phenomenex.RTM., Inc) and identity confirmedeither by LC/MS (6550 Q-TOF, Agilent Technologies.RTM.) or MSQPlus.TM. (Thermo Electron.RTM., North America).

7.2 Example 2: HLA Binding

[0221] In this example, the HLA binding affinity of selectedphosphopeptides (synthesized according to the method set forth inExample 1) was determined.

[0222] Phosphopeptides were synthesized according to the methodsdescribed in Example 1.

[0223] An AlphaScreen.RTM. assay was used to evaluate the bindingof peptides to HLA molecules. Donor beads conjugated withstreptavidin, and acceptor beads conjugated with the anti-human HLAclass I antibody W6/32, were used to assess peptide binding.Biotinylated HLAs (A*02:01, B*07:02, C*07:01, or C*07:02) weremixed with a fixed excess of .beta.2m and the mixtures added toeach well of a 384-well microplate. Serial dilutions of thesynthesized phosphopeptides were added to the wells, and theresultant HLA/.beta.2/peptide mixtures were incubated overnight at18.degree. C. W6/32 conjugated acceptor beads were subsequentlyadded to the wells, and the mixture was incubated for 1 hour at21.degree. C. Streptavidin conjugated donor beads were then addedto the wells, and the mixture was incubated for a further 1 hour at21.degree. C.

[0224] The microplate was read using the PerkinElmer.RTM. platereader, and data were plotted using the Michaelis-Menten equationto determine the K.sub.d for each phosphopeptide.

[0225] Table 8 lists the K.sub.d of each of the selectedphosphopeptides to the indicated HLAs (A*02:01, B*07:02, C*07:01,or C*07:02). NT means that binding was not tested. NB means nobinding was detected. LB stands for low binding and indicates thatwhile some binding was observed, it was below the level that wouldallow accurate calculation of a K.sub.d.

TABLE-US-00008 TABLE 8 HLA binding characteristics of selectedphosphopeptides SEQ Kd Kd Kd Kd ID in nM in nM in nM in nM PeptideNO: A*02:01 B*07:01 C*07:01 C*07:02 RTLsHISEA 2332 157 NB 380 LBRVAsPTSGV 2363 241.6 227 LB NB SIMsPEIQL 2451 83.96 NB LB LBSISsMEVNV 2453 305.9 NB NB NB SISStPPAV 2454 168.8 NB NB NBSLFGGsVKL 2463 53.89 NB LB LB SLFsGDEENA 2465 277.8 NB NB NBSLFsPQNTL 2467 115.8 LB LB LB SLFsSEESNL 2470 466.2 NB NB NBSLFsSEESNLGA 2471 148.7 NB NB NB SLHDIQLsL 2472 31.86 642 962 413SLQPRSHsV 2485 779.8 LB NB NB SLQsLETSV 2486 120.8 NB NB NBSMSsLSREV 2505 926.6 NB NB NB SMTRsPPRV 2507 701.3 NB NB NBSVKPRRTsL 2706 NB LB NB NB TVFsPTLPAA 2784 46.94 NB NB NB VLFSsPPQM2793 226.7 NB LB NB VLLsPVPEL 2803 149.5 NB LB NB VLYsPQMAL 281340.45 LB NB LB VMIGsPKKV 2816 LB NB NB NB yLQSRYYRA 2872 255.4 LBNB LB RQAsIELPSMAV 1812 14.8 NB NB NB RIYQyIQSR 1217 NB NT NT NTRPRsPTGPSNSFL 1735 NB 360.2 NT NT RPRIPsPIGF 1658 NB 84.37 NT NTLPRPAsPAL 1049 NB 222.73 NT NT RPAFFsPSL 1486 NB 397.5 NT NTRPKtPPVVI 1598 NB LB NT NT KIKsFEVVF 642 LB NB NT NT YRYsPQSFL 2911NB NB NT NT RPFsPREAL 1552 NT 162.72 NT NT GPRSASLLsL 457 NT 47.07NT NT SPFKRQLsL 2525 NT 64.68 NT NT SPAsPKISL 2512 NT 274.8 NT NTRPDVAKRLsL 1539 NT 216.1 NT NT RPRPVsPSSLL 1670 NT 186.4 NT NTKRFsGTVRL 911 NT NB NT NT KAFsPVRSV 611 NT NB NT NT RLLsFQRYL 130049.72 NB NT NT RLSsPLHFV 1350 90.61 NT NT NT TPRsPPLGL 2751 NB75.55 NT LB TPRsPPLGLI 2753 NB 90.98 NB LB QPRtPSPLVL 1149 NT198.75 NT NT GPRSAsLLSL 456 NB 34.09 NT NT RPYsPPFFSL 1804 NT 156.7NT NT LPAsPRARL 1028 NT 83.46 NT NT RPSsLPDL 1763 NB 369.4 NT NTRPRsISVEEF 1683 NT 86.14 NT NT RRGsFEVTL 1918 NT NB 16.58 15.87RRLsFLVSY 1981 NT NT 1574 112.8 RIYQyIQSRF 1218 NT NT 476.8 377.2RRPsLLSEF 2078 NT NT 804.1 35.69 RRSsFLQVF 2111 NT NB LB 18.98RRIsDPQVF 1927 NT NB 11.41 19.94 RRFsGTAVY 1867 NT NB 2176 16.69FRRsPTKSSLDY 355 NT NT NT 98.63 QPRtPsPLVL 1148 NB LB NB NBRQAsIELPSM 1811 20.37 NB NB NB KLIDRTEsL 670 260 LB NB NBGPRSAsLLsL 455 500 50 NB NB RPTsRLNRL 1779 NB 117.35 NB NBRPRPVsPSSL 1669 NB 218 NB NB AVRPTRLsL 221 NB 117 NT NT GLLGsPVRA421 431 NB NT NT EPRsPSHSM 296 NB 198.6 NT NT RVRsPTRSP 2400 NB 551NT NT RLLsAAENFL 8808 114 NT NT NT `s`, `t` and `y` indicatephosphorylated serine, threonine and tyrosine, respectively.

[0226] The invention is not to be limited in scope by the specificembodiments described herein. Indeed, various modificationsdisclosed herein in addition to those described will becomeapparent to those skilled in the art from the foregoing descriptionand accompanying figures. Such modifications are intended to fallwithin the scope of the appended claims.

[0227] All references (e.g., publications or patents or patentapplications) cited herein are incorporated herein by reference intheir entirety and for all purposes to the same extent as if eachindividual reference (e.g., publication or patent or patentapplication) was specifically and individually indicated to beincorporated by reference in its entirety for all purposes. Otherembodiments are within the following claims.

* * * * *

References

• seqdata.uspto.gov/?pageRequest=docDetail&DocID=US20220275049A1